<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Prostate MRI, with or without MRI‐targeted biopsy, and systematic biopsy for detecting prostate cancer - Drost, FJH - 2019 | Cochrane Library</title> <meta content="Prostate MRI, with or without MRI‐targeted biopsy, and systematic biopsy for detecting prostate cancer - Drost, FJH - 2019 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012663.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Prostate MRI, with or without MRI‐targeted biopsy, and systematic biopsy for detecting prostate cancer - Drost, FJH - 2019 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012663.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD012663.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Prostate MRI, with or without MRI‐targeted biopsy, and systematic biopsy for detecting prostate cancer" name="citation_title"/> <meta content="Frank‐Jan H Drost" name="citation_author"/> <meta content="Daniël F Osses" name="citation_author"/> <meta content="Daan Nieboer" name="citation_author"/> <meta content="Erasmus University Medical Center" name="citation_author_institution"/> <meta content="Ewout W Steyerberg" name="citation_author"/> <meta content="Erasmus University Medical Center" name="citation_author_institution"/> <meta content="Chris H Bangma" name="citation_author"/> <meta content="Erasmus University Medical Center" name="citation_author_institution"/> <meta content="Monique J Roobol" name="citation_author"/> <meta content="Erasmus University Medical Center" name="citation_author_institution"/> <meta content="Ivo G Schoots" name="citation_author"/> <meta content="Erasmus University Medical Center" name="citation_author_institution"/> <meta content="i.schoots@erasmusmc.nl" name="citation_author_email"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="4" name="citation_issue"/> <meta content="10.1002/14651858.CD012663.pub2" name="citation_doi"/> <meta content="2019" name="citation_date"/> <meta content="2019/04/25" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012663.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012663.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012663.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Biopsy [*methods]; Magnetic Resonance Imaging [*methods]; Prostate [*pathology]; Prostatic Neoplasms [*diagnosis, pathology]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012663.pub2&amp;doi=10.1002/14651858.CD012663.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012663.pub2&amp;doi=10.1002/14651858.CD012663.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012663.pub2&amp;doi=10.1002/14651858.CD012663.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012663.pub2&amp;doi=10.1002/14651858.CD012663.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012663.pub2&amp;doi=10.1002/14651858.CD012663.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012663.pub2&amp;doi=10.1002/14651858.CD012663.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012663.pub2&amp;doi=10.1002/14651858.CD012663.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012663.pub2&amp;doi=10.1002/14651858.CD012663.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012663.pub2&amp;doi=10.1002/14651858.CD012663.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012663.pub2&amp;doi=10.1002/14651858.CD012663.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012663.pub2&amp;doi=10.1002/14651858.CD012663.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012663.pub2&amp;doi=10.1002/14651858.CD012663.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012663.pub2&amp;doi=10.1002/14651858.CD012663.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012663.pub2&amp;doi=10.1002/14651858.CD012663.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012663.pub2&amp;doi=10.1002/14651858.CD012663.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012663.pub2&amp;doi=10.1002/14651858.CD012663.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012663.pub2&amp;doi=10.1002/14651858.CD012663.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012663.pub2&amp;doi=10.1002/14651858.CD012663.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012663.pub2&amp;doi=10.1002/14651858.CD012663.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012663.pub2&amp;doi=10.1002/14651858.CD012663.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012663.pub2&amp;doi=10.1002/14651858.CD012663.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012663.pub2&amp;doi=10.1002/14651858.CD012663.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012663.pub2&amp;doi=10.1002/14651858.CD012663.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="ZCrlluee";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD012663\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD012663\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012663\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012663\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","ms","fr","pl","zh_HANS","hr","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD012663.pub2",title:"Prostate MRI, with or without MRI\\u2010targeted biopsy, and systematic biopsy for detecting prostate cancer",firstPublishedDate:"Apr 25, 2019 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Urology Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=ZCrlluee&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012663.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD012663.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD012663.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD012663.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012663.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD012663.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Zusammenfassung&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Laienverständliche Zusammenfassung&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD012663.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD012663.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD012663.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD012663.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>16921 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD012663.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012663.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012663.pub2/full#CD012663-abs-0005"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012663.pub2/full#CD012663-sec-0125"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012663.pub2/full#CD012663-sec-0036"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012663.pub2/full#CD012663-sec-0037"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012663.pub2/full#CD012663-sec-0047"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012663.pub2/full#CD012663-sec-0050"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012663.pub2/full#CD012663-sec-0073"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012663.pub2/full#CD012663-sec-0108"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012663.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012663.pub2/appendices#CD012663-sec-0136"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012663.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012663.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/table_n/CD012663StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/table_n/CD012663StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012663.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012663.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012663.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD012663.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD012663.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD012663.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2019 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Diagnostic</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Prostate MRI, with or without MRI‐targeted biopsy, and systematic biopsy for detecting prostate cancer </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012663.pub2/information#CD012663-cr-0002">Frank‐Jan H Drost</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012663.pub2/information#CD012663-cr-0003">Daniël F Osses</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012663.pub2/information#CD012663-cr-0004">Daan Nieboer</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012663.pub2/information#CD012663-cr-0005">Ewout W Steyerberg</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012663.pub2/information#CD012663-cr-0006">Chris H Bangma</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012663.pub2/information#CD012663-cr-0007">Monique J Roobol</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012663.pub2/information#CD012663-cr-0008"><i class="icon corresponding-author fa fa-envelope"></i>Ivo G Schoots</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/information/en#CD012663-sec-0149">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 25 April 2019 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD012663.pub2">https://doi.org/10.1002/14651858.CD012663.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD012663-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012663-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD012663-abs-0002">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD012663-abs-0004">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD012663-abs-0014">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD012663-abs-0003">Français</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD012663-abs-0011">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD012663-abs-0001" lang="en"> <section id="CD012663-sec-0001"> <h3 class="title" id="CD012663-sec-0001">Background</h3> <p>Multiparametric magnetic resonance imaging (MRI), with or without MRI‐targeted biopsy, is an alternative test to systematic transrectal ultrasonography‐guided biopsy in men suspected of having prostate cancer. At present, evidence on which test to use is insufficient to inform detailed evidence‐based decision‐making. </p> </section> <section id="CD012663-sec-0002"> <h3 class="title" id="CD012663-sec-0002">Objectives</h3> <p>To determine the diagnostic accuracy of the index tests MRI only, MRI‐targeted biopsy, the MRI pathway (MRI with or without MRI‐targeted biopsy) and systematic biopsy as compared to template‐guided biopsy as the reference standard in detecting clinically significant prostate cancer as the target condition, defined as International Society of Urological Pathology (ISUP) grade 2 or higher. Secondary target conditions were the detection of grade 1 and grade 3 or higher‐grade prostate cancer, and a potential change in the number of biopsy procedures. </p> </section> <section id="CD012663-sec-0003"> <h3 class="title" id="CD012663-sec-0003">Search methods</h3> <p>We performed a comprehensive systematic literature search up to 31 July 2018. We searched CENTRAL, MEDLINE, Embase, eight other databases and one trials register. </p> </section> <section id="CD012663-sec-0004"> <h3 class="title" id="CD012663-sec-0004">Selection criteria</h3> <p>We considered for inclusion any cross‐sectional study if it investigated one or more index tests verified by the reference standard, or if it investigated the agreement between the MRI pathway and systematic biopsy, both performed in the same men. We included only studies on men who were biopsy naïve or who previously had a negative biopsy (or a mix of both). Studies involving MRI had to report on both MRI‐positive and MRI‐negative men. All studies had to report on the primary target condition. </p> </section> <section id="CD012663-sec-0005"> <h3 class="title" id="CD012663-sec-0005">Data collection and analysis</h3> <p>Two reviewers independently extracted data and assessed the risk of bias using the QUADAS‐2 tool. To estimate test accuracy, we calculated sensitivity and specificity using the bivariate model. To estimate agreement between the MRI pathway and systematic biopsy, we synthesised detection ratios by performing random‐effects meta‐analyses. To estimate the proportions of participants with prostate cancer detected by only one of the index tests, we used random‐effects multinomial or binary logistic regression models. For the main comparisions, we assessed the certainty of evidence using GRADE. </p> </section> <section id="CD012663-sec-0006"> <h3 class="title" id="CD012663-sec-0006">Main results</h3> <p>The test accuracy analyses included 18 studies overall.</p> <p><b>MRI compared to template‐guided biopsy:</b> Based on a pooled sensitivity of 0.91 (95% confidence interval (CI): 0.83 to 0.95; 12 studies; low certainty of evidence) and a pooled specificity of 0.37 (95% CI: 0.29 to 0.46; 12 studies; low certainty of evidence) using a baseline prevalence of 30%, MRI may result in 273 (95% CI: 249 to 285) true positives, 441 false positives (95% CI: 378 to 497), 259 true negatives (95% CI: 203 to 322) and 27 (95% CI: 15 to 51) false negatives per 1000 men. We downgraded the certainty of evidence for study limitations and inconsistency. </p> <p><b>MRI‐targeted biopsy compared to template‐guided biopsy:</b> Based on a pooled sensitivity of 0.80 (95% CI: 0.69 to 0.87; 8 studies; low certainty of evidence) and a pooled specificity of 0.94 (95% CI: 0.90 to 0.97; 8 studies; low certainty of evidence) using a baseline prevalence of 30%, MRI‐targeted biopsy may result in 240 (95% CI: 207 to 261) true positives, 42 (95% CI: 21 to 70) false positives, 658 (95% CI: 630 to 679) true negatives and 60 (95% CI: 39 to 93) false negatives per 1000 men. We downgraded the certainty of evidence for study limitations and inconsistency. </p> <p><b>The MRI pathway compared to template‐guided biopsy:</b> Based on a pooled sensitivity of 0.72 (95% CI: 0.60 to 0.82; 8 studies; low certainty of evidence) and a pooled specificity of 0.96 (95% CI: 0.94 to 0.98; 8 studies; low certainty of evidence) using a baseline prevalence of 30%, the MRI pathway may result in 216 (95% CI: 180 to 246) true positives, 28 (95% CI: 14 to 42) false positives, 672 (95% CI: 658 to 686) true negatives and 84 (95% CI: 54 to 120) false negatives per 1000 men. We downgraded the certainty of evidence for study limitations, inconsistency and imprecision. </p> <p><b>Systemic biopsy compared to template‐guided biopsy:</b> Based on a pooled sensitivity of 0.63 (95% CI: 0.19 to 0.93; 4 studies; low certainty of evidence) and a pooled specificity of 1.00 (95% CI: 0.91 to 1.00; 4 studies; low certainty of evidence) using a baseline prevalence of 30%, systematic biopsy may result in 189 (95% CI: 57 to 279) true positives, 0 (95% CI: 0 to 63) false positives, 700 (95% CI: 637 to 700) true negatives and 111 (95% CI: 21 to 243) false negatives per 1000 men. We downgraded the certainty of evidence for study limitations and inconsistency. </p> <p><b>Agreement analyses:</b> In a mixed population of both biopsy‐naïve and prior‐negative biopsy men comparing the MRI pathway to systematic biopsy, we found a pooled detection ratio of 1.12 (95% CI: 1.02 to 1.23; 25 studies). We found pooled detection ratios of 1.44 (95% CI 1.19 to 1.75; 10 studies) in prior‐negative biopsy men and 1.05 (95% CI: 0.95 to 1.16; 20 studies) in biopsy‐naïve men. </p> </section> <section id="CD012663-sec-0007"> <h3 class="title" id="CD012663-sec-0007">Authors' conclusions</h3> <p>Among the diagnostic strategies considered, the MRI pathway has the most favourable diagnostic accuracy in clinically significant prostate cancer detection. Compared to systematic biopsy, it increases the number of significant cancer detected while reducing the number of insignificant cancer diagnosed. The certainty in our findings was reduced by study limitations, specifically issues surrounding selection bias, as well as inconsistency. Based on these findings, further improvement of prostate cancer diagnostic pathways should be pursued. </p> </section> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD012663-abs-0005" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012663-abs-0005">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD012663-abs-0006">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD012663-abs-0010">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD012663-abs-0015">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD012663-abs-0008">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD012663-abs-0013">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ms#CD012663-abs-0007">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pl#CD012663-abs-0009">Polski</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD012663-abs-0012">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD012663-abs-0005" lang="en"> <h3>Is prostate MRI, with or without MRI‐targeted biopsy, better than systematic biopsy for detecting prostate cancer in men? </h3> <p><b>Background</b> </p> <p>Many prostate cancers are slow growing and may not have any harmful effects during a man's lifetime. Meanwhile, clinically significant cancers can cause problems such as blockage of the urinary tract, painful bone lesions and death. The prostate‐specific antigen (PSA) test followed by tissue samples of the prostate with ultrasound guidance is often used to detect these cancers early. More recently, magnetic resonance imaging (MRI) has also been used to help make the diagnosis. </p> <p><b>What is the aim of this review?</b> </p> <p>The aim of this review was to compare MRI alone, MRI together with a biopsy, and a pathway that uses MRI to help decide whether to do a biopsy or not (hereinafter named ‘the MRI pathway’) with the standard ultrasound guided biopsy (hereinafter called ‘systematic biopsy’) in reference to template‐guided biopsy. </p> <p><b>What are the main results?</b> </p> <p>We examined evidence up to July 2018. The review included 43 studies, mainly from Western countries, of men aged 61 to 73 years. </p> <p>In a population of 1000 men at risk for prostate cancer, where 300 men actually have clinically significant prostate cancer, MRI will correctly identify 273 men as having clinically significant prostate cancer but miss the remaining 27 men; for the 700 men that do not have clinically significant prostate cancer, MRI will correctly identify 259 as not having prostate cancer but will misclassify 441 men as having clinically significant prostate cancer. </p> <p>In the same population, MRI‐targeted biopsy will correctly identify 240 of 300 men as having clinically significant prostate cancer but miss the remaining 60 men; for the 700 men that do not have clinically significant prostate cancer, MRI will correctly identify 658 as not having prostate cancer but misclassify 42 men as having clinically significant prostate cancer. </p> <p>The MRI pathway will correctly identify 216 of 300 men as having clinically significant prostate cancer but miss the remaining 84 men; for the 700 men that do not have clinically significant prostate cancer, MRI pathway will correctly identify 672 as not having prostate cancer but will misclassify 28 men as having clinically significant prostate cancer. </p> <p>Systematic biopsies will correctly identify 189 of 300 men as having clinically significant prostate cancer but miss the remaining 111 men; for the 700 men that do not have clinically significant prostate cancer, systematic biopsies may correctly identify all 700 as not having prostate cancer and will not misclassify any men as having clinically significant prostate cancer. </p> <p>When comparing the MRI pathway to systematic biopsy in a mixed group of men who may or may not have had a prior biopsy, we found that MRI pathway is 12% more likely to make the correct diagnosis. In men without a prior biopsy, the MRI pathway is 5% more likely to make the correct diagnosis, whereas in men who have had a negative biospy, it is 44% more likely to make the correct diagnosis. </p> <p><b>How reliable is the evidence?</b> </p> <p>We rated the quality of evidence for the main findings of this review as low. Additional high‐quality research is likely to change these findings. </p> <p><b>What are the implications of this review?</b> </p> <p>The findings of this Cochrane review suggest that the MRI pathway is better than systematic biopsies in making a correct diagnosis of clinically significant prostate cancer. However, the MRI pathway still misses some men with clinically significant prostate cancer. Therefore, further research in this area is important. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD012663-sec-0125" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD012663-sec-0125"></div> <h3 class="title" id="CD012663-sec-0126">Implications for practice</h3> <section id="CD012663-sec-0126"> <section id="CD012663-sec-0127"> <h5 class="title">MRI‐directed biopsy management</h5> <p>The diagnostic workup of prostate cancer may benefit from including prostate MRI prior to biopsy. We found evidence that both the MRI pathway and systematic biopsy missed considerable proportions of grade 2 or higher prostate cancer but that the MRI pathway missed less than systematic biopsy. The difference between the detection rates of the MRI pathway and systematic biopsy was largest in men with a prior negative biopsy and insignificant in biopsy‐naïve men. Evidence further suggested that the MRI pathway beneficially missed more grade 1 prostate cancer than systematic biopsy in both population types. Therefore, the MRI pathway could potentially reduce the amount of overdiagnosis, and harms related to surveillance and overtreatment. </p> <p>The benefits of MRI—a reduction in the number of biopsy procedures performed and the frequency of overdiagnosis of grade 1 prostate cancer, combined with an improvement in the detection of grade 2 and higher prostate cancer—are greatest when MRI has a direct impact on biopsy decision management and shared decision making. In other words, the MRI before any biopsy and the MRI pathway as the replacement for systematic biopsy, thus omitting systematic biopsy in specified circumstances, might provide the most favourable diagnostic strategy. </p> <section id="CD012663-sec-0128"> <h6 class="title">MRI‐negative men and systematic biopsy</h6> <p>This meta‐analysis showed that approximately one‐third of all men had a negative MRI. The added value of performing systematic biopsy in MRI‐negative men for the detection of grade 2 or higher prostate cancer could be considered as limited with regard to total detection and additional harms. As a prostate biopsy is associated with patient burden, overdiagnosis and related overtreatment, infection and morbidity, it should be avoided when possible (<a href="./references#CD012663-bbs2-0074" title="BorghesiM , AhmedH , NamR , SchaefferE , SchiavinaR , TanejaE , et al. Complications after systematic, random, and image‐guided prostate biopsy. European Urology2017;71(3):353–65. ">Borghesi 2017</a>; <a href="./references#CD012663-bbs2-0116" title="LoebS , VellekoopA , AhmedHU , CattoJ , EmbertonM , NamR , et al. Systematic review of complications of prostate biopsy. European Urology2013;64(6):876‐92. ">Loeb 2013</a>). Omitting systematic biopsy in men with a negative MRI might be considered acceptable in some clinical situations. However, benefits and harms are difficult to balance on an individual basis. Therefore, men with a negative MRI could be counselled to pursue clinical and biochemical monitoring as a reasonable alternative for systematic biopsy, as also argued by <a href="./references#CD012663-bbs2-0119" title="MoldovanPC , Van denBroeckT , SylvesterR , MarconiL , BellmuntJ , Van denBerghRC , et al. What is the negative predictive value of multiparametric magnetic resonance imaging in excluding prostate cancer at biopsy? A systematic review and meta‐analysis from the European Association of Urology Prostate Cancer Guidelines Panel. European Urology2017;72(2):250‐66. ">Moldovan 2017</a>, <a href="./references#CD012663-bbs2-0125" title="PadhaniAR , WeinrebJ , RosenkrantzAB , VilleirsG , TurkbeyB , BarentszJ . Prostate Imaging‐Reporting and Data System Steering Committee: PI‐RADS v2 status update and future directions. European Urology2019;75(3):358‐96. ">Padhani 2019</a> and <a href="./references#CD012663-bbs2-0127" title="PanebiancoV , BarchettiG , SimoneG , DelMonteM , CiardiA , GromponeMD , et al. Negative multiparametric magnetic resonance imaging for prostate cancer: what's next?. European Urology2018;74(1):48‐54. ">Panebianco 2018</a>. </p> </section> <section id="CD012663-sec-0129"> <h6 class="title">MRI‐positive men and systematic biopsy</h6> <p>Men with a positive MRI have a clear indication for MRI‐targeted biopsy and can opt for additional systematic biopsy. The added value of performing systematic biopsy in MRI‐positive men for the detection of grade 2 or higher prostate cancer, however, could be considered as limited with regard to total detection and additional harms. The conditions under which systematic biopsy could be safely avoided in men with a positive MRI remain to be defined (<a href="./references#CD012663-bbs2-0131" title="RichenbergJ , LogagerV , PanebiancoV , RouviereO , VilleirsG , SchootsIG . The primacy of multiparametric MRI in men with suspected prostate cancer. European Radiology2019 (in press). ">Richenberg 2019</a>; <a href="./references#CD012663-bbs2-0125" title="PadhaniAR , WeinrebJ , RosenkrantzAB , VilleirsG , TurkbeyB , BarentszJ . Prostate Imaging‐Reporting and Data System Steering Committee: PI‐RADS v2 status update and future directions. European Urology2019;75(3):358‐96. ">Padhani 2019</a>; <a href="./references#CD012663-bbs2-0135" title="RouvièreO , SouchonR , MelodelimaC . Pitfalls in interpreting positive and negative predictive values: application to prostate multiparametric magnetic resonance imaging. Diagnostic and Interventional Imaging2018;99(9):515‐8. ">Rouvière 2018</a>). When in this risk population the MRI pathway fails to detect significant prostate cancer, a monitoring approach based on clinical, biochemical and imaging parameters could be introduced in the place of of systematic biopsy and would result in a ‘safety net’ that could be easily adopted in the shared decision‐making of the current diagnostic workup—as already recommended in international guidelines (<a href="./references#CD012663-bbs2-0068" title="CarterHB , AlbertsenPC , BarryMJ , EtzioniR , FreedlandSJ , GreeneKL , et al. American Urological Associations Guideline Panel. Early detection of prostate cancer: AUA guideline. www.auanet.org/guidelines/prostate‐cancer‐early‐detection‐(2013‐reviewed‐for‐currency‐2018)#x2637 2018 (accessed on 15‐01‐2019). ">AUA Guideline 2018</a>; <a href="./references#CD012663-bbs2-0091" title="MottetN , Van denBerghRCN , BriersE , BourkeL , CornfordP , DeSantisM , et al. European Association of Urology: guideline on prostate cancer. uroweb.org/guideline/prostate‐cancer/ 2018 (accessed on 15‐01‐2019). ">EAU Guideline 2018</a>; <a href="./references#CD012663-bbs2-0124" title="National Complrehensive Cancer Network (NCCN) Guidelines on Prostate Cancer: 2018 update. www.nccn.org/professionals/physician_gls/default.aspx 2018 (accessed on 15‐01‐2019). ">NCCN Guideline 2018</a>). </p> </section> <section id="CD012663-sec-0130"> <h6 class="title">MRI‐positivity threshold</h6> <p>Data suggest that the use of an MRI‐positivity threshold of MRI suspicion score 3 out of 5 would be most beneficial in the detection of grade 2 or higher prostate cancer. Any higher threshold would result in unacceptably missing a substantial proportion of men with grade 2 or higher and grade 3 or higher prostate cancer. Therefore, the threshold should only be increased in the context of shared decision‐making with the patient after a thorough discussion of the potential risks. Further research is warranted to decrease the grade 2 or higher prostate cancer detection in these ‘equivocal’ or ‘indeterminate’ MRI lesions assessed as score 3 (<a href="./references#CD012663-bbs2-0138" title="SchootsIG . MRI in early prostate cancer detection: how to manage indeterminate or equivocal PI‐RADS 3 lesions?. Translational Andrology and Urology2018;7(1):70‐82. ">Schoots 2018</a>). </p> </section> </section> <section id="CD012663-sec-0131"> <h5 class="title">Costs and availability</h5> <p>The potential benefit of MRI within the diagnostic workup will have implications on economic metrics. Although cost‐effectiveness was not part of our analyses, this review may contribute to assumptions made in such analyses (<a href="./references#CD012663-bbs2-0070" title="BarnettCL , DavenportMS , MontgomeryJS , WeiJT , MontieJE , DentonBT . Cost‐effectiveness of magnetic resonance imaging and targeted fusion biopsy for early detection of prostate cancer. BJU International2018;122(1):50‐8. ">Barnett 2018</a>; <a href="./references#CD012663-bbs2-0087" title="DeRooijM , CrienenS , WitjesJA , BarentszJO , RoversMM , GruttersJP . Cost‐effectiveness of magnetic resonance (MR) imaging and MR‐guided targeted biopsy versus systematic transrectal ultrasound‐guided biopsy in diagnosing prostate cancer: a modelling study from a health care perspective. European Urology2014;66(3):430‐6. ">De Rooij 2014b</a>; <a href="./references#CD012663-bbs2-0097" title="FariaR , SoaresMO , SpackmanE , AhmedHU , BrownLC , KaplanR , et al. Optimising the diagnosis of prostate cancer in the era of multiparametric magnetic resonance imaging: a cost‐effectiveness analysis based on the Prostate MR Imaging Study (PROMIS). European Urology2018;73(1):23‐30. ">Faria 2018</a>; <a href="./references#CD012663-bbs2-0126" title="PahwaS , SchiltzNK , PonskyLE , LuZ , GriswoldMA , GulaniV . Cost‐effectiveness of MR imaging‐guided strategies for detection of prostate cancer in biopsy‐naïve men. Radiology2017;285(1):157‐66. ">Pahwa 2017</a>; <a href="./references#CD012663-bbs2-0149" title="VenderinkW , GoversTM , DeRooijM , FüttererJJ , SedelaarJP . Cost‐effectiveness comparison of imaging‐guided prostate biopsy techniques: systematic transrectal ultrasound, direct in‐bore MRI, and image fusion. American Journal of Roentgenology2017;208(5):1058‐63. ">Venderink 2017</a>). A recent cost‐effectiveness study was performed by <a href="./references#CD012663-bbs2-0077" title="BrownLC , AhmedHU , FariaR , El‐Shater BosailyA , GabeR , KaplanRS , et al. Multiparametric MRI to improve detection of prostate cancer compared with transrectal ultrasound‐guided prostate biopsy alone: the PROMIS study. Health Technology Assessment2018;22(39):1‐176. ">Brown 2018</a> based on a study included in our review (the PROMIS study (<a href="./references#CD012663-bbs2-0002" title="AhmedHU , El‐Shater BosailyA , BrownLC , GabeR , KaplanR , ParmarMK , et al. Diagnostic accuracy of multi‐parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. Lancet2017;389(10071):815‐22. ">Ahmed 2017</a>)). They found that the most cost‐effective strategy involved testing all men with prostate MRI, followed by an MRI‐directed biopsy in those men with suspected clinically significant prostate cancer (the MRI pathway), followed by rebiopsy if clinically significant prostate cancer was not detected. This strategy was cost‐effective and detected 95% (95% CI 92% to 98%) of clinically significant prostate cancer. However, in the study on which these findings were based, the diagnostic workup did not take any MRI‐targeted biopsies of MRI suspicious lesions. The investigators made the assumption that MRI‐targeted biopsy was as accurate as MRI. As shown by the results of our meta‐analysis, this assumption may be incorrect. The sensitivity for grade 2 or higher prostate cancer decreased substantially when comparing MRI with MRI‐targeted biopsy and MRI pathway. Hence, as cost‐effectiveness analyses heavily rely on assumed input parameters and, in addition, depend on regional differences in the healthcare system, readers should interpret these cost‐effectiveness results carefully. </p> </section> <section id="CD012663-sec-0132"> <h5 class="title">Final considerations</h5> <p>Balancing the potential disadvantages (missing some grade 2 or higher prostate cancer) against the potential benefits (reduction of biopsies and a decrease of grade 1 prostate cancer overdiagnosis) and without taking into accounteconomic metrics (availability and costs), we conclude that the results show that MRI pathway may represent a more favourable diagnostic test than systematic biopsy. Our certainty in our findings was reduced by study limitations, specifically issues surrounding the selection bias, as well as inconsistency. Furthermore, the MRI pathway relies on experience and skills in reading MRI and targeting biopsy and on the use of high‐end MRI equipment and biopsy hardware and software—elements that are not yet widely available. This diagnostic chain is only as strong as its weakest link (<a href="./references#CD012663-bbs2-0136" title="RouvièreO , SchootsIG , MottetN , EAU‐EANM‐ESTRO‐ESUR‐SIOG Prostate Cancer Guidelines Panel. Multiparametric magnetic resonance imaging before prostate biopsy: a chain is only as strong as its weakest link. European Urology2019 (Epub ahead of print). [DOI: 10.1016/j.eururo.2019.03.023] ">Rouvière 2019b</a>). Based on these considerations, further improvement of the prostate cancer diagnostic pathways should be pursued. </p> </section> </section> <h3 class="title" id="CD012663-sec-0133">Implications for research</h3> <section id="CD012663-sec-0133"> <p>This systematic review provides diagnostic accuracy evidence of MRI, MRI‐targeted biopsy, the MRI pathway and systematic biopsy, with additional evidence by agreement analyses. To improve the clinical utility of MRI‐driven tests, several factors should be further investigated. </p> <p>The number of well‐performed studies investigating the index tests verified by template‐guided biopsy, as in our test accuracy analyses, should be increased where the burden of testing allows. Studies should be performed according to the START (<a href="./references#CD012663-bbs2-0120" title="MooreCM , KasivisvanathanV , EggenerS , EmbertonM , FuttererJJ , GillIS , et al. Standards of reporting for MRI‐targeted biopsy studies (START) of the prostate: recommendations from an International Working Group. European Urology2013;64(4):544‐52. ">Moore 2013a</a>) and STARD (<a href="./references#CD012663-bbs2-0083" title="CohenJF , KorevaarDA , AltmanDG , BrunsDE , GatsonisCA , HooftL , et al. STARD 2015 guidelines for reporting diagnostic accuracy studies: explanation and elaboration. BMJ Open2016;6(11):e012799. ">Cohen 2016</a>) criteria to ensure clear and complete description of interchangeable methods that increase comparability between study results. Special effort should be taken to differentiate possible subgroups, methodology and definitions of target conditions. The quality and applicability of evidence greatly depend on the criteria described in our QUADAS‐2 tool (<a href="#CD012663-tbl-0007">Table 1</a>). This also applies to studies that investigate the agreement between the MRI pathway and systematic biopsy. With an increased number of well‐performed and well‐presented studies, subgroup analyses will be more reliable and more details can be elucidated. </p> <p>The considerable reduction in grade 2 or higher prostate cancer detection between MRI and the MRI pathway should be assessed with per‐lesion–based data to overcome the lack of spatial concordance between MRI findings and biopsy findings, thereby investigating what factors influence the underlying MRI reading problems and inaccurate MRI‐targeted biopsy. Furthermore, quality control in the MRI pathway should be employed to improve MRI reading and MRI‐targeted biopsy methods. Education, training, procedural standardisation and better imaging and biopsy equipment require a multidisciplinary approach in the management of men with suspected prostate cancer (<a href="./references#CD012663-bbs2-0121" title="MooreCM , RobertsonNL , ArsaniousN , MiddletonT , VillersA , KlotzL , et al. Image‐guided prostate biopsy using magnetic resonance imaging‐derived targets: a systematic review. European Urology2013;63(1):125‐40. ">Moore 2013b</a>; <a href="./references#CD012663-bbs2-0122" title="MooreCM , GigantiF , AlbertsenP , AllenC , BangmaC , BrigantiA , et al. Reporting magnetic resonance imaging in men on active surveillance for prostate cancer: the precise recommendations‐a report of a European School of Oncology task force. European Urology2017;71(4):648‐55. ">Moore 2017</a>; <a href="./references#CD012663-bbs2-0129" title="PuechP , RandazzoM , OuzzaneA , GaillardV , RastinehadA , LemaitreL , et al. How are we going to train a generation of radiologists (and urologists) to read prostate MRI?. Current Opinion in Urology2015;25(6):522‐35. ">Puech 2015</a>; <a href="./references#CD012663-bbs2-0151" title="WeinrebJC , BarentszJO , ChoykePL , CornudF , HaiderMA , MacuraKJ , et al. PI‐RADS prostate imaging ‐ reporting and data system: 2015, version 2. European Urology2016;69(1):16‐40. ">Weinreb 2016</a>). The urologist, radiologist and pathologist must collaborate from the moment of clinical suspicion through the process of prostate biopsy and afterwards to accurately make a diagnosis. </p> <p>Future studies may consider assessing different MRI‐positivity thresholds for MRI‐targeted biopsy, as men with MRI suspicion scores 2, 4 or 5 might have a different pretest risk profile than men with MRI suspicion score 3 (<a href="./references#CD012663-bbs2-0138" title="SchootsIG . MRI in early prostate cancer detection: how to manage indeterminate or equivocal PI‐RADS 3 lesions?. Translational Andrology and Urology2018;7(1):70‐82. ">Schoots 2018</a>). In addition, improved MRI interpretation with the reduced number of equivocal or indeterminate lesions (PI‐RADS assessment score 3) may decrease overdiagnosis as demonstrated by <a href="./references#CD012663-bbs2-0043" title="Van derLeestMM , CornelEB , IsraëlB , HendriksRJ , PadhaniAR , HoogenboomM , et al. Head‐to‐head comparison of transrectal ultrasound‐guided prostate biopsy versus multiparametric prostate resonance imaging with subsequent magnetic resonance‐guided biopsy in biopsy‐naïve men with elevated prostate‐specific antigen: a large prospective multicenter clinical study. European Urology 23 November 2018 [Epub ahead of print];S0302‐2838(18):30880‐7. [DOI: 10.1016/j.eururo.2018.11.023] ">Van der Leest 2018</a>. </p> <p>Whether the number of MRI‐targeted biopsy cores influence athe outcome of the MRI pathway should be investigated, because its diagnostic accuracy could depend on the relation between tumour heterogeneity and the intensity and trajectories of cores taken (<a href="./references#CD012663-bbs2-0109" title="HuoAS , HossackT , SymonsJL , PeBenitoR , DelpradoWJ , BrennerP , et al. Accuracy of primary systematic template guided transperineal biopsy of the prostate for locating prostate cancer: a comparison with radical prostatectomy specimens. Journal of Urology2012;187(6):2044‐9. ">Huo 2012</a>; <a href="./references#CD012663-bbs2-0128" title="PhamKN , PorterCR , Odem‐DavisK , WolffEM , JeldresC , WeiJT , et al. Transperineal template guided prostate biopsy selects candidates for active surveillance‐‐how many cores are enough?. Journal of Urology2015;194(3):674‐9. ">Pham 2015</a>; <a href="./references#CD012663-bbs2-0147" title="ValerioM , DonaldsonI , EmbertonM , EhdaieB , HadaschikBA , MarksLS , et al. Detection of clinically significant prostate cancer using magnetic resonance imaging‐ultrasound fusion targeted biopsy: a systematic review. European Urology2015;68(1):8‐19. ">Valerio 2015</a>). The fact that a high number of MRI‐targeted biopsy cores per suspicious lesion may benefit diagnostic yield may be an argument for focal saturation biopsy (<a href="./references#CD012663-bbs2-0078" title="BrykDJ , LlukaniE , TanejaSS , RosenkrantzAB , HuangWC , LeporH . The role of ipsilateral and contralateral transrectal ultrasound‐guided systematic prostate biopsy in men with unilateral magnetic resonance imaging lesion undergoing magnetic resonance imaging‐ultrasound fusion‐targeted prostate biopsy. Journal of Urology2017;102:178‐82. ">Bryk 2017</a>; <a href="./references#CD012663-bbs2-0125" title="PadhaniAR , WeinrebJ , RosenkrantzAB , VilleirsG , TurkbeyB , BarentszJ . Prostate Imaging‐Reporting and Data System Steering Committee: PI‐RADS v2 status update and future directions. European Urology2019;75(3):358‐96. ">Padhani 2019</a>; <a href="./references#CD012663-bbs2-0038" title="RouvièreO , PuechP , Renard‐PennaR , ClaudonM , RoyC , Mège‐LechavallierF , et al. MRI‐FIRST Investigators. Use of prostate systematic and targeted biopsy on the basis of multiparametric MRI in biopsy‐naïve patients (MRI‐FIRST): a prospective, multicentre, paired diagnostic study. Lancet Oncology2019;20(1):100‐9. ">Rouvière 2019a</a>; <a href="./references#CD012663-bbs2-0043" title="Van derLeestMM , CornelEB , IsraëlB , HendriksRJ , PadhaniAR , HoogenboomM , et al. Head‐to‐head comparison of transrectal ultrasound‐guided prostate biopsy versus multiparametric prostate resonance imaging with subsequent magnetic resonance‐guided biopsy in biopsy‐naïve men with elevated prostate‐specific antigen: a large prospective multicenter clinical study. European Urology 23 November 2018 [Epub ahead of print];S0302‐2838(18):30880‐7. [DOI: 10.1016/j.eururo.2018.11.023] ">Van der Leest 2018</a>), although none of the studies included in this review described or investigated such a strategy. </p> <p>Most risk classification criteria are still based on systematic biopsy sampling. The potential of risk migration towards higher‐risk categories by an MRI‐directed biopsy management could lead to overtreatment. MRI‐targeted biopsy of suspected lesions on MRI might find higher‐rated risk features than when the prostate is sampled by systematic biopsy. Moreover, traditional risk criteria, including tumour volume measures, cannot be applied to MRI‐targeted biopsy findings. This could result in so‐called ‘risk inflation’, and patients and physicians may be erroneously encouraged to pursue more active treatment because of an apparent increase in risk (reclassification) rather than a true change in their cancer (<a href="./references#CD012663-bbs2-0132" title="RobertsonNL , HuY , AhmedHU , FreemanA , BarrattD , EmbertonM . Prostate cancer risk inflation as a consequence of image‐targeted biopsy of the prostate: a computer simulation study. European Urology2014;65:628‐34. ">Robertson 2014</a>). Appropriate risk classification is not yet fully understood when MRI‐targeted biopsy is used. Therefore, the results of MRI‐targeted biopsy must be regarded with caution and future research on risk migration needs to be encouraged. </p> <p>Risk calculators may aid in balancing harms and benefits by further refining the selection of those men that are at risk of potentially life‐threatening disease. Research should be initiated with recently introduced multivariable risk prediction models, including the MRI suspicion score as an extra input variable, to better identify who would benefit from MRI and subsequent MRI‐targeted biopsy or additional systematic biopsy or both (<a href="./references#CD012663-bbs2-0066" title="AlbertsAR , RoobolMJ , VerbeekJF , SchootsIG , ChiuPK , OssesDF , et al. Prediction of high‐grade prostate cancer following multiparametric magnetic resonance imaging: improving the Rotterdam European Randomized Study of Screening for Prostate Cancer risk calculators. European Urology2019;75(2):310‐8. ">Alberts 2019</a>; <a href="./references#CD012663-bbs2-0067" title="AnkerstDP , StraubingerJ , SeligK , GuerriosL , DeHoedtA , HernandezJ , et al. A contemporary prostate biopsy risk calculator based on multiple heterogeneous cohorts. European Urology2018;74(2):197‐203. ">Ankerst 2018</a>; <a href="./references#CD012663-bbs2-0100" title="FoleyRW , MaweniRM , GormanL , MurphyK , LundonDJ , DurkanG , et al. European Randomised Study of Screening for Prostate Cancer (ERSPC) risk calculators significantly outperform the Prostate Cancer Prevention Trial (PCPT) 2.0 in the prediction of prostate cancer: a multi‐institutional study. BJU International2016;118(5):706‐13. ">Foley 2016</a>; <a href="./references#CD012663-bbs2-0118" title="MehralivandS , ShihJH , Rais‐BahramiS , OtoA , BednarovaS , NixJW , et al. A magnetic resonance imaging‐based prediction model for prostate biopsy risk stratification. JAMA Oncology2018;4(5):678‐85. ">Mehralivand 2018</a>; <a href="./references#CD012663-bbs2-0130" title="RadtkeJP , WiesenfarthM , KeschC , FreitagMT , AltCD , CelikK , et al. Combined clinical parameters and multiparametric magnetic resonance imaging for advanced risk modeling of prostate cancer‐patient‐tailored risk stratification can reduce unnecessary biopsies. European Urology2017;72(6):888‐96. ">Radtke 2017</a>). We have not included risk calculators in this review, however, and their impact cannot be assessed through meta‐analyses of literature because individual participant data would be needed. Similarly, whether clinical parameters and biomarkers can predict which patients may benefit from the MRI pathway (or systematic biopsy) remains outside the scope of this review and should be a subject of future research. Decision‐curve analyses, cost‐effectiveness and the feasibility of obtaining prebiopsy MRI in all patients referred for biopsy were also beyond the scope of this review and should be a subject of future research. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD012663-sec-0036" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD012663-sec-0036"></div> <div class="table" id="CD012663-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Detecting ISUP grade 2 or higher prostate cancer by MRI, MRI‐targeted biopsy, MRI‐pathway and systematic biopsy</span></div> <tbody> <tr class="table-header separated"> <td align="left" class="table-header" colspan="11" rowspan="1" valign="top"> <p><b>Detecting ISUP grade 2 or higher prostate cancer by MRI, MRI‐targeted biopsy, MRI pathway and systematic biopsy</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="10" rowspan="1" valign="top"> <p>13,770 men with a suspicion of prostate cancer (PSA‐ or DRE‐based) undergoing their first biopsy (biopsy‐naïve men) or a repeat biopsy (prior‐negative biopsy men) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Setting</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="10" rowspan="1" valign="top"> <p>University hospitals and specialized care centers</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Index tests</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="10" rowspan="1" valign="top"> <p>MRI; MRI‐targeted biopsy (MRI‐TBx) in men with a positive MRI; the MRI pathway (MRI with or without MRI‐TBx); and systematic biopsy (SBx) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reference standard</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="10" rowspan="1" valign="top"> <p>Template‐guided biopsy, which comprehensively samples all zones of the prostate</p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Tests</b> </p> </td> <td align="center" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Population type (biopsy‐naïve, prior‐negative biopsy, or mixed)</b> </p> </td> <td align="center" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Summary<br/> sensitivity<br/> (95% CI)</b> </p> </td> <td align="center" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Summary<br/> specificity<br/> (95% CI)</b> </p> </td> <td align="center" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Detection<br/> ratio<br/> (95% CI)</b> </p> </td> <td align="center" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Missed grade 2 or higher prostate cancer per 1000 men (95% CI)<sup>a</sup> </b> </p> </td> <td align="center" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Number of<br/> participants<br/> (studies)</b> </p> </td> <td align="center" class="table-header" colspan="4" rowspan="1" valign="top"> <p><b>Number of studies with a<br/> high or unclear risk of bias</b> </p> </td> </tr> <tr class="table-header separated"> <td align="center" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Participant<br/> selection</b> </p> </td> <td align="center" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Index<br/> test(s)</b> </p> </td> <td align="center" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Reference<br/> standard</b> </p> </td> <td align="center" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Flow and timing</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MRI</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mixed</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0.91</b><br/> (0.83 to 0.95) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0.37</b><br/> (0.29 to 0.46) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>27</b><br/> (15 to 51) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3091 (12)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MRI‐TBx</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mixed</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0.80</b><br/> (0.69 to 0.87) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0.94</b><br/> (0.90 to 0.97) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>60</b><br/> (39 to 93) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1553 (8)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MRI pathway</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mixed</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0.72</b><br/> (0.60 to 0.82) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0.96</b><br/> (0.94 to 0.98) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>84</b><br/> (54 to 120) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2257 (8)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>SBx</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mixed</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0.63</b><br/> (0.19 to 0.93) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1.00</b><br/> (0.91 to 1.00) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>111</b><br/> (21 to 243) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3421 (4)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>MRI pathway<b>vs SBx</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mixed</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.12</b><br/> (1.02 to 1.23) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MRI pathway <b>missed 12% (2 to 23) less</b> than SBx </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6944 (25)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> </tr> <tr class="separated"> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Biopsy‐naïve</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1.05</b><br/> (0.95 to 1.16) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MRI pathway <b>missed 5% (−5 to 16) less</b> than SBx </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5219 (20)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> </tr> <tr class="separated"> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prior‐negative biopsy</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1.44</b><br/> (1.19 to 1.75) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MRI pathway <b>missed 44% (19 to 75) less</b> than SBx </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1564 (10)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="11" rowspan="1" valign=""> <p><b>DRE:</b> digital rectal exam; <b>ISUP:</b> International Society of Urological Pathology; <b>MRI:</b> magnetic resonance imaging; <b>MRI‐TBx:</b> MRI‐targeted biopsy; MRI pathway<b>:</b> magnetic resonance imaging with or without magnetic resonance imaging‐targeted biopsy; <b>N:</b> number; <b>NA:</b> not applicable; <b>PSA:</b> prostate‐specific antigen; <b>SBx:</b> systematic biopsy.<br/> <sup>a</sup>At the representative pre‐test probability of 30% of having grade 2 or higher prostate cancer, based on prevalence findings in the test accuracy analysis (proportion missed = [prevalence*1000]*[1‐sensitivity]). </p> </td> </tr> </tbody> </table> </div> <div class="table" id="CD012663-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Detecting ISUP grade 1 prostate cancer by MRI, MRI‐targeted biopsy, MRI‐pathway and systematic biopsy</span></div> <tbody> <tr class="table-header separated"> <td align="left" class="table-header" colspan="11" rowspan="1" valign="top"> <p><b>Detecting ISUP grade 1 prostate cancer by MRI, MRI‐targeted biopsy, MRI pathway and systematic biopsy</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="10" rowspan="1" valign="top"> <p>10,051 men with a suspicion of prostate cancer (PSA‐ or DRE‐based) undergoing their first biopsy (biopsy‐naïve men) or a repeat biopsy (prior‐negative biopsy men) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Setting</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="10" rowspan="1" valign="top"> <p>University hospitals and specialized care centers</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Index tests</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="10" rowspan="1" valign="top"> <p>MRI; MRI‐targeted biopsy (MRI‐TBx) in men with a positive MRI; the MRI pathway (MRI with or without MRI‐TBx); and systematic biopsy (SBx) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reference standard</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="10" rowspan="1" valign="top"> <p>Template‐guided biopsy, which comprehensively samples all zones of the prostate</p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Tests</b> </p> </td> <td align="center" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Population type (biopsy‐naïve, prior‐negative biopsy, or mixed)</b> </p> </td> <td align="center" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Summary<br/> sensitivity<br/> (95% CI)</b> </p> </td> <td align="center" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Summary<br/> specificity<br/> (95% CI)</b> </p> </td> <td align="center" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Detection<br/> ratio<br/> (95% CI)</b> </p> </td> <td align="center" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Avoided<br/> overdiagnosis<br/> per 1000<br/> men (95% CI)<sup>a</sup> </b> </p> </td> <td align="center" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Number of<br/> participants<br/> (studies)</b> </p> </td> <td align="center" class="table-header" colspan="4" rowspan="1" valign="top"> <p><b>Number of studies with a<br/> high or unclear risk of bias</b> </p> </td> </tr> <tr class="table-header separated"> <td align="center" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Participant<br/> selection</b> </p> </td> <td align="center" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Index<br/> test(s)</b> </p> </td> <td align="center" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Reference<br/> standard</b> </p> </td> <td align="center" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Flow and timing</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MRI</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mixed</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0.70</b><br/> (0.59‐0.80) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0.27</b><br/> (0.19‐0.37) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>63</b><br/> (42‐86) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1764 (10)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MRI‐TBx</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mixed</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0.51</b><br/> (0.21‐0.81) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1.00</b><br/> (0.77‐1.00) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>103</b><br/> (40‐166) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>497 (5)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MRI pathway</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mixed</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0.34</b><br/> (0.19‐0.53) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1.00</b><br/> (0.90‐1.00) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>139</b><br/> (99‐170) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>681 (5)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>SBx</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mixed</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0.55</b><br/> (0.25‐0.83) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0.99</b><br/> (0.81‐1.00) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>95</b><br/> (36‐158) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3421 (4)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>MRI pathway<b>vs SBx</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mixed</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.61</b><br/> (0.52‐0.71) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>MRI pathway<br/> <b>avoided more</b><br/> overdiagnosis<br/> (and biopsy<br/> procedures<sup>b</sup>)<br/> than SBx </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5442 (21)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> </tr> <tr class="separated"> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Biopsy‐naïve</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0.63</b><br/> (0.54‐0.74) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4079 (17)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> </tr> <tr class="separated"> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prior‐negative biopsy</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0.62</b><br/> (0.44‐0.88) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1202 (8)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="11" rowspan="1" valign=""> <p><b>DRE:</b> digital rectal exam; ISUP<b>:</b> International Society of Urological Pathology; <b>MRI:</b> magnetic resonance imaging; <b>MRI‐TBx:</b> MRI‐targeted biopsy; MRI pathway<b>:</b> magnetic resonance imaging with or without magnetic resonance imaging‐targeted biopsy; <b>N:</b> number; <b>NA:</b> not applicable; <b>PSA:</b> prostate‐specific antigen; <b>SBx:</b> systematic biopsy. </p> <p><sup>a</sup>At the representative pre‐test probability of 21% of having grade 1 prostate cancer, based on prevalence findings in the test accuracy analysis (proportion avoided = [prevalence*1000]*[1‐sensitivity]).<br/> <sup>b</sup>MRI‐TBx is not performed in 29% (24‐35) of men with a negative MRI, whereas SBx is performed in 100% of men. </p> </td> </tr> </tbody> </table> </div> <div class="table" id="CD012663-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Should MRI be used to diagnose ISUP grade ≥ 2 prostate cancer in men suspected of having clinically significant prostate cancer?</span></div> <tbody> <tr class="table-header separated"> <td align="" class="table-header" colspan="6" rowspan="1" valign=""> <p><b>Question: Should MRI be used to diagnose ISUP grade 2 or higher prostate cancer in men suspected of having clinically significant prostate cancer?</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Population:</b> men suspected of having clinically significant prostate cancer undergoing their first biopsy (biopsy‐naïve men) or a repeat biopsy (prior‐negative biopsy men) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Setting:</b> university hospitals and specialized care centers </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>New test:</b> MRI only | <b>Cut‐off value:</b> MRI score ≥ 3 out of 5 </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Reference test:</b> template‐guided biopsy, which comprehensively samples all zones of the prostate | <b>Threshold:</b> ISUP grade 2 or higher prostate cancer </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Pooled sensitivity:</b> 0.91 (95% CI: 0.83 to 0.95) | <b>Pooled specificity:</b> 0.37 (95% CI: 0.29 to 0.46) </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="2" valign=""> <p><b>Test result</b> </p> </td> <td align="center" class="table-header" colspan="3" rowspan="1" valign="top"> <p><b>Number of results per 1,000 men tested (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="2" valign=""> <p><b>Number of participants (studies)</b> </p> </td> <td align="center" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence (GRADE)</b> </p> </td> </tr> <tr class="separated"> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Prevalence 10%</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Prevalence 30%</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Prevalence 40%</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="1" valign=""> <p><b>True positives</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9 (83 to 95)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>273 (249 to 285)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>364 (332 to 380)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>3091 (12)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕○○ LOW<sup>a, b</sup> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="1" valign=""> <p><b>False negatives</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9 (5 to 17)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27 (15 to 51)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36 (20 to 68)</p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="1" valign=""> <p><b>True negatives</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>333 (261 to 414)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>259 (203 to 322)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>222 (174 to 276)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>3091 (12)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕○○ LOW<sup>a, b</sup> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="1" valign=""> <p><b>False positives</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>567 (486 to 639)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>441 (378 to 497)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>378 (324 to 426)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>MRI:</b> magnetic resonance imaging; <b>ISUP:</b> International Society of Urological Pathology; <b>CI:</b> confidence interval </p> <p><sup>a</sup>A considerable number of studies had a high or unclear risk of bias, mainly in the participant selection and reference standard domains.<br/> <sup>b</sup>A considerable, clinically relevant heterogeneity was observed across pooled study results. </p> </td> </tr> </tbody> </table> </div> <div class="table" id="CD012663-tbl-0004"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Should MRI‐targeted biopsy be used to diagnose ISUP grade ≥ 2 prostate cancer in men suspected of having clinically significant prostate cancer?</span></div> <tbody> <tr class="table-header separated"> <td align="" class="table-header" colspan="6" rowspan="1" valign=""> <p><b>Question: Should MRI‐targeted biopsy be used to diagnose ISUP grade 2 or higher prostate cancer in men suspected of having clinically significant prostate cancer?</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Population:</b> men with a positive MRI suspected of having clinically significant prostate cancer undergoing their first biopsy (biopsy‐naïve men) or a repeat biopsy (prior‐negative biopsy men) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Setting:</b> university hospitals and specialized care centers </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>New test:</b> MRI‐targeted biopsy | <b>Threshold:</b> ISUP grade 2 or higher prostate cancer </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Reference test:</b> template‐guided biopsy, which comprehensively samples all zones of the prostate | <b>Threshold:</b> ISUP grade 2 or higher prostate cancer </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Pooled sensitivity:</b> 0.80 (95% CI: 0.69 to 0.87) | <b>Pooled specificity:</b> 0.94 (95% CI: 0.90 to 0.97) </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="2" valign=""> <p><b>Test result</b> </p> </td> <td align="center" class="table-header" colspan="3" rowspan="1" valign="top"> <p><b>Number of results per 1,000 men tested (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="2" valign=""> <p><b>Number of participants (studies)</b> </p> </td> <td align="center" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence (GRADE)</b> </p> </td> </tr> <tr class="separated"> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Prevalence 10%</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Prevalence 30%</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Prevalence 40%</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="1" valign=""> <p><b>True positives</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80 (69 to 87)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>240 (207 to 261)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>320 (276 to 348)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>1553 (8)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕○○ LOW<sup>a, b</sup> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="1" valign=""> <p><b>False negatives</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20 (13 to 31)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60 (39 to 93)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80 (52 to 124)</p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="1" valign=""> <p><b>True negatives</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>846 (810 to 873)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>658 (630 to 679)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>564 (540 to 582)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>1553 (8)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕○○ LOW<sup>a, b</sup> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="1" valign=""> <p><b>False positives</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54 (27 to 90)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42 (21 to 70)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36 (18 to 60)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>MRI:</b> magnetic resonance imaging; <b>ISUP:</b> International Society of Urological Pathology; <b>CI:</b> confidence interval </p> <p><sup>a</sup>A considerable number of studies had a high or unclear risk of bias, mainly in the participant selection and reference standard domains.<br/> <sup>b</sup>A considerable, clinically relevant heterogeneity was observed across pooled study results. </p> </td> </tr> </tbody> </table> </div> <div class="table" id="CD012663-tbl-0005"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Should an MRI‐pathway be used to diagnose ISUP grade ≥ 2 prostate cancer in men suspected of having clinically significant prostate cancer?</span></div> <tbody> <tr class="table-header separated"> <td align="" class="table-header" colspan="6" rowspan="1" valign=""> <p><b>Question: Should an MRI pathway be used to diagnose ISUP grade 2 or higher prostate cancer in men suspected of having clinically significant prostate cancer?</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Population:</b> men suspected of having clinically significant prostate cancer undergoing their first biopsy (biopsy‐naïve men) or a repeat biopsy (prior‐negative biopsy men) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Setting:</b> university hospitals and specialized care centers </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>New test:</b> MRI pathway | <b>Threshold:</b> ISUP grade 2 or higher prostate cancer </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Reference test:</b> template‐guided biopsy, which comprehensively samples all zones of the prostate | <b>Threshold:</b> ISUP grade 2 or higher prostate cancer </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Pooled sensitivity:</b> 0.72 (95% CI: 0.60 to 0.82) | <b>Pooled specificity:</b> 0.96 (95% CI: 0.94 to 0.98) </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="2" valign=""> <p><b>Test result</b> </p> </td> <td align="center" class="table-header" colspan="3" rowspan="1" valign="top"> <p><b>Number of results per 1,000 men tested (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="2" valign=""> <p><b>Number of participants (studies)</b> </p> </td> <td align="center" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence (GRADE)</b> </p> </td> </tr> <tr class="separated"> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Prevalence 10%</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Prevalence 30%</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Prevalence 40%</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="1" valign=""> <p><b>True positives</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>72 (60 to 82)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>216 (180 to 246)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>288 (240 to 328)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>2257 (8)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕○○ LOW<sup>a, b</sup> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="1" valign=""> <p><b>False negatives</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28 (18 to 40)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>84 (54 to 120)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>112 (72 to 160)</p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="1" valign=""> <p><b>True negatives</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>864 (846 to 882)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>672 (658 to 686)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>576 (564 to 588)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>2257 (8)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕○○ LOW<sup>a, b</sup> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="1" valign=""> <p><b>False positives</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36 (18 to 54)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28 (14 to 42)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 (12 to 36)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>MRI pathway<b>:</b> magnetic resonance imaging with or without magnetic resonance imaging‐targeted biopsy; <b>ISUP:</b> International Society of Urological Pathology; <b>CI:</b> confidence interval </p> <p><sup>a</sup>A considerable number of studies had a high or unclear risk of bias, mainly in the participant selection and reference standard domains.<br/> <sup>b</sup>A considerable, clinically relevant heterogeneity was observed across pooled study results. </p> </td> </tr> </tbody> </table> </div> <div class="table" id="CD012663-tbl-0006"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Should systematic biopsy be used to diagnose ISUP grade ≥ 2 prostate cancer in men suspected of having clinically significant prostate cancer?</span></div> <tbody> <tr class="table-header separated"> <td align="" class="table-header" colspan="6" rowspan="1" valign=""> <p><b>Question: Should systematic biopsy be used to diagnose ISUP grade 2 or higher prostate cancer in men suspected of having clinically significant prostate cancer?</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Population:</b> men suspected of having clinically significant prostate cancer undergoing their first biopsy (biopsy‐naïve men) or a repeat biopsy (prior‐negative biopsy men) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Setting:</b> university hospitals and specialized care centers </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>New test:</b> systematic biopsy | <b>Threshold:</b> ISUP grade 2 or higher prostate cancer </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Reference test:</b> template‐guided biopsy, which comprehensively samples all zones of the prostate | <b>Threshold:</b> ISUP grade 2 or higher prostate cancer </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Pooled sensitivity:</b> 0.63 (95% CI: 0.19 to 0.93) | <b>Pooled specificity:</b> 1.00 (95% CI: 0.91 to 1.00) </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="2" valign=""> <p><b>Test result</b> </p> </td> <td align="center" class="table-header" colspan="3" rowspan="1" valign="top"> <p><b>Number of results per 1,000 men tested (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="2" valign=""> <p><b>Number of participants (studies)</b> </p> </td> <td align="center" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence (GRADE)</b> </p> </td> </tr> <tr class="separated"> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Prevalence 10%</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Prevalence 30%</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Prevalence 40%</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="1" valign=""> <p><b>True positives</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>63 (19 to 93)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>189 (57 to 279)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>252 (76 to 372)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>3421 (4)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕○ MODERATE<sup>a, b, c</sup> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="1" valign=""> <p><b>False negatives</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37 (7 to 81)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>111 (21 to 243)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>148 (28 to 324)</p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="1" valign=""> <p><b>True negatives</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>900 (819 to 900)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>700 (637 to 700)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>600 (546 to 600)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>3421 (4)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕○○ LOW<sup>a, b, c</sup> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="1" valign=""> <p><b>False positives</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 (0 to 81)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 (0 to 63)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 (0 to 54)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>ISUP:</b> International Society of Urological Pathology; <b>CI:</b> confidence interval </p> <p><sup>a</sup>A considerable number of studies had a high or unclear risk of bias, mainly in the participant selection and reference standard domains.<br/> <sup>b</sup>A considerable, clinically relevant heterogeneity was observed across pooled study results.<br/> <sup>c</sup>Important imprecision was noted, which contributed to decision to downgrade for inconsistency. </p> </td> </tr> </tbody> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD012663-sec-0037" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD012663-sec-0037"></div> <section id="CD012663-sec-0038"> <h3 class="title" id="CD012663-sec-0038">Target condition being diagnosed</h3> <p>Prostate cancer is the most frequently diagnosed solid cancer among men in high‐income countries (<a href="./references#CD012663-bbs2-0146" title="TorreLA , BrayF , SiegelRL , FerlayJ , Lortet‐TieulentJ , JemalA . Global cancer statistics, 2012. CA: a Cancer Journal for Clinicians2015;65(2):87‐108. ">Torre 2015</a>). Prostate cancer is the sixth leading cause of cancer death (7.4% of deaths) among men worldwide (<a href="./references#CD012663-bbs2-0082" title="Center MM, JemalA , Lortet‐TieulentJ , WardE , FerlayJ , BrawleyO , et al. International variation in prostate cancer incidence and mortality rates. European Urology2012;61(6):1079‐92. ">Center 2012</a>). A large proportion of prostate cancer, however, is indolent and will not lead to any complaints or death if left undetected (<a href="./references#CD012663-bbs2-0073" title="BellKJ , DelMarC , WrightG , DickinsonJ , GlasziouP . Prevalence of incidental prostate cancer: a systematic review of autopsy studies. International Journal of Cancer2015;137(7):1749‐57. ">Bell 2015</a>). When indolent prostate cancer is detected, it can be managed by active surveillance and does not necessarily need direct treatment. In contrast, clinically significant prostate cancer has direct therapeutic implications as it may progress, metastasise and lead to prostate cancer‐specific mortality. </p> <p>Next to the psychological burden of becoming a cancer patient, the harm of overdiagnosing indolent prostate cancer mainly lies in overtreatment, as many men are still offered radical prostatectomy or radiotherapy. Given the sharp increase in prostate‐specific antigen (PSA)‐testing, prostate cancer diagnoses and the increasing concerns of overdiagnosis and overtreatment, the distinction between indolent and clinically significant prostate cancer has become more important (<a href="./references#CD012663-bbs2-0110" title="IlicD , NeubergerMM , DjulbegovicM , DahmP . Screening for prostate cancer. Cochrane Database of Systematic Reviews2013, Issue 1. [DOI: 10.1002/14651858.CD004720.pub3] ">Ilic 2013</a>). Defining clinically significant prostate cancer, however, remains difficult with varying definitions in the world literature (<a href="./references#CD012663-bbs2-0120" title="MooreCM , KasivisvanathanV , EggenerS , EmbertonM , FuttererJJ , GillIS , et al. Standards of reporting for MRI‐targeted biopsy studies (START) of the prostate: recommendations from an International Working Group. European Urology2013;64(4):544‐52. ">Moore 2013a</a>). Established definitions are based on histologic parameters scored by the Gleason grading (<a href="./references#CD012663-bbs2-0094" title="EpsteinJI . An update of the Gleason grading system. Journal of Urology2010;183(2):433‐40. ">Epstein 2010</a>), or the International Society of Urological Pathology (ISUP) grade systems (<a href="./references#CD012663-bbs2-0096" title="EpsteinJI , EgevadL , AminMB , DelahuntB , SrigleyJR , HumphreyPA , et al. The 2014 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma: definition of grading patterns and proposal for a new grading system. American Journal of Surgical Pathology2016;40(2):244‐52. ">Epstein 2016</a>), with some using additional parameters like PSA, familial history, race or volume of cancer (<a href="./references#CD012663-bbs2-0093" title="EpsteinJI , WalshPC , CarmichaelM , BrendlerCB . Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA1994;271(5):368‐74. ">Epstein 1994</a>; <a href="./references#CD012663-bbs2-0104" title="GotoY , OhoriM , ArakawaA , KattanMW , WheelerTM , ScardinoPT . Distinguishing clinically important from unimportant prostate cancers before treatment: value of systematic biopsies. Journal of Urology1996;156(3):1059‐63. ">Goto 1996</a>; <a href="./references#CD012663-bbs2-0106" title="HarndenP , NaylorB , ShelleyMD , ClementsH , ColesB , MasonMD . The clinical management of patients with a small volume of prostatic cancer on biopsy: what are the risks of progression? A systematic review and meta‐analysis. Cancer2008;112(5):971‐81. ">Harnden 2008</a>; <a href="./references#CD012663-bbs2-0153" title="WoltersT , RoobolMJ , VanLeeuwenPJ , Van denBerghRC , HoedemaekerRF , VanLeendersGJ , et al. A critical analysis of the tumor volume threshold for clinically insignificant prostate cancer using a data set of a randomized screening trial. Journal of Urology2011;185(1):121‐5. ">Wolters 2011</a>). Moreover, other clinical parameters such as age and comorbidity may also influence the potential for progression and mortality of the individual with prostate cancer. </p> </section> <section id="CD012663-sec-0039"> <h3 class="title" id="CD012663-sec-0039">Clinical pathway</h3> <p>Opportunistic PSA‐based screening is practised worldwide and men considered to be at risk of clinically significant prostate cancer (elevated PSA level, abnormal digital rectal examination, African‐American origin and positive family history) are generally advised to have a systematic biopsy (<a href="./references#CD012663-bbs2-0080" title="CarterHB , AlbertsenPC , BarryMJ , EtzioniR , FreedlandSJ , GreeneKL , et al. Early detection of prostate cancer: AUA Guideline. Journal of Urology2013;190(2):419‐26. ">Carter 2013</a>; <a href="./references#CD012663-bbs2-0079" title="CarrollPR , ParsonsJK , AndrioleG , BahnsonRR , CastleEP , CatalonaWJ , et al. NCCN guidelines insights: prostate cancer early detection, version 2. Journal of the National Comprehensive Cancer Network2016;14(5):509‐19. ">Carroll 2016</a>; <a href="./references#CD012663-bbs2-0123" title="MottetN , BellmuntJ , BollaM , BriersE , CumberbatchMG , DeSantisM , et al. EAU‐ESTRO‐SIOG guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent. European Urology2017;71(4):618‐29. ">Mottet 2017</a>). Prediction models and clinical risk calculators, using a variety of clinical parameters and biomarkers, are being investigated and implemented to help select patients for biopsy (<a href="./references#CD012663-bbs2-0066" title="AlbertsAR , RoobolMJ , VerbeekJF , SchootsIG , ChiuPK , OssesDF , et al. Prediction of high‐grade prostate cancer following multiparametric magnetic resonance imaging: improving the Rotterdam European Randomized Study of Screening for Prostate Cancer risk calculators. European Urology2019;75(2):310‐8. ">Alberts 2019</a>; <a href="./references#CD012663-bbs2-0067" title="AnkerstDP , StraubingerJ , SeligK , GuerriosL , DeHoedtA , HernandezJ , et al. A contemporary prostate biopsy risk calculator based on multiple heterogeneous cohorts. European Urology2018;74(2):197‐203. ">Ankerst 2018</a>; <a href="./references#CD012663-bbs2-0099" title="FerroM , BuonerbaC , TerraccianoC , LucarelliG , CosimatoV , BotteroD , et al. Biomarkers in localized prostate cancer. Future Oncology2016;12(3):399‐411. ">Ferro 2016</a>; <a href="./references#CD012663-bbs2-0100" title="FoleyRW , MaweniRM , GormanL , MurphyK , LundonDJ , DurkanG , et al. European Randomised Study of Screening for Prostate Cancer (ERSPC) risk calculators significantly outperform the Prostate Cancer Prevention Trial (PCPT) 2.0 in the prediction of prostate cancer: a multi‐institutional study. BJU International2016;118(5):706‐13. ">Foley 2016</a>; <a href="./references#CD012663-bbs2-0130" title="RadtkeJP , WiesenfarthM , KeschC , FreitagMT , AltCD , CelikK , et al. Combined clinical parameters and multiparametric magnetic resonance imaging for advanced risk modeling of prostate cancer‐patient‐tailored risk stratification can reduce unnecessary biopsies. European Urology2017;72(6):888‐96. ">Radtke 2017</a>). The systematic biopsy may be repeated several times in the case of persistent suspicion of clinically significant prostate cancer after a prior‐negative biopsy or during active surveillance of indolent prostate cancer. </p> <p>Any prostate biopsy is associated with a risk of infection (1% to 8%) and an increased risk of life‐threatening sepsis (1% to 4%), as a consequence of increasing antibiotic resistance (<a href="./references#CD012663-bbs2-0074" title="BorghesiM , AhmedH , NamR , SchaefferE , SchiavinaR , TanejaE , et al. Complications after systematic, random, and image‐guided prostate biopsy. European Urology2017;71(3):353–65. ">Borghesi 2017</a>; <a href="./references#CD012663-bbs2-0116" title="LoebS , VellekoopA , AhmedHU , CattoJ , EmbertonM , NamR , et al. Systematic review of complications of prostate biopsy. European Urology2013;64(6):876‐92. ">Loeb 2013</a>). Other associated morbidities include dysuria, hematospermia, haematuria, rectal bleeding, vasovagal episodes and urinary retention (<a href="./references#CD012663-bbs2-0090" title="DjavanB , WaldertM , ZlottaA , DobronskiP , SeitzC , RemziM , et al. Safety and morbidity of first and repeat transrectal ultrasound guided prostate needle biopsies: results of a prospective European prostate cancer detection study. Journal of Urology2001;166(3):856‐60. ">Djavan 2001</a>; <a href="./references#CD012663-bbs2-0116" title="LoebS , VellekoopA , AhmedHU , CattoJ , EmbertonM , NamR , et al. Systematic review of complications of prostate biopsy. European Urology2013;64(6):876‐92. ">Loeb 2013</a>). These drawbacks of prostate biopsy limit the willingness of physicians and patients to perform and undergo potentially unnecessary biopsies. </p> <p>In contrast with systematic biopsy, magnetic resonance imaging (MRI)‐targeted biopsy is only performed when suspected lesions for clinically significant prostate cancer are detected on MRI. Due to the selective performance of targeted biopsies, the MRI, with MRI‐targeted biopsy, is able to more accurately detect clinically significant prostate cancer while purposefully detecting less indolent prostate cancer (<a href="./references#CD012663-bbs2-0137" title="SchootsIG , RoobolMJ , NieboerD , BangmaCH , SteyerbergEW , HuninkMG . Magnetic resonance imaging‐targeted biopsy may enhance the diagnostic accuracy of significant prostate cancer detection compared to standard transrectal ultrasound‐guided biopsy: a systematic review and meta‐analysis. European Urology2015;68(3):438‐50. ">Schoots 2015</a>; <a href="./references#CD012663-bbs2-0141" title="SiddiquiMM , Rais‐BahramiS , TurkbeyB . Comparison of MR/ultrasound fusion–guided biopsy with ultrasound‐guided biopsy for the diagnosis of prostate cancer. JAMA2015;313(4):390‐7. ">Siddiqui 2015</a>). Therefore, MRI and MRI‐targeted biopsy are increasingly investigated in addition to or as a replacement for systematic biopsy, either in the setting of prior‐negative biopsy, initial biopsy or during active surveillance. Studies have shown that MRI and MRI‐targeted biopsy significantly improved the detection rate in the prior‐negative biopsy men, but not in biopsy‐naïve men (<a href="./references#CD012663-bbs2-0137" title="SchootsIG , RoobolMJ , NieboerD , BangmaCH , SteyerbergEW , HuninkMG . Magnetic resonance imaging‐targeted biopsy may enhance the diagnostic accuracy of significant prostate cancer detection compared to standard transrectal ultrasound‐guided biopsy: a systematic review and meta‐analysis. European Urology2015;68(3):438‐50. ">Schoots 2015</a>; <a href="./references#CD012663-bbs2-0147" title="ValerioM , DonaldsonI , EmbertonM , EhdaieB , HadaschikBA , MarksLS , et al. Detection of clinically significant prostate cancer using magnetic resonance imaging‐ultrasound fusion targeted biopsy: a systematic review. European Urology2015;68(1):8‐19. ">Valerio 2015</a>). Moreover, randomised controlled trials performed in biopsy‐naïve men provide contradictory findings as to whether or not MRI with MRI‐targeted biopsy has a higher detection rate for clinically significant prostate cancer as compared to systematic biopsy (<a href="./references#CD012663-bbs2-0045" title="BacoE , RudE , EriLM , MoenG , VlatkovicL , SvindlandA , et al. A randomized controlled trial to assess and compare the outcomes of two‐core prostate biopsy guided by fused magnetic resonance and transrectal ultrasound images and traditional 12‐core systematic biopsy. European Urology2016;69(1):149‐56. ">Baco 2016</a>; <a href="./references#CD012663-bbs2-0051" title="KasivisvanathanV , RannikkoAS , BorghiM , PanebiancoV , MynderseLA , VaaralaMH , et al. MRI‐targeted or standard biopsy for prostate‐cancer diagnosis. New England Journal of Medicine2018;378:1767‐77. ">Kasivisvanathan 2018</a>; <a href="./references#CD012663-bbs2-0033" title="PanebiancoV , BarchettiF , SciarraA , CiardiA , IndinoEL , PapaliaR , et al. Multiparametric magnetic resonance imaging vs. standard care in men being evaluated for prostate cancer: a randomized study. Urologic Oncology2015;33(1):17.e1‐17.e7. ">Panebianco 2015</a>; <a href="./references#CD012663-bbs2-0057" title="PorpigliaF , ManfrediM , MeleF , CossuM , BollitoE , VeltriA , et al. Diagnostic pathway with multiparametric magnetic resonance imaging versus standard pathway: results from a randomized prospective study in biopsy‐naïve patients with suspected prostate cancer. European Urology2017;72(2):282‐8. ">Porpiglia 2017</a>; <a href="./references#CD012663-bbs2-0041" title="TonttilaPP , LanttoJ , PääkköE , PiippoU , KauppilaS , LammentaustaE , et al. Prebiopsy multiparametric magnetic resonance imaging for prostate cancer diagnosis in biopsy‐naïve men with suspected prostate cancer based on elevated prostate‐specific antigen values: results from a randomized prospective blinded controlled trial. European Urology2016;69(3):419‐25. ">Tonttilla 2016</a>). Consequently, international guidelines recommend considering the use of MRI and MRI‐targeted biopsy, if available, in the setting of persistent clinical suspicion of prostate cancer after prior‐negative biopsy (<a href="./references#CD012663-bbs2-0068" title="CarterHB , AlbertsenPC , BarryMJ , EtzioniR , FreedlandSJ , GreeneKL , et al. American Urological Associations Guideline Panel. Early detection of prostate cancer: AUA guideline. www.auanet.org/guidelines/prostate‐cancer‐early‐detection‐(2013‐reviewed‐for‐currency‐2018)#x2637 2018 (accessed on 15‐01‐2019). ">AUA Guideline 2018</a>; <a href="./references#CD012663-bbs2-0091" title="MottetN , Van denBerghRCN , BriersE , BourkeL , CornfordP , DeSantisM , et al. European Association of Urology: guideline on prostate cancer. uroweb.org/guideline/prostate‐cancer/ 2018 (accessed on 15‐01‐2019). ">EAU Guideline 2018</a>). However, international guidelines do not recommend a pre‐biopsy MRI or upfront MRI‐directed biopsy management in biopsy‐naïve men, let alone MRI‐directed biopsy management as an alternative to systematic biopsy. <a href="#CD012663-fig-0001">Figure 1</a> illustrates the clinical pathway and design of this review. </p> <div class="figure" id="CD012663-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Clinical pathway flow diagram and study design" data-id="CD012663-fig-0001" src="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_n/nCD012663-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Clinical pathway flow diagram and study design</p> </div> </div> </div> <section id="CD012663-sec-0040"> <h4 class="title">Index tests</h4> <section id="CD012663-sec-0041"> <h5 class="title">MRI</h5> <p>MRI is used to identify and locate suspicious lesions for clinically significant prostate cancer. Different MRI techniques and MRI systems from different vendors are used worldwide. The multiparametric pulse sequences are T2‐weighted imaging (T2W), diffusion‐weighted imaging (DWI), dynamic contrast‐enhanced (DCE) imaging and spectroscopy. Furthermore, different MRI magnets on different platforms from different vendors exist. </p> <p>In addition, several scoring systems for the suspicion of prostate cancer on MRI have been developed. Radiologists use multi‐level scoring systems according to the Likert scale principle; where the presence of clinically significant prostate cancer in a lesion can be subjectively categorised as highly unlikely to highly likely, with a varying number of subdivisions. The 1 to 5 scale according to the Prostate Imaging ‐ Reporting and Data System (PI‐RADS) version 2 (<a href="./references#CD012663-bbs2-0151" title="WeinrebJC , BarentszJO , ChoykePL , CornudF , HaiderMA , MacuraKJ , et al. PI‐RADS prostate imaging ‐ reporting and data system: 2015, version 2. European Urology2016;69(1):16‐40. ">Weinreb 2016</a>), provides guidance for radiologists with more objective criteria and is currently most often used. </p> </section> <section id="CD012663-sec-0042"> <h5 class="title">MRI‐targeted biopsy</h5> <p>MRI‐targeted biopsy in men with a positive MRI can either be performed with MRI‐guidance within the MRI scanner (in‐bore), or by ultrasound guidance with the use of computer‐based software that overlays the target identified on MRI onto the ultrasound image, 'software registration', or without the use of software, 'visual registration'. No significant differences in clinically significant prostate cancer detection appear to exist between these navigational approaches (<a href="./references#CD012663-bbs2-0120" title="MooreCM , KasivisvanathanV , EggenerS , EmbertonM , FuttererJJ , GillIS , et al. Standards of reporting for MRI‐targeted biopsy studies (START) of the prostate: recommendations from an International Working Group. European Urology2013;64(4):544‐52. ">Moore 2013a</a>; <a href="./references#CD012663-bbs2-0137" title="SchootsIG , RoobolMJ , NieboerD , BangmaCH , SteyerbergEW , HuninkMG . Magnetic resonance imaging‐targeted biopsy may enhance the diagnostic accuracy of significant prostate cancer detection compared to standard transrectal ultrasound‐guided biopsy: a systematic review and meta‐analysis. European Urology2015;68(3):438‐50. ">Schoots 2015</a>; <a href="./references#CD012663-bbs2-0150" title="WegelinO , VanMelickHH , HooftL , BoschJL , ReitsmaHB , BarentszJO , et al. Comparing three different techniques for magnetic resonance imaging‐targeted prostate biopsies: a systematic review of in‐bore versus magnetic resonance imaging‐transrectal ultrasound fusion versus cognitive registration. Is there a preferred technique?. European Urology2017;71(4):517‐31. ">Wegelin 2017</a>). </p> </section> <section id="CD012663-sec-0043"> <h5 class="title">MRI pathway</h5> <p>The MRI pathway (MRI with or without MRI‐targeted biopsy) comprises the performance of an MRI and subsequent performance of MRI‐targeted biopsies if a suspicious lesion is seen. Therefore, men with a negative MRI do not receive MRI‐targeted biopsy. </p> </section> <section id="CD012663-sec-0044"> <h5 class="title">Systematic biopsy</h5> <p>Systematic transrectal ultrasound (TRUS)‐guided biopsy is a biopsy technique in which the peripheral zone of the prostate is sampled by 8 to 12 cores (with a maximum of 19), depending on the size of the prostate. TRUS is performed primarily for anatomic guidance, as suspicious lesions for prostate cancer, in general, cannot be visualised by ultrasound. This approach may, therefore, result in random and systematic errors, which can lead to hitting insignificant lesions while missing significant lesions (<a href="./references#CD012663-bbs2-0092" title="El‐Shater BosailyA , ParkerC , BrownLC , GabeR , HindleyRG , KaplanR , et al. PROMIS ‐ Prostate MR imaging study: a paired validating cohort study evaluating the role of multi‐parametric MRI in men with clinical suspicion of prostate cancer. Contemporary Clinical Trials2015;42:26‐40. ">El‐Shater Bosaily 2015</a>). The estimated false‐negative rate of systematic biopsy for any cancer is 25% to 40% (<a href="./references#CD012663-bbs2-0108" title="HuY , AhmedHU , CarterT , ArumainayagamN , LecornetE , BarzellW , et al. A biopsy simulation study to assess the accuracy of several transrectal ultrasonography (TRUS)‐biopsy strategies compared with template prostate mapping biopsies in patients who have undergone radical prostatectomy. BJU International2012;110(6):812‐20. ">Hu 2012</a>). Also, misclassification occurs by not hitting the cancer lesion at its greatest diameter or highest grade, shown by reclassification in almost half of men when a more accurate biopsy test is applied (<a href="./references#CD012663-bbs2-0071" title="BarzellWE , MelamedMR . Appropriate patient selection in the focal treatment of prostate cancer: the role of transperineal 3‐dimensional pathologic mapping of the prostate ‐‐ a 4‐year experience. Urology2007;70(6 Suppl):27‐35. ">Barzell 2007</a>; <a href="./references#CD012663-bbs2-0072" title="BarzellWE , MelamedMR , CathcartP , MooreCM , AhmedHU , EmbertonM . Identifying candidates for active surveillance: an evaluation of the repeat biopsy strategy for men with favorable risk prostate cancer. Journal of Urology2012;188(3):762‐7. ">Barzell 2012</a>; <a href="./references#CD012663-bbs2-0144" title="TairaAV , MerrickGS , GalbreathRW , AndreiniH , TaubenslagW , CurtisR , et al. Performance of transperineal template‐guided mapping biopsy in detecting prostate cancer in the initial and repeat biopsy setting. Prostate Cancer and Prostatic Diseases2010;13(1):71‐7. ">Taira 2010</a>; <a href="./references#CD012663-bbs2-0145" title="TairaAV , MerrickGS , BennettA , AndreiniH , TaubenslagW , GalbreathRW , et al. Transperineal template‐guided mapping biopsy as a staging procedure to select patients best suited for active surveillance. American Journal of Clinical Oncology2013;36(2):116‐20. ">Taira 2013</a>). </p> </section> </section> <section id="CD012663-sec-0045"> <h4 class="title">Alternative test(s)</h4> <p>Different biopsy approaches, such as transrectal or transperineal, with different numbers of biopsy cores are used. Transrectal saturation biopsy (defined as more than 20 biopsies of the prostate) aims comprehensively to sample the prostate (<a href="./references#CD012663-bbs2-0114" title="KuruTH , WadhwaK , ChangRT , EcheverriaLM , RoethkeM , PolsonA , et al. Definitions of terms, processes and a minimum dataset for transperineal prostate biopsies: a standardization approach of the Ginsburg Study Group for Enhanced Prostate Diagnostics. BJU International2013;112(5):568‐77. ">Kuru 2013b</a>). However, most transrectal biopsy approaches do not sample the anterior zones of the prostate and therefore lack accuracy. In addition, such an intensified biopsy approach is less frequently used in daily clinical practice as it is widely seen as being a high burden to patients, having an increased complication rate and contributing to overdiagnosing insignificant prostate cancer (<a href="./references#CD012663-bbs2-0111" title="JiangX , ZhuS , FengG , ZhangZ , LiC , LiH , et al. Is an initial saturation prostate biopsy scheme better than an extended scheme for detection of prostate cancer? A systematic review and meta‐analysis. European Urology2013;63(6):1031‐9. ">Jiang 2013</a>). Furthermore, different ultrasound imaging techniques for localizing suspicious lesions in the prostate are also being developed and evaluated, including contrast‐enhanced ultrasound, computer‐assisted TRUS, sonoelastography and histoscanning. However, these techniques need further development before considering a potential application in daily clinical care (<a href="./references#CD012663-bbs2-0115" title="KuruTH , FüttererJJ , SchiffmannJ , PorresD , SalomonG , RastinehadAR . Transrectal ultrasound (US), contrast‐enhanced US, real‐time elastography, histoscanning, magnetic resonance imaging (MRI), and MRI‐US fusion biopsy in the diagnosis of prostate cancer. European Urology Focus2015;1(2):117‐26. ">Kuru 2015</a>). </p> </section> </section> <section id="CD012663-sec-0046"> <h3 class="title" id="CD012663-sec-0046">Rationale</h3> <p>To reduce overdiagnosis and overtreatment of indolent prostate cancer, while improving the detection of clinically significant prostate cancer and reducing the number of biopsy procedures, we need more accurate diagnostic methods and better risk‐stratification (<a href="./references#CD012663-bbs2-0065" title="AlbertsAR , SchootsIG , RoobolMJ . Prostate‐specific antigen‐based prostate cancer screening: past and future. International Journal of Urology2015;22(6):524‐32. ">Alberts 2015</a>). In a recent international multicentre randomised controlled trial, MRI in combination with MRI‐targeted biopsy (the MRI pathway) detected 12% more clinically significant prostate cancer and 13% less indolent prostate cancer than systematic biopsy in biopsy‐naïve men, and achieved a 28% reduction of biopsies, because men with a negative MRI did not receive prostate biopsy (<a href="./references#CD012663-bbs2-0051" title="KasivisvanathanV , RannikkoAS , BorghiM , PanebiancoV , MynderseLA , VaaralaMH , et al. MRI‐targeted or standard biopsy for prostate‐cancer diagnosis. New England Journal of Medicine2018;378:1767‐77. ">Kasivisvanathan 2018</a>). These results indicate that a pre‐biopsy MRI and MRI‐targeted biopsy in the presence of an MRI‐suspicious lesion would be superior to a systematic biopsy. If that is confirmed by other studies and longer follow‐up of those men not biopsied, it may initiate a change to the guidelines. </p> <p>Previous systematic reviews on diagnostic performances of the MRI pathway or the pre‐biopsy MRI approach written by <a href="./references#CD012663-bbs2-0086" title="DeRooijM , HamoenEH , FuttererJJ , BarentszJO , RoversMM . Accuracy of multiparametric MRI for prostate cancer detection: a meta‐analysis. American Journal of Roentgenology2014;202(2):343‐51. ">De Rooij 2014a</a>, <a href="./references#CD012663-bbs2-0101" title="FuttererJJ , BrigantiA , DeVisschereP , EmbertonM , GiannariniG , KirkhamA , et al. Can clinically significant prostate cancer be detected with multiparametric magnetic resonance imaging? A systematic review of the literature. European Urology2015;68(6):1045‐53. ">Futterer 2015</a>, <a href="./references#CD012663-bbs2-0102" title="GayetM , Van derAaA , BeerlageHP , SchrierBP , MuldersPF , WijkstraH . The value of magnetic resonance imaging and ultrasonography (MRI/US)‐fusion biopsy platforms in prostate cancer detection: a systematic review. BJU International2016;117(3):392‐400. ">Gayet 2016</a>, <a href="./references#CD012663-bbs2-0105" title="HamoenEH , deRooijM , WitjesJA , BarentszJO , RoversMM . Use of the prostate imaging reporting and data system (PI‐RADS) for prostate cancer detection with multiparametric magnetic resonance imaging: a diagnostic meta‐analysis. European Urology2015;67(6):1112‐21. ">Hamoen 2015</a>, <a href="./references#CD012663-bbs2-0121" title="MooreCM , RobertsonNL , ArsaniousN , MiddletonT , VillersA , KlotzL , et al. Image‐guided prostate biopsy using magnetic resonance imaging‐derived targets: a systematic review. European Urology2013;63(1):125‐40. ">Moore 2013b</a>, <a href="./references#CD012663-bbs2-0137" title="SchootsIG , RoobolMJ , NieboerD , BangmaCH , SteyerbergEW , HuninkMG . Magnetic resonance imaging‐targeted biopsy may enhance the diagnostic accuracy of significant prostate cancer detection compared to standard transrectal ultrasound‐guided biopsy: a systematic review and meta‐analysis. European Urology2015;68(3):438‐50. ">Schoots 2015</a>, <a href="./references#CD012663-bbs2-0147" title="ValerioM , DonaldsonI , EmbertonM , EhdaieB , HadaschikBA , MarksLS , et al. Detection of clinically significant prostate cancer using magnetic resonance imaging‐ultrasound fusion targeted biopsy: a systematic review. European Urology2015;68(1):8‐19. ">Valerio 2015</a> and <a href="./references#CD012663-bbs2-0148" title="VanHoveA , SavoiePH , MaurinC , BrunelleS , GravisG , SalemN , et al. Comparison of image‐guided targeted biopsies versus systematic randomized biopsies in the detection of prostate cancer: a systematic literature review of well‐designed studies. World Journal of Urology2014;32(4):847‐58. ">Van Hove 2014</a> have been based on study designs that did not accurately capture target conditions and index or reference test definitions, leading to a number of biases and inaccurate findings. Studies in these reviews included mainly men with a positive MRI, and disregarded men with a negative MRI, inevitably leading to inaccurate true‐negative and false‐negative values of the MRI pathway. In addition, they used systematic biopsy or radical whole‐mount surgical specimens as reference standards, which inherently have a number of biases: systematic biopsy may miss clinically significant prostate cancer caused by both random and systematic errors, whereas radical whole‐mount surgical specimens are only available for men with a positive biopsy who opted for surgery. Furthermore, the established definitions of clinically significant prostate cancer, based on histology from systematic biopsy and possibly additional non‐histological parameters, cannot be applied to results from the MRI pathway (<a href="./references#CD012663-bbs2-0132" title="RobertsonNL , HuY , AhmedHU , FreemanA , BarrattD , EmbertonM . Prostate cancer risk inflation as a consequence of image‐targeted biopsy of the prostate: a computer simulation study. European Urology2014;65:628‐34. ">Robertson 2014</a>). The intention of the MRI pathway is to oversample areas of high suspicion, with the result that MRI‐targeted biopsies tend to show longer cancer core length and higher Gleason grading than systematic biopsies (<a href="./references#CD012663-bbs2-0049" title="HaffnerJ , LemaitreL , PuechP , HaberGP , LeroyX , JonesJS , et al. Role of magnetic resonance imaging before initial biopsy: comparison of magnetic resonance imaging‐targeted and systematic biopsy for significant prostate cancer detection. BJU International2011;108(8 B):E171‐E8. ">Haffner 2011</a>). This results in a drift towards higher risk classification, which is an artefact of the MRI‐targeted sampling method and may prompt men and physicians to more radical treatment. Based on these observations, the International Working Group on Standards of Reporting for MRI‐targeted biopsy studies (START) agreed that definitions of clinical significance in MRI‐targeted biopsy studies should solely focus on histologic definitions, that is, Gleason grade and maximum cancer core length (<a href="./references#CD012663-bbs2-0120" title="MooreCM , KasivisvanathanV , EggenerS , EmbertonM , FuttererJJ , GillIS , et al. Standards of reporting for MRI‐targeted biopsy studies (START) of the prostate: recommendations from an International Working Group. European Urology2013;64(4):544‐52. ">Moore 2013a</a>). </p> <p>Considering the above information, we performed a systematic review and meta‐analysis of the literature. We only included studies with data on both MRI‐positive and ‐negative men, that reported histologically confirmed target conditions only. Furthermore, we only included studies that used an appropriate reference standard (described in <a href="#CD012663-sec-0060">Reference standards</a>) for the test accuracy analyses. To provide additional evidence where test accuracy evidence was limited, we selected from the agreement evidence only those studies that investigated the MRI pathway and systematic biopsy in the same men according to the above‐stated criteria. </p> <p>We aimed to assess the diagnostic accuracy of the four index tests (MRI, MRI‐targeted biopsy, the MRI pathway and systematic biopsy) and the agreement between the two main index tests (the MRI pathway versus systematic biopsy) for detecting prostate cancer. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD012663-sec-0047" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD012663-sec-0047"></div> <section id="CD012663-sec-0048"> <h3 class="title" id="CD012663-sec-0048">Primary objective</h3> <p>To determine the diagnostic accuracy of the index tests MRI only, MRI‐targeted biopsy, MRI pathway (MRI with or without MRI‐targeted biopsy) and systematic biopsy as compared to template‐guided biopsy as the reference standard in detecting ISUP grade 2 or higher, grade 3 or higher and grade 1 prostate cancer. </p> </section> <section id="CD012663-sec-0049"> <h3 class="title" id="CD012663-sec-0049">Secondary objectives</h3> <p> <ol id="CD012663-list-0001"> <li> <p>To compare the diagnostic accuracy between the index tests MRI only, MRI‐targeted biopsy, MRI pathway (MRI with or without MRI‐targeted biopsy) and systematic biopsy in detecting grade 2 or higher, grade 3 or higher and grade 1 prostate cancer. </p> </li> <li> <p>To determine the agreement between the two index tests, the MRI pathway and systematic biopsy, for detecting grade 2 or higher, grade 3 or higher and grade 1 prostate cancer. </p> </li> <li> <p>To determine the proportion of prostate cancer not detected by systematic biopsy but only by the MRI pathway (added value MRI pathway) and the proportion of prostate cancer not detected by the MRI pathway but only by systematic biopsy (added value systematic biopsy) for grade 2 or higher, grade 3 or higher and grade 1 prostate cancer. </p> </li> <li> <p>To determine the potential change in the number of biopsy procedures between the MRI pathway and systematic biopsy in the test accuracy and the agreement analyses. </p> </li> <li> <p>To investigate what clinical and methodological sources of heterogeneity affect the index tests, including type of population (prior‐negative biopsy or biopsy‐naïve), MRI pulse sequences (mpMRI or bpMRI or additional spectroscopy), MRI scoring system, MRI suspicion score threshold for MRI‐targeted biopsy, navigational approach of MRI‐targeted biopsy, MRI lesion location, number of biopsy cores (or biopsy density) and core distribution in the reference standard. </p> </li> </ol> </p> </section> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD012663-sec-0050" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD012663-sec-0050"></div> <section id="CD012663-sec-0051"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD012663-sec-0052"> <h4 class="title">Types of studies</h4> <p>We considered any cross‐sectional study, if it investigated:</p> <p> <ol id="CD012663-list-0002"> <li> <p>the diagnostic accuracy of one or more of the index tests (MRI, MRI pathway (including MRI‐targeted biopsy) or systematic biopsy) verified by the reference standard (template‐guided biopsy), with each index test and reference standard performed in the same men or compared as in a randomised trial of test accuracy; or </p> </li> <li> <p>agreement evidence between the MRI pathway and systematic biopsy, with each test performed in the same men. </p> </li> </ol> </p> <p>Studies involving MRI had to report on both MRI‐positive and MRI‐negative men.</p> <p>We excluded studies when we could not extract a complete two‐by‐two table on a per‐participant basis for the primary target condition, even after contacting the study authors. </p> <p>We did not apply any language or other restrictions.</p> </section> <section id="CD012663-sec-0053"> <h4 class="title">Participants</h4> <p>The study population consisted of men with a clinical suspicion of prostate cancer (based on PSA or digital rectal exam (DRE) outcome) in the biopsy‐naïve or prior‐negative biopsy setting (or a mix of both). We excluded men with a previous diagnosis of prostate cancer. </p> </section> <section id="CD012663-sec-0054"> <h4 class="title">Index tests</h4> <section id="CD012663-sec-0055"> <h5 class="title">MRI</h5> <p>MRI was comprised of at least T2‐weighted imaging and one functional imaging technique (DWI or DCE), reported according to any MRI‐scoring system. The assessment categories for prostate MRI are based on a 5‐point scale (Likert or PI‐RADS), defined as very low (1), low (2), intermediate (3), high (4) and very high (5) (<a href="./references#CD012663-bbs2-0089" title="DickinsonL , AhmedHU , AllenC , BarentszJO , CareyB , FuttererJJ , et al. Magnetic resonance imaging for the detection, localisation, and characterisation of prostate cancer: recommendations from a European consensus meeting. European Urology2011;59(4):477‐94. ">Dickinson 2011</a>; <a href="./references#CD012663-bbs2-0151" title="WeinrebJC , BarentszJO , ChoykePL , CornudF , HaiderMA , MacuraKJ , et al. PI‐RADS prostate imaging ‐ reporting and data system: 2015, version 2. European Urology2016;69(1):16‐40. ">Weinreb 2016</a>). We defined the default threshold for MRI‐positivity as 3/5 or more where possible. We categorised thresholds from related assessment scores such as 2/4 or more, 6/10 or more and 5/15 or more as low, intermediate and high, based on expert opinion, for the purpose of heterogeneity analyses. We performed sensitivity analyses with studies that used a threshold of 3/5 or more. We performed additional analyses by increasing or decreasing the MRI‐positivity threshold, categorizing the MRI scores into 4/5 or more and 2/5 or more. We based all the analyses on per‐participant analysis and not on per‐lesion analysis, therefore, we did not take into account spatial concordance between MRI findings and biopsy findings. </p> </section> <section id="CD012663-sec-0056"> <h5 class="title">MRI‐targeted biopsy</h5> <p>MRI‐targeted biopsy included only MRI‐positive men. We included all methods for MRI‐targeted biopsy (direct in‐bore, visual‐registration or software‐registration). We extracted data for this index test from studies reporting on the MRI pathway verified by the reference standard. We defined a positive MRI‐targeted biopsy as a histopathological confirmation of one of the target conditions in the MRI‐targeted biopsy cores. </p> </section> <section id="CD012663-sec-0057"> <h5 class="title">The MRI pathway</h5> <p>The MRI pathway included MRI‐positive men (in whom MRI‐targeted biopsy was performed) and MRI‐negative men (in whom no MRI‐targeted biopsy was performed), reflecting the complete spectrum of men in the clinical population. We defined a positive MRI pathway as a histopathological confirmation of one of the target conditions by MRI‐targeted biopsy in MRI‐positive men. Therefore, we defined a negative MRI pathway as a negative MRI or a negative MRI‐targeted biopsy <a href="./appendices#CD012663-sec-0137">Appendix 1</a>. </p> </section> <section id="CD012663-sec-0058"> <h5 class="title">Systematic biopsy</h5> <p>Systematic biopsy included either systematic transrectal or transperineal ultrasound‐guided biopsies, with generally 8 to 12 cores dedicated to the peripheral zone of the prostate; we excluded studies on additional ultrasound imaging techniques. We defined a positive systematic biopsy as a histopathological confirmation of one of the target conditions in the biopsy cores. </p> </section> </section> <section id="CD012663-sec-0059"> <h4 class="title">Target conditions</h4> <p>The primary target condition was clinically significant prostate cancer, defined as ISUP grade 2 or higher, based on histopathology findings and scored as Gleason score (GS) 3 + 4 or higher (<a href="./references#CD012663-bbs2-0096" title="EpsteinJI , EgevadL , AminMB , DelahuntB , SrigleyJR , HumphreyPA , et al. The 2014 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma: definition of grading patterns and proposal for a new grading system. American Journal of Surgical Pathology2016;40(2):244‐52. ">Epstein 2016</a>). Secondary target conditions were grade 1 (GS 3 + 3, indolent prostate cancer) and grade 3 or higher (GS 4 + 3 or higher). We based all target conditions on ISUP grade only, without cancer volume criteria, in order to overcome differences between definitions and biopsy methods, according to START guidelines (<a href="./references#CD012663-bbs2-0120" title="MooreCM , KasivisvanathanV , EggenerS , EmbertonM , FuttererJJ , GillIS , et al. Standards of reporting for MRI‐targeted biopsy studies (START) of the prostate: recommendations from an International Working Group. European Urology2013;64(4):544‐52. ">Moore 2013a</a>). </p> </section> <section id="CD012663-sec-0060"> <h4 class="title">Reference standards</h4> <p>Template‐guided biopsy served as the reference standard. In general, two different techniques are used: the transperineal template‐guided mapping biopsy (TTMB) and the template‐guided saturation biopsy (TSB). TTMB is defined as “transperineal TRUS‐guided biopsies of the prostate performed with the patient in lithotomy position using a 5‐mm brachytherapy grid, with at least one biopsy from each hole”. TSB is defined as “20 or more transperineal or transrectal TRUS‐guided biopsies of the prostate performed with the intention to comprehensively sample the whole prostate, according to a predefined core distribution pattern” (<a href="./references#CD012663-bbs2-0114" title="KuruTH , WadhwaK , ChangRT , EcheverriaLM , RoethkeM , PolsonA , et al. Definitions of terms, processes and a minimum dataset for transperineal prostate biopsies: a standardization approach of the Ginsburg Study Group for Enhanced Prostate Diagnostics. BJU International2013;112(5):568‐77. ">Kuru 2013b</a>; <a href="./references#CD012663-bbs2-0143" title="SivaramanA , Sanchez‐SalasR , BarretE , AhallalY , RozetF , GalianoM , et al. Transperineal template‐guided mapping biopsy of the prostate. International Journal of Urology2015;22(2):146‐51. ">Sivaraman 2015</a>). Template‐guided biopsies using a uniform grid and taken at 5 mm intervals can technically only miss those tumours that are smaller than the distance between the adjacent cores (<a href="./references#CD012663-bbs2-0064" title="AhmedHU , HuY , CarterT , ArumainayagamN , LecornetE , FreemanA , et al. Characterizing clinically significant prostate cancer using template prostate mapping biopsy. Journal of Urology2011;186(2):458‐64. ">Ahmed 2011</a>; <a href="./references#CD012663-bbs2-0143" title="SivaramanA , Sanchez‐SalasR , BarretE , AhallalY , RozetF , GalianoM , et al. Transperineal template‐guided mapping biopsy of the prostate. International Journal of Urology2015;22(2):146‐51. ">Sivaraman 2015</a>). The sensitivity and negative predictive value of this technique for detecting grade 2 or higher prostate cancer 0.5 cm<sup>3</sup> or greater in volume have both been shown to be 95%, with a sensitivity of 76% for detecting all cancers (<a href="./references#CD012663-bbs2-0064" title="AhmedHU , HuY , CarterT , ArumainayagamN , LecornetE , FreemanA , et al. Characterizing clinically significant prostate cancer using template prostate mapping biopsy. Journal of Urology2011;186(2):458‐64. ">Ahmed 2011</a>; <a href="./references#CD012663-bbs2-0085" title="CrawfordED , RoveKO , BarqawiAB , MaroniPD , WeraheraPN , BaerCA , et al. Clinical‐pathologic correlation between transperineal mapping biopsies of the prostate and three‐dimensional reconstruction of prostatectomy specimens. Prostate2013;73(7):778‐87. ">Crawford 2013</a>; <a href="./references#CD012663-bbs2-0142" title="SimmonsLA , AhmedHU , MooreCM , PunwaniS , FreemanA , HuY , et al. The PICTURE study ‐‐ prostate imaging (multi‐parametric MRI and Prostate HistoScanning) compared to transperineal ultrasound guided biopsy for significant prostate cancer risk evaluation. Contemporary Clinical Trials2014;37(1):69‐83. ">Simmons 2014</a>). Although the template‐guided biopsy is not perfect, owing to the fact that the test accuracy depends on the intensity of cores taken and core trajectory (<a href="./references#CD012663-bbs2-0109" title="HuoAS , HossackT , SymonsJL , PeBenitoR , DelpradoWJ , BrennerP , et al. Accuracy of primary systematic template guided transperineal biopsy of the prostate for locating prostate cancer: a comparison with radical prostatectomy specimens. Journal of Urology2012;187(6):2044‐9. ">Huo 2012</a>; <a href="./references#CD012663-bbs2-0128" title="PhamKN , PorterCR , Odem‐DavisK , WolffEM , JeldresC , WeiJT , et al. Transperineal template guided prostate biopsy selects candidates for active surveillance‐‐how many cores are enough?. Journal of Urology2015;194(3):674‐9. ">Pham 2015</a>; <a href="./references#CD012663-bbs2-0147" title="ValerioM , DonaldsonI , EmbertonM , EhdaieB , HadaschikBA , MarksLS , et al. Detection of clinically significant prostate cancer using magnetic resonance imaging‐ultrasound fusion targeted biopsy: a systematic review. European Urology2015;68(1):8‐19. ">Valerio 2015</a>), it is the optimal reference standard, as it avoids the biases of other reference standards that have been used as described in the <a href="#CD012663-sec-0046">Rationale</a>. An alternative approach could be to use template‐guided biopsy in combination with other biopsy methods (a ‘composite’ reference standard) to overcome the inadequacy of template‐guided biopsy only; however, this would introduce incorporation bias. </p> <p>Therefore, in this analysis, we used only template‐guided biopsy as the reference standard. Template‐guided biopsy had to comprehensively sample all (including the anterior) zones of the prostate, with a minimum of 20 biopsy cores. We defined a positive template‐guided biopsy as histopathological confirmation of one of the target conditions within the biopsy cores. We used the alternative composite reference standard in the sensitivity analyses. </p> </section> </section> <section id="CD012663-sec-0061"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD012663-sec-0062"> <h4 class="title">Electronic searches</h4> <p>We performed a comprehensive search, with no restriction on language of publication or publication status, in the following electronic databases: </p> <p> <ol id="CD012663-list-0003"> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL; 2018, Issue 7) in the Cochrane Library (searched 31 July 2018), including ClinicalTrials; </p> </li> <li> <p>MEDLINE Ovid, including electronic publications ahead of print (from inception to 31 July 2018); </p> </li> <li> <p>Embase.com (from inception to 31 July 2018);</p> </li> <li> <p>CINAHL EBSCO (Cumulative Index to Nursing and Allied Health Literature; from inception to 31 July 2018); </p> </li> <li> <p>Web of Science (Core Collection) (from inception to 31 July 2018);</p> </li> <li> <p>Scopus (from inception to 31 July 2018);</p> </li> <li> <p>Google.com (31 July 2018);</p> </li> <li> <p>Google Scholar (31 July 2018);</p> </li> <li> <p>WorldCat (31 July 2018);</p> </li> <li> <p>ProQuest (ProQuest Dissertations &amp; Theses; 31 July 2018);</p> </li> <li> <p>OpenGrey (31 July 2018).</p> </li> </ol> </p> <p>The search strategies are provided in <a href="./appendices#CD012663-sec-0142">Appendix 2</a>. </p> </section> <section id="CD012663-sec-0063"> <h4 class="title">Searching other resources</h4> <p>We searched for additional references in the Science Citation Index of Web of Science and by manually searching the references of relevant articles. </p> <p>We also searched the following trials registers for planned or ongoing studies:</p> <p> <ol id="CD012663-list-0004"> <li> <p><a href="https://clinicaltrials.gov/" target="_blank">ClinicalTrials.gov</a> (31 July 2018); </p> </li> <li> <p>World Health Organization International Clinical Trials Registry Platform (<a href="http://apps.who.int/trialsearch" target="_blank">apps.who.int/trialsearch</a>; searched 31 July 2018); </p> </li> <li> <p>Open trials (<a href="https://opentrials.net/" target="_blank">https://opentrials.net/</a>, searched 31 July 2018). </p> </li> </ol> </p> <p>We searched Embase and Web of Science for conference proceedings.</p> </section> </section> <section id="CD012663-sec-0064"> <h3 class="title" id="CD012663-sec-0064">Data collection and analysis</h3> <section id="CD012663-sec-0065"> <h4 class="title">Selection of studies</h4> <p>We checked the primary search results for overlapping content and Cochrane Urology's Information Specialist deduplicated the search results (<a href="./references#CD012663-bbs2-0076" title="BramerWM , GiustiniD , deJongeGB , HollandL , BekhuisT . De‐duplication of database search results for systematic reviews in EndNote. Journal of the Medical Library Association: JMLA2016;104(3):240‐3. ">Bramer 2016</a>). Two reviewers (FD, DO) independently screened all abstracts and full‐text articles for eligibility according to the <a href="#CD012663-sec-0051">Criteria for considering studies for this review</a>. We contacted study authors to obtain additional information when reported data were insufficient. When more than one publication on the same cohort was found, we selected the most complete publication. We resolved disagreements by consensus (FD, DO and IS). </p> </section> <section id="CD012663-sec-0066"> <h4 class="title">Data extraction and management</h4> <p>Two review authors (FD, DO) extracted data using a predefined data‐extraction form. FD and DO extracted variables on study methodology, patient characteristics, test characteristics, the definition of target conditions and results. We constructed two‐by‐two tables for cross‐classification of the index tests versus reference standard for test accuracy data, and the MRI pathway versus systematic biopsy for agreement data, based on per‐participant data (<a href="./appendices#CD012663-sec-0137">Appendix 1</a>). We contacted study authors to obtain additional information when necessary. We resolved any data extraction disagreements by consensus (FD, DO, IS). </p> </section> <section id="CD012663-sec-0067"> <h4 class="title">Assessment of methodological quality</h4> <p>Two review authors (FD, DO) independently assessed all included studies for methodological quality using the Quality Assessment of Diagnostic Accuracy Studies (QUADAS‐2) tool (<a href="./references#CD012663-bbs2-0152" title="WhitingPF , RutjesAW , WestwoodME , MallettS , DeeksJJ , ReitsmaJB , et al. QUADAS‐2: a revised tool for the quality assessment of diagnostic accuracy studies. Annals of Internal Medicine2011;155(8):529‐36. ">Whiting 2011</a>), tailored to this review (<a href="#CD012663-tbl-0007">Table 1</a>). We resolved any discrepancies by discussion (FD, DO, IS). </p> <div class="table" id="CD012663-tbl-0007"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">QUADAS‐2 tool for assessing methodological quality of included studies</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Domain 1: Participant selection</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>SQ 1</b>: Was a consecutive or random sample of participants enrolled? </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes: if stated that participants were consecutively or randomly selected</p> <p>No: if one of these criteria was not met</p> <p>Unclear: if insufficient information to make a judgement</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>SQ 2:</b> Did the study avoid inappropriate exclusions? </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes: if stated that the study did not exclude men 1) aged between 50 and 70 years, 2) with PSA values between 4 and 10 ng/mL, or 3) with an abnormal DRE </p> <p>No: if one of these criteria was not met</p> <p>Unclear: insufficient information to make a judgement</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Risk of bias</b> </p> <p>Could the selection of participants have introduced bias?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk: if ‘Yes’ for all SQ's</p> <p>High risk: if ‘No’ for at least 1 SQ</p> <p>Unclear risk: if 'Unclear' for at least 1 SQ</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Concerns for applicability</b> </p> <p>Are there concerns that the included participants and setting do not match the review question? </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low concern: the participants were referred because of a suspicion of prostate cancer.</p> <p>High concern: the participants were not referred because of a suspicion of prostate cancer, e.g. PSA‐screening trials are less applicable to the current clinical practice. </p> <p>Unclear concern: insufficient information to make a judgement</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Domain 2: Index texts</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>SQ 1</b>: If applicable, was the MRI assessed without knowledge of the results of the reference (or other index) biopsies? </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes: if stated that the radiologist was unaware of all biopsy results; or, if the order of testing was MRI before all biopsies for every participant </p> <p>No: if stated that the radiologist was aware of any biopsy results during MRI assessment</p> <p>Unclear: insufficient information to make a judgement</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>SQ 2</b>: If applicable, were the MRI‐targeted biopsies performed independently of the performance and the results of the reference (or other index) biopsies? </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes: if stated that the performance of MRI‐targeted biopsies was not influenced by the performance or trajectory of reference (or other index) biopsies </p> <p>No: if stated that MRI‐targeted biopsies were not, or differently, taken from locations already hit by the reference (or other index) biopsies; or, if the performance of MRI‐targeted biopsies was dependent on the judgement of the same operator that also performed the reference (or other index) biopsies without blinding </p> <p>Unclear: insufficient information to make a judgement</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>SQ 3</b>: If applicable, were the systematic biopsies taken independently of the performance and the results of the reference (of other index) biopsies? </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes: if stated that the systematic biopsies were taken blinded for</p> <p> <ol id="CD012663-list-0005"> <li> <p>the results of the MRI</p> </li> <li> <p>the reference or other index biopsy trajectories</p> </li> </ol> </p> <p>No: if stated that the systematic biopsy operator was not blinded for MRI results, or was the same operator that also performed the reference (or other index) biopsies without blinding </p> <p>Unclear: insufficient information to make a judgement</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Risk of bias</b> </p> <p>Could the conduct or interpretation of the index test have introduced bias?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk: ‘Yes’ for all applicable SQs</p> <p>High risk: ‘No’ for at least one applicable SQ</p> <p>Unclear risk: ‘Unclear’ for at least one applicable SQ</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Concerns for applicability</b> </p> <p>Are there concerns that the index tests, their conduct or their interpretation differ from the review question? </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low concern: if stated that, when applicable,</p> <p> <ol id="CD012663-list-0006"> <li> <p>a 1.5 or 3 Tesla magnet was used for MRI acquisition, with at least T2 and DWI or DCE sequencing; </p> </li> <li> <p>the MRI‐scoring system and positivity‐threshold for MRI‐targeted biopsy consisted of a 1‐5 score with threshold ≥ 3; </p> </li> <li> <p>software‐assisted, cognitive or in‐bore MRI‐targeted biopsies were taken,</p> </li> <li> <p>an extended sextant systematic biopsy was performed with 8‐19 cores distributed appropriately to sample the peripheral zone. </p> </li> </ol> </p> <p>High concern: the index test did not meet the criteria above</p> <p>Unclear concern: insufficient information to make a judgement</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Domain 3: Reference standard</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>SQ1</b>: Is the reference standard likely to correctly classify the target condition? (i.e. Is histological diagnosis made from appropriately sampled tissue?) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes: if stated that the whole prostate was comprehensively sampled by a full 5‐mm transperineal TTMB, or by a equivalently well described transperineal template‐guided biopsy method with a prostate volume based median of ≤ 20 biopsy cores. </p> <p>No: one of these criteria was not met (i.e. in‐house transperineal saturation biopsy or transrectal saturation biopsy are less likely to appropriately sample the whole prostate). </p> <p>Unclear: insufficient information to make a judgement</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>SQ2</b>: Was the reference standard performed independent of the index test? </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes: if stated that the reference biopsies were taken without knowledge of the MRI‐score and location of target lesions; and, if incorporation was avoided (i.e. the index test was not part of the reference standard). </p> <p>No: one of these criteria was not met</p> <p>Unclear: insufficient information to make a judgement</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Risk of bias</b> </p> <p>Could the reference standard, its conduct, or its interpretation have introduced bias?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk: 'Yes’ for all SQs</p> <p>High risk: ’No’ for at least 1 of the 3 SQs</p> <p>Unclear risk: ’Unclear’ for at least 1 SQ</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Concerns for applicability</b> </p> <p>Are there concerns that the target condition as defined by the reference standard does not match the question? </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low concern: data were presented for GS ≥ 3+4 without any volume criteria (ISUP grade ≥ 2), if necessary after requesting additional data from study authors </p> <p>High concern: data were presented for an alternative target condition definition and study authors did not provide additional data. </p> <p>Unclear: insufficient information to make a judgement</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Domain 4: Flow and timing</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>SQ1</b>: Did all participants receive the same biopsy methods (i.e. was differential verification avoided)? </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes: if stated that all participants received the same type of index test(s) and reference standard, prostate volume dependency was allowed. </p> <p>No: if one of these criteria was not met</p> <p>Unclear: if insufficient information to make a judgement</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>SQ2</b>: Were all enrolled participants included in the analysis, or were exclusions explained and not leading to a relevant bias? </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes: if stated that all eligible participants were enrolled and included in the final analyses; or, if reasons to excluded participants did not cause a relevant bias (e.g. participants with claustrophobia who refused MRI). </p> <p>No: one of these criteria was not met.</p> <p>Unclear: if insufficient information to make a judgement</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Risk of bias</b> </p> <p>Could the participant flow have introduced bias?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk: ’Yes’ for all SQs</p> <p>High risk: ’No’ for at least 1 SQ</p> <p>Unclear risk: ’Unclear’, for at least 1 SQ</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>DCE:</b> dynamic contrast‐enhanced; <b>DRE:</b> digital rectal examination; <b>DWI:</b> diffusion‐weighted imaging; <b>MRI:</b> magnetic resonance imaging; <b>PSA:</b> prostate‐specific antigen; <b>QUADAS:</b> Quality Assessment of Diagnostic Accuracy Studies; <b>SQ:</b> signalling question; <b>TTMB:</b> template‐guided mapping biopsy; <b>ISUP:</b> International Society of Urological Pathology </p> </td> </tr> </tbody> </table> </div> </section> <section id="CD012663-sec-0068"> <h4 class="title">Statistical analysis and data synthesis</h4> <p>For the test accuracy analyses (MRI, MRI‐targeted biopsy, MRI pathway, systematic biopsy versus reference standard (template‐guided biopsy)), we calculated pooled estimates of sensitivity and specificity using the bivariate model, in accordance with the <i>Cochrane Handbook for Diagnostic Test Accuracy Reviews</i> (<a href="./references#CD012663-bbs2-0117" title="MacaskillP , GatsonisC , DeeksJJ , HarbordRM , TakwoingiY . Chapter 10: Analysing and presenting results. In: Deeks JJ, Bossuyt PM, Gatsonis C (editors), Cochrane Handbook for Systematic Reviews of Diagnostic Test Accuracy Version 1.0. The Cochrane Collaboration, 2010. Available from: srdta.cochrane.org/. ">Macaskill 2010</a>). Furthermore, we assessed heterogeneity graphically using paired forest plots of sensitivity and specificity (<a href="./references#CD012663-bbs2-0117" title="MacaskillP , GatsonisC , DeeksJJ , HarbordRM , TakwoingiY . Chapter 10: Analysing and presenting results. In: Deeks JJ, Bossuyt PM, Gatsonis C (editors), Cochrane Handbook for Systematic Reviews of Diagnostic Test Accuracy Version 1.0. The Cochrane Collaboration, 2010. Available from: srdta.cochrane.org/. ">Macaskill 2010</a>). If we observed little or no heterogeneity, we considered simplifications of the bivariate models by dropping the correlation between sensitivity and specificity. We compared index tests by combining all the studies that investigated the index test of interest and adding a covariate to the bivariate model for the type of index test. We used likelihood ratio tests to assess whether the pooled sensitivity and specificity differed significantly between index tests. We based prevalences on the number of prostate cancers detected by the reference standard. </p> <p>For the agreement analysis (MRI pathway versus systematic biopsy), we focused on the number of target conditions identified (concordance and discordance of test results) because neither test is a valid reference test. We calculated the proportion of detected cases (total number of cancers) as the number of concordant positive results plus the number of discordant positive results of both tests (<a href="./appendices#CD012663-sec-0137">Appendix 1</a>). We calculated the detection rate of either test as the number of positive results of that test divided by the total number of cancers detected. We synthesised pooled estimates of detection ratios (detection rate of the MRI pathway:detection rate of systematic biopsy) by performing random‐effects meta‐analyses. We calculated the variance of the detection ratio taking into account the paired data in the analysis. We pooled the detection ratio on a log‐scale and used the delta method to estimate the standard error of the detection ratio on the log scale. </p> <p>To calculate pooled proportions of prostate cancer not detected by systematic biopsy but only by the MRI pathway (added value MRI pathway) and pooled proportions of prostate cancer not detected by the MRI pathway but only by systematic biopsy (added value systematic biopsy), we used mixed models (multinomial logistic regression models with a random intercept for study effects). To calculate the pooled proportions of participants with prostate cancer and a negative MRI, we performed a random‐effects meta‐analysis on these proportions after transformation to the log‐odds scale. The added‐value data were constructed such that we assessed the tests as add‐on tests (i.e. considering reclassification by each test) (<a href="./appendices#CD012663-sec-0143">Appendix 3</a>). We based post‐test probability estimates (negative predictive values (NPV) and positive predictive values (PPV)) on Bayes’ theorem, using the point estimates and 95% confidence intervals of the pooled positive and negative likelihood ratio, with prevalences based on the test accuracy data and given clinically useful percentages (10% (low) to 50% (high)). We used Statistical Analysis Software (SAS) version 9.3 for Windows and R version 3.5.0 to perform all statistical analyses. </p> </section> <section id="CD012663-sec-0069"> <h4 class="title">Investigations of heterogeneity</h4> <p>To explore sources of heterogeneity, we assessed the following covariates by adding them one by one in our bivariate model: population setting (biopsy naïve versus prior negative biopsy); MRI magnet strength (3 versus 1.5 T); MRI sequence (multiparametric MRI versus biparametric MRI); MRI positivity threshold (4/5 or more (high) versus 3/5 or more (intermediate) versus 2/5 or more (low)); use of endorectal coil; MRI‐targeted biopsy method (software versus visual registration); biopsy approach (transperineal versus transrectal); and radiologist experience (high versus little or unclear). We scored radiologist experience in studies as high when the radiologist was 'experienced', 'dedicated', a 'uro‐' or 'mpMRI‐radiologist', or when radiologists had prostate MRI training, more than one year's or more than 100 cases' experience in reading prostate MRI. We scored radiologist experience as 'little' when studies reported a lack of experience. We tested the same covariates using meta‐regression techniques for the detection ratio. To ensure adequate data for the analyses, we applied an arbitrary threshold of five studies for each subgroup of a covariate investigated in the analyses of heterogeneity. </p> </section> <section id="CD012663-sec-0070"> <h4 class="title">Sensitivity analyses</h4> <p>To examine the robustness of our findings, we performed several sensitivity analyses, limited to studies meeting certain quality or additional criteria. The quality criteria comprised low risk of bias and no applicability concerns in the QUADAS‐2 domains. The additional criteria comprised: </p> <p> <ol id="CD012663-list-0007"> <li> <p>using an MRI positivity threshold of 3/5 of more;</p> </li> <li> <p>tests with head‐to‐head comparative data only (MRI versus the MRI pathway; MRI positivity threshold effect (3/5 or more to 4/5 or more)); </p> </li> <li> <p>comparison within the same study (biopsy naïve versus prior negative biopsy);</p> </li> <li> <p>a reference standard with template‐guided biopsy via the transperineal approach;</p> </li> <li> <p>a composite reference standard (template‐guided biopsy and MRI‐targeted biopsy); and</p> </li> <li> <p>highly experienced radiologist(s).</p> </li> </ol> </p> </section> <section id="CD012663-sec-0071"> <h4 class="title">Assessment of reporting bias</h4> <p>We did not assess reporting bias, since there is no evidence of reporting bias in test accuracy reviews nor is there a reliable method to detect this (<a href="./references#CD012663-bbs2-0088" title="DeeksJJ , MacaskillP , IrwigL . The performance of tests of publication bias and other sample size effects in systematic reviews of diagnostic test accuracy was assessed. Journal of Clinical Epidemiology2005;58(9):882‐93. ">Deeks 2005</a>). </p> <section id="CD012663-sec-0072"> <h5 class="title">Certainty of evidence and summary of findings tables</h5> <p>We rated the certainty of evidence on a per‐outcome basis according to Grading of Recommendations Assessment, Development and Evaluation (GRADE) guidance for studies of diagnostic accuracy (<a href="./references#CD012663-bbs2-0140" title="SchünemannHJ , OxmanAD , BrozekJ , GlasziouP , JaeschkeR , VistGE , et al. Grading quality of evidence and strength of recommendations for diagnostic tests and strategies. British Medical Journal2008;336(7653):1106‐10. ">Schünemann 2008</a>). GRADE takes into account five criteria related not only to internal validity (study limitations or risk of bias, inconsistency, imprecision, publication bias), but also to external validity (directness of results). We applied the following methods: </p> <p> <ul id="CD012663-list-0008"> <li> <p><i>Study limitations and risk of bias:</i> We used QUADAS‐2 to assess risk of bias. </p> </li> <li> <p><i>Indirectness:</i> We considered indirectness from the perspective of test accuracy. We used QUADAS‐2 for concerns of applicability and looked for important differences between the populations studied (for example, in the spectrum of disease) and the setting. </p> </li> <li> <p><i>Inconsistency:</i> We assessed pooled sensitivity and specificity estimates for clinically important inconsistency and downgraded if this remained unexplained by prespecified secondary analyses. </p> </li> <li> <p><i>Imprecision:</i> We used a contextualized approach and considered a precise estimate to be one that would allow a clinically meaningful decision. When assessing the need to downgrade for imprecision, we assessed whether an effect size taken from the upper or lower boundary of the confidence intervals for our projected true positives, false negatives, true negatives and false positives for a given prevalence would have changed these clinical judgments about the usefulness of a given test. </p> </li> <li> <p><i>Publication bias:</i> See above. </p> </li> </ul> </p> <p>For the four main comparisons, we rated the certainty of evidence for true positives and false negatives as well as true negatives and false positives as 'high', 'moderate', 'low', or 'very low' using GRADEpro GDT. We present summaries of the evidence in 'Summary of findings' tables (<a href="./full#CD012663-tbl-0003">summary of findings Table 3</a>; <a href="./full#CD012663-tbl-0004">summary of findings Table 4</a>; <a href="./full#CD012663-tbl-0005">summary of findings Table 5</a>; <a href="./full#CD012663-tbl-0006">summary of findings Table 6</a>), which provide key information about the best estimate of the magnitude of the effect in relative terms and absolute differences for each relevant comparison of alternative management strategies; numbers of participants and studies addressing each important outcome; and the rating of the confidence in effect estimates. </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD012663-sec-0073" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD012663-sec-0073"></div> <section id="CD012663-sec-0074"> <h3 class="title" id="CD012663-sec-0074">Results of the search</h3> <p>Of the 18,286 records found through the search strategy, we assessed 551 full‐text articles for eligibility (<a href="#CD012663-fig-0002">Figure 2</a>). A total of 43 studies were eligible for inclusion in this review and provided data for multiple tests. We present study and patient baseline characteristics per test in <a href="#CD012663-tbl-0008">Table 2</a> and <a href="#CD012663-tbl-0009">Table 3</a> for the test accuracy analysis and <a href="#CD012663-tbl-0010">Table 4</a> and <a href="#CD012663-tbl-0011">Table 5</a> for the agreement analysis (and <a href="./appendices#CD012663-sec-0144">Appendix 4</a>). </p> <div class="figure" id="CD012663-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Study flow chart  csPCa: clinically significant prostate cancer; MRI: magnetic resonance imaging; MRI pathway: magnetic resonance imaging with subsequent magnetic resonance imaging‐targeted biopsy; MRI‐TBx: magnetic resonance imaging‐targeted biopsy; SBx: systematic biopsy" data-id="CD012663-fig-0002" src="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_n/nCD012663-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow chart<br/> <b>csPCa:</b> clinically significant prostate cancer; <b>MRI:</b> magnetic resonance imaging; MRI pathway<b>:</b> magnetic resonance imaging with subsequent magnetic resonance imaging‐targeted biopsy; <b>MRI‐TBx:</b> magnetic resonance imaging‐targeted biopsy; <b>SBx:</b> systematic biopsy </p> </div> </div> </div> <div class="table" id="CD012663-tbl-0008"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Study characteristics of the diagnostic test accuracy analyses studies</span></div> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="4" rowspan="1" valign="top"> <p><b>Study</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>MRI</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Index biopsy</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Reference standard</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Target<br/> conditions</b> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Consecutive<br/> enrolment<br/> (study design<sup>a</sup>)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>N of<br/> participants</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Index<br/> test(s)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MRI‐scale;<br/> threshold</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MRI‐TBx<br/> Technique/route</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Technique</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Median N<br/> cores (range)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Independence</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>ISUP<br/> grade<br/> (G)</b> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012663-bbs2-0001" title="Abd‐Alazeez , M , AryaHU , CharmanSC , AnastasiadisE , FreemanA , EmbertonM , et al. The accuracy of multiparametric MRI in men with negative biopsy and elevated PSA level‐Can it rule out clinically significant prostate cancer?. Urologic Oncology2014;32(1):45.e17‐45.e22. ">Abd‐Alazeez 2014</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No<br/> (retrospective) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MRI</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1‐5; ≥ 3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cognitive/transperineal</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TTMB</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45 (21‐137)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G = 1<br/> G ≥ 2<br/> G ≥ 3 </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012663-bbs2-0002" title="AhmedHU , El‐Shater BosailyA , BrownLC , GabeR , KaplanR , ParmarMK , et al. Diagnostic accuracy of multi‐parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. Lancet2017;389(10071):815‐22. ">Ahmed 2017</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes<br/> (prospective) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>576</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MRI, SBx</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1‐5; ≥ 3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA/transrectal</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TTMB</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&gt; 40<sup>b</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G = 1<br/> G ≥ 2<br/> G ≥ 3 </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012663-bbs2-0011" title="Dal MoroF , ZecchiniG , MorlaccoA , GardimanMP , LacognataCS , LauroA , et al. Does 1.5 T mpMRI play a definite role in detection of clinically significant prostate cancer? Findings from a prospective study comparing blind 24‐core saturation and targeted biopsies with a novel data remodeling model. Aging Clinical and Experimental Research2019;31(1):115‐23. ">Dal Moro 2019</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes<br/> (prospective) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>123</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MRI,<br/> MRI‐TBx,<br/> MRI‐pathway </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1‐5; ≥ 3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cognitive/transrectal</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TSB<sup>c</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24<sup>d</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G = 1<br/> G ≥ 2<br/> G ≥ 3 </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012663-bbs2-0013" title="DistlerFA , RadtkeJP , BonekampD , KeschC , SchlemmerHP , WieczorekK , et al. The value of PSA density in combination with PI‐RADS for the accuracy of prostate cancer prediction. The Journal of Urology2017;198(3):575‐82. ">Distler 2017</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes<br/> (prospective) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bx‐naïve: 597<br/> Prior‐negative Bx: 443 </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MRI,<br/> MRI‐TBx,<br/> MRI‐pathway </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1‐5; ≥ 3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Software/transperineal</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TSB<sup>e</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 (22‐25)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G ≥ 2</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012663-bbs2-0016" title="GreyAD , ChanaMS , PopertR , WolfeK , LiyanageSH , AcherPL . Diagnostic accuracy of magnetic resonance imaging (MRI) prostate imaging reporting and data system (PI‐RADS) scoring in a transperineal prostate biopsy setting. BJU International2015;115(5):728‐35. ">Grey 2015</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes<br/> (prospective) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bx‐naïve: 83<br/> Prior‐negative Bx: 103 </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MRI</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1‐5; ≥ 3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cognitive/transperineal</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TSB<sup>e</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(24‐40)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G = 1<br/> G ≥ 2<br/> G ≥ 3 </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012663-bbs2-0018" title="HansenN , PatrunoG , WadhwaK , GazievG , MianoR , BarrettT , et al. Magnetic resonance and ultrasound image fusion supported transperineal prostate biopsy using the Ginsburg protocol: technique, learning points, and biopsy results. Eurpean Urology2016;70(2):332‐40. ">Hansen 2016a</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes<br/> (prospective) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>295</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MRI,<br/> MRI‐TBx,<br/> MRI‐pathway </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1‐5; ≥ 3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Software/transperineal</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TSB<sup>e</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(18‐24)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G = 1<br/> G ≥ 2<br/> G ≥ 3 </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012663-bbs2-0020" title="HansenNL , BarrettT , KeschC , PepdjonovicL , BonekampD , O'SullivanR , et al. Multicentre evaluation of magnetic resonance imaging supported transperineal prostate biopsy in biopsy naïve men with suspicion of prostate cancer. BJU International2018;122(1):40‐9. ">Hansen 2018</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes<br/> (prospective) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Centre 1: 163<br/> Centre 3: 242 </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MRI</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1‐5; ≥ 3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Software,<br/> cognitive/transperineal </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TSB<sup>e</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 (22‐26<sup>f</sup>),<br/> 20 (20‐21<sup>f</sup>) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G = 1<br/> G ≥ 2<br/> G ≥ 3 </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012663-bbs2-0019" title="HansenNL , KeschC , BarrettT , KooB , RadtkeJP , BonekampD , et al. Multicentre evaluation of targeted and systematic biopsies using magnetic resonance and ultrasound image‐fusion guided transperineal prostate biopsy in patients with a previous negative biopsy. BJU International2017;120(5):631‐8. ">Hansen 2017</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear<br/> (prospective) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>287</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MRI,<br/> MRI‐TBx,<br/> MRI‐pathway </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1‐5; ≥ 3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Software/transperineal</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TSB<sup>e</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 (24‐25)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G ≥ 2</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012663-bbs2-0023" title="KeschC , RadtkeJP , PopeneciuIV , GaschC , DieffenbacherSC , KleinT , et al. TOP: prospective evaluation of a volume based, computer assisted method for transperineal optimized prostate biopsy. Urologia Internationalis2017;99(2):149‐55. ">Kesch 2017</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear<br/> (prospective) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bx‐naïve: 95<br/> Prior‐negative Bx: 51 </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MRI,<br/> MRI‐TBx,<br/> MRI‐pathway </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1‐5; ≥ 3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Software/transperineal</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TSB<sup>g</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 (23‐27<sup>f</sup>) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G = 1<br/> G ≥ 2<br/> G ≥ 3 </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012663-bbs2-0025" title="LawrenceEM , TangSY , BarrettT , KooB , GoldmanDA , WarrenAY , et al. Prostate cancer: performance characteristics of combined T2W and DW‐MRI scoring in the setting of template transperineal re‐biopsy using MR‐TRUS fusion. European Radiology2014;24(7):1497‐505. ">Lawrence 2014</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No<br/> (retrospective) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MRI,<br/> MRI‐TBx,<br/> MRI‐pathway </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1‐4; ≥2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Software/transperineal</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TSB<sup>e</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 (14‐34)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G = 1<br/> G ≥ 2 </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012663-bbs2-0028" title="MortezaviA , MärzendorferO , DonatiOF , RizziG , RuppNJ , WettsteinMS , et al. Diagnostic accuracy of multiparametric magnetic resonance imaging and fusion guided targeted biopsy evaluated by transperineal template saturation prostate biopsy for the detection and characterization of prostate cancer. Journal of Urology2018;200(2):309‐18. ">Mortezavi 2018</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes<br/> (retrospective) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>163<br/> 86 </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MRI,<br/> MRI‐TBx,<br/> MRI‐pathway </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1‐5; ≥ 3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Software/Transrectal</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TSB</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40 (30‐55)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G = 1<br/> G ≥ 2<br/> G ≥ 3 </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012663-bbs2-0029" title="MuthuveloeD , TelfordR , VineyR , PatelP . The detection and upgrade rates of prostate adenocarcinoma following transperineal template‐guided prostate biopsy – a tertiary referral centre experience. Central European Journal of Urology2016;69(1):42‐7. ">Muthuveloe 2016</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear<br/> (retrospective) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9<br/> 162 </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MRI</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1‐5; ≥ 3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TSB<sup>h</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 (24–28)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G = 1<br/> G ≥ 2<br/> G ≥ 3 </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012663-bbs2-0035" title="PepeP , GarufiA , PrioloG , CandianoG , PietropaoloF , PennisiM , et al. Prostate cancer detection at repeat biopsy: can pelvic phased array multiparametric MRI replace saturation biopsy?. Anticancer Research2013;33(3):1195‐200. ">Pepe 2013</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear<br/> (prospective) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>78</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MRI,<br/> MRI‐TBx,<br/> MRI‐pathway </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0‐1: ≥1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cognitive/transrectal</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TSB<sup>h</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28 (26‐32)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G = 1<br/> G ≥ 2 </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012663-bbs2-0040" title="ThompsonJE , VanLeeuwenPJ , MosesD , ShnierR , BrennerP , DelpradoW , et al. The diagnostic performance of multiparametric magnetic resonance imaging to detect significant prostate cancer. Journal of Urology2016;195(5):1428‐35. ">Thompson 2016</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes<br/> (prospective) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>344</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MRI</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1‐5; ≥ 3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Software,<br/> cognitive/transperineal </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TTMB</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G = 1<br/> G ≥ 2<br/> G ≥ 3 </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012663-bbs2-0042" title="TsivianM , GuptaRT , TsivianE , QiP , MendezMH , AbernMR , et al. Assessing clinically significant prostate cancer: diagnostic properties of multiparametric magnetic resonance imaging compared to three‐dimensional transperineal template mapping histopathology. International Journal of Urology2017;24(2):137‐43. ">Tsivian 2017</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear<br/> (retrospective) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MRI</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1‐5; ≥ 3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TTMB</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55 (42‐63<sup>f</sup>) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G = 1<br/> G ≥ 2<br/> G ≥ 3 </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012663-bbs2-0030" title="NafieS , MellonJK , DormerJP , KhanMA . The role of transperineal template prostate biopsies in prostate cancer diagnosis in biopsy naïve men with PSA less than 20 ng mL‐1. Prostate Cancer and Prostatic Diseases2014;17(2):170‐3. ">Nafie 2014</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear<br/> (prospective) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SBx</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA/transrectal</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TSB<sup>h</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G = 1<br/> G ≥ 2<br/> G ≥ 3 </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012663-bbs2-0031" title="NafieS , WanisM , KhanM . The efficacy of transrectal ultrasound guided biopsy versus transperineal template biopsy of the prostate in diagnosing prostate cancer in men with previous negative transrectal ultrasound guided biopsy. Urology Journal2017;14(2):3008‐12. ">Nafie 2017</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear<br/> (prospective) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SBx</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA/transrectal</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TSB<sup>h</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G = 1<br/> G ≥ 2 </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012663-bbs2-0036" title="PloussardG , NicolaiewN , MarchandC , TerryS , VacherotF , VordosD , et al. Prospective evaluation of an extended 21‐core biopsy scheme as initial prostate cancer diagnostic strategy. European Urology2014;65(1):154‐61. ">Ploussard 2014</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes<br/> (prospective) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2753</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SBx</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA/transrectal</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TSB<sup>c</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G = 1<br/> G ≥ 2 </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="10" rowspan="1" valign=""> <p><b>Bx:</b> biopsy; <b>ISUP G :</b> International Society of Urological Pathology grade; <b>MRI:</b> magnetic resonance imaging; <b>MRI‐pathway:</b> magnetic resonance imaging with or without magnetic resonance imaging‐targeted biopsy; <b>MRI‐TBx:</b> magnetic resonance imaging‐targeted biopsy; <b>N:</b> number; <b>NA:</b> not applicable; <b>PI‐RADS v1, v2:</b> Prostate Imaging Reporting Data System version 1 or 2; <b>SBx:</b> systematic biopsy; <b>TSB:</b> transperineal saturation biopsy; <b>TTMB:</b> transperineal template mapping biopsy </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>a</sup>Included participants were part of the same study cohort (no randomised populations were included).<br/> <sup>b</sup>Not reported but estimated.<br/> <sup>c</sup>Transrectal.<br/> <sup>d</sup>Mean value (as opposed to median).<br/> <sup>e</sup>Ginsburg biopsies.<br/> <sup>f</sup>Interquartile range (as opposed to range).<br/> <sup>g</sup>Transperineal optimised prostate biopsy (TOP).<br/> <sup>h</sup>In‐house transperineal saturation biopsy </p> </div> </div> <div class="table" id="CD012663-tbl-0009"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Patient characteristics of the diagnostic test accuracy studies</span></div> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Patient characteristics of the included diagnostic test accuracy studies</b> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Population</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Median age<br/> (range/SD)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Median PSA<br/> in ng/mL (range)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Median prostate<br/> volume in cm<sup>3</sup><br/> (range)</b> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012663-bbs2-0001" title="Abd‐Alazeez , M , AryaHU , CharmanSC , AnastasiadisE , FreemanA , EmbertonM , et al. The accuracy of multiparametric MRI in men with negative biopsy and elevated PSA level‐Can it rule out clinically significant prostate cancer?. Urologic Oncology2014;32(1):45.e17‐45.e22. ">Abd‐Alazeez 2014</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prior‐negative Bx</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64 (39‐75)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 (2‐23)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>53 (19‐136)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012663-bbs2-0002" title="AhmedHU , El‐Shater BosailyA , BrownLC , GabeR , KaplanR , ParmarMK , et al. Diagnostic accuracy of multi‐parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. Lancet2017;389(10071):815‐22. ">Ahmed 2017</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bx‐naïve</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>63 (7.6)<sup>a</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.1 (2.9)<sup>a</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012663-bbs2-0011" title="Dal MoroF , ZecchiniG , MorlaccoA , GardimanMP , LacognataCS , LauroA , et al. Does 1.5 T mpMRI play a definite role in detection of clinically significant prostate cancer? Findings from a prospective study comparing blind 24‐core saturation and targeted biopsies with a novel data remodeling model. Aging Clinical and Experimental Research2019;31(1):115‐23. ">Dal Moro 2019</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prior‐negative Bx</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62 (57‐68<sup>b</sup>) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.3 (4,8‐8,9<sup>b</sup>) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55 (20‐149)<sup>a</sup> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012663-bbs2-0013" title="DistlerFA , RadtkeJP , BonekampD , KeschC , SchlemmerHP , WieczorekK , et al. The value of PSA density in combination with PI‐RADS for the accuracy of prostate cancer prediction. The Journal of Urology2017;198(3):575‐82. ">Distler 2017</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mixed<sup>c</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65 (60‐71<sup>b</sup>) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.2 (5.3‐10.4<sup>b</sup>) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45 (34‐64<sup>b</sup>) </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012663-bbs2-0016" title="GreyAD , ChanaMS , PopertR , WolfeK , LiyanageSH , AcherPL . Diagnostic accuracy of magnetic resonance imaging (MRI) prostate imaging reporting and data system (PI‐RADS) scoring in a transperineal prostate biopsy setting. BJU International2015;115(5):728‐35. ">Grey 2015</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mixed<sup>c</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64 (6.8)<sup>a</sup><br/> 65 (7.6)<sup>a</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13.3 (12,1)<sup>a</sup><br/> 12.6 (13.7)<sup>a</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>68 (35)<sup>a</sup><br/> 54 (31)<sup>a</sup> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012663-bbs2-0018" title="HansenN , PatrunoG , WadhwaK , GazievG , MianoR , BarrettT , et al. Magnetic resonance and ultrasound image fusion supported transperineal prostate biopsy using the Ginsburg protocol: technique, learning points, and biopsy results. Eurpean Urology2016;70(2):332‐40. ">Hansen 2016a</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prior‐negative Bx</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65 (59‐69<sup>b</sup>) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.8 (6.0‐12<sup>b</sup>) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65 (44‐83<sup>b</sup>) </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012663-bbs2-0020" title="HansenNL , BarrettT , KeschC , PepdjonovicL , BonekampD , O'SullivanR , et al. Multicentre evaluation of magnetic resonance imaging supported transperineal prostate biopsy in biopsy naïve men with suspicion of prostate cancer. BJU International2018;122(1):40‐9. ">Hansen 2018</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bx‐naïve</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64 (57‐69<sup>b</sup>)<br/> 65 (60‐70<sup>b</sup>) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.6 (4.6‐9.0<sup>b</sup>)<br/> 5.9 (4.6‐8.0<sup>b</sup>) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44 (33‐55<sup>b</sup>)<br/> 25 (24‐47<sup>b</sup>) </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012663-bbs2-0019" title="HansenNL , KeschC , BarrettT , KooB , RadtkeJP , BonekampD , et al. Multicentre evaluation of targeted and systematic biopsies using magnetic resonance and ultrasound image‐fusion guided transperineal prostate biopsy in patients with a previous negative biopsy. BJU International2017;120(5):631‐8. ">Hansen 2017</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prior‐negative Bx</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66 (61‐72<sup>b</sup>) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.7 (7.1‐13.9<sup>b</sup>) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52 (36‐75<sup>b</sup>) </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012663-bbs2-0023" title="KeschC , RadtkeJP , PopeneciuIV , GaschC , DieffenbacherSC , KleinT , et al. TOP: prospective evaluation of a volume based, computer assisted method for transperineal optimized prostate biopsy. Urologia Internationalis2017;99(2):149‐55. ">Kesch 2017</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mixed<sup>c</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65 (58‐71<sup>b</sup>) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.2 (5.4‐10.2<sup>b</sup>) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46 (36‐60<sup>b</sup>) </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012663-bbs2-0025" title="LawrenceEM , TangSY , BarrettT , KooB , GoldmanDA , WarrenAY , et al. Prostate cancer: performance characteristics of combined T2W and DW‐MRI scoring in the setting of template transperineal re‐biopsy using MR‐TRUS fusion. European Radiology2014;24(7):1497‐505. ">Lawrence 2014</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prior‐negative Bx</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64 (47‐77)<sup>a</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 (1.2‐36)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012663-bbs2-0028" title="MortezaviA , MärzendorferO , DonatiOF , RizziG , RuppNJ , WettsteinMS , et al. Diagnostic accuracy of multiparametric magnetic resonance imaging and fusion guided targeted biopsy evaluated by transperineal template saturation prostate biopsy for the detection and characterization of prostate cancer. Journal of Urology2018;200(2):309‐18. ">Mortezavi 2018</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bx‐naïve<br/> Prior‐negative Bx </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>63 (57‐68<sup>b</sup>)<br/> 64 (60‐69<sup>b</sup>) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.8 (4.4‐8.9<sup>b</sup>)<br/> 8.6 (5.7‐13<sup>b</sup>) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44 (34‐60<sup>b</sup>)<br/> 54 (41‐70<sup>b</sup>) </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012663-bbs2-0029" title="MuthuveloeD , TelfordR , VineyR , PatelP . The detection and upgrade rates of prostate adenocarcinoma following transperineal template‐guided prostate biopsy – a tertiary referral centre experience. Central European Journal of Urology2016;69(1):42‐7. ">Muthuveloe 2016</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bx‐naïve<br/> Prior‐negative Bx </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>68 (46‐81)<br/> 65 (47‐78)<sup>d</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11.5 (1.2‐92.5)</p> <p>10 (2.7‐61)<sup>d</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012663-bbs2-0035" title="PepeP , GarufiA , PrioloG , CandianoG , PietropaoloF , PennisiM , et al. Prostate cancer detection at repeat biopsy: can pelvic phased array multiparametric MRI replace saturation biopsy?. Anticancer Research2013;33(3):1195‐200. ">Pepe 2013</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prior‐negative Bx</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>63 (49‐72)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11 (3.7‐45)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012663-bbs2-0040" title="ThompsonJE , VanLeeuwenPJ , MosesD , ShnierR , BrennerP , DelpradoW , et al. The diagnostic performance of multiparametric magnetic resonance imaging to detect significant prostate cancer. Journal of Urology2016;195(5):1428‐35. ">Thompson 2016</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bx‐naïve</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>63 (56‐67<sup>b</sup>) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.2 (3.7‐7.1<sup>b</sup>) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40 (30‐54<sup>b</sup>) </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012663-bbs2-0042" title="TsivianM , GuptaRT , TsivianE , QiP , MendezMH , AbernMR , et al. Assessing clinically significant prostate cancer: diagnostic properties of multiparametric magnetic resonance imaging compared to three‐dimensional transperineal template mapping histopathology. International Journal of Urology2017;24(2):137‐43. ">Tsivian 2017</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prior‐negative Bx</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65 (61‐69<sup>b</sup>) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.1 (5.1‐13.6<sup>b</sup>) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44 (32‐65<sup>b</sup>) </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012663-bbs2-0030" title="NafieS , MellonJK , DormerJP , KhanMA . The role of transperineal template prostate biopsies in prostate cancer diagnosis in biopsy naïve men with PSA less than 20 ng mL‐1. Prostate Cancer and Prostatic Diseases2014;17(2):170‐3. ">Nafie 2014</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bx‐naïve</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>67 (54‐84)<sup>a</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 (4‐18)<sup>a</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>58 (19‐165)<sup>a</sup> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012663-bbs2-0031" title="NafieS , WanisM , KhanM . The efficacy of transrectal ultrasound guided biopsy versus transperineal template biopsy of the prostate in diagnosing prostate cancer in men with previous negative transrectal ultrasound guided biopsy. Urology Journal2017;14(2):3008‐12. ">Nafie 2017</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prior‐negative Bx</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65 (50‐75)<sup>a</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.3 (4.4‐19)<sup>a</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59 (21‐152)<sup>a</sup> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012663-bbs2-0036" title="PloussardG , NicolaiewN , MarchandC , TerryS , VacherotF , VordosD , et al. Prospective evaluation of an extended 21‐core biopsy scheme as initial prostate cancer diagnostic strategy. European Urology2014;65(1):154‐61. ">Ploussard 2014</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bx‐naïve</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64 (8)<sup>a</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12.5 (7.2)<sup>a</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46 (25)<sup>a</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Bx:</b> biopsy; <b>NR:</b> not reported; <b>PSA:</b> prostate specific antigen </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>a</sup>Mean (standard deviation or range) (as opposed to median (range)).<br/> <sup>b</sup>Interquartile range (as opposed to range).<br/> <sup>c</sup>Results not reported per population type.<br/> <sup>d</sup>Reported per transperineal saturation biopsy‐positive (n = 71) and transperineal saturation biopsy‐negative men (n = 103), respectively. </p> </div> </div> <div class="table" id="CD012663-tbl-0010"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Study characteristics of the agreement analyses studies</span></div> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="4" rowspan="1" valign="top"> <p><b>Study</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>MRI</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="4" rowspan="1" valign="top"> <p><b>Index biopsy</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Target<br/> conditions</b> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Study</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Consecutive<br/> enrolment<br/> (study design<sup>a</sup>)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>N of<br/> participants</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Index tests</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>MRI‐scale;<br/> threshold</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MRI‐TBx</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>SBx</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MRI‐TBx &amp;<br/> SBx</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>ISUP<br/> grade<br/> (G)</b> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Technique</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Median N<br/> cores (range)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Independence</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Route</b> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012663-bbs2-0003" title="AlbertsAR , SchootsIG , BokhorstLP , DrostFH , VanLeendersGJ , KrestinGP , et al. Characteristics of prostate cancer found at fifth screening in the European Randomized Study of Screening for Prostate Cancer Rotterdam: can we selectively detect high‐grade prostate cancer with upfront multivariable risk stratification and magnetic resonance imaging?. European Urology 19 June 2017 [Epub ahead of print];S0302‐2838(17):30514‐6. ">Alberts 2017</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes<br/> (prospective) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bx‐naïve: 74<br/> Prior‐negative Bx: 84 </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MRI‐pathway<br/> vs. SBx </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1‐5; ≥ 3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Software</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> <p>(12‐12<sup>b</sup>) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Transrectal</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G = 1<br/> G ≥ 2<br/> G ≥ 3 </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012663-bbs2-0004" title="BoesenL , NørgaardN , LøgagerV , BalslevI , ThomsenHS . A prospective comparison of selective multiparametric magnetic resonance imaging fusion‐targeted and systematic transrectal ultrasound‐guided biopsies for detecting prostate cancer in men undergoing repeated biopsies. Urologia Internationalis2017;99(4):384‐91. ">Boesen 2017a</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear<br/> (prospective) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>206</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MRI‐pathway<br/> vs. SBx </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1‐5; ≥ 3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Software</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> <p>(10‐10)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Transrectal</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G = 1<br/> G ≥ 2<br/> G ≥ 3 </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012663-bbs2-0005" title="BoesenL , NørgaardN , LøgagerV , BalslevI , BisbjergR , ThestrupK‐C , Winther , et al. Assessment of the diagnostic accuracy of biparametric magnetic resonance imaging for prostate cancer in biopsy‐naïve men the Biparametric MRI for Detection of Prostate Cancer (BIDOC) Study. JAMA Network Open2018;1(2):e180219. ">Boesen 2018</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes<br/> (prospective) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1020</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MRI‐pathway<br/> vs. SBx </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1‐5; ≥ 3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Software</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10<sup>c</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Transrectal</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G = 1<br/> G ≥ 2<br/> G ≥ 3 </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012663-bbs2-0006" title="CastellucciR , Linares QuevedoAI , Sánchez GómezFJ , Díez RodríguezJ , CogornoL , Cogollos AcuñaI , et al. Prospective nonrandomized study of diagnostic accuracy comparing prostate cancer detection by transrectal ultrasound‐guided biopsy to magnetic resonance imaging with subsequent MRI‐guided biopsy in biopsy‐naïve patients. Minerva Urologica e Nefrologica2017;69(6):589‐95. ">Castellucci 2017</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes<br/> (prospective) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>168</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MRI‐pathway<br/> vs. SBx </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1‐5; ≥ 3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cognitive</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(8‐19)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Transrectal</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G = 1<br/> G ≥ 2<br/> G ≥ 3 </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012663-bbs2-0007" title="ChangCH , ChiuHC , LinWC , HoTL , ChangH , ChangYH , et al. The influence of serum prostate‐specific antigen on the accuracy of magnetic resonance imaging targeted biopsy versus saturation biopsy in patients with previous negative biopsy. BioMed Research International2017;2017:7617148. ">Chang 2017</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes<br/> (retrospective) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MRI‐pathway<br/> vs. SBx </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1‐5; ≥ 3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cognitive</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18 (16.2‐19.8<sup>b</sup>) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Transrectal</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G = 1<br/> G ≥ 2<br/> G ≥ 3 </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012663-bbs2-0008" title="ChenJ , YiXL , JiangLX , WangR , ZhaoJG , LiYH , et al. 3‐tesla magnetic resonance imaging improves the prostate cancer detection rate in transrectral ultrasound‑guided biopsy. Experimental and Therapeutic Medicine2015;9(1):207‐12. ">Chen 2015</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes<br/> (prospective) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>420</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MRI‐pathway<br/> vs. SBx </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1‐5; ≥ 3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cognitive</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12<sup>d</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Transperineal</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G ≥ 2</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012663-bbs2-0009" title="CoolDW , RomagnoliC , IzawaJI , ChinJ , GardiL , TessierD , et al. Comparison of prostate MRI‐3D transrectal ultrasound fusion biopsy for first‐time and repeat biopsy patients with previous atypical small acinar proliferation. Canadian Urological Association Journal2016;10(9‐10):342‐8. ">Cool 2016</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear<br/> (prospective) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bx‐naïve: 50<br/> Prior‐negative Bx: 50 </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MRI‐pathway<br/> vs. SBx </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Other</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Software</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12‐14<sup>e</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Transrectal</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G = 1<br/> G ≥ 2 </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012663-bbs2-0010" title="CostaDN , BlochBN , YaoDF , SandaMG , NgoL , GenegaEM , et al. Diagnosis of relevant prostate cancer using supplementary cores from magnetic resonance imaging‐prompted areas following multiple failed biopsies. Magnetic Resonance Imaging2013;31(6):947‐52. ">Costa 2013</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No<br/> (retrospective) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MRI‐pathway<br/> vs. SBx </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1‐5; ≥4</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cognitive</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Transrectal</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G ≥ 2<br/> G ≥ 3 </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012663-bbs2-0012" title="DelongchampsNB , PeyromaureM , SchullA , BeuvonF , BouazzaN , FlamT , et al. Prebiopsy magnetic resonance imaging and prostate cancer detection: comparison of random and targeted biopsies. The Journal of Urology2013;189(2):493‐9. ">Delongchamps 2013</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes<br/> (prospective) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>391</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MRI‐pathway<br/> vs. SBx </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TZ: 0‐4; ≥2<br/> PZ: 0‐10; ≥6 </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Software</p> <p>Cognitive</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> <p>(10‐12)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Transrectal</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G ≥ 2</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012663-bbs2-0014" title="FilsonCP , NatarajanS , MargolisDJ , HuangJ , LieuP , DoreyFJ , et al. Prostate cancer detection with magnetic resonance‐ultrasound fusion biopsy: the role of systematic and targeted biopsies. Cancer2016;122(6):884‐92. ">Filson 2016</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes<br/> (prospective) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bx‐naïve: 329<br/> Prior‐negative Bx: 324 </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MRI‐pathway<br/> vs. SBx </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1‐5; ≥ 3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Software</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Transrectal</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G ≥ 2<br/> G ≥ 3 </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012663-bbs2-0015" title="Garcia BennettJ , VilanovaJC , Guma PadroJ , ParadaD , ConejeroA . Evaluation of MR imaging‐targeted biopsies of the prostate in biopsy naïve patients. A single centre study. Diagnostic and Interventional Imaging2017;98(10):677‐84. ">Garcia Bennett 2017</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear<br/> (prospective) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MRI‐pathway<br/> vs. SBx </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1‐5; ≥ 3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cognitive</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Transperineal</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G = 1<br/> G ≥ 2<br/> G ≥ 3 </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012663-bbs2-0017" title="GrönbergH , EklundM , PickerW , AlyM , JäderlingF , AdolfssonJ , et al. Prostate cancer diagnostics using a combination of the Stockholm3 blood test and multiparametric magnetic resonance imaging. European Urology2018;74(6):722‐8. ">Grönberg 2018</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes<br/> (prospective) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bx‐naïve: 387<br/> Prior‐negative Bx: 145 </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MRI‐pathway<br/> vs. SBx </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1‐5; ≥ 3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Software</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> <p>(10‐12)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Transrectal</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G = 1<br/> G ≥ 2<br/> G ≥ 3 </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012663-bbs2-0021" title="JamborI , KähkönenE , TaimenP , MerisaariH , SaunavaaraJ , AlanenK , et al. Prebiopsy multiparametric 3T prostate MRI in patients with elevated PSA, normal digital rectal examination, and no previous biopsy. Journal of Magnetic Resonance Imaging2015;41(5):1394‐404. ">Jambor 2015</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear<br/> (unclear) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>53</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MRI‐pathway<br/> vs. SBx </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1‐5; ≥4</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cognitive</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Transrectal</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G = 1<br/> G ≥ 2<br/> G ≥ 3 </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012663-bbs2-0022" title="JamborI , BoströmPJ , TaimenP , SyvänenK , KähkönenE , KallajokiM , et al. Novel biparametric MRI and targeted biopsy improves risk stratification in men with a clinical suspicion of prostate cancer (IMPROD Trial). Journal of Magnetic Resonance Imaging2017;46(4):1089‐95. ">Jambor 2017</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear<br/> (prospective) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bx‐naïve: 134<br/> Prior‐negative Bx: 27 </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MRI‐pathway<br/> vs. SBx </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1‐5; ≥ 3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cognitive</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12<sup>c</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Transrectal</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G = 1<br/> G ≥ 2<br/> G ≥ 3 </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012663-bbs2-0024" title="KimEH , WeaverJK , ShettyAS , VetterJM , AndrioleGL , StropeSA . Magnetic resonance imaging provides added value to the prostate cancer prevention trial risk calculator for patients with estimated risk of high‐grade prostate cancer less than or equal to 10%. Urology2017;102:183‐9. ">Kim 2017</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear<br/> (retrospective) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bx‐naïve: 183<br/> Prior‐negative Bx: 154 </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MRI‐pathway<br/> vs. SBx </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1‐5; ≥4</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Software Cognitive</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14<sup>c</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Transrectal</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G = 1<br/> G ≥ 2<br/> G ≥ 3 </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012663-bbs2-0026" title="LeeDH , NamJK , ParkSW , LeeSS , HanJY , LeeSD , et al. Visually estimated MRI targeted prostate biopsy could improve the detection of significant prostate cancer in patients with a PSA level. Yonsei Medical Journal2016;57(3):565‐71. ">Lee 2016</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear<br/> (retrospective) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>76</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MRI‐pathway<br/> vs. SBx </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1‐4; ≥2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cognitive</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> <p>(12‐12)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Transrectal</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G = 1<br/> G ≥ 2<br/> G ≥ 3 </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012663-bbs2-0027" title="LeeDH , NamJK , LeeSS , HanJY , LeeJW , ChungMK , et al. Comparison of multiparametric and biparametric MRI in first round cognitive targeted prostate biopsy in patients with PSA levels under 10 ng/mL. Yonsei Medical Journal2017;58(5):994‐9. ">Lee 2017</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear<br/> (retrospective) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>123</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MRI‐pathway<br/> vs. SBx </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1‐4; ≥2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cognitive</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Transrectal</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G = 1<br/> G ≥ 2<br/> G ≥ 3 </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012663-bbs2-0032" title="OkcelikS , SoydanH , AtesF , BerberU , SayginH , SonmezG , et al. Evaluation of PCA3 and multiparametric MRI's: collective benefits before deciding initial prostate biopsy for patients with PSA level between 3‐10ng/mL. International Brazillian Journal of Urology2016;42(3):449‐55. ">Okcelik 2016</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear<br/> (prospective) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MRI‐pathway<br/> vs. SBx </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0‐1: ≥1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cognitive</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Transrectal</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G = 1<br/> G ≥ 2 </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012663-bbs2-0033" title="PanebiancoV , BarchettiF , SciarraA , CiardiA , IndinoEL , PapaliaR , et al. Multiparametric magnetic resonance imaging vs. standard care in men being evaluated for prostate cancer: a randomized study. Urologic Oncology2015;33(1):17.e1‐17.e7. ">Panebianco 2015</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes<br/> (prospective) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bx‐naïve: 570<br/> Prior‐negative Bx: 355 </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MRI‐pathway<br/> vs. SBx </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1‐5; ≥ 3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cognitive</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10, 14 or 45<sup>f</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Transrectal</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G = 1<br/> G ≥ 2<br/> G ≥ 3 </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012663-bbs2-0034" title="PeltierA , AounF , LemortM , KwizeraF , PaesmansM , VanVelthovenR . MRI‐targeted biopsies versus systematic transrectal ultrasound guided biopsies for the diagnosis of localized prostate cancer in biopsy naïve men. Biomed Research International2015;2015:571708. ">Peltier 2015</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes<br/> (prospective) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>110</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MRI‐pathway<br/> vs. SBx </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1‐4; ≥2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Software</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15<br/> (12‐18) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Transrectal</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G = 1<br/> G ≥ 2<br/> G ≥ 3 </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012663-bbs2-0037" title="PokornyMR , DeRooijM , DuncanE , SchröderFH , ParkinsonR , BarentszJO , et al. Prospective study of diagnostic accuracy comparing prostate cancer detection by transrectal ultrasound‐guided biopsy versus magnetic resonance (MR) imaging with subsequent MR‐guided biopsy in men without previous prostate biopsies. European Urology2014;66(1):22‐9. ">Pokorny 2014</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes<br/> (prospective) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>223</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MRI‐pathway<br/> vs. SBx </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1‐5; ≥ 3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>In‐bore</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Transrectal</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G = 1<br/> G ≥ 2<br/> G ≥ 3 </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012663-bbs2-0038" title="RouvièreO , PuechP , Renard‐PennaR , ClaudonM , RoyC , Mège‐LechavallierF , et al. MRI‐FIRST Investigators. Use of prostate systematic and targeted biopsy on the basis of multiparametric MRI in biopsy‐naïve patients (MRI‐FIRST): a prospective, multicentre, paired diagnostic study. Lancet Oncology2019;20(1):100‐9. ">Rouvière 2019a</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes<br/> (prospective) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>251</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MRI‐pathway<br/> vs. SBx </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1‐5; ≥ 3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Software</p> <p>Cognitive</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12.2<sup>c</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Transrectal</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G = 1<br/> G ≥ 2<br/> G ≥ 3 </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012663-bbs2-0039" title="SayRK . MRI‐ultrasound fusion targeted biopsy in men with prior negative prostate biopsy for prostate cancer [PhD thesis]. Vol. 2078, New Haven, CT: Yale Medicine Thesis Digital Library, 2016. [elischolar.library.yale.edu/ymtdl/2078] ">Say 2016</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes<br/> (retrospective) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>143</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MRI‐pathway<br/> vs. SBx </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1‐4; ≥2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Software</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12<sup>c</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Transrectal</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G = 1<br/> G ≥ 2<br/> G ≥ 3 </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012663-bbs2-0041" title="TonttilaPP , LanttoJ , PääkköE , PiippoU , KauppilaS , LammentaustaE , et al. Prebiopsy multiparametric magnetic resonance imaging for prostate cancer diagnosis in biopsy‐naïve men with suspected prostate cancer based on elevated prostate‐specific antigen values: results from a randomized prospective blinded controlled trial. European Urology2016;69(3):419‐25. ">Tonttilla 2016</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes<br/> (prospective) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>53</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MRI‐pathway<br/> vs. SBx </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1‐4; ≥2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cognitive</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> <p>(12‐14)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Transrectal</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G = 1<br/> G ≥ 2<br/> G ≥ 3 </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012663-bbs2-0043" title="Van derLeestMM , CornelEB , IsraëlB , HendriksRJ , PadhaniAR , HoogenboomM , et al. Head‐to‐head comparison of transrectal ultrasound‐guided prostate biopsy versus multiparametric prostate resonance imaging with subsequent magnetic resonance‐guided biopsy in biopsy‐naïve men with elevated prostate‐specific antigen: a large prospective multicenter clinical study. European Urology 23 November 2018 [Epub ahead of print];S0302‐2838(18):30880‐7. [DOI: 10.1016/j.eururo.2018.11.023] ">Van der Leest 2018</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes<br/> (prospective) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>626</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MRI‐pathway<br/> vs. SBx </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1‐5; ≥ 3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>In‐bore</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12<sup>c</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Transrectal</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G = 1<br/> G ≥ 2<br/> G ≥ 3 </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="10" rowspan="1" valign=""> <p><b>Bx:</b> biopsy; <b>ISUP G :</b> International Society of Urological Pathology grade; <b>MRI:</b> magnetic resonance imaging; <b>MRI‐pathway:</b> magnetic resonance imaging with or without magnetic resonance imaging‐targeted biopsy; <b>MRI‐TBx:</b> magnetic resonance imaging‐targeted biopsy; <b>N:</b> number; <b>NA:</b> not applicable; <b>PI‐RADS v1, v2:</b> Prostate Imaging Reporting Data System version 1 or 2; <b>PZ:</b> peripheral zone; <b>SBx:</b> systematic biopsy; <b>TSB:</b> transperineal saturation biopsy; <b>TTMB:</b> transperineal template mapping biopsy; <b>TZ:</b> transition zone </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>a</sup>Included participants were part of the same study cohort (no randomised populations were included).<br/> <sup>b</sup>Interquartile range (as opposed to range).<br/> <sup>c</sup>Mean value (as opposed to median value).<br/> <sup>d</sup>10 cores in peripheral zone, two cores in transition zone.<br/> <sup>e</sup>2 additional cores in transitional zone in prior‐negative Bx men.<br/> <sup>f</sup>10 and 14 in Bx‐naïve men with positive and negative MRI, respectively; 10 and 45 in prior‐negative Bx men with a positive and negative MRI, respectively. </p> </div> </div> <div class="table" id="CD012663-tbl-0011"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Patient characteristics of the agreement analyses studies</span></div> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Population</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Median age<br/> (range)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Median PSA<br/> in ng/mL (range)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Median prostate<br/> volume in cm<sup>3</sup><br/> (range)</b> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012663-bbs2-0003" title="AlbertsAR , SchootsIG , BokhorstLP , DrostFH , VanLeendersGJ , KrestinGP , et al. Characteristics of prostate cancer found at fifth screening in the European Randomized Study of Screening for Prostate Cancer Rotterdam: can we selectively detect high‐grade prostate cancer with upfront multivariable risk stratification and magnetic resonance imaging?. European Urology 19 June 2017 [Epub ahead of print];S0302‐2838(17):30514‐6. ">Alberts 2017</a><sup>a</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bx‐naïve<br/> Prior‐negative Bx </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>73 (72‐74<sup>b</sup>) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.2 (3.4–5.8<sup>b</sup>) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>53 (37‐71<sup>b</sup>) </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012663-bbs2-0004" title="BoesenL , NørgaardN , LøgagerV , BalslevI , ThomsenHS . A prospective comparison of selective multiparametric magnetic resonance imaging fusion‐targeted and systematic transrectal ultrasound‐guided biopsies for detecting prostate cancer in men undergoing repeated biopsies. Urologia Internationalis2017;99(4):384‐91. ">Boesen 2017a</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prior‐negative Bx</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65 (58‐68<sup>b</sup>) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12.8 (8.9‐19.6<sup>b</sup>) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012663-bbs2-0005" title="BoesenL , NørgaardN , LøgagerV , BalslevI , BisbjergR , ThestrupK‐C , Winther , et al. Assessment of the diagnostic accuracy of biparametric magnetic resonance imaging for prostate cancer in biopsy‐naïve men the Biparametric MRI for Detection of Prostate Cancer (BIDOC) Study. JAMA Network Open2018;1(2):e180219. ">Boesen 2018</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bx‐naïve</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>67 (61‐71<sup>b</sup>) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 (5.7‐13<sup>b</sup>) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>53 (40‐72<sup>b</sup>) </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012663-bbs2-0006" title="CastellucciR , Linares QuevedoAI , Sánchez GómezFJ , Díez RodríguezJ , CogornoL , Cogollos AcuñaI , et al. Prospective nonrandomized study of diagnostic accuracy comparing prostate cancer detection by transrectal ultrasound‐guided biopsy to magnetic resonance imaging with subsequent MRI‐guided biopsy in biopsy‐naïve patients. Minerva Urologica e Nefrologica2017;69(6):589‐95. ">Castellucci 2017</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bx‐naïve</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61 (8)<sup>c</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.3 (6.1)<sup>c</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49 (7)<sup>c</sup> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012663-bbs2-0007" title="ChangCH , ChiuHC , LinWC , HoTL , ChangH , ChangYH , et al. The influence of serum prostate‐specific antigen on the accuracy of magnetic resonance imaging targeted biopsy versus saturation biopsy in patients with previous negative biopsy. BioMed Research International2017;2017:7617148. ">Chang 2017</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prior‐negative Bx</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64 (60‐68<sup>b</sup>) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.9 (7.2‐14.7<sup>b</sup>) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48 (34‐63<sup>b</sup>) </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012663-bbs2-0008" title="ChenJ , YiXL , JiangLX , WangR , ZhaoJG , LiYH , et al. 3‐tesla magnetic resonance imaging improves the prostate cancer detection rate in transrectral ultrasound‑guided biopsy. Experimental and Therapeutic Medicine2015;9(1):207‐12. ">Chen 2015</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bx‐naïve</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>67 (45‐91)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.7 (2.4‐35.7)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45 (21‐83)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012663-bbs2-0009" title="CoolDW , RomagnoliC , IzawaJI , ChinJ , GardiL , TessierD , et al. Comparison of prostate MRI‐3D transrectal ultrasound fusion biopsy for first‐time and repeat biopsy patients with previous atypical small acinar proliferation. Canadian Urological Association Journal2016;10(9‐10):342‐8. ">Cool 2016</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bx‐naïve<br/> Prior‐negative Bx </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59 (8)<sup>c</sup><br/> 62 (7)<sup>c</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.0 (3.5)<sup>c</sup><br/> 7.9 (3.9)<sup>c</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38 (18)<sup>c</sup><br/> 56 (27)<sup>c</sup> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012663-bbs2-0010" title="CostaDN , BlochBN , YaoDF , SandaMG , NgoL , GenegaEM , et al. Diagnosis of relevant prostate cancer using supplementary cores from magnetic resonance imaging‐prompted areas following multiple failed biopsies. Magnetic Resonance Imaging2013;31(6):947‐52. ">Costa 2013</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prior‐negative Bx</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64 (48‐77)<sup>c</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14.4 (1.8‐33.1)<sup>c</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012663-bbs2-0012" title="DelongchampsNB , PeyromaureM , SchullA , BeuvonF , BouazzaN , FlamT , et al. Prebiopsy magnetic resonance imaging and prostate cancer detection: comparison of random and targeted biopsies. The Journal of Urology2013;189(2):493‐9. ">Delongchamps 2013</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bx‐naïve</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64 (7)<sup>c</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.5 (3.9)<sup>c</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56 (30)<sup>c</sup> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012663-bbs2-0014" title="FilsonCP , NatarajanS , MargolisDJ , HuangJ , LieuP , DoreyFJ , et al. Prostate cancer detection with magnetic resonance‐ultrasound fusion biopsy: the role of systematic and targeted biopsies. Cancer2016;122(6):884‐92. ">Filson 2016</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bx‐naïve<br/> Prior‐negative Bx </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64 (59‐69<sup>b</sup>)<br/> 66 (59‐70<sup>b</sup>) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.8 (4.4‐8.1<sup>b</sup>)<br/> 7.6 (5‐11.5<sup>b</sup>) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45(33‐62<sup>b</sup>)<br/> 58 (40‐84<sup>b</sup>) </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012663-bbs2-0015" title="Garcia BennettJ , VilanovaJC , Guma PadroJ , ParadaD , ConejeroA . Evaluation of MR imaging‐targeted biopsies of the prostate in biopsy naïve patients. A single centre study. Diagnostic and Interventional Imaging2017;98(10):677‐84. ">Garcia Bennett 2017</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bx‐naïve</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64 (6.7)<sup>c</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.2 (6‐9.4<sup>b</sup>) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48 (35‐63<sup>b</sup>) </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012663-bbs2-0017" title="GrönbergH , EklundM , PickerW , AlyM , JäderlingF , AdolfssonJ , et al. Prostate cancer diagnostics using a combination of the Stockholm3 blood test and multiparametric magnetic resonance imaging. European Urology2018;74(6):722‐8. ">Grönberg 2018</a><sup>a</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bx‐naïve<br/> Prior‐negative Bx </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64 (45–74)<sup>c</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.3 (4.4<sup>b</sup>) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(32‐70)<sup>d</sup> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012663-bbs2-0021" title="JamborI , KähkönenE , TaimenP , MerisaariH , SaunavaaraJ , AlanenK , et al. Prebiopsy multiparametric 3T prostate MRI in patients with elevated PSA, normal digital rectal examination, and no previous biopsy. Journal of Magnetic Resonance Imaging2015;41(5):1394‐404. ">Jambor 2015</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bx‐naïve</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66 (47‐76)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.4 (4‐14)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42 (17‐107)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012663-bbs2-0022" title="JamborI , BoströmPJ , TaimenP , SyvänenK , KähkönenE , KallajokiM , et al. Novel biparametric MRI and targeted biopsy improves risk stratification in men with a clinical suspicion of prostate cancer (IMPROD Trial). Journal of Magnetic Resonance Imaging2017;46(4):1089‐95. ">Jambor 2017</a><sup>a</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mixed</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65 (6)<sup>c</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.5 (5.7‐9.6<sup>b</sup>) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37 (28‐49<sup>b</sup>) </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012663-bbs2-0024" title="KimEH , WeaverJK , ShettyAS , VetterJM , AndrioleGL , StropeSA . Magnetic resonance imaging provides added value to the prostate cancer prevention trial risk calculator for patients with estimated risk of high‐grade prostate cancer less than or equal to 10%. Urology2017;102:183‐9. ">Kim 2017</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bx‐naïve<br/> Prior‐negative Bx </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64 (7)<sup>c</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.2 (15.1)<sup>c</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012663-bbs2-0026" title="LeeDH , NamJK , ParkSW , LeeSS , HanJY , LeeSD , et al. Visually estimated MRI targeted prostate biopsy could improve the detection of significant prostate cancer in patients with a PSA level. Yonsei Medical Journal2016;57(3):565‐71. ">Lee 2016</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bx‐naïve</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66 (43‐83)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.4 (3.3‐9.8)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39 (17‐127)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012663-bbs2-0027" title="LeeDH , NamJK , LeeSS , HanJY , LeeJW , ChungMK , et al. Comparison of multiparametric and biparametric MRI in first round cognitive targeted prostate biopsy in patients with PSA levels under 10 ng/mL. Yonsei Medical Journal2017;58(5):994‐9. ">Lee 2017</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bx‐naïve</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62 (10)<sup>c</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.4 (1.8)<sup>c</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40 (18)<sup>c</sup> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012663-bbs2-0032" title="OkcelikS , SoydanH , AtesF , BerberU , SayginH , SonmezG , et al. Evaluation of PCA3 and multiparametric MRI's: collective benefits before deciding initial prostate biopsy for patients with PSA level between 3‐10ng/mL. International Brazillian Journal of Urology2016;42(3):449‐55. ">Okcelik 2016</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bx‐naïve</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62 (43‐79)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 (3‐8.9)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45 (17‐93)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012663-bbs2-0033" title="PanebiancoV , BarchettiF , SciarraA , CiardiA , IndinoEL , PapaliaR , et al. Multiparametric magnetic resonance imaging vs. standard care in men being evaluated for prostate cancer: a randomized study. Urologic Oncology2015;33(1):17.e1‐17.e7. ">Panebianco 2015</a><sup>a</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bx‐naïve<br/> Prior‐negative Bx </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64 (51‐82)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012663-bbs2-0034" title="PeltierA , AounF , LemortM , KwizeraF , PaesmansM , VanVelthovenR . MRI‐targeted biopsies versus systematic transrectal ultrasound guided biopsies for the diagnosis of localized prostate cancer in biopsy naïve men. Biomed Research International2015;2015:571708. ">Peltier 2015</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bx‐naïve</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65 (7)<sup>c</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.4 (6.3)<sup>c</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49 (22)<sup>c</sup> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012663-bbs2-0037" title="PokornyMR , DeRooijM , DuncanE , SchröderFH , ParkinsonR , BarentszJO , et al. Prospective study of diagnostic accuracy comparing prostate cancer detection by transrectal ultrasound‐guided biopsy versus magnetic resonance (MR) imaging with subsequent MR‐guided biopsy in men without previous prostate biopsies. European Urology2014;66(1):22‐9. ">Pokorny 2014</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bx‐naïve</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>63 (57‐68<sup>b</sup>) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.3 (4.1‐6.6<sup>b</sup>) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41 (30‐59<sup>b</sup>) </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012663-bbs2-0038" title="RouvièreO , PuechP , Renard‐PennaR , ClaudonM , RoyC , Mège‐LechavallierF , et al. MRI‐FIRST Investigators. Use of prostate systematic and targeted biopsy on the basis of multiparametric MRI in biopsy‐naïve patients (MRI‐FIRST): a prospective, multicentre, paired diagnostic study. Lancet Oncology2019;20(1):100‐9. ">Rouvière 2019a</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bx‐naïve</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64 (59‐68<sup>b</sup>) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.5 (5.6‐9.6<sup>b</sup>) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50 (38‐63<sup>b</sup>) </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012663-bbs2-0039" title="SayRK . MRI‐ultrasound fusion targeted biopsy in men with prior negative prostate biopsy for prostate cancer [PhD thesis]. Vol. 2078, New Haven, CT: Yale Medicine Thesis Digital Library, 2016. [elischolar.library.yale.edu/ymtdl/2078] ">Say 2016</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prior‐negative Bx</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64 (47‐82)<sup>c</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11.59 (0.4‐96.9)<sup>c</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>69 (17‐309)<sup>c</sup> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012663-bbs2-0041" title="TonttilaPP , LanttoJ , PääkköE , PiippoU , KauppilaS , LammentaustaE , et al. Prebiopsy multiparametric magnetic resonance imaging for prostate cancer diagnosis in biopsy‐naïve men with suspected prostate cancer based on elevated prostate‐specific antigen values: results from a randomized prospective blinded controlled trial. European Urology2016;69(3):419‐25. ">Tonttilla 2016</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bx‐naïve</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>63 (60‐66<sup>b</sup>) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.1 (4.2‐9.9<sup>b</sup>) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28 (24‐37<sup>b</sup>) </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012663-bbs2-0043" title="Van derLeestMM , CornelEB , IsraëlB , HendriksRJ , PadhaniAR , HoogenboomM , et al. Head‐to‐head comparison of transrectal ultrasound‐guided prostate biopsy versus multiparametric prostate resonance imaging with subsequent magnetic resonance‐guided biopsy in biopsy‐naïve men with elevated prostate‐specific antigen: a large prospective multicenter clinical study. European Urology 23 November 2018 [Epub ahead of print];S0302‐2838(18):30880‐7. [DOI: 10.1016/j.eururo.2018.11.023] ">Van der Leest 2018</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bx‐naïve</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65 (59‐68<sup>b</sup>) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.4 (4.6‐8.2<sup>b</sup>) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55 (41‐77<sup>b</sup>) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Bx:</b> biopsy; <b>NR:</b> not reported; <b>PSA:</b> prostate specific antigen </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>a</sup>Results not reported per population type.<br/> <sup>b</sup>Interquartile range (as apposed to range).<br/> <sup>c</sup>Mean (SD or range) (as opposed to median (range)).<br/> <sup>d</sup>Range of interquartile ranges across three centres. </p> </div> </div> <p>Eighteen studies addressed the test accuracy analysis (index tests versus reference standard (template‐guided biopsy)): 15 studies on MRI (<a href="./references#CD012663-bbs2-0001" title="Abd‐Alazeez , M , AryaHU , CharmanSC , AnastasiadisE , FreemanA , EmbertonM , et al. The accuracy of multiparametric MRI in men with negative biopsy and elevated PSA level‐Can it rule out clinically significant prostate cancer?. Urologic Oncology2014;32(1):45.e17‐45.e22. ">Abd‐Alazeez 2014</a>; <a href="./references#CD012663-bbs2-0002" title="AhmedHU , El‐Shater BosailyA , BrownLC , GabeR , KaplanR , ParmarMK , et al. Diagnostic accuracy of multi‐parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. Lancet2017;389(10071):815‐22. ">Ahmed 2017</a>; <a href="./references#CD012663-bbs2-0011" title="Dal MoroF , ZecchiniG , MorlaccoA , GardimanMP , LacognataCS , LauroA , et al. Does 1.5 T mpMRI play a definite role in detection of clinically significant prostate cancer? Findings from a prospective study comparing blind 24‐core saturation and targeted biopsies with a novel data remodeling model. Aging Clinical and Experimental Research2019;31(1):115‐23. ">Dal Moro 2019</a>; <a href="./references#CD012663-bbs2-0013" title="DistlerFA , RadtkeJP , BonekampD , KeschC , SchlemmerHP , WieczorekK , et al. The value of PSA density in combination with PI‐RADS for the accuracy of prostate cancer prediction. The Journal of Urology2017;198(3):575‐82. ">Distler 2017</a>; <a href="./references#CD012663-bbs2-0016" title="GreyAD , ChanaMS , PopertR , WolfeK , LiyanageSH , AcherPL . Diagnostic accuracy of magnetic resonance imaging (MRI) prostate imaging reporting and data system (PI‐RADS) scoring in a transperineal prostate biopsy setting. BJU International2015;115(5):728‐35. ">Grey 2015</a>; <a href="./references#CD012663-bbs2-0018" title="HansenN , PatrunoG , WadhwaK , GazievG , MianoR , BarrettT , et al. Magnetic resonance and ultrasound image fusion supported transperineal prostate biopsy using the Ginsburg protocol: technique, learning points, and biopsy results. Eurpean Urology2016;70(2):332‐40. ">Hansen 2016a</a>; <a href="./references#CD012663-bbs2-0020" title="HansenNL , BarrettT , KeschC , PepdjonovicL , BonekampD , O'SullivanR , et al. Multicentre evaluation of magnetic resonance imaging supported transperineal prostate biopsy in biopsy naïve men with suspicion of prostate cancer. BJU International2018;122(1):40‐9. ">Hansen 2018</a>; <a href="./references#CD012663-bbs2-0019" title="HansenNL , KeschC , BarrettT , KooB , RadtkeJP , BonekampD , et al. Multicentre evaluation of targeted and systematic biopsies using magnetic resonance and ultrasound image‐fusion guided transperineal prostate biopsy in patients with a previous negative biopsy. BJU International2017;120(5):631‐8. ">Hansen 2017</a>; <a href="./references#CD012663-bbs2-0023" title="KeschC , RadtkeJP , PopeneciuIV , GaschC , DieffenbacherSC , KleinT , et al. TOP: prospective evaluation of a volume based, computer assisted method for transperineal optimized prostate biopsy. Urologia Internationalis2017;99(2):149‐55. ">Kesch 2017</a>; <a href="./references#CD012663-bbs2-0025" title="LawrenceEM , TangSY , BarrettT , KooB , GoldmanDA , WarrenAY , et al. Prostate cancer: performance characteristics of combined T2W and DW‐MRI scoring in the setting of template transperineal re‐biopsy using MR‐TRUS fusion. European Radiology2014;24(7):1497‐505. ">Lawrence 2014</a>; <a href="./references#CD012663-bbs2-0028" title="MortezaviA , MärzendorferO , DonatiOF , RizziG , RuppNJ , WettsteinMS , et al. Diagnostic accuracy of multiparametric magnetic resonance imaging and fusion guided targeted biopsy evaluated by transperineal template saturation prostate biopsy for the detection and characterization of prostate cancer. Journal of Urology2018;200(2):309‐18. ">Mortezavi 2018</a>; <a href="./references#CD012663-bbs2-0029" title="MuthuveloeD , TelfordR , VineyR , PatelP . The detection and upgrade rates of prostate adenocarcinoma following transperineal template‐guided prostate biopsy – a tertiary referral centre experience. Central European Journal of Urology2016;69(1):42‐7. ">Muthuveloe 2016</a>; <a href="./references#CD012663-bbs2-0035" title="PepeP , GarufiA , PrioloG , CandianoG , PietropaoloF , PennisiM , et al. Prostate cancer detection at repeat biopsy: can pelvic phased array multiparametric MRI replace saturation biopsy?. Anticancer Research2013;33(3):1195‐200. ">Pepe 2013</a>; <a href="./references#CD012663-bbs2-0040" title="ThompsonJE , VanLeeuwenPJ , MosesD , ShnierR , BrennerP , DelpradoW , et al. The diagnostic performance of multiparametric magnetic resonance imaging to detect significant prostate cancer. Journal of Urology2016;195(5):1428‐35. ">Thompson 2016</a>; <a href="./references#CD012663-bbs2-0042" title="TsivianM , GuptaRT , TsivianE , QiP , MendezMH , AbernMR , et al. Assessing clinically significant prostate cancer: diagnostic properties of multiparametric magnetic resonance imaging compared to three‐dimensional transperineal template mapping histopathology. International Journal of Urology2017;24(2):137‐43. ">Tsivian 2017</a>); eight studies on MRI, MRI‐targeted biopsy and the MRI pathway in the same men (<a href="./references#CD012663-bbs2-0011" title="Dal MoroF , ZecchiniG , MorlaccoA , GardimanMP , LacognataCS , LauroA , et al. Does 1.5 T mpMRI play a definite role in detection of clinically significant prostate cancer? Findings from a prospective study comparing blind 24‐core saturation and targeted biopsies with a novel data remodeling model. Aging Clinical and Experimental Research2019;31(1):115‐23. ">Dal Moro 2019</a>; <a href="./references#CD012663-bbs2-0013" title="DistlerFA , RadtkeJP , BonekampD , KeschC , SchlemmerHP , WieczorekK , et al. The value of PSA density in combination with PI‐RADS for the accuracy of prostate cancer prediction. The Journal of Urology2017;198(3):575‐82. ">Distler 2017</a>; <a href="./references#CD012663-bbs2-0018" title="HansenN , PatrunoG , WadhwaK , GazievG , MianoR , BarrettT , et al. Magnetic resonance and ultrasound image fusion supported transperineal prostate biopsy using the Ginsburg protocol: technique, learning points, and biopsy results. Eurpean Urology2016;70(2):332‐40. ">Hansen 2016a</a>; <a href="./references#CD012663-bbs2-0019" title="HansenNL , KeschC , BarrettT , KooB , RadtkeJP , BonekampD , et al. Multicentre evaluation of targeted and systematic biopsies using magnetic resonance and ultrasound image‐fusion guided transperineal prostate biopsy in patients with a previous negative biopsy. BJU International2017;120(5):631‐8. ">Hansen 2017</a>; <a href="./references#CD012663-bbs2-0023" title="KeschC , RadtkeJP , PopeneciuIV , GaschC , DieffenbacherSC , KleinT , et al. TOP: prospective evaluation of a volume based, computer assisted method for transperineal optimized prostate biopsy. Urologia Internationalis2017;99(2):149‐55. ">Kesch 2017</a>; <a href="./references#CD012663-bbs2-0025" title="LawrenceEM , TangSY , BarrettT , KooB , GoldmanDA , WarrenAY , et al. Prostate cancer: performance characteristics of combined T2W and DW‐MRI scoring in the setting of template transperineal re‐biopsy using MR‐TRUS fusion. European Radiology2014;24(7):1497‐505. ">Lawrence 2014</a>; <a href="./references#CD012663-bbs2-0028" title="MortezaviA , MärzendorferO , DonatiOF , RizziG , RuppNJ , WettsteinMS , et al. Diagnostic accuracy of multiparametric magnetic resonance imaging and fusion guided targeted biopsy evaluated by transperineal template saturation prostate biopsy for the detection and characterization of prostate cancer. Journal of Urology2018;200(2):309‐18. ">Mortezavi 2018</a>; <a href="./references#CD012663-bbs2-0035" title="PepeP , GarufiA , PrioloG , CandianoG , PietropaoloF , PennisiM , et al. Prostate cancer detection at repeat biopsy: can pelvic phased array multiparametric MRI replace saturation biopsy?. Anticancer Research2013;33(3):1195‐200. ">Pepe 2013</a>); and four studies on systematic biopsy (<a href="./references#CD012663-bbs2-0002" title="AhmedHU , El‐Shater BosailyA , BrownLC , GabeR , KaplanR , ParmarMK , et al. Diagnostic accuracy of multi‐parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. Lancet2017;389(10071):815‐22. ">Ahmed 2017</a>; <a href="./references#CD012663-bbs2-0030" title="NafieS , MellonJK , DormerJP , KhanMA . The role of transperineal template prostate biopsies in prostate cancer diagnosis in biopsy naïve men with PSA less than 20 ng mL‐1. Prostate Cancer and Prostatic Diseases2014;17(2):170‐3. ">Nafie 2014</a>; <a href="./references#CD012663-bbs2-0031" title="NafieS , WanisM , KhanM . The efficacy of transrectal ultrasound guided biopsy versus transperineal template biopsy of the prostate in diagnosing prostate cancer in men with previous negative transrectal ultrasound guided biopsy. Urology Journal2017;14(2):3008‐12. ">Nafie 2017</a>; <a href="./references#CD012663-bbs2-0036" title="PloussardG , NicolaiewN , MarchandC , TerryS , VacherotF , VordosD , et al. Prospective evaluation of an extended 21‐core biopsy scheme as initial prostate cancer diagnostic strategy. European Urology2014;65(1):154‐61. ">Ploussard 2014</a>). These studies included 6871 men, of whom 5075 were biopsy naïve and 1796 had a history of at least one prior negative biopsy. We did not find any studies that investigated both the MRI pathway and systematic biopsy verified by the reference standard in the same men. </p> <p>Twenty‐five studies addressed the agreement analysis between the MRI pathway and systematic biopsy in detecting prostate cancer (<a href="./references#CD012663-bbs2-0003" title="AlbertsAR , SchootsIG , BokhorstLP , DrostFH , VanLeendersGJ , KrestinGP , et al. Characteristics of prostate cancer found at fifth screening in the European Randomized Study of Screening for Prostate Cancer Rotterdam: can we selectively detect high‐grade prostate cancer with upfront multivariable risk stratification and magnetic resonance imaging?. European Urology 19 June 2017 [Epub ahead of print];S0302‐2838(17):30514‐6. ">Alberts 2017</a>; <a href="./references#CD012663-bbs2-0004" title="BoesenL , NørgaardN , LøgagerV , BalslevI , ThomsenHS . A prospective comparison of selective multiparametric magnetic resonance imaging fusion‐targeted and systematic transrectal ultrasound‐guided biopsies for detecting prostate cancer in men undergoing repeated biopsies. Urologia Internationalis2017;99(4):384‐91. ">Boesen 2017a</a>; <a href="./references#CD012663-bbs2-0005" title="BoesenL , NørgaardN , LøgagerV , BalslevI , BisbjergR , ThestrupK‐C , Winther , et al. Assessment of the diagnostic accuracy of biparametric magnetic resonance imaging for prostate cancer in biopsy‐naïve men the Biparametric MRI for Detection of Prostate Cancer (BIDOC) Study. JAMA Network Open2018;1(2):e180219. ">Boesen 2018</a>; <a href="./references#CD012663-bbs2-0006" title="CastellucciR , Linares QuevedoAI , Sánchez GómezFJ , Díez RodríguezJ , CogornoL , Cogollos AcuñaI , et al. Prospective nonrandomized study of diagnostic accuracy comparing prostate cancer detection by transrectal ultrasound‐guided biopsy to magnetic resonance imaging with subsequent MRI‐guided biopsy in biopsy‐naïve patients. Minerva Urologica e Nefrologica2017;69(6):589‐95. ">Castellucci 2017</a>; <a href="./references#CD012663-bbs2-0007" title="ChangCH , ChiuHC , LinWC , HoTL , ChangH , ChangYH , et al. The influence of serum prostate‐specific antigen on the accuracy of magnetic resonance imaging targeted biopsy versus saturation biopsy in patients with previous negative biopsy. BioMed Research International2017;2017:7617148. ">Chang 2017</a>; <a href="./references#CD012663-bbs2-0008" title="ChenJ , YiXL , JiangLX , WangR , ZhaoJG , LiYH , et al. 3‐tesla magnetic resonance imaging improves the prostate cancer detection rate in transrectral ultrasound‑guided biopsy. Experimental and Therapeutic Medicine2015;9(1):207‐12. ">Chen 2015</a>; <a href="./references#CD012663-bbs2-0009" title="CoolDW , RomagnoliC , IzawaJI , ChinJ , GardiL , TessierD , et al. Comparison of prostate MRI‐3D transrectal ultrasound fusion biopsy for first‐time and repeat biopsy patients with previous atypical small acinar proliferation. Canadian Urological Association Journal2016;10(9‐10):342‐8. ">Cool 2016</a>; <a href="./references#CD012663-bbs2-0010" title="CostaDN , BlochBN , YaoDF , SandaMG , NgoL , GenegaEM , et al. Diagnosis of relevant prostate cancer using supplementary cores from magnetic resonance imaging‐prompted areas following multiple failed biopsies. Magnetic Resonance Imaging2013;31(6):947‐52. ">Costa 2013</a>; <a href="./references#CD012663-bbs2-0012" title="DelongchampsNB , PeyromaureM , SchullA , BeuvonF , BouazzaN , FlamT , et al. Prebiopsy magnetic resonance imaging and prostate cancer detection: comparison of random and targeted biopsies. The Journal of Urology2013;189(2):493‐9. ">Delongchamps 2013</a>; <a href="./references#CD012663-bbs2-0014" title="FilsonCP , NatarajanS , MargolisDJ , HuangJ , LieuP , DoreyFJ , et al. Prostate cancer detection with magnetic resonance‐ultrasound fusion biopsy: the role of systematic and targeted biopsies. Cancer2016;122(6):884‐92. ">Filson 2016</a>; <a href="./references#CD012663-bbs2-0015" title="Garcia BennettJ , VilanovaJC , Guma PadroJ , ParadaD , ConejeroA . Evaluation of MR imaging‐targeted biopsies of the prostate in biopsy naïve patients. A single centre study. Diagnostic and Interventional Imaging2017;98(10):677‐84. ">Garcia Bennett 2017</a>; <a href="./references#CD012663-bbs2-0017" title="GrönbergH , EklundM , PickerW , AlyM , JäderlingF , AdolfssonJ , et al. Prostate cancer diagnostics using a combination of the Stockholm3 blood test and multiparametric magnetic resonance imaging. European Urology2018;74(6):722‐8. ">Grönberg 2018</a>; <a href="./references#CD012663-bbs2-0021" title="JamborI , KähkönenE , TaimenP , MerisaariH , SaunavaaraJ , AlanenK , et al. Prebiopsy multiparametric 3T prostate MRI in patients with elevated PSA, normal digital rectal examination, and no previous biopsy. Journal of Magnetic Resonance Imaging2015;41(5):1394‐404. ">Jambor 2015</a>; <a href="./references#CD012663-bbs2-0022" title="JamborI , BoströmPJ , TaimenP , SyvänenK , KähkönenE , KallajokiM , et al. Novel biparametric MRI and targeted biopsy improves risk stratification in men with a clinical suspicion of prostate cancer (IMPROD Trial). Journal of Magnetic Resonance Imaging2017;46(4):1089‐95. ">Jambor 2017</a>; <a href="./references#CD012663-bbs2-0024" title="KimEH , WeaverJK , ShettyAS , VetterJM , AndrioleGL , StropeSA . Magnetic resonance imaging provides added value to the prostate cancer prevention trial risk calculator for patients with estimated risk of high‐grade prostate cancer less than or equal to 10%. Urology2017;102:183‐9. ">Kim 2017</a>; <a href="./references#CD012663-bbs2-0026" title="LeeDH , NamJK , ParkSW , LeeSS , HanJY , LeeSD , et al. Visually estimated MRI targeted prostate biopsy could improve the detection of significant prostate cancer in patients with a PSA level. Yonsei Medical Journal2016;57(3):565‐71. ">Lee 2016</a>; <a href="./references#CD012663-bbs2-0027" title="LeeDH , NamJK , LeeSS , HanJY , LeeJW , ChungMK , et al. Comparison of multiparametric and biparametric MRI in first round cognitive targeted prostate biopsy in patients with PSA levels under 10 ng/mL. Yonsei Medical Journal2017;58(5):994‐9. ">Lee 2017</a>; <a href="./references#CD012663-bbs2-0032" title="OkcelikS , SoydanH , AtesF , BerberU , SayginH , SonmezG , et al. Evaluation of PCA3 and multiparametric MRI's: collective benefits before deciding initial prostate biopsy for patients with PSA level between 3‐10ng/mL. International Brazillian Journal of Urology2016;42(3):449‐55. ">Okcelik 2016</a>; <a href="./references#CD012663-bbs2-0033" title="PanebiancoV , BarchettiF , SciarraA , CiardiA , IndinoEL , PapaliaR , et al. Multiparametric magnetic resonance imaging vs. standard care in men being evaluated for prostate cancer: a randomized study. Urologic Oncology2015;33(1):17.e1‐17.e7. ">Panebianco 2015</a>; <a href="./references#CD012663-bbs2-0034" title="PeltierA , AounF , LemortM , KwizeraF , PaesmansM , VanVelthovenR . MRI‐targeted biopsies versus systematic transrectal ultrasound guided biopsies for the diagnosis of localized prostate cancer in biopsy naïve men. Biomed Research International2015;2015:571708. ">Peltier 2015</a>; <a href="./references#CD012663-bbs2-0037" title="PokornyMR , DeRooijM , DuncanE , SchröderFH , ParkinsonR , BarentszJO , et al. Prospective study of diagnostic accuracy comparing prostate cancer detection by transrectal ultrasound‐guided biopsy versus magnetic resonance (MR) imaging with subsequent MR‐guided biopsy in men without previous prostate biopsies. European Urology2014;66(1):22‐9. ">Pokorny 2014</a>; <a href="./references#CD012663-bbs2-0038" title="RouvièreO , PuechP , Renard‐PennaR , ClaudonM , RoyC , Mège‐LechavallierF , et al. MRI‐FIRST Investigators. Use of prostate systematic and targeted biopsy on the basis of multiparametric MRI in biopsy‐naïve patients (MRI‐FIRST): a prospective, multicentre, paired diagnostic study. Lancet Oncology2019;20(1):100‐9. ">Rouvière 2019a</a>; <a href="./references#CD012663-bbs2-0039" title="SayRK . MRI‐ultrasound fusion targeted biopsy in men with prior negative prostate biopsy for prostate cancer [PhD thesis]. Vol. 2078, New Haven, CT: Yale Medicine Thesis Digital Library, 2016. [elischolar.library.yale.edu/ymtdl/2078] ">Say 2016</a>; <a href="./references#CD012663-bbs2-0041" title="TonttilaPP , LanttoJ , PääkköE , PiippoU , KauppilaS , LammentaustaE , et al. Prebiopsy multiparametric magnetic resonance imaging for prostate cancer diagnosis in biopsy‐naïve men with suspected prostate cancer based on elevated prostate‐specific antigen values: results from a randomized prospective blinded controlled trial. European Urology2016;69(3):419‐25. ">Tonttilla 2016</a>; <a href="./references#CD012663-bbs2-0043" title="Van derLeestMM , CornelEB , IsraëlB , HendriksRJ , PadhaniAR , HoogenboomM , et al. Head‐to‐head comparison of transrectal ultrasound‐guided prostate biopsy versus multiparametric prostate resonance imaging with subsequent magnetic resonance‐guided biopsy in biopsy‐naïve men with elevated prostate‐specific antigen: a large prospective multicenter clinical study. European Urology 23 November 2018 [Epub ahead of print];S0302‐2838(18):30880‐7. [DOI: 10.1016/j.eururo.2018.11.023] ">Van der Leest 2018</a>), with 6944 men, of whom 5353 were biopsy naïve and 1591 had a history of at least one prior negative biopsy. </p> </section> <section id="CD012663-sec-0075"> <h3 class="title">Methodological quality of included studies</h3> <section id="CD012663-sec-0076"> <h4 class="title">Test accuracy studies</h4> <p>Thirteen out of 18 test accuracy studies used a prospective study design, while the remaining studies used a retrospective design (<a href="#CD012663-tbl-0008">Table 2</a>). According to our QUADAS‐2 assessment (<a href="#CD012663-tbl-0007">Table 1</a>), the studies assessed and presented results per index test (MRI (<a href="#CD012663-fig-0003">Figure 3</a>); MRI‐targeted biopsy (<a href="#CD012663-fig-0004">Figure 4</a>); the MRI pathway (<a href="#CD012663-fig-0005">Figure 5</a>); and systematic biopsy (<a href="#CD012663-fig-0006">Figure 6</a>)). A considerable number of studies had a high or unclear risk of bias in the participant selection (n = 9/18) and reference standard domains (n = 12/18). Almost no risk of bias was present in the index test (n = 1/18) and flow and timing domains (n = 3/18). Furthermore, only three out of 18 studies had applicability concerns because either they had selected an explicitly high‐risk population or had used an alternative MRI‐scale or MRI‐positivity threshold (other than the default 5‐point scale with an MRI‐positivity threshold of 3/5 or more). </p> <div class="figure" id="CD012663-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Diagnostic test accuracy of magnetic resonance imaging (MRI) verified by template‐guided biopsy: risk of bias and applicability concerns summary: review authors' judgements about each domain for each included study" data-id="CD012663-fig-0003" src="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_n/nCD012663-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Diagnostic test accuracy of magnetic resonance imaging (MRI) verified by template‐guided biopsy: risk of bias and applicability concerns summary: review authors' judgements about each domain for each included study </p> </div> </div> </div> <div class="figure" id="CD012663-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Diagnostic test accuracy of magnetic resonance imaging‐targeted biopsy (MRI‐TBx) in MRI‐positive men: risk of bias and applicability concerns summary: review authors' judgements about each domain for each included study" data-id="CD012663-fig-0004" src="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_n/nCD012663-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Diagnostic test accuracy of magnetic resonance imaging‐targeted biopsy (MRI‐TBx) in MRI‐positive men: risk of bias and applicability concerns summary: review authors' judgements about each domain for each included study </p> </div> </div> </div> <div class="figure" id="CD012663-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Diagnostic test accuracy of the MRI pathway: risk of bias and applicability concerns summary: review authors' judgements about each domain for each included study" data-id="CD012663-fig-0005" src="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_n/nCD012663-AFig-FIG05.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Diagnostic test accuracy of the MRI pathway: risk of bias and applicability concerns summary: review authors' judgements about each domain for each included study </p> </div> </div> </div> <div class="figure" id="CD012663-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="Diagnostic test accuracy of systematic biopsy (SBx): risk of bias and applicability concerns summary: review authors' judgements about each domain for each included study" data-id="CD012663-fig-0006" src="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_n/nCD012663-AFig-FIG06.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Diagnostic test accuracy of systematic biopsy (SBx): risk of bias and applicability concerns summary: review authors' judgements about each domain for each included study </p> </div> </div> </div> </section> <section id="CD012663-sec-0077"> <h4 class="title">Agreement studies</h4> <p>Eighteen out of 25 agreement studies used a prospective study design, while the remaining studies used a retrospective design (<a href="#CD012663-tbl-0010">Table 4</a>). A considerable number of studies (n = 13/25) had a high or unclear risk of bias in the participant selection domain (<a href="#CD012663-fig-0007">Figure 7</a>). In the index test domain, a considerable number of studies (n = 15/25) had a high or unclear risk of bias in the performance of systematic biopsy but almost no risk of bias was present in the performance of the MRI pathway (n = 1/18). Few studies had a high or unclear risk of bias in the flow and timing domain (n = 8/25). Furthermore, applicability concerns were present in 15 out of 25 studies, mainly because they used an alternative method to perform one of the index tests (other than that defined in <a href="#CD012663-tbl-0007">Table 1</a>). </p> <div class="figure" id="CD012663-fig-0007"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 7</div> </div> <hr class="top"/><img alt="Agreement analyses between the MRI pathway and systematic biopsy (SBx): risk of bias and applicability concerns summary: review authors' judgements about each domain for each included study" data-id="CD012663-fig-0007" src="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_n/nCD012663-AFig-FIG07.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Agreement analyses between the MRI pathway and systematic biopsy (SBx): risk of bias and applicability concerns summary: review authors' judgements about each domain for each included study </p> </div> </div> </div> <p>Overall, we acknowledge concerns about the independence and applicability of tests in both test accuracy and agreement analyses, for which we performed sensitivity analyses to exclude studies with such quality concerns. </p> </section> </section> <section id="CD012663-sec-0078"> <h3 class="title" id="CD012663-sec-0078">Findings</h3> <section id="CD012663-sec-0079"> <h4 class="title">Test accuracy: index tests verified by the reference standard, template‐guided biopsy</h4> <p>In this section, we quantified the test accuracy of the different index tests for detecting grade 2 or higher, grade 3 or higher and grade 1 prostate cancer, in mixed populations of men with first and repeat biopsies, using sensitivity, specificity and predictive values. </p> <section id="CD012663-sec-0080"> <h5 class="title">Sensitivity and specificity</h5> <section id="CD012663-sec-0081"> <h6 class="title">Detection of grade 2 or higher prostate cancer</h6> <section id="CD012663-sec-0082"> <p><b>1. MRI compared with template‐guided biopsy</b></p> <p>For grade 2 or higher prostate cancer, the pooled sensitivity and specificity of prostate MRI was 0.91 (95% CI 0.83 to 0.95) and 0.37 (95% CI 0.29 to 0.46), respectively (12 studies, 3091 men; prevalence 29% (95% CI 22% to 38%); <a href="#CD012663-tbl-0012">Table 6</a>; <a href="#CD012663-fig-0008">Figure 8</a>). Hence, 9% of men with grade 2 or higher prostate cancer were not identified as such by MRI. In other words, at the assumptive prevalence of 30%, MRI may result in 273 (95% CI: 249 to 285) true positives, 441 false positives (95% CI: 378 to 497), 259 true negatives (95% CI: 203 to 322) and 27 (95% CI: 15 to 51) false negatives per 1000 men (<a href="./full#CD012663-tbl-0003">summary of findings Table 3</a>). </p> <div class="figure" id="CD012663-fig-0008"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 8</div> </div> <hr class="top"/><img alt="Diagnostic test accuracy of MRI for indicating grade 2 and higher prostate cancer.Summary ROC plot of MRI verified by template‐guided biopsy. The 95% confidence region illustrates the uncertainty around the pooled summary point; the 95% prediction region illustrates the heterogeneity  MRI: magnetic resonance imaging" data-id="CD012663-fig-0008" src="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_n/nCD012663-AFig-FIG08.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Diagnostic test accuracy of MRI for indicating grade 2 and higher prostate cancer.</p> <p>Summary ROC plot of MRI verified by template‐guided biopsy. The 95% confidence region illustrates the uncertainty around the pooled summary point; the 95% prediction region illustrates the heterogeneity<br/> MRI: magnetic resonance imaging </p> </div> </div> </div> <div class="table" id="CD012663-tbl-0012"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Diagnostic accuracy of the index tests</span></div> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>Diagnostic accuracy of the index tests verified by template‐guided biopsy as the reference standard</b> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Index test</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MRI<br/> population<sup>a</sup> </b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Target<br/> condition</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>N participants<br/> (studies)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Proportion<br/> negative MRI<br/> (95% CI)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sensitivity<br/> (95% CI)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Specificity<br/> (95% CI)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>P value</b> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>MRI</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Positive + negative</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G = 1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1764 (10)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.28 (0.20 to 0.38)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.70 (0.59 to 0.80)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.27 (0.19 to 0.37)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P &lt; 0.01<sup>b</sup> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>G ≥ 1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1764 (10)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.39 (0.30 to 0.50)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.84 (0.74 to 0.90)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.39 (0.30 to 0.50)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G ≥ 2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3091 (12)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.29 (0.22 to 0.37)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.91 (0.83 to 0.95)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.37 (0.29 to 0.46)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P &lt; 0.01<sup>b</sup> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G ≥ 3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1438 (7)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.31 (0.21 to 0.42)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.95 (0.87 to 0.99)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.35 (0.26 to 0.46)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ID</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>MRI‐TBx</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Positive</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G = 1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>497 (5)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.51 (0.21 to 0.81)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.00 (0.77 to 1.00)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>G ≥ 1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>611 (6)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.71 (0.61 to 0.80)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.93 (0.87 to 0.96)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G ≥ 2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1553 (8)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.80 (0.69 to 0.87)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.94 (0.90 to 0.97)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G ≥ 3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>428 (3)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ID</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ID</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ID</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>MRI‐pathway</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Positive + negative</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G = 1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>681 (5)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.24 (0.16 to 0.36)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.34 (0.19 to 0.53)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.00 (0.90 to 1.00)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P = 0.52<sup>c</sup> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>G ≥ 1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>844 (6)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.28 (0.21 to 0.35)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.58 (0.52 to 0.65)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.96 (0.92 to 0.98)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G ≥ 2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2257 (8)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.29 (0.24 to 0.35)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.72 (0.60 to 0.82)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.96 (0.94 to 0.98)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P = 0.06<sup>c</sup> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G ≥ 3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>604 (3)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.29 (0.26 to 0.33)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ID</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ID</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ID</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>SBx</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>NA</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G = 1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3421 (4)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.55 (0.25 to 0.83)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.99 (0.81 to 1.00)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>G ≥ 1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3421 (4)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.65 (0.31 to 0.88)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.00 (0.88 to 1.00)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G ≥ 2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3421 (4)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.63 (0.19 to 0.93)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.00 (0.91 to 1.00)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G ≥ 3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>626 (2)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ID</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ID</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ID</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>CI:</b> confidence interval; <b>G:</b> International Society of Urological Pathology grade; <b>ID:</b> inadequate data; <b>MRI:</b> magnetic resonance imaging; <b>MRI‐pathway:</b> magnetic resonance imaging with or without magnetic resonance imaging‐targeted biopsy; <b>MRI‐TBx:</b> magnetic resonance imaging‐targeted biopsy; <b>N:</b> number; <b>NA:</b> not applicable; <b>SBx:</b> systematic biopsy </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>a</sup>Data did not allow differentiation between the mix of included participants (biopsy‐naïve and prior‐negative biopsy men).<br/> <sup>b</sup>Comparing sensitivity between MRI and the MRI‐pathway.<br/> <sup>c</sup>Comparing sensitivity between the MRI‐pathway and SBx. </p> </div> </div> </section> <section id="CD012663-sec-0083"> <p><b>2. MRI‐targeted biopsy compared with template‐guided biopsy</b></p> <p>For grade 2 or higher prostate cancer, the pooled sensitivity and specificity of MRI‐targeted biopsy (in men with a positive MRI) were 0.80 (95% CI 0.69 to 0.87) and 0.94 (95% CI 0.90 to 0.97), respectively (8 studies, 1553 men; prevalence 34% (95% CI 24% to 46%); <a href="#CD012663-tbl-0012">Table 6</a>; <a href="#CD012663-fig-0009">Figure 9</a>). Hence, MRI‐targeted biopsy in men with a positive MRI missed 20% of men with grade 2 or higher prostate cancer. At the assumptive prevalence of 30%, MRI‐targeted biopsy may result in 240 (95% CI: 207 to 261) true positives, 42 (95% CI: 21 to 70) false positives, 658 (95% CI: 630 to 669) true negatives and 60 (95% CI: 39 to 93) false negatives per 1000 men biopsied (<a href="./full#CD012663-tbl-0004">summary of findings Table 4</a>). </p> <div class="figure" id="CD012663-fig-0009"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 9</div> </div> <hr class="top"/><img alt="Diagnostic test accuracy of MRI‐targeted biopsy for detecting grade 2 and higher prostate cancerSummary ROC plot of MRI‐targeted biopsy (in an MRI‐positive population) verified by template‐guided biopsy. The 95% confidence region illustrates the uncertainty around the pooled summary point; the 95% prediction region illustrates the heterogeneity  MRI: magnetic resonance imaging" data-id="CD012663-fig-0009" src="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_n/nCD012663-AFig-FIG09.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Diagnostic test accuracy of MRI‐targeted biopsy for detecting grade 2 and higher prostate cancer </p> <p>Summary ROC plot of MRI‐targeted biopsy (in an MRI‐positive population) verified by template‐guided biopsy. The 95% confidence region illustrates the uncertainty around the pooled summary point; the 95% prediction region illustrates the heterogeneity<br/> MRI: magnetic resonance imaging </p> </div> </div> </div> </section> <section id="CD012663-sec-0084"> <p><b>3. MRI pathway (MRI with or without MRI‐targeted biopsy) compared with template‐guided biopsy</b></p> <p>For grade 2 or higher prostate cancer, the pooled sensitivity and specificity of MRI pathway were 0.72 (95% CI 0.60 to 0.82) and 0.96 (95% CI 0.94 to 0.98), respectively (8 studies, 2257 men; prevalence 26% (95% CI 18% to 36%); <a href="#CD012663-tbl-0012">Table 6</a>; <a href="#CD012663-fig-0010">Figure 10</a>). Hence, the MRI pathway missed 28% of men with grade 2 or higher prostate cancer. At the assumptive prevalence of 30%, the MRI pathway may result in 216 (95% CI: 180 to 246) true positives, 28 (95% CI: 14 to 42) false positives, 672 (95% CI: 658 to 686) true negatives and 84 (95% CI: 54 to 120) false negatives per 1000 men (<a href="./full#CD012663-tbl-0005">summary of findings Table 5</a>). The implications of these results, taking into account each step in the MRI pathway (MRI with subsequent MRI‐targeted biopsy in MRI‐positive men only), are shown in <a href="#CD012663-fig-0011">Figure 11</a>. </p> <div class="figure" id="CD012663-fig-0010"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 10</div> </div> <hr class="top"/><img alt="Diagnostic test accuracy of the MRI pathway for detecting grade 2 and higher prostate cancerSummary ROC plot of the MRI pathway verified by template‐guided biopsy. The 95% confidence region illustrates the uncertainty around the pooled summary point; the 95% prediction region illustrates the heterogeneity  MRI: magnetic resonance imaging; MRI pathway: MRI with or without MRI‐targeted biopsy" data-id="CD012663-fig-0010" src="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_n/nCD012663-AFig-FIG10.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Diagnostic test accuracy of the MRI pathway for detecting grade 2 and higher prostate cancer </p> <p>Summary ROC plot of the MRI pathway verified by template‐guided biopsy. The 95% confidence region illustrates the uncertainty around the pooled summary point; the 95% prediction region illustrates the heterogeneity<br/> MRI: magnetic resonance imaging; MRI pathway: MRI with or without MRI‐targeted biopsy </p> </div> </div> </div> <div class="figure" id="CD012663-fig-0011"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 11</div> </div> <hr class="top"/><img alt="Test consequence graphic showing results that would be obtained if a hypothetical cohort of 1000 men were tested for prostate cancer using the MRI pathway." data-id="CD012663-fig-0011" src="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_n/nCD012663-AFig-FIG11.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Test consequence graphic showing results that would be obtained if a hypothetical cohort of 1000 men were tested for prostate cancer using the MRI pathway. </p> </div> </div> </div> </section> <section id="CD012663-sec-0085"> <p><b>4. Systematic biopsy compared with template‐guided biopsy</b></p> <p>For grade 2 or higher prostate cancer, the pooled sensitivity and specificity of systematic biopsy were 0.63 (95% CI 0.19 to 0.93) and 1.00 (95% CI 0.91 to 1.00), respectively (4 studies, 3421 men; prevalence 34% (95% CI 21% to 51%); <a href="#CD012663-tbl-0012">Table 6</a>; <a href="#CD012663-fig-0012">Figure 12</a>). This analysis included the large and high‐quality PROMIS‐study, <a href="./references#CD012663-bbs2-0002" title="AhmedHU , El‐Shater BosailyA , BrownLC , GabeR , KaplanR , ParmarMK , et al. Diagnostic accuracy of multi‐parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. Lancet2017;389(10071):815‐22. ">Ahmed 2017</a> (sensitivity 0.48 (95% CI 0.43 to 0.54); specificity 0.99 (95% CI 0.97 to 1.00); 576 men; prevalence 53%). Hence, the systematic biopsy approach missed approximately 37% of men with grade 2 or higher prostate cancer. At the assumptive prevalence of 30%, systematic biopsy may result in 189 (95% CI: 57 to 279) true positives, 0 (95% CI: 0 to 63) false positives, 700 (95% CI: 637 to 700) true negatives and 111 (95% CI: 21 to 243) false negatives per 1000 men (<a href="./full#CD012663-tbl-0006">summary of findings Table 6</a>, <a href="#CD012663-fig-0013">Figure 13</a>). </p> <div class="figure" id="CD012663-fig-0012"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 12</div> </div> <hr class="top"/><img alt="Diagnostic test accuracy of systematic biopsy for detecting grade 2 and higher prostate cancerSummary ROC plot of systematic biopsy verified by template‐guided biopsy" data-id="CD012663-fig-0012" src="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_n/nCD012663-AFig-FIG12.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Diagnostic test accuracy of systematic biopsy for detecting grade 2 and higher prostate cancer </p> <p>Summary ROC plot of systematic biopsy verified by template‐guided biopsy</p> </div> </div> </div> <div class="figure" id="CD012663-fig-0013"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 13</div> </div> <hr class="top"/><img alt="Test consequence graphic showing results that would be obtained if a hypothetical cohort of 1000 men were tested for prostate cancer using systematic biopsy." data-id="CD012663-fig-0013" src="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_n/nCD012663-AFig-FIG13.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Test consequence graphic showing results that would be obtained if a hypothetical cohort of 1000 men were tested for prostate cancer using systematic biopsy. </p> </div> </div> </div> </section> <section id="CD012663-sec-0086"> <p><b>5. Comparison of diagnostic accuracy between the index tests</b></p> <p>Comparing the accuracy of the MRI with the accuracy of the MRI pathway showed a substantial decrease in sensitivity (0.91 versus 0.72) and increase in specificity (0.37 versus 0.96), which were both statistically significant (P &lt; 0.01; <a href="#CD012663-fig-0014">Figure 14</a>). Comparing the accuracy of the MRI pathway with the accuracy of systematic biopsy showed a substantial decrease in sensitivity (0.72 versus 0.63; P = 0.06) and similar specificities (<a href="#CD012663-fig-0015">Figure 15</a>). </p> <div class="figure" id="CD012663-fig-0014"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 14</div> </div> <hr class="top"/><img alt="Comparison of diagnostic test accuracy between MRI and the MRI pathway for detecting grade 2 and higher prostate cancer.Summary ROC plot of MRI and the MRI pathway verified by template‐guided biopsy  G: International Society of Urological Pathology grade; MRI: magnetic resonance imaging; MRI pathway: MRI with or without MRI‐targeted biopsy" data-id="CD012663-fig-0014" src="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_n/nCD012663-AFig-FIG14.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison of diagnostic test accuracy between MRI and the MRI pathway for detecting grade 2 and higher prostate cancer. </p> <p>Summary ROC plot of MRI and the MRI pathway verified by template‐guided biopsy<br/> G: International Society of Urological Pathology grade; MRI: magnetic resonance imaging; MRI pathway: MRI with or without MRI‐targeted biopsy </p> </div> </div> </div> <div class="figure" id="CD012663-fig-0015"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 15</div> </div> <hr class="top"/><img alt="Comparison of diagnostic test accuracy between the MRI pathway and systematic biopsy for detecting grade 2 and higher prostate cancer.Summary ROC plot of the MRI pathway versus systematic biopsy, verified by template‐guided biopsy  G: International Society of Urological Pathology grade; MRI: magnetic resonance imaging; MRI pathway: MRI with or without MRI‐targeted biopsy; SBx: systematic biopsy" data-id="CD012663-fig-0015" src="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_n/nCD012663-AFig-FIG15.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison of diagnostic test accuracy between the MRI pathway and systematic biopsy for detecting grade 2 and higher prostate cancer. </p> <p>Summary ROC plot of the MRI pathway versus systematic biopsy, verified by template‐guided biopsy<br/> G: International Society of Urological Pathology grade; MRI: magnetic resonance imaging; MRI pathway: MRI with or without MRI‐targeted biopsy; SBx: systematic biopsy </p> </div> </div> </div> </section> </section> <section id="CD012663-sec-0087"> <h6 class="title">Detection of grade 3 or higher prostate cancer</h6> <section id="CD012663-sec-0088"> <p><b>1. MRI compared with template‐guided biopsy</b></p> <p>The pooled sensitivity and specificity of MRI were 0.95 (95% CI 0.87 to 0.99) and 0.35 (95% CI 0.26 to 0.46), respectively (7 studies, 1438 men; prevalence 14% (95% CI 8% to 23%); <a href="#CD012663-tbl-0012">Table 6</a>). Hence, 5% of men with grade 3 or higher prostate cancer were not identified by MRI. At the assumptive prevalence of 14%, MRI may result in 133 (95% CI: 122 to 139) true positives, 559 (95% CI: 464 to 636) false positives, 301 (95% CI: 244 to 396) true negatives and 7 (95% CI: 1 to 18) false negatives per 1000 men. </p> </section> <section id="CD012663-sec-0089"> <p><b>2. MRI‐targeted biopsy, MRI pathway and systematic biopsy compared with template‐guided biopsy</b></p> <p>For MRI‐targeted biopsy, the MRI pathway and systematic biopsy, insufficient data on grade 3 or higher prostate cancer were available to perform meta‐analyses; individual study results are presented in the <a href="./references#CD012663-fig-0038" title="">Data table 19</a>, <a href="./references#CD012663-fig-0042" title="">Data table 23</a> and <a href="./references#CD012663-fig-0046" title="">Data table 27</a>, respectively. </p> </section> </section> <section id="CD012663-sec-0090"> <h6 class="title">Detection of grade 1 prostate cancer</h6> <p>The sensitivities and specificities for grade 1 prostate cancer were as follows:</p> <p><i>1. MRI:</i> 0.70 (95% CI 0.59 to 0.80) and 0.27 (95% CI 0.19 to 0.37), respectively (10 studies, 1764 men; prevalence 20% (95% CI 17% to 23%); <a href="#CD012663-tbl-0012">Table 6</a>); </p> <p><i>2. MRI‐targeted biopsy:</i> 0.51 (95% CI 0.21 to 0.81) and 1.00 (95% CI 0.77 to 1.00), respectively (5 studies, 497 men; prevalence 22% (95% CI 19% to 26%); <a href="#CD012663-tbl-0012">Table 6</a>); </p> <p><i>3. MRI pathway:</i> 0.34 (95% CI 0.19 to 0.53) and 1.00 (95% CI 0.90 to 1.00), respectively (5 studies, 681 men; prevalence 21% (95% CI 18% to 24%); <a href="#CD012663-tbl-0012">Table 6</a>); </p> <p><i>4. systematic biopsy:</i> 0.55 (95% CI 0.25 to 0.83) and 0.99 (95% CI 0.81 to 1.00), respectively (4 studies, 3421 men; prevalence 20% (95% CI 16% to 25%); <a href="#CD012663-tbl-0012">Table 6</a>). </p> <p>Hence, comparing the sensitivity of the MRI pathway and systematic biopsy, the MRI pathway potentially avoided the detection of 66% of men with indolent prostate cancer, whereas systematic biopsy potentially avoided detection of 45% of men with indolent prostate cancer (P = 0.52). </p> </section> </section> <section id="CD012663-sec-0091"> <h5 class="title">Predictive values</h5> <p>The pooled prevalences of grade 2 or higher prostate cancer in the accuracy studies that assessed MRI, MRI‐targeted biopsy, MRI pathway and systematic biopsy, were 29% (95% CI 22% to 38%), 34% (95% CI 24% to 46%), 26% (95% CI 18% to 36%), and 34% (95% CI 21% to 51%), respectively (<a href="#CD012663-tbl-0013">Table 7</a>). Obviously, the prevalence of grade 2 or higher prostate cancer for MRI‐targeted biopsy is higher than that for the other index tests, due to the 'enriched' population resulting from the selection of only MRI‐positive men. </p> <div class="table" id="CD012663-tbl-0013"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">Predictive values of the index tests and prevalences</span></div> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Predictive values of the index tests and prostate cancer prevalences</b> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Test</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MRI<br/> population<sup>a</sup> </b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Target<br/> condition</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>N participants<br/> (studies)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Prevalence<sup>b</sup><br/> (95% CI)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>NPV<sup>c</sup><br/> (95% CI)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>PPV<sup>c</sup><br/> (95% CI)</b> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>MRI</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Positive + negative</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G = 1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1764 (10)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.20 (0.17 to 0.23)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.79 (0.74 to 0.82)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.20 (0.18 to 0.21)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G ≥ 2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3091 (12)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.29 (0.22 to 0.38)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.91 (0.86 to 0.94)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.37 (0.35 to 0.39)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G ≥ 3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1438 (7)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.14 (0.08 to 0.23)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.98 (0.95 to 0.99)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.19 (0.17 to 0.21)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>MRI‐TBx</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Positive</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G = 1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>497 (5)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.22 (0.19 to 0.26)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.88 (0.78 to 0.94)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.98 (0.23 to 1.00)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G ≥ 2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1553 (8)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.34 (0.24 to 0.46)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.90 (0.85 to 0.93)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.88 (0.80 to 0.92)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G ≥ 3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>428 (3)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.21 (0.12 to 0.35)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ID</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ID</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>MRI‐pathway</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Positive + negative</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G = 1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>681 (5)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.21 (0.18 to 0.24)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.85 (0.81 to 0.88)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.95 (0.38 to 1.00)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G ≥ 2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2257 (8)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.26 (0.18 to 0.36)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.91 (0.87 to 0.94)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.88 (0.80 to 0.92)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G ≥ 3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>604 (3)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.16 (0.09 to 0.27)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ID</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ID</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>SBx</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>NA</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G = 1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3421 (4)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.20 (0.16 to 0.25)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.90 (0.81 to 0.95)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.94 (0.37 to 1.00)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G ≥ 2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3421 (4)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.34 (0.21 to 0.51)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.84 (0.60 to 0.95)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.00 (0.76 to 1.00)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G ≥ 3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>626 (2)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.10 (0.08 to 0.12)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ID</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ID</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>CI:</b> confidence interval; <b>G:</b> International Society of Urological Pathology grade; <b>ID:</b> inadequate data; <b>MRI:</b> magnetic resonance imaging; <b>MRI‐pathway:</b> magnetic resonance imaging with or without magnetic resonance imaging‐targeted biopsy; <b>MRI‐TBx:</b> magnetic resonance imaging‐targeted biopsy; <b>NA:</b> not applicable; <b>NPV:</b> negative predictive value; <b>PPV:</b> positive predictive value; <b>SBx</b>: systematic biopsy </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>a</sup>Data did not allow differentiation between the mix of included participants (biopsy‐naïve and prior‐negative biopsy men).<br/> <sup>b</sup>Prevalence is pooled estimate of all detected cancer by template‐guided biopsy.<br/> <sup>c</sup>Based on the Bayes’ theorem using the point estimates and 95% confidence intervals of the pooled positive and negative likelihood ratio and the point estimate of the prevalence. </p> </div> </div> <p>The NPVs and PPVs of the index tests as a function of the pooled grade 2 or higher, grade 3 or higher and grade 1 prostate cancer prevalences are presented in <a href="#CD012663-tbl-0013">Table 7</a>. We are only able to compare these predictive values for the index tests at a prespecified prevalence. At a prespecified prevalence of 30% grade 2 or higher prostate cancer (based on the prevalence findings in the test accuracy analysis), the NPVs for MRI, MRI‐targeted biopsy, the MRI pathway and systematic biopsy are 91% (95% CI 86 to 94%), 92% (95% CI 88 to 94%), 89% (95% CI 85 to 92%) and 86% (95% CI 65 to 95%), respectively (<a href="./appendices#CD012663-sec-0145">Appendix 5</a>). Consequently, in the MRI pathway, a negative MRI falsely predicts the absence of grade 2 or higher prostate cancer in 9% of men (Figure 9), while a negative systematic biopsy falsely predicts the absence of grade 2 or higher prostate cancer in 14% of men (Figure 13). </p> </section> <section id="CD012663-sec-0092"> <h5 class="title">Sensitivity and specificity at a higher MRI‐positive threshold</h5> <p>In clinical practice, lesions with an MRI suspicion score of 3 (likelihood for clinically significant cancer is equivocal (<a href="./references#CD012663-bbs2-0069" title="BarentszJO , RichenbergJ , ClementsR , ChoykeP , VermaS , VilleirsG , et al. ESUR prostate MR guidelines 2012. European Radiology2012;22(4):746‐57. ">Barentsz 2012</a>)) might or might not be targeted with biopsies. By increasing the threshold of MRI‐positivity from 3/5 to 4/5, the proportion of negative MRI increased from 30% (95% CI 23% to 38%) to 59% (95% CI 43% to 74%) (<a href="#CD012663-tbl-0014">Table 8</a>). The pooled sensitivity of MRI for detecting grade 2 or higher prostate cancer decreased from 0.89 (95% CI 0.82 to 0.94) to 0.72 (95% CI 0.52 to 0.86). The pooled specificity increased from 0.39 (95% CI 0.32 to 0.47) to 0.78 (95% CI 0.68 to 0.86), indicating that with a threshold 4/5 for MRI positivity, a negative MRI failed to identify 28% of men with grade 2 or higher prostate cancer. </p> <div class="table" id="CD012663-tbl-0014"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 8.</span> <span class="table-title">MRI‐positivity threshold effect</span></div> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>MRI‐positivity threshold effect, verified by template‐guided biopsy as the reference standard, with threshold ≥ 3and ≥ 4 out of 5 for identifying prostate cancer</b> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MRI threshold</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Target<br/> condition</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>N participants<br/> (studies)<sup>a</sup> </b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Proportion<br/> negative MRI<br/> (95% CI)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sensitivity<br/> (95% CI)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Specificity<br/> (95% CI)</b> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>≥ 3/5</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G = 1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1647 (8)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.29 (0.21 to 0.40)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.68 (0.57 to 0.77)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.28 (0.19 to 0.39)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G ≥ 2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2974 (10)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.30 (0.23 to 0.38)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.89 (0.82 to 0.94)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.39 (0.32 to 0.47)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G ≥ 3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1438 (7)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.31 (0.21 to 0.42)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.96 (0.87 to 0.99)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.35 (0.26 to 0.46)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>≥ 4/5</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G = 1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>834 (4)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.60 (0.38 to 0.78)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.26 (0.16 to 0.40)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.57 (0.36 to 0.76)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G ≥ 2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1083 (5)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.59 (0.43 to 0.74)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.72 (0.52 to 0.86)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.78 (0.68 to 0.86)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G ≥ 3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>834 (4)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.60 (0.38 to 0.78)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.86 (0.51 to 0.97)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.68 (0.51 to 0.81)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>CI:</b> confidence interval; <b>G:</b> International Society of Urological Pathology grade; <b>MRI:</b> magnetic resonance imaging; <b>N:</b> number </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>a</sup>Data did not allow differentiation between the mix of included participants (biopsy‐naïve and prior‐negative biopsy men). </p> </div> </div> <p>Furthermore, the pooled sensitivity of MRI for detecting grade 3 or higher prostate cancer at a threshold of 4/5 is 0.86 (95% CI 0.51 to 0.97), indicating that a positive MRI missed 14% of men with grade 3 or higher prostate cancer. The MRI‐threshold dependency (3/5 versus 4/5) for detecting grade 2 or higher and grade 3 or higher prostate cancer is depicted by ROC plots in <a href="#CD012663-fig-0016">Figure 16</a> and <a href="#CD012663-fig-0017">Figure 17</a>, respectively. </p> <div class="figure" id="CD012663-fig-0016"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 16</div> </div> <hr class="top"/><img alt="MRI‐positivity threshold effect for indicating grade 2 and higher prostate cancer.Summary ROC plot of MRI verified by template‐guided biopsy, with different thresholds for positivity: intermediate (3/5) vs high (4/5)  G: International Society of Urological Pathology grade; MRI: magnetic resonance imaging" data-id="CD012663-fig-0016" src="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_n/nCD012663-AFig-FIG16.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>MRI‐positivity threshold effect for indicating grade 2 and higher prostate cancer.</p> <p>Summary ROC plot of MRI verified by template‐guided biopsy, with different thresholds for positivity: intermediate (3/5) vs high (4/5)<br/> G: International Society of Urological Pathology grade; MRI: magnetic resonance imaging </p> </div> </div> </div> <div class="figure" id="CD012663-fig-0017"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 17</div> </div> <hr class="top"/><img alt="MRI‐positivity threshold effect for indicating grade 3 and higher prostate cancer.Summary ROC plot of MRI verified by template‐guided biopsy, with different thresholds for positivity: intermediate (3/5) vs high (4/5)  G: International Society of Urological Pathology grade; MRI: magnetic resonance imaging" data-id="CD012663-fig-0017" src="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_n/nCD012663-AFig-FIG17.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>MRI‐positivity threshold effect for indicating grade 3 and higher prostate cancer.</p> <p>Summary ROC plot of MRI verified by template‐guided biopsy, with different thresholds for positivity: intermediate (3/5) vs high (4/5)<br/> G: International Society of Urological Pathology grade; MRI: magnetic resonance imaging </p> </div> </div> </div> </section> </section> <section id="CD012663-sec-0093"> <h4 class="title">Agreement between the MRI pathway and systematic biopsy</h4> <p>In this section, we focused on agreement and disagreement (concordance and discordance) in the number of target conditions identified by the MRI pathway and systematic biopsy. In addition, we have presented the proportions of participants with prostate cancer detected only by the MRI pathway and only by systematic biopsy (added values). </p> <section id="CD012663-sec-0094"> <h5 class="title">Prostate cancer detection in the MRI pathway and systematic biopsy</h5> <section id="CD012663-sec-0095"> <h6 class="title">Detection ratios for grade 2 or higher prostate cancer</h6> <p>In a mixed population (of biopsy‐naïve and prior‐negative biopsy men), the pooled detection ratio of grade 2 or higher prostate cancer was 1.12 (95% CI 1.02 to 1.23; 25 studies, 6944 men; <a href="#CD012663-tbl-0015">Table 9</a>; <a href="#CD012663-fig-0018">Figure 18</a>), meaning that the MRI pathway increased the grade 2 or higher prostate cancer detection rate by 12% over systematic biopsy. </p> <div class="figure" id="CD012663-fig-0018"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 18</div> </div> <hr class="top"/><img alt="Forest plots of the agreement analysis (MRI pathway vs systematic biopsy) for detecting grade 2 and higher prostate cancer" data-id="CD012663-fig-0018" src="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_n/nCD012663-AFig-FIG18.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plots of the agreement analysis (MRI pathway vs systematic biopsy) for detecting grade 2 and higher prostate cancer </p> </div> </div> </div> <div class="table" id="CD012663-tbl-0015"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 9.</span> <span class="table-title">Agreement analysis: detection ratio MRI‐pathway versus systematic biopsy</span></div> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Population</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Target</b> </p> <p><b>condition</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>N participants</b> </p> <p><b>(studies)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Proportion prostate cancer detected in % (95% CI)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Detection ratio<sup>b</sup><br/> (95% CI)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Difference<br/> between<br/> populations,<br/> P value<sup>c</sup> </b> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Biopsy status</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>MRI, proportion in % (95% CI)<sup>a</sup> </b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MRI‐pathway and SBx combined (total cancer detected)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MRI‐pathway</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>SBx</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>MRI‐pathway versus SBx</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>P value</b> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="8" valign=""> <p><b>Mixed<sup>d</sup> </b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>Positive + negative<br/> 100 (100 to 100) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>G = 1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5442 (21)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25.6 (22.8 to 28.8)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12.3 (10.1 to 15.1)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20.8 (18.0 to 24.1)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.61 (0.52 to 0.71)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P &lt; 0.01</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>G ≥ 1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6524 (24)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50.2 (46.4 to 54.3)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>37.9 (33.4 to 42.6)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>43.3 (39.1 to 47.8)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.88 (0.81 to 0.95)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P &lt; 0.01</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>G ≥ 2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6944 (25)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26.7 (23.3 to 30.7)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22.9 (19.5 to 26.8)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19.4 (15.9 to 23.5)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.12 (1.02 to 1.23)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.01</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>G ≥ 3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5981 (21)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15.0 (12.7 to 18.0)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12.7 (10.5 to 15.6)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.7 (7.5 to 12.7)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.20 (1.06 to 1.36)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P &lt; 0.01</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>Positive<br/> 67.6 (60.2 to 74.3) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>G = 1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3460 (19)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29.5 (26.0 to 33.8)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18.8 (15.2 to 23.4)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22.4 (18.9 to 26.9)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.85 (0.75 to 0.97)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.01</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>G ≥ 1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3998 (20)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>68.0 (62.3 to 73.5)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>61.1 (54.1 to 67.7)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>58.9 (51.5 to 65.9)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.03 (0.95 to 1.10)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.52</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>G ≥ 2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3998 (20)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42.6 (37.6 to 48.1)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37.9 (32.7 to 43.7)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31.6 (26.2 to 37.9)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.17 (1.07 to 1.28)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P &lt; 0.01</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>G ≥ 3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3902 (18)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24.2 (20.9 to 28.1)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21.0 (17.8 to 24.8)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16.3 (13.1 to 20.3)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.24 (1.11 to 1.38)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P &lt; 0.01</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="8" valign=""> <p><b>Biopsy‐naïve</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>Positive + negative<br/> 100 (100 to 100) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>G = 1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4079 (17)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27.2 (23.9 to 31.1)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13.5 (10.7 to 17.2)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22.4 (19.1 to 26.3)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.63 (0.54 to 0.74)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P &lt; 0.01</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.91</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>G ≥ 1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4799 (19)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>53.2 (48.7 to 57.9)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>41.0 (35.8 to 46.4)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>47.8 (42.8 to 52.9)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.85 (0.77 to 0.93)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P &lt; 0.01</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.12</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>G ≥ 2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5219 (20)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27.7 (23.7 to 32.6)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23.4 (19.3 to 28.1)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21.4 (17.2 to 26.5)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.05 (0.95 to 1.16)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.35</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P &lt; 0.01</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>G ≥ 3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4306 (16)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15.5 (12.6 to 19.5)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12.7 (9.9 to 16.5)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.8 (8.0 to 14.8)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.09 (0.94 to 1.26)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.27</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P &lt; 0.01</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>Positive<br/> 67.0 (58.7 to 74.4) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>G = 1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2682 (16)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31.8 (27.7 to 36.9)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21.3 (17.0 to 26.9)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23.7 (19.6 to 29.1)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.85 (0.74 to 0.98)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.03</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.35</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>G ≥ 1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2955 (17)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>70.9 (65.0 to 76.6)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63.7 (56.3 to 70.6)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63.8 (56.2 to 70.7)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.99 (0.92 to 1.08)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.88</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.05</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>G ≥ 2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2955 (17)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44.2 (38.6 to 50.4)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39.2 (33.3 to 45.7)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34.4 (28.3 to 41.3)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.12 (1.01 to 1.23)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.03</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P &lt; 0.01</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>G ≥ 3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2899 (15)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24.8 (21.0 to 29.6)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21.2 (17.4 to 25.7)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17.5 (13.8 to 22.3)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.16 (1.02 to 1.31)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.02</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P &lt; 0.01</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="8" valign=""> <p><b>Prior‐negative</b> </p> <p><b>biopsy</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>Positive + negative<br/> 100 (100 to 100) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>G = 1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1202 (8)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23.0 (18.0 to 30.2)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.9 (7.9 to 15.3)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17.8 (12.7 to 25.2)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.62 (0.44 to 0.88)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P &lt; 0.01</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.91</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>G ≥ 1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1564 (10)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40.7 (35.1 to 47.2)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30.0 (24.1 to 37.0)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30.3 (24.3 to 37.5)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.97 (0.85 to 1.11)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.70</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.12</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>G ≥ 2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1564 (10)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22.8 (20.0 to 26.2)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20.5 (17.7 to 23.5)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13.2 (10.8 to 16.4)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.44 (1.19 to 1.75)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P &lt; 0.01</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P &lt; 0.01</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>G ≥ 3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1514 (9)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12.6 (10.5 to 15.6)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11.5 (9.4 to 14.2)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.3 (4.4 to 9.1)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.64 (1.27 to 2.11)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P &lt; 0.01</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P &lt; 0.01</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>Positive<br/> 69.6 (54.7 to 81.3) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>G = 1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>655 (7)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27.9 (22.1 to 36.2)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18.2 (12.8 to 26.7)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18.9 (13.3 to 27.5)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.03 (0.89 to 1.18)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.71</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.35</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>G ≥ 1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>920 (8)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>54.8 (44.6 to 66.4)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48.5 (37.0 to 61.5)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>39.4 (27.1 to 53.9)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.16 (1.02 to 1.32)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.02</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.05</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>G ≥ 2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>920 (8)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31.3 (27.4 to 36.1)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28.6 (24.7 to 33.1)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18.3 (15.1 to 22.5)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.49 (1.22 to 1.82)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P &lt; 0.01</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P &lt; 0.01</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>G ≥ 3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>880 (7)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17.9 (14.3 to 22.9)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16.7 (13.1 to 21.5)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.4 (6.4 to 14.2)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.65 (1.30 to 2.09)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P &lt; 0.01</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P &lt; 0.01</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="10" rowspan="1" valign=""> <p><b>CI:</b> confidence interval; <b>G:</b> International Society of Urological Pathology grade; <b>MRI:</b> magnetic resonance imaging; <b>MRI‐pathway:</b> magnetic resonance imaging with or without magnetic resonance imaging‐targeted biopsy; <b>MRI‐TBx:</b> magnetic resonance imaging‐targeted biopsy; <b>N:</b> number; <b>SBx:</b> systematic biopsy </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>a</sup>Proportion of participants with a positive or negative magnetic resonance imaging result, based on the studies reporting grade 2 or higher.<br/> <sup>b</sup>Detection ratio is detection rate of magnetic resonance imaging‐pathway divided by detection rate of systematic biopsy; the detection rate is the pooled number of positive results of the test divided by the pooled total number of positive results from both tests.<br/> <sup>c</sup>Evaluating the difference in detection ratio's between the populations (biopsy‐naïve men versus prior‐negative biopsy) for each target condition.<br/> <sup>d</sup>Mixed: biopsy‐naïve and prior‐negative biopsy men. </p> </div> </div> <p>For men in the biopsy‐naïve setting, cancer proportion (total prostate cancer detected by both tests) was 27.7% (95% CI 23.7 to 32.6%; 20 studies, 5219 men), versus prior‐negative biopsy setting 22.8% (95% CI 20.0 to 26.2%; 10 studies, 1564 men). The pooled detection ratios for grade 2 or higher prostate cancer were 1.05 (95% CI 0.95 to 1.16) versus 1.44 (95% CI 1.19 to 1.75), respectively (P &lt; 0.01; <a href="#CD012663-tbl-0015">Table 9</a>, <a href="#CD012663-fig-0018">Figure 18</a>). </p> <p>When focusing on only MRI‐positive men in both subgroups, the pooled detection ratio increased from 1.05 to 1.12 (95% CI 1.01 to 1.23) and from 1.44 to 1.49 (95% CI 1.22 to 1.82), respectively (<a href="#CD012663-fig-0018">Figure 18</a>). </p> </section> <section id="CD012663-sec-0096"> <h6 class="title">Detection ratios for grade 3 or higher prostate cancer</h6> <p>For men in the biopsy‐naïve setting, cancer proportion was 15.5% (95% CI 12.6 to 19.5%; 16 studies, 4306 men), and in the prior‐negative biopsy setting cancer proportion was 12.6% (95% CI 10.5 to 15.6%; 9 studies; 1514 men). The pooled detection ratio of grade 3 or higher prostate cancer was 1.09 (95% CI 0.94 to 1.26) and 1.64 (95% CI 1.27 to 2.11), respectively (<a href="#CD012663-tbl-0015">Table 9</a>). When focusing on only MRI‐positive men in both subgroups, the pooled detection ratio increased from 1.09 to 1.16 (95% CI 1.02 to 1.31) and from 1.64 to 1.65 (95% CI 1.30 to 2.09), respectively. </p> </section> <section id="CD012663-sec-0097"> <h6 class="title">Detection ratios for grade 1 prostate cancer</h6> <p>For men in the biopsy‐naïve setting, cancer proportion was 27.2% (95% CI 23.9 to 31.1%; 17 studies, 4079 men), and in the prior‐negative biopsy setting, cancer proportion was 23.0% (95% CI 18.0 to 30.2%; 8 studies; 1202 men). The pooled detection ratio of grade 1 prostate cancer was 0.63 (95% CI 0.54 to 0.74) and 0.62 (95% CI 0.44 to 0.88), respectively (<a href="#CD012663-tbl-0015">Table 9</a>). </p> <p>The agreement data results based on meta‐analysis with mixed modelling (multinomial logistic regression models) are presented in <a href="#CD012663-tbl-0015">Table 9</a>; the results based on direct random‐effects meta‐analysis are presented in <a href="./appendices#CD012663-sec-0146">Appendix 6</a>. </p> </section> </section> <section id="CD012663-sec-0098"> <h5 class="title">Added values of the MRI pathway and systematic biopsy in prostate cancer detection</h5> <section id="CD012663-sec-0099"> <h6 class="title">Added values in grade 2 or higher prostate cancer detection</h6> <p>Per 100 biopsy‐naïve men, the MRI pathway detected approximately 23 men with grade 2 or higher prostate cancer (23.4%, 95% CI 19.4 to 28.2%; 20 studies, 5219 men; <a href="#CD012663-tbl-0016">Table 10</a>). In addition to the MRI pathway, systematic biopsy detected four additional men (4.3%, 95% CI 2.6% to 6.9%) (<a href="#CD012663-tbl-0016">Table 10</a>). The total number of detected cases was 27 (27.7%, 95% CI 23.7% to 32.6%). Conversely, systematic biopsy detected 21 men (21.4%, 95% CI 17.2% to 26.5%), and the MRI pathway detected six additional men (6.3%, 95% CI 4.8% to 8.2%). </p> <div class="table" id="CD012663-tbl-0016"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 10.</span> <span class="table-title">Agreement analysis: added values of MRI‐pathway and systematic biopsy</span></div> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Population</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Target<br/> condition</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>N participants<br/> (studies)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Proportion prostate cancer detected in % (95% CI)</b> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Biopsy status</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MRI,<br/> proportion in % (95% CI)<sup>a</sup> </b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MRI‐pathway and SBx combined (total cancer detected)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MRI‐pathway</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>SBx</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Both MRI‐pathway and SBx</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Only MRI‐pathway (added value<sup>b</sup>)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Only SBx (added value<sup>b</sup>)</b> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="12" valign=""> <p><b>Mixed<sup>c</sup> </b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>Positive + negative<br/> 100 (100 to 100) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>G = 1<sup>d</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5442 (21)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19.5 (16.9 to 22.7)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10.3 (8.1 to 13.1)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16.8 (14.2 to 19.9)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.6 (5.5 to 10.2)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.7 (1.8 to 4.0)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9.2 (7.4 to 11.4)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>G ≥ 1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6524 (24)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50.2 (46.4 to 54.3)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>37.9 (33.4 to 42.6)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>43.3 (39.1 to 47.8)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30.9 (26.3 to 36.0)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6.9 (5.2 to 9.2)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12.4 (10.2 to 14.9)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>G ≥ 2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6944 (25)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26.7 (23.3 to 30.7)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22.9 (19.5 to 26.9)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19.4 (15.9 to 23.6)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15.6 (12.2 to 19.6)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.3 (5.9 to 9.0)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.8 (2.5 to 5.7)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>G ≥ 3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5981 (21)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15.0 (12.7 to 18.0)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12.7 (10.5 to 15.6)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9.7 (7.5 to 12.7)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.4 (5.3 to 10.2)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.3 (4.3 to 6.5)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.3 (1.4 to 3.7)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>Positive<br/> 67.6 (60.2 to 74.3) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>G = 1<sup>d</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3460 (19)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19.7 (15.9 to 24.7)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15.8 (12.2 to 20.7)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15.8 (12 to 20.8)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12.0 (8.4 to 16.8)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.9 (2.6 to 5.7)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.8 (2.3 to 6.2)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>G ≥ 1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3998 (20)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>68.0 (62.3 to 73.5)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>61.1 (54.1 to 67.7)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>58.9 (51.5 to 65.9)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52.0 (43.6 to 59.9)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9.1 (5.9 to 13.5)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6.9 (4.6 to 10.1)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>G ≥ 2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3998 (20)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42.6 (37.6 to 48.1)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>37.9 (32.7 to 43.7)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31.6 (26.2 to 37.9)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27.0 (21.4 to 33.4)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10.9 (8.5 to 13.9)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.6 (2.9 to 7.2)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>G ≥ 3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3902 (18)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24.2 (20.9 to 28.1)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21 (17.8 to 24.8)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16.3 (13.1 to 20.3)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13.2 (10.1 to 16.9)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.9 (6.3 to 9.7)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.1 (1.9 to 5.2)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>Negative<br/> 32.4 (25.7 to 39.8) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>G = 1<sup>d</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1666 (19)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16.8 (12.9 to 21.6)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16.8 (12.9 to 21.6)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16.8 (12.9 to 21.6)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>G ≥ 1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1781 (20)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23.1 (19.7 to 26.9)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23.1 (19.7 to 26.9)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23.1 (19.7 to 26.9)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>G ≥ 2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1781 (20)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.2 (5.3 to 9.8)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.2 (5.3 to 9.8)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.2 (5.3 to 9.8)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>G ≥ 3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1725 (18)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.7 (1.6 to 4.6)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.7 (1.6 to 4.6)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.7 (1.6 to 4.6)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="12" valign="top"> <p><b>Biopsy‐naïve</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Positive + negative<br/> 100 (100 to 100) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G = 1<sup>d</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4079 (17)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20.9 (18.0 to 24.7)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11.2 (8.4 to 14.9)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18.5 (15.6 to 22.2)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.8 (6.2 to 12.3)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.4 (1.4 to 4.0)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.8 (8.0 to 11.8)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>G ≥ 1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4799 (19)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>53.2 (48.7 to 57.9)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>41.0 (35.8 to 46.4)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>47.8 (42.8 to 52.9)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35.6 (30.2 to 41.2)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.4 (3.6 to 8.0)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12.2 (8.7 to 16.7)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G ≥ 2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5219 (20)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27.7 (23.7 to 32.6)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23.4 (19.4 to 28.2)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21.4 (17.2 to 26.5)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17.1 (13.0 to 22)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.3 (4.8 to 8.2)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.3 (2.6 to 6.9)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G ≥ 3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4306 (16)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15.5 (12.6 to 19.5)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12.7 (9.9 to 16.5)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.8 (8.0 to 14.8)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.0 (5.4 to 11.6)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.7 (3.5 to 6.3)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.8 (1.7 to 4.8)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Positive<br/> 67.0 (58.7 to 74.4) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G = 1<sup>d</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2682 (16)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21.1 (16.7 to 27.1)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17.0 (12.6 to 22.9)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17.7 (13.3 to 23.8)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13.6 (9.3 to 19.5)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.4 (2.1 to 5.3)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.1 (2.5 to 6.7)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>G ≥ 1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2955 (17)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>70.9 (65.0 to 76.6)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63.7 (56.3 to 70.6)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63.8 (56.2 to 70.7)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>56.6 (47.7 to 64.6)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.1 (4.2 to 11.9)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.2 (4.7 to 10.8)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G ≥ 2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2955 (17)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44.2 (38.6 to 50.4)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39.2 (33.3 to 45.7)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34.4 (28.3 to 41.3)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>29.5 (23.2 to 36.5)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.8 (7.1 to 13.2)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.9 (2.8 to 8.3)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G ≥ 3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2899 (15)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24.8 (21.0 to 29.6)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21.2 (17.4 to 25.7)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17.5 (13.8 to 22.3)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13.9 (10.3 to 18.3)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.3 (5.4 to 9.7)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.7 (2.2 to 6.1)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Negative<br/> 33.0 (25.6 to 41.3) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G = 1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1287 (16)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18.4 (14.2 to 23.7)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18.4 (14.2 to 23.7)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18.4 (14.2 to 23.7)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>G ≥ 1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1343 (17)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25.5 (20.7 to 30.9)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25.5 (20.7 to 30.9)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25.5 (20.7 to 30.9)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G ≥ 2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1343 (17)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.1 (5.6 to 11.6)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.1 (5.6 to 11.6)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.1 (5.6 to 11.6)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G ≥ 3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1297 (15)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.0 (1.6 to 5.5)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.0 (1.6 to 5.5)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.0 (1.6 to 5.5)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="12" valign="top"> <p><b>Prior‐negative</b> </p> <p><b>biopsy</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Positive + negative<br/> 100 (100 to 100) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G = 1<sup>d</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1202 (8)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17.6 (13.0 to 25.0)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.8 (6.9 to 14.3)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13.5 (8.9 to 21.0)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.8 (3.2 to 10.0)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.1 (2.6 to 6.2)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.7 (3.9 to 14.8)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>G ≥ 1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1564 (10)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40.7 (35.1 to 47.2)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30.0 (24.1 to 37.0)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30.3 (24.3 to 37.5)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19.6 (13.7 to 27.1)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10.3 (7.5 to 13.9)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10.7 (7.4 to 15)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G ≥ 2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1564 (10)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22.8 (20.0 to 26.2)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20.5 (17.7 to 23.5)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13.2 (10.8 to 16.4)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10.9 (8.7 to 13.5)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.6 (7.7 to 11.8)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.3 (1.2 to 4.5)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G ≥ 3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1514 (9)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12.6 (10.5 to 15.6)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11.5 (9.4 to 14.2)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.3 (4.4 to 9.1)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.1 (3.4 to 7.7)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.3 (5.2 to 7.7)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.1 (0.5 to 2.6)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Positive<br/> 69.6 (54.7 to 81.3) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G = 1<sup>d</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>655 (7)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19.5 (13.9 to 28.8)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16.5 (11.0 to 25.2)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12.4 (7.2 to 21.6)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9.4 (4.6 to 17.9)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.1 (4.1 to 11.8)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.0 (1.0 to 8.0)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>G ≥ 1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>920 (8)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>54.8 (44.6 to 66.4)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48.5 (37.0 to 61.5)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>39.4 (27.1 to 53.9)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>33.1 (20.1 to 48.7)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15.4 (8.2 to 26.4)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6.3 (3.8 to 9.8)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G ≥ 2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>920 (8)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31.3 (27.4 to 36.1)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28.6 (24.7 to 33.1)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18.3 (15.1 to 22.5)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15.7 (12.7 to 19.1)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13.0 (9.7 to 17.0)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.7 (1.2 to 5.7)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G ≥ 3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>880 (7)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17.9 (14.3 to 22.9)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16.7 (13.1 to 21.5)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.4 (6.4 to 14.2)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.2 (5.2 to 12.6)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.5 (6.1 to 11.5)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.2 (0.4 to 3.2)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Negative<br/> 30.4 (18.7 to 45.3) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G = 1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>341 (7)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14.2 (5.9 to 30.2)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14.2 (5.9 to 30.2)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14.2 (5.9 to 30.2)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>G ≥ 1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>400 (8)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19.5 (12.9 to 28.3)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19.5 (12.9 to 28.3)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19.5 (12.9 to 28.3)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G ≥ 2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>400 (8)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.3 (3.1 to 8.9)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.3 (3.1 to 8.9)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.3 (3.1 to 8.9)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G ≥ 3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>390 (7)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.3 (1.7 to 6.3)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.3 (1.7 to 6.3)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.3 (1.7 to 6.3)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="10" rowspan="1" valign=""> <p><b>CI:</b> confidence interval; <b>G:</b> International Society of Urological Pathology grade; <b>MRI:</b> magnetic resonance imaging; <b>MRI‐pathway:</b> magnetic resonance imaging with or without magnetic resonance imaging‐targeted biopsy; <b>MRI‐TBx:</b> magnetic resonance imaging‐targeted biopsy: <b>N:</b> number; <b>NA:</b> not applicable; <b>SBx:</b> systematic biopsy </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>a</sup>Proportion of participants with a positive or negative MRI result, based on the studies reporting grade 2 or higher.<br/> <sup>b</sup>Added value MRI‐pathway is the proportion of prostate cancer not detected by systematic biopsy but only by the MRI‐pathway; added value of systematic biopsy is the proportion of prostate cancer not detected by the MRI‐pathway but only by systematic biopsy.<br/> <sup>c</sup>Mixed: biopsy‐naïve and prior‐negative biopsy men.<br/> <sup>d</sup>The tests are considered as 'add‐on tests', taking into account grade reclassification by each test (<a href="./appendices#CD012663-sec-0143">Appendix 3</a>). Therefore, G = 1 results differ from results in <a href="#CD012663-tbl-0015">Table 9</a>, where the tests are considered as 'replacement tests', not taking into account grade reclassification. </p> </div> </div> <p>Per 100 men with prior negative biopsy, the MRI pathway detected 21 men with grade 2 or higher prostate cancer (20.5%, 95% CI 17.7% to 23.5%; 10 studies, 1564 men; <a href="#CD012663-tbl-0016">Table 10</a>). In addition to the MRI pathway, systematic biopsy detected two additional men (2.3%, 95% CI 1.2% to 4.5%). The total number of detected cases was 23 (22.8%, 95% CI 20.0% to 26.2%). Conversely, systematic biopsy detected 13 men (13.2%, 95% CI 10.8% to 16.4%), and the MRI pathway detected 10 additional men (9.6%, 95% CI 7.7% to 11.8%). </p> <p><a href="#CD012663-fig-0019">Figure 19</a> shows the point estimates of the added values with their 95% confidence region and 95% prediction region. The 95% confidence region illustrates the uncertainty around the point estimate; the 95% prediction region illustrates the heterogeneity. Although the uncertainty of the point estimates was reasonably small, the heterogeneity was large, especially in the direction of systematic biopsy. This indicates that future individual studies might find considerable divergent results, especially for the added value of systematic biopsy. Furthermore, the heterogeneity appeared to be larger in biopsy‐naïve men than in prior‐negative men. </p> <div class="figure" id="CD012663-fig-0019"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 19</div> </div> <hr class="top"/><img alt="Added value of systematic biopsy plotted against the added value of the MRI pathway per population type in the agreement analysis, for detecting grade 2 and higher prostate cancer" data-id="CD012663-fig-0019" src="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_n/nCD012663-AFig-FIG19.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Added value of systematic biopsy plotted against the added value of the MRI pathway per population type in the agreement analysis, for detecting grade 2 and higher prostate cancer </p> </div> </div> </div> </section> <section id="CD012663-sec-0100"> <h6 class="title">Added values in grade 3 or higher prostate cancer detection</h6> <p>Per 100 biopsy‐naïve men, the MRI pathway detected approximately 13 men with grade 3 or higher prostate cancer (12.7%, 95% CI 9.9% to 16.5%; 16 studies, 4306 men; Table 10). In addition to the MRI pathway, systematic biopsy detected three additional men (2.8%, 95% CI 1.7% to 4.8%; <a href="#CD012663-tbl-0016">Table 10</a>). The total number of detected cases was 16 (15.5%, 95% CI 12.6% to 19.5%). Conversely, systematic biopsy detected 11 men (10.8%, 95% CI 8.0% to 14.8%) and the MRI pathway detected five additional men (4.7%, 95% CI 3.5% to 6.3%). </p> <p>Per 100 men with prior negative biopsy, the MRI pathway detected 12 men with grade 3 or higher prostate cancer (11.5%, 95% CI 9.4% to 14.2%; 9 studies, 1514 men; <a href="#CD012663-tbl-0016">Table 10</a>). In addition to the MRI pathway, systematic biopsy detected one additional man (1.1%, 95% CI 0.5% to 2.6%). The total number of detected cases was 13 (12.6%, 95% CI 10.5% to 15.6%). Conversely, systematic biopsy detected six men (6.3%, 95% CI 4.4% to 9.1%), and the MRI pathway detected six additional men (6.3%, 95% CI 5.2% to 7.7%). </p> </section> <section id="CD012663-sec-0101"> <h6 class="title">Added values in grade 1 prostate cancer detection</h6> <p>Per 100 biopsy‐naïve men, the MRI pathway detected approximately 11 men with grade 1 prostate cancer (11.2%, 95% CI 8.4% to 14.9%; 17 studies, 4079 men; <a href="#CD012663-tbl-0016">Table 10</a>). In addition to the MRI pathway, systematic biopsy detected 10 additional men (9.8%, 95% CI 8.0% to 11.8%). The total number of detected cases was 21 (20.9%, 95% CI 18.0% to 24.7%). Conversely, systematic biopsy detected 19 men (18.5%, 95% CI 15.6% to 22.2%) and the MRI pathway detected two additional men (2.4%, 95% CI 1.4% to 4.0%). </p> <p>Per 100 men with prior negative biopsy, the MRI pathway detected 10 men with grade 1 prostate cancer (9.8%, 95% CI 6.9% to 14.3%; 8 studies, 1202 men; <a href="#CD012663-tbl-0016">Table 10</a>). In addition to the MRI pathway, systematic biopsy detected eight additional men (7.7%, 95% CI 3.9% to 14.8%). The total number of detected cases was 18 (17.6%, 95% CI 13.0% to 25.0%). Conversely, systematic biopsy detected 14 men (13.5%, 95% CI 8.9% to 21.0%), and the MRI pathway detected four additional men (4.1%, 95% CI 2.6% to 6.2%). </p> </section> </section> <section id="CD012663-sec-0102"> <h5 class="title">Added values of the MRI pathway and systematic biopsy in MRI‐positive and MRI‐negative men </h5> <p>Stratifying men further into MRI positive and MRI negative aids in interpreting the added value in each of these categories. The pooled proportions of positive and negative MRI were respectively 67.0% (95% CI 58.7% to 74.4%) and 33.0% (95% CI 25.6% to 41.3%) in the biopsy‐naïve setting and were equivalent in the prior negative biopsy setting (<a href="#CD012663-tbl-0016">Table 10</a>). </p> <p>Per 100 biopsy‐naïve men with a positive MRI, the MRI pathway detected approximately 39 men with grade 2 or higher prostate cancer (39.2%, 95% CI 33.3% to 45.7%; 17 studies, 2955 men; <a href="#CD012663-tbl-0016">Table 10</a>). In addition to the MRI pathway, systematic biopsy detected five men (4.9%, 95% CI 2.8% to 8.3%). The total number of detected cases was 44 (44.2%, 95% CI 38.6% to 50.4%). Conversely, systematic biopsy detected 34 men (34.4%, 95% CI 28.3% to 41.3%) and the MRI pathway detected 10 additional men (9.8%, 95% CI 7.1% to 13.2%). </p> <p>Per 100 biopsy‐naïve men with a negative MRI, systematic biopsy detected eight additional men with grade 2 or higher prostate cancer (8.1%, 95% CI 5.6% to 11.6%; 17 studies, 1343 men) and 18 additional men with grade 1 prostate cancer (18.4%, 95% CI 14.2% to 23.7%; 16 studies, 1287 men). </p> <p>Per 100 men with a prior negative biopsy and a positive MRI, the MRI pathway detected approximately 29 men with grade 2 or higher prostate cancer (28.6%, 95% CI 24.7% to 33.1%; 8 studies, 920 men). In addition to the MRI pathway, systematic biopsy detected three men (2.7%, 95% CI 1.2% to 5.7%). The total number of detected cases was 31 (31.3%, 95% CI 27.4% to 36.1%). Conversely, systematic biopsy detected 18 men (18.3%, 95% CI 15.1% to 22.5%) and the MRI pathway detected an extra 13 men (13.0%, 95% CI 9.7% to 17.0%). </p> <p>Per 100 men with a prior negative biopsy and a negative MRI, systematic biopsy detected five men with grade 2 or higher prostate cancer (5.3%, 95% CI 3.1% to 8.9%; 8 studies, 400 men) and an 14 additional men with grade 1 prostate cancer (14.2%, 95% CI 5.9% to 30.2%; 7 studies, 341 men). </p> </section> <section id="CD012663-sec-0103"> <h5 class="title">Number needed to biopsy by systematic biopsy in addition to the MRI pathway</h5> <p>In biopsy‐naïve men with a positive MRI, the number needed to biopsy (NNB) for systematic biopsy in addition to MRI‐targeted biopsy for grade 2 or higher prostate cancer detection was 20 (95% CI 12 to 36; <a href="#CD012663-tbl-0017">Table 11</a>). In other words, to detect one additional man with grade 2 or higher prostate cancer, 20 men need to be biopsied by systematic biopsy in addition to MRI‐targeted biopsy. The NNB for detecting grade 3 or higher prostate cancer was 27 (95% CI 16 to 45). </p> <div class="table" id="CD012663-tbl-0017"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 11.</span> <span class="table-title">Agreement analysis: number needed to biopsy</span></div> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p><b>Agreement analysis: number needed to biopsy by systematic biopsy to detect one extra prostate cancer not detected by the MRI‐pathway</b> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Population</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Target<br/> condition</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>NNB<sup>a</sup><br/> (95% CI)</b> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Biopsy status</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MRI</b> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>Biopsy‐naïve</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Positive</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G = 1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 (15 to 40)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G ≥ 2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20 (12 to 36)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G ≥ 3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27 (16 to 45)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Negative</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G = 1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 (4 to 7)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G ≥ 2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13 (9 to 18)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G ≥ 3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33 (18 to 63)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>Prior‐negative biopsy</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Positive</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G = 1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33 (13 to 100)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G ≥ 2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37 (18 to 83)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G ≥ 3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>83 (31 to 250)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Negative</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G = 1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7 (3 to 17)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G ≥ 2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19 (11 to 32)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G ≥ 3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31 (16 to 63)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p><b>CI:</b> confidence interval; <b>G:</b> International Society of Urological Pathology grade; <b>MRI:</b> magnetic resonance imaging; <b>MRI‐pathway:</b> magnetic resonance imaging with or without magnetic resonance imaging‐targeted biopsy; <b>N:</b> number; <b>NA:</b> not applicable; NNB: number needed to biopsy; <b>SBx:</b> systematic biopsy </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>a</sup>Number needed to biopsy by systematic biopsy is 100 divided by the added value of systematic biopsy. </p> </div> </div> <p>In biopsy‐naïve men with a negative MRI, the NNB for grade 2 or higher prostate cancer detection was 13 (95% CI 9 to 18). The NNB for detecting grade 3 or higher was 33 (95% CI 18 to 63), considerably higher than for detecting grade 2 or higher prostate cancer. </p> <p>In men with a prior negative biopsy and a positive MRI, the NNBs for grade 2 or higher and grade 3 or higher prostate cancer were 37 (95% CI 18 to 83) and 83 (95% CI 31 to 250), respectively. The NNBs in MRI‐negative men were 19 (95% CI 11 to 32) and 31 (95% CI 16 to 63), respectively. </p> </section> </section> <section id="CD012663-sec-0104"> <h4 class="title">Heterogeneity analyses</h4> <p>For the test accuracy analyses (index tests versus reference standard (template‐guided biopsy)), the heterogeneity is illustrated by the 95% prediction region around the pooled estimates, as shown in <a href="#CD012663-fig-0008">Figure 8</a> (MRI), <a href="#CD012663-fig-0009">Figure 9</a> (MRI‐targeted biopsy), <a href="#CD012663-fig-0010">Figure 10</a> (MRI pathway) and <a href="#CD012663-fig-0012">Figure 12</a> (systematic biopsy). We observed considerable heterogeneity in all index tests. Due to limited data, we were unable to explore heterogeneity for these tests. </p> <p>For the agreement analyses (MRI pathway versus systematic biopsy), the heterogeneity (total τ<sup>2</sup> = 0.03) is illustrated in <a href="#CD012663-fig-0018">Figure 18</a>. Due to limited data, exploration of heterogeneity was only possible by independent analyses of different population types, endorectal coil use, MRI pulse sequences, MRI risk thresholds and MRI‐targeted biopsy techniques (<a href="#CD012663-tbl-0018">Table 12</a>). We found a statistically significant difference in the detection ratio of the MRI pathway versus systematic biopsy between the subgroups of population (prior negative biopsy versus biopsy naïve) and endorectal coil use (‘yes’ versus ‘no’), suggesting that they may be sources of heterogeneity. There was no statistically significant difference in the detection ratio of the MRI pathway versus systematic biopsy, between studies using mpMRI or bpMRI, between studies with a low or intermediate MRI risk threshold, and between studies using a software or a cognitive MRI‐targeted biopsy technique. </p> <div class="table" id="CD012663-tbl-0018"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 12.</span> <span class="table-title">Heterogeneity exploration in the agreement analysis</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Heterogeneity exploration in the agreement analysis: detection ratio MRI‐pathway vs systematic biopsy for G ≥ 2 prostate cancer</b> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Covariate</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Category</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>N participants<br/> (studies)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Detection ratio<br/> for G ≥ 2 PCa<br/> (95% CI)<sup>a</sup> </b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>P value</b> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Population</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Biopsy‐naïve</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5219 (20)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.05 (0.95 to 1.16)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>0.002</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Prior to negative biopsy</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1564 (10)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.44 (1.19 to 1.75)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Field strength</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3T</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5407 (19)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ID</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ID</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.5T</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1143 (4)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ID</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ID</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Endorectal coil</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1815 (6)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.42 (1.07 to 1.88)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>0.008</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4082 (14)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.03 (0.94 to 1.12)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p><b>MRI pulse sequence</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>mpMRI</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4941 (16)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.18 (1.05 to 1.33)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>0.233</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>bpMRI</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1775 (6)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.03 (0.91 to 1.17)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>mpMRI + spectroscopy</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>105 (2)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ID</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ID</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p><b>MRI risk threshold</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>605 (6)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.18 (1.03 to 1.35)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>0.556</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intermediate</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5859 (15)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.14 (1.03 to 1.26)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>High</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>428 (3)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ID</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ID</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p><b>MRI‐TBx technique</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Software</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3313 (9)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.15 (0.99 to 1.33)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>0.483</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cognitive</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2194 (12)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.17 (1.00 to 1.36)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>In‐bore</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>849 (2)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ID</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ID</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Route index test</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Transrectal</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6464 (23)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ID</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ID</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Transperineal</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>480 (2)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ID</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ID</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>bpMRI:</b> biparametric magnetic resonance imaging; <b>CI:</b> confidence interval; <b>G:</b> International Society of Urological Pathology grade; <b>ID:</b> inadequate data; <b>mpMRI:</b> multiparametric magnetic resonance imaging; <b>MRI:</b> magnetic resonance imaging; <b>MRI‐pathway:</b> magnetic resonance imaging with or without magnetic resonance imaging‐targeted biopsy; <b>MRI‐TBx:</b> magnetic resonance imaging‐targeted biopsy; <b>N:</b> number; <b>SBx:</b> systematic biopsy </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>a</sup>Detection ratio is the detection rate of MRI‐pathway divided by detection rate of systematic biopsy; the detection rate = the pooled number of positive results of the test divided by the pooled total number of positive results from both tests. </p> </div> </div> </section> <section id="CD012663-sec-0105"> <h4 class="title">Sensitivity analyses</h4> <p>We performed sensitivity analyses for the detection of grade 2 or higher prostate cancer by excluding studies based on certain quality and additional criteria. </p> <section id="CD012663-sec-0106"> <h5 class="title">Test accuracy analyses</h5> <p>Excluding studies with a high or unclear risk of bias or applicability concern in one of the four QUADAS‐2 domains did not substantially change the accuracy results of MRI, MRI‐targeted biopsy and the MRI pathway (<a href="#CD012663-tbl-0019">Table 13</a>), although we were unable to confirm this for applicability concerns in MRI‐targeted biopsy and the MRI pathway analyses because of a limited number of studies. We could not perform any sensitivity analyses for systematic biopsy due to the limited number of studies. </p> <div class="table" id="CD012663-tbl-0019"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 13.</span> <span class="table-title">Sensitivity analysis of the diagnostic test accuracy analyses</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="9" rowspan="1" valign=""> <p><b>Sensitivity analyses of the diagnostic test accuracy of MRI and the MRI‐pathway for detecting G ≥ 2 prostate cancer, verified by template‐guided biopsy as the reference standard</b> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="2" valign=""> <p><b>Covariate</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Category</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>MRI</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>MRI‐pathway<sup>a</sup> </b> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>N<br/> studies</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Sensitivity<br/> (95% CI)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Specificity<br/> (95% CI)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>N<br/> studies</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Sensitivity<br/> (95% CI)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Specificity<br/> (95% CI)</b> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Main analyses (as reference</b>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No selection</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.91 (0.83 to 0.95)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.37 (0.29 to 0.46)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.72 (0.60 to 0.82)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.96 (0.94 to 0.98)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="7" valign=""> <p><b>QUADAS domains</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Participant selection</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Only low risk of bias</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.86 (0.83 to 0.88)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.39 (0.31 to 0.47)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.61 (0.54 to 0.69)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.97 (0.92 to 0.99)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Only low applicability concern</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.91 (0.83 to 0.96)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.36 (0.28 to 0.46)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.69 (0.60 to 0.77)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.97 (0.94 to 0.98)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Index test</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Only low risk of bias</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.91 (0.83 to 0.95)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.37 (0.29 to 0.46)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.72 (0.60 to 0.82)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.96 (0.94 to 0.98)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Only low applicability concern</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.90 (0.85 to 0.94)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.37 (0.31 to 0.43)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.68 (0.59 to 0.77)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.97 (0.94 to 0.99)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Reference standard</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Only low risk of bias</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.93 (0.82 to 0.98)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.34 (0.24 to 0.45)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ID</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ID</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Only low applicability concern</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.91 (0.83 to 0.95)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.37 (0.29 to 0.46)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.72 (0.60 to 0.82)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.96 (0.94 to 0.98)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Flow and timing</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Only low risk of bias</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.91 (0.83 to 0.96)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.36 (0.28 to 0.46)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.72 (0.60 to 0.82)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.96 (0.94 to 0.98)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="7" valign=""> <p><b>Additional analyses</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>MRI positivity threshold</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Only threshold 3/5</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.89 (0.82 to 0.94)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.39 (0.32 to 0.47)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.68 (0.59 to 0.77)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.97 (0.94 to 0.98)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>MRI positivity threshold effect</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MRI positivity threshold 3/5 (only studies with also 4/5)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.87 (0.73 to 0.94)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.45 (0.33 to 0.57)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ID</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ID</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MRI positivity threshold 4/5 (only studies with also 3/5)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.72 (0.52 to 0.86)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.78 (0.68 to 0.86)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ID</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ID</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>MRI vs MRI‐pathway</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Only MRI and MRI‐pathway in the same men (paired data)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.92 (0.83 to 0.96)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.35 (0.27 to 0.44)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.72 (0.60 to 0.82)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.96 (0.94 to 0.98)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Reference standard</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Only TTMB, TSB or TOP</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.90 (0.84 to 0.93)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.36 (0.29 to 0.44)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.69 (0.58 to 0.78)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.96 (0.93 to 0.97)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Template‐guided biopsy + MRI‐TBx (composite reference standard)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.94 (0.91 to 0.96)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.00 (1.00 to 1.00)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.72 (0.63 to 0.80)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.00 (1.00 to 1.00)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Experience of radiologist</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Only high experience</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.91 (0.85 to 0.95)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.34 (0.27 to 0.42)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.69 (0.60 to 0.77)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.97 (0.94 to 0.98)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="9" rowspan="1" valign=""> <p><b>CI:</b> confidence interval; <b>G:</b> International Society of Urological Pathology grade; <b>ID:</b> inadequate data; <b>MRI:</b> magnetic resonance imaging; <b>MRI‐pathway:</b> magnetic resonance imaging with or without magnetic resonance imaging‐targeted biopsy; <b>MRI‐TBx:</b> magnetic resonance imaging‐targeted biopsy; <b>N:</b> number; <b>NA:</b> not applicable; <b>QUADAS:</b> Quality Assessment of Diagnostic Accuracy Studies; <b>SBx:</b> systematic biopsy; <b>TOP:</b> transperineal optimised prostate biopsy;<b>TSB:</b> Ginsburg transperineal saturation biopsy; <b>TTMB:</b> transperineal template mapping biopsy </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>a</sup>The diagnostic test accuracy analyses of magnetic resonance imaging‐targeted biopsy are based on the same studies as the MRI‐pathway. </p> </div> </div> <p>To further assess the reliability of our results, we performed additional sensitivity analyses. In particular, excluding studies with MRI‐positivity thresholds other than threshold 3/5 did not substantially change the accuracy results of all MRI‐involved tests. Furthermore, the accuracy of MRI and the MRI pathway did not substantially change when assessed only in studies that had performed both tests in the same men (paired data), indicating no selection bias in the analysis comparing MRI with the MRI pathway (<a href="#CD012663-fig-0014">Figure 14</a>). Similarly, the accuracy of MRI did not substantially change when assessed only in studies that had investigated multiple MRI‐positivity thresholds in the same men (paired data), indicating no selection bias in the MRI‐positivity threshold effect analyses (<a href="#CD012663-fig-0016">Figure 16</a>). Regarding our choice of reference standard, excluding studies with an in‐house TSB or a transrectal TSB (potentially less accurate techniques than TTMB, with biopsies at every 5 mm) did not substantially change the accuracy of MRI and the MRI pathway. In addition, using a composite reference standard (template‐guided biopsy + MRI‐targeted biopsy), thus regarding the additional prostate cancer detected by MRI‐targeted biopsy as ‘true’ positives instead of ‘false’ positives, did not substantially change the accuracy of MRI, MRI‐targeted biopsy and the MRI pathway. Excluding studies in which the radiologist had little or unclear experience did not change the accuracy results of MRI, MRI‐targeted biopsy and the MRI pathway. </p> </section> <section id="CD012663-sec-0107"> <h5 class="title">Agreement analyses</h5> <p>Excluding studies with a high or unclear risk of bias or applicability concern in three of the four QUADAS‐2 domains (participant selection, index test (MRI pathway), flow &amp; timing) did not substantially change the detection ratio between the MRI pathway and systematic biopsy (<a href="#CD012663-tbl-0020">Table 14</a>). Excluding studies with a high or unclear risk of bias and applicability concern in the index test (systematic biopsy) domain, however, did result in an equal detection rate of both index tests instead of a higher detection rate of the MRI pathway. Furthermore, excluding studies with MRI‐positivity thresholds other than threshold 3/5 did not substantially change the detection ratio between the MRI pathway and systematic biopsy. The difference in the detection ratios between population types did not notably change when we analysed only studies that compared biopsy‐naïve and prior‐negative biopsy men in the same study. Excluding studies in which the radiologist had little or unclear experience did not change the detection ratio between the MRI pathway and systematic biopsy. </p> <div class="table" id="CD012663-tbl-0020"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 14.</span> <span class="table-title">Sensitivity analysis of the agreement analyses</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Sensitivity analyses of the agreement between the MRI‐pathway vs systematic biopsy for detecting G ≥ 2 prostate cancer</b> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Covariate</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Category</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>N<br/> studies</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Detection ratio<br/> (95% CI)<sup>a</sup> </b> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Main analyses (as reference)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mixed population</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.12 (1.02 to 1.23)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="7" valign=""> <p><b>QUADAS domains</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Patient selection</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Only low risk of bias</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.08 (1.00 to 1.17)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Only low applicability concern</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.09 (1.01 to 1.17)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Index test (MRI‐pathway)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Only low risk of bias</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.11 (1.02 to 1.22)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Only low applicability concern</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.13 (1.01 to 1.26)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Index test (SBx)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Only low risk of bias</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.04 (0.94 to 1.15)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Only low applicability concern</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.07 (0.99 to 1.15)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Flow and timing</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Only low risk of bias</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.10 (1.00 to 1.22)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p><b>Additional analyses</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>MRI positivity threshold</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Only threshold 3/5</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.14 (1.03 to 1.26)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Biopsy‐naïve (only studies with also prior‐negative biopsy men)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.98 (0.76 to 1.28)<sup>b</sup> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Prior‐negative biopsy (only studies with also biopsy‐naïve men)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.42 (1.03 to 1.95)<sup>b</sup> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Experience of radiologist</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Only high experience</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.13 (1.03 to 1.24)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>CI:</b> confidence interval; <b>G:</b> International Society of Urological Pathology grade; <b>MRI‐pathway:</b> magnetic resonance imaging (MRI) with or without MRI‐targeted biopsy; <b>N:</b> number; <b>QUADAS:</b> Quality Assessment of Diagnostic Accuracy Studies; <b>SBx:</b> systematic biopsy </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>a</sup>Detection ratio is the detection rate of the MRI‐pathway divided by detection rate of systematic biopsy; the detection rate is the pooled number of positive results of the test divided by the pooled total number of positive results from both tests.<br/> <sup>b</sup>The reference detection ratio for these categories are 1.05 (95% CI 0.95 to 1.16) for the biopsy‐naïve men and 1.44 (95% CI 1.19 to 1.75) for the prior‐negative biopsy men (<a href="#CD012663-tbl-0015">Table 9</a>). </p> </div> </div> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD012663-sec-0108" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD012663-sec-0108"></div> <section id="CD012663-sec-0109"> <h3 class="title" id="CD012663-sec-0109">Summary of main results</h3> <p>This systematic review presents the test accuracy of the MRI, MRI‐targeted biopsy, the MRI pathway (MRI with or without MRI‐targeted biopsy) and the current standard testing with systematic biopsies in prostate cancer diagnosis, using template‐guided biopsy sampling of the whole prostate as the reference standard (<a href="#CD012663-fig-0001">Figure 1</a>). Although the results of the MRI pathway represent the complete MRI‐informed clinical pathway, the diagnostic test accuracy results of the MRI and MRI‐targeted biopsy inform us on each diagnostic step in between (Figure 9). The MRI test alone indicates the presence of disease without MRI‐targeted biopsy results. The MRI‐targeted biopsy refers to only MRI‐positive men with targeted biopsy results. </p> <p>We carried out two types of analyses:</p> <p> <ol id="CD012663-list-0009"> <li> <p>test accuracy analyses of four index tests in prostate cancer diagnosis, providing evidence to determine their discriminative value in current clinical practice; and </p> </li> <li> <p>agreement analyses for detecting prostate cancer between two index tests (the MRI pathway and the current practice of systematic biopsy), providing additional evidence for biopsy decision making. </p> </li> </ol> </p> <section id="CD012663-sec-0110"> <h4 class="title">Quantity and quality of evidence</h4> <p>A considerable number of studies in both the diagnostic accuracy (n = 9/18) and agreement analyses (n = 13/25) had a high or unclear risk of bias or applicability concern in one of the QUADAS‐2 domains. These issues, in addition to concerns over inconsistency and imprecision, prompted us to downgrade the certainty of evidence to low for all four main comparisons and outcomes. Overall, we acknowledge concerns about the independent performance and applicability of tests in both test accuracy and agreement analyses, for which we performed sensitivity analyses to exclude studies with such quality concerns. Furthermore, a considerable amount of heterogeneity was present in both diagnostic accuracy and agreement analyses, but only limited exploration was possible due to the paucity of studies in each subgroup. Only population type (biopsy‐naïve versus prior‐negative biopsy men) and the usage of an endorectal coil (‘yes ’ versus ‘no ’) may have explained some of the heterogeneity in the agreement analyses. </p> </section> <section id="CD012663-sec-0111"> <h4 class="title">Test accuracy analysis of MRI, MRI‐targeted biopsy, MRI pathway and systematic biopsy, verified by the reference standard, template‐guided biopsy </h4> <p>The MRI missed the identification of 9% of men with grade 2 or higher prostate cancer (pooled sensitivity 0.91, 95% CI 0.83 to 0.95; specificity 0.37, 95% CI 0.29 to 0.46; <a href="./full#CD012663-tbl-0003">summary of findings Table 3</a>); MRI‐targeted biopsy in MRI‐positive men missed the diagnosis in 20% of men with grade 2 or higher prostate cancer (pooled sensitivity of 0.80, 95% CI 0.69 to 0.87; specificity 0.94, 95% CI 0.90 to 0.97; <a href="./full#CD012663-tbl-0004">summary of findings Table 4</a>); whereas the MRI pathway (in both MRI‐positive and MRI‐negative men) missed the diagnosis in 28% (pooled sensitivity 0.72, 95% CI 0.60 to 0.82; specificity 0.96, 95% CI 0.94 to 0.98; <a href="./full#CD012663-tbl-0005">summary of findings Table 5</a>). Systematic biopsy missed 37% of men with grade 2 or higher prostate cancer (pooled sensitivity 0.63, 95% CI 0.19 to 0.93; specificity 1.00, 95% CI 0.91 to 1.00; <a href="./full#CD012663-tbl-0006">summary of findings Table 6</a>). Hence, systematic biopsy had a substantially lower sensitivity than the MRI pathway (P = 0.06; <a href="#CD012663-fig-0015">Figure 15</a>; <a href="./full#CD012663-tbl-0001">summary of findings Table 1</a>). </p> <p>The MRI pathway beneficially avoided the detection of 66% of grade 1 prostate cancer (pooled sensitivity 0.34, 95% CI 0.19 to 0.53) and reduced 29% of biopsies all in MRI‐negative men (pooled percentage negative MRI 29%, 95% CI 24% to 35%; <a href="./full#CD012663-tbl-0002">summary of findings Table 2</a>). In contrast, the systematic biopsy approach avoided 45% of grade 1 prostate cancer (pooled sensitivity 0.55, 95% CI 0.25 to 0.83) and a biopsy procedure was performed in all men (100%). </p> </section> <section id="CD012663-sec-0112"> <h4 class="title">Agreement analyses between the MRI pathway and systematic biopsy</h4> <p>The MRI pathway significantly outperformed systematic biopsy by detecting 12% more grade 2 or higher prostate cancer (pooled detection ratio 1.12, 95% CI 1.02 to 1.23), irrespective of population type (<a href="./full#CD012663-tbl-0001">summary of findings Table 1</a>). This percentage increased in men with prior negative biopsies to 44% (pooled detection ratio 1.44, 95% CI 1.19 to 1.75) but decreased in biopsy‐naïve men to 5% (pooled detection ratio 1.05, 95% CI 0.95 to 1.16). We observed similar outcomes for the detection of grade 3 or higher prostate cancer. </p> <p>The MRI pathway beneficially detected less grade 1 prostate cancer than systematic biopsy, with a reduction of 37% in biopsy‐naïve men (pooled detection ratio 0.63, 95% CI 0.54 to 0.74) and 38% in men with prior negative biopsy (pooled detection ratio 0.62, 95% CI 0.44 to 0.88; <a href="./full#CD012663-tbl-0002">summary of findings Table 2</a>). The MRI pathway beneficially reduced a third of biopsies, all in MRI‐negative men (pooled percentage negative MRI 33%, 95% CI 26% to 41%; and 30%, 95% CI 19% to 44%; in biopsy‐naïve and prior‐negative biopsy men, respectively). </p> </section> </section> <section id="CD012663-sec-0113"> <h3 class="title" id="CD012663-sec-0113">Strengths and weaknesses of the review</h3> <section id="CD012663-sec-0114"> <h4 class="title">Strengths and weaknesses of included studies.</h4> <p>Strengths included that the test accuracy studies investigated one or more index tests verified by template‐guided biopsy in the same men, comprehensively sampling all zones of the prostate with a minimum of 20 biopsy cores (reference standard). The studies in the agreement analysis investigated the MRI pathway and systematic biopsy in the same men. We included only studies involving MRI for both test accuracy and agreement analyses that investigated men with positive and negative MRIs. These criteria ensured that we avoided a number of biases and inaccurate findings, as stated in the <a href="#CD012663-sec-0046">Rationale</a>. This systematic review contains many large studies, including the appraised PROMIS study (<a href="./references#CD012663-bbs2-0002" title="AhmedHU , El‐Shater BosailyA , BrownLC , GabeR , KaplanR , ParmarMK , et al. Diagnostic accuracy of multi‐parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. Lancet2017;389(10071):815‐22. ">Ahmed 2017</a>) and others (<a href="./references#CD012663-bbs2-0013" title="DistlerFA , RadtkeJP , BonekampD , KeschC , SchlemmerHP , WieczorekK , et al. The value of PSA density in combination with PI‐RADS for the accuracy of prostate cancer prediction. The Journal of Urology2017;198(3):575‐82. ">Distler 2017</a>; <a href="./references#CD012663-bbs2-0018" title="HansenN , PatrunoG , WadhwaK , GazievG , MianoR , BarrettT , et al. Magnetic resonance and ultrasound image fusion supported transperineal prostate biopsy using the Ginsburg protocol: technique, learning points, and biopsy results. Eurpean Urology2016;70(2):332‐40. ">Hansen 2016a</a>; <a href="./references#CD012663-bbs2-0019" title="HansenNL , KeschC , BarrettT , KooB , RadtkeJP , BonekampD , et al. Multicentre evaluation of targeted and systematic biopsies using magnetic resonance and ultrasound image‐fusion guided transperineal prostate biopsy in patients with a previous negative biopsy. BJU International2017;120(5):631‐8. ">Hansen 2017</a>; <a href="./references#CD012663-bbs2-0023" title="KeschC , RadtkeJP , PopeneciuIV , GaschC , DieffenbacherSC , KleinT , et al. TOP: prospective evaluation of a volume based, computer assisted method for transperineal optimized prostate biopsy. Urologia Internationalis2017;99(2):149‐55. ">Kesch 2017</a>; <a href="./references#CD012663-bbs2-0028" title="MortezaviA , MärzendorferO , DonatiOF , RizziG , RuppNJ , WettsteinMS , et al. Diagnostic accuracy of multiparametric magnetic resonance imaging and fusion guided targeted biopsy evaluated by transperineal template saturation prostate biopsy for the detection and characterization of prostate cancer. Journal of Urology2018;200(2):309‐18. ">Mortezavi 2018</a>) that showed results very consistent with the pooled accuracy estimates from our meta‐analyses. We have summarised the limitations of the included studies with reference to each of the four, quality domains, as assessed by our QUADAS‐2 tool: </p> <p> <ol id="CD012663-list-0010"> <li> <p><i>Participant selection:</i> In both test accuracy and agreement analyses, multiple studies showed an unclear or high risk of bias in this domain. Retrospective and nonconsecutive inclusion of participants might have led to manipulation of data. </p> </li> <li> <p><i>Index tests</i>: In the test accuracy studies, we identified almost no high or unclear risk of bias in the performance of index tests. In the agreement analysis, however, multiple studies did not perform the MRI pathway and systematic biopsy blinded from each other. This could possibly have led to MRI‐informed systematic biopsy in some studies, with (sub‐)conscious over‐ or underperformance of systematic biopsies. </p> </li> <li> <p><i>Reference test:</i> Similar concerns exist for the reference standard in the diagnostic accuracy analyses, because multiple studies showed an unclear or high risk of bias regarding the independent performance of template‐guided biopsies or appropriate sampling of the whole prostate. Both factors possibly led to (sub‐)conscious under‐ or overestimation of index test accuracy in some studies. Because template‐guided biopsy is performed mostly in the context of scientific research and is not performerd regularly in most clinical practices, the possibility of selection bias should be taken into consideration. However, investigators responsible for the largest test accuracy studies included in this review do perform template‐guided biopsy in regular practice. </p> </li> <li> <p><i>Flow and timing:</i> Only a limited number of studies showed a high or unclear risk of bias, indicating that most studies performed the tests in a similar manner in all participants and did not exclude any participants for reasons that could cause bias. </p> </li> </ol> </p> <p>Despite the risks of biases as described in the above domains, the sensitivity analyses, which excluded studies with a high or unclear risk of bias, demonstrated the robustness of the main results (<a href="#CD012663-tbl-0019">Table 13</a>; <a href="#CD012663-tbl-0020">Table 14</a>). </p> </section> <section id="CD012663-sec-0115"> <h4 class="title">Strengths and weaknesses of the review process</h4> <section id="CD012663-sec-0116"> <h5 class="title">Quality assessment and data extraction</h5> <p>We selected the included studies from the available literature using a very sensitive method, without restrictions, and two review authors independently extracted data, according to the Cochrane DTA principles (<a href="./references#CD012663-bbs2-0107" title="HigginsJP , DeeksJJ . Chapter 7: Selecting studies and collecting data. In: HigginsJPT , GreenS editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. The Cochrane Collaboration. Available from www.handbook.cochrane.org, 2011. ">Higgins 2011</a>). We successfully requested additional data from study authors to enable accurate extraction of two‐by‐two contingency tables, which otherwise we would have had to exclude from this review. Similarly, in order to minimise heterogeneity, extensive effort was undertaken to retrieve data for the target condition solely based on Gleason Score grading. Regardless, we had to exclude several eligible studies due to insufficient reported data. Limited reporting of methodological details resulted in multiple ‘unclear’ assessments of methodological quality items and limited heterogeneity explorations. </p> </section> <section id="CD012663-sec-0117"> <h5 class="title">Review analyses</h5> <p>The use of template‐guided biopsy to verify the index tests ensured that the absence or presence of the disease was accurately investigated in the whole population referred for biopsy. This approach excluded all the inherent biases of other reference standards (i.e. systematic biopsies and radical prostatectomies) used in previous systematic reviews. However, it should be noted that template‐guided biopsy is not a perfect test, as its diagnostic accuracy is dependent on the intensity and trajectory of cores taken. This is reflected by the pooled specificity of MRI‐targeted biopsy (0.94, 95% CI 0.90 to 0.97), which indicates that MRI‐targeted biopsy detected 6% grade 2 or higher prostate cancer in addition to those detected by the reference standard. These ‘false’ positives, however, would likely be regarded as ‘true’ positives in clinical practice. Because the results of both tests are based on the same histopathological diagnosis, either positive result will be considered in subsequent decision making. Sensitivity analyses with a composite reference standard (template‐guided biopsy + MRI‐targeted biopsy), thus regarding these ‘false’ positives as ‘true’ positives, however, showed no substantial difference in the accuracy of MRI and the MRI pathway. Nevertheless, underestimation of the specificity and PPV of both MRI‐targeted biopsy and MRI pathway should be considered accordingly. Furthermore, the inherent chance of up‐ or downgrading of prostate cancer of any biopsy result following radical prostatectomy should be taken into account (<a href="./references#CD012663-bbs2-0095" title="EpsteinJI , FengZ , TrockBJ , PierorazioPM . Upgrading and downgrading of prostate cancer from biopsy to radical prostatectomy: incidence and predictive factors using the modified Gleason grading system and factoring in tertiary grades. European Urology2012;61(5):1019‐24. ">Epstein 2012</a>). </p> <p>It should also be taken into consideration that the results are based on per‐participant analyses and not on per‐lesion analyses. Therefore, spatial concordance between (multiple) MRI findings and biopsy findings are not taken into account. For example, when a suspicious MRI lesion is identified in the right apex, while cancer is detected by template‐guided biopsy in the left apex, the MRI is regarded as a true positive in the per‐participant analyses; in reality, however, the MRI reading is a false positive in the right apex and false negative in the left apex. The underlying cause could be both interpretative problems with MRI, such as original misreading or truly invisible tumours (<a href="./references#CD012663-bbs2-0075" title="BorofskyS , GeorgeAK , GaurS , BernardoM , GreerMD , MertanFV , et al. What are we missing? False‐negative cancers at multiparametric MR imaging of the prostate. Radiology2018;286(1):186‐95. ">Borofsky 2018</a>; <a href="./references#CD012663-bbs2-0134" title="RosenkrantzAB , BabbJS , TanejaSS , ReamJM . Proposed adjustments to PI‐RADS version 2 decision rules: impact on prostate cancer detection. Radiology2017;283(1):119‐29. ">Rosenkrantz 2017</a>; <a href="./references#CD012663-bbs2-0139" title="SchoutenMG , Van derLeestM , PokornyM , HoogenboomM , BarentszJO , ThompsonLC , et al. Why and where do we miss significant prostate cancer with multi‐parametric magnetic resonance imaging followed by magnetic resonance‐guided and transrectal ultrasound‐guided biopsy in biopsy‐naïve men?. European Urology2017;71(6):896‐903. ">Schouten 2017</a>), and inaccurate MRI‐targeted biopsy, due to technical or mechanical flaws or intralesional heterogeneity (<a href="./references#CD012663-bbs2-0081" title="CashH , GunzelK , MaxeinerA , StephanC , FischerT , DurmusT , et al. Prostate cancer detection on transrectal ultrasonography‐guided random biopsy despite negative real‐time magnetic resonance imaging/ultrasonography fusion‐guided targeted biopsy: reasons for targeted biopsy failure. BJU International2016;118(1):35‐43. ">Cash 2016</a>; <a href="./references#CD012663-bbs2-0084" title="CokerMA , GlaserZA , GordetskyJB , ThomasJV , Rais‐BahramiS . Targets missed: predictors of MRI‐targeted biopsy failing to accurately localize prostate cancer found on systematic biopsy. Prostate Cancer and Prostatic Diseases2018;21(4):549‐55. ">Coker 2018</a>; <a href="./references#CD012663-bbs2-0103" title="GoldSA , HaleGR , BloomJB , SmithCP , RaynKN , ValeraV , et al. Follow‐up of negative MRI‐targeted prostate biopsies: when are we missing cancer?. World Journal of Urology2019;37(2):235‐41. ">Gold 2019</a>). As a consequence, the sensitivity of the MRI might be overestimated. Unfortunately, no data were available to assess the individual contributions of these factors in this review. </p> <p>We analysed the test accuracy of MRI, MRI‐targeted biopsy and MRI pathway separately to provide insight into the accuracy of different steps in the MRI‐informed clinical pathway. MRI‐targeted biopsy is only performed in MRI‐positive men, and therefore its results disregard men with false‐negative MRIs. Caution must be taken when applying the results of only MRI or MRI‐targeted biopsy to the clinical practice in which the MRI pathway applies, as suggested in previous studies and reviews (<a href="./references#CD012663-bbs2-0086" title="DeRooijM , HamoenEH , FuttererJJ , BarentszJO , RoversMM . Accuracy of multiparametric MRI for prostate cancer detection: a meta‐analysis. American Journal of Roentgenology2014;202(2):343‐51. ">De Rooij 2014a</a>; <a href="./references#CD012663-bbs2-0101" title="FuttererJJ , BrigantiA , DeVisschereP , EmbertonM , GiannariniG , KirkhamA , et al. Can clinically significant prostate cancer be detected with multiparametric magnetic resonance imaging? A systematic review of the literature. European Urology2015;68(6):1045‐53. ">Futterer 2015</a>; <a href="./references#CD012663-bbs2-0102" title="GayetM , Van derAaA , BeerlageHP , SchrierBP , MuldersPF , WijkstraH . The value of magnetic resonance imaging and ultrasonography (MRI/US)‐fusion biopsy platforms in prostate cancer detection: a systematic review. BJU International2016;117(3):392‐400. ">Gayet 2016</a>; <a href="./references#CD012663-bbs2-0105" title="HamoenEH , deRooijM , WitjesJA , BarentszJO , RoversMM . Use of the prostate imaging reporting and data system (PI‐RADS) for prostate cancer detection with multiparametric magnetic resonance imaging: a diagnostic meta‐analysis. European Urology2015;67(6):1112‐21. ">Hamoen 2015</a>; <a href="./references#CD012663-bbs2-0121" title="MooreCM , RobertsonNL , ArsaniousN , MiddletonT , VillersA , KlotzL , et al. Image‐guided prostate biopsy using magnetic resonance imaging‐derived targets: a systematic review. European Urology2013;63(1):125‐40. ">Moore 2013b</a>; <a href="./references#CD012663-bbs2-0137" title="SchootsIG , RoobolMJ , NieboerD , BangmaCH , SteyerbergEW , HuninkMG . Magnetic resonance imaging‐targeted biopsy may enhance the diagnostic accuracy of significant prostate cancer detection compared to standard transrectal ultrasound‐guided biopsy: a systematic review and meta‐analysis. European Urology2015;68(3):438‐50. ">Schoots 2015</a>; <a href="./references#CD012663-bbs2-0147" title="ValerioM , DonaldsonI , EmbertonM , EhdaieB , HadaschikBA , MarksLS , et al. Detection of clinically significant prostate cancer using magnetic resonance imaging‐ultrasound fusion targeted biopsy: a systematic review. European Urology2015;68(1):8‐19. ">Valerio 2015;</a><a href="./references#CD012663-bbs2-0148" title="VanHoveA , SavoiePH , MaurinC , BrunelleS , GravisG , SalemN , et al. Comparison of image‐guided targeted biopsies versus systematic randomized biopsies in the detection of prostate cancer: a systematic literature review of well‐designed studies. World Journal of Urology2014;32(4):847‐58. ">Van Hove 2014</a>). The diagnostic accuracy analyses of the MRI pathway in this review overcome the above‐discussed difficulties of MRI and MRI‐targeted biopsy by presenting histological findings of the whole population. </p> <p>In addition to the assessment of test accuracy, this review also analysed the agreement of prostate cancer detection between the MRI pathway and systematic biopsy in studies that performed both tests in the same men. Agreement evidence focuses on the number of target conditions identified (concordance and discordance of test results) because neither test is a valid reference test. Consequently, agreement analysis does not provide diagnostic accuracy measures like sensitivity and specificity but rather a detection ratio that indicates which test detects more of the target condition. These analyses enabled us to provide evidence in clinical scenarios in addition to evidence from test accuracy data. </p> <p>Despite strict inclusion criteria, we still included a relatively large number of studies in the test accuracy analyses of MRI (n = 15), MRI‐targeted biopsy (n = 8) and the MRI pathway (n = 8)—and an even larger number of studies in the agreement analyses between the MRI pathway and systematic biopsy (n = 25) —resulting in reliable analyses regarding the primary objectives. However, a relatively limited number of studies was available to assess the diagnostic accuracy of systematic biopsy (n = 4), with the consequence that the pooled sensitivity estimate of systematic biopsy was imprecise. The small number of studies per covariate precluded us form performing subgroup analyses for test accuracy analyses. Similarly, a relatively limited number of agreement studies resulted in large 95% confidence intervals around some of the pooled detection ratio estimates in the subgroup analyses. </p> <p>Regarding the heterogeneity exploration in the agreement analyses, only population type (prior‐negative biopsy versus biopsy‐naïve men) and endorectal coil use (‘yes’ versus ‘no’) were statistically significant factors that may have explained some of the heterogeneity. A sensitivity analysis suggested population type to be a significant factor. However, we were not able to rule out the possibility that the statistically significant difference between studies with and without the use of an endorectal coil is caused by dependence on other factors, such as period of investigation (most prior to 2015) or risk of bias and applicability concerns in the performance of the tests. Furthermore, heterogeneity exploration suggested that MRI pulse sequences (mpMRI versus bpMRI) or MRI‐targeted biopsy techniques (software versus cognitive) were not significant sources of heterogeneity. Although we could not perform any reliable heterogeneity exploration in the test accuracy analyses, it should be considered that the test accuracy estimates were based on studies with (a mix of) different population types and methods of index tests. </p> <p>Furthermore, we evaluated several test accuracy measures to inform both policymakers and clinical physicians. These measures are related to two categories: </p> <p> <ol id="CD012663-list-0011"> <li> <p>differentiation between men with and without clinically significant prostate cancer (discrimination); and </p> </li> <li> <p>estimation of the post‐test probability of clinically significant prostate cancer (prediction). </p> </li> </ol> </p> <p>While discrimination purposes are mainly of concern in health‐policy decisions, predictive measures are most useful in daily practice for predicting the probability of clinically significant prostate cancer in a man suspected of having prostate cancer, once the test result is known. </p> <section id="CD012663-sec-0118"> <h6 class="title">Within‐ and between‐study comparisons</h6> <p>We compared the test accuracy of MRI and the MRI pathway with a mix of within‐ and between‐study evidence. We confirmed the findings in sensitivity analyses with only within‐study data; however, we could only compare test accuracy between the MRI pathway and systematic biopsy with between‐study data. Although the agreement analyses between MRI pathway and systematic biopsy do not provide diagnostic test accuracy estimates, we investigated it only in within‐study data, in which individual studies performed both tests in the same population. </p> </section> <section id="CD012663-sec-0119"> <h6 class="title">Diagnostic test accuracy analysis versus agreement analysis</h6> <p>In the test accuracy analysis in a mixed population, the pooled sensitivity for detecting grade 2 or higher prostate cancer was 0.72 (95% CI 0.60 to 0.82) for the MRI pathway and 0.63 (95% CI 0.19 to 0.93) for systematic biopsy—substantially in favour of the MRI pathway (P = 0.06). Similarly, in the agreement analysis between MRI pathway and systematic biopsy in the mixed population, the pooled detection ratio for detecting grade 2 or higher prostate cancer was 1.12 (95% CI 1.02 to 1.23; P = 0.01), statistically significantly in favour of the MRI pathway. Furthermore, the results of both analyses regarding grade 1 prostate cancer show that the MRI pathway beneficially detected less than systematic biopsy. Therefore, the results and conclusions from the test accuracy analysis and agreement analysis are consistent, despite the numerous differences between the two types of analyses. </p> </section> </section> </section> <section id="CD012663-sec-0120"> <h4 class="title">Comparison with previous research</h4> <p>Previously published reviews on test accuracy of the MRI pathway or the prebiopsy MRI approach have been based on study designs that did not accurately capture target conditions and index or reference test definitions, leading to a number of biases and inaccurate findings, as described in the <a href="#CD012663-sec-0046">Rationale</a> (<a href="./references#CD012663-bbs2-0086" title="DeRooijM , HamoenEH , FuttererJJ , BarentszJO , RoversMM . Accuracy of multiparametric MRI for prostate cancer detection: a meta‐analysis. American Journal of Roentgenology2014;202(2):343‐51. ">De Rooij 2014a</a>; <a href="./references#CD012663-bbs2-0101" title="FuttererJJ , BrigantiA , DeVisschereP , EmbertonM , GiannariniG , KirkhamA , et al. Can clinically significant prostate cancer be detected with multiparametric magnetic resonance imaging? A systematic review of the literature. European Urology2015;68(6):1045‐53. ">Futterer 2015</a>; <a href="./references#CD012663-bbs2-0102" title="GayetM , Van derAaA , BeerlageHP , SchrierBP , MuldersPF , WijkstraH . The value of magnetic resonance imaging and ultrasonography (MRI/US)‐fusion biopsy platforms in prostate cancer detection: a systematic review. BJU International2016;117(3):392‐400. ">Gayet 2016</a>; <a href="./references#CD012663-bbs2-0105" title="HamoenEH , deRooijM , WitjesJA , BarentszJO , RoversMM . Use of the prostate imaging reporting and data system (PI‐RADS) for prostate cancer detection with multiparametric magnetic resonance imaging: a diagnostic meta‐analysis. European Urology2015;67(6):1112‐21. ">Hamoen 2015</a>; <a href="./references#CD012663-bbs2-0121" title="MooreCM , RobertsonNL , ArsaniousN , MiddletonT , VillersA , KlotzL , et al. Image‐guided prostate biopsy using magnetic resonance imaging‐derived targets: a systematic review. European Urology2013;63(1):125‐40. ">Moore 2013b</a>; <a href="./references#CD012663-bbs2-0137" title="SchootsIG , RoobolMJ , NieboerD , BangmaCH , SteyerbergEW , HuninkMG . Magnetic resonance imaging‐targeted biopsy may enhance the diagnostic accuracy of significant prostate cancer detection compared to standard transrectal ultrasound‐guided biopsy: a systematic review and meta‐analysis. European Urology2015;68(3):438‐50. ">Schoots 2015</a>; <a href="./references#CD012663-bbs2-0147" title="ValerioM , DonaldsonI , EmbertonM , EhdaieB , HadaschikBA , MarksLS , et al. Detection of clinically significant prostate cancer using magnetic resonance imaging‐ultrasound fusion targeted biopsy: a systematic review. European Urology2015;68(1):8‐19. ">Valerio 2015</a>; <a href="./references#CD012663-bbs2-0148" title="VanHoveA , SavoiePH , MaurinC , BrunelleS , GravisG , SalemN , et al. Comparison of image‐guided targeted biopsies versus systematic randomized biopsies in the detection of prostate cancer: a systematic literature review of well‐designed studies. World Journal of Urology2014;32(4):847‐58. ">Van Hove 2014</a>; <a href="./references#CD012663-bbs2-0150" title="WegelinO , VanMelickHH , HooftL , BoschJL , ReitsmaHB , BarentszJO , et al. Comparing three different techniques for magnetic resonance imaging‐targeted prostate biopsies: a systematic review of in‐bore versus magnetic resonance imaging‐transrectal ultrasound fusion versus cognitive registration. Is there a preferred technique?. European Urology2017;71(4):517‐31. ">Wegelin 2017</a>; <a href="./references#CD012663-bbs2-0154" title="WooS , SuhCH , KimSY , ChoJY , KimSH , MoonMH . Head‐to‐head comparison between biparametric and multiparametric MRI for the diagnosis of prostate cancer: a systematic review and meta‐analysis. ARJ. American Journal of Roentgenology2018;211(5):W226‐41. ">Woo 2018</a>). These reviews included studies that reported only on men with a positive MRI, thereby disregarding men with a negative MRI, inevitably leading to inaccurate true‐negative and false‐negative values for the MRI pathway. In addition, they used systematic biopsy or radical whole‐mount surgical specimens as reference standards. </p> <p>Distinguishing between biopsy‐naïve men and men with prior‐negative biopsy is paramount in daily practice. Several international prostate cancer guidelines recently started to recommend prebiopsy MRI in prior‐negative biopsy men, based on a beneficial prostate cancer detection by the MRI pathway over systematic biopsy (<a href="./references#CD012663-bbs2-0091" title="MottetN , Van denBerghRCN , BriersE , BourkeL , CornfordP , DeSantisM , et al. European Association of Urology: guideline on prostate cancer. uroweb.org/guideline/prostate‐cancer/ 2018 (accessed on 15‐01‐2019). ">EAU Guideline 2018</a>, <a href="./references#CD012663-bbs2-0124" title="National Complrehensive Cancer Network (NCCN) Guidelines on Prostate Cancer: 2018 update. www.nccn.org/professionals/physician_gls/default.aspx 2018 (accessed on 15‐01‐2019). ">NCCN Guideline 2018</a>). However, international guidelines have not made any such recommendations in biopsy‐naïve men. High‐level evidence of prostate cancer detection by the MRI pathway as compared to systematic biopsy in biopsy‐naïve men has been scarce. Single‐centre, randomised controlled trials provided contradictory findings as to whether or not the MRI pathway has a higher detection rate for clinically significant prostate cancer compared to systematic biopsy (<a href="./references#CD012663-bbs2-0045" title="BacoE , RudE , EriLM , MoenG , VlatkovicL , SvindlandA , et al. A randomized controlled trial to assess and compare the outcomes of two‐core prostate biopsy guided by fused magnetic resonance and transrectal ultrasound images and traditional 12‐core systematic biopsy. European Urology2016;69(1):149‐56. ">Baco 2016</a>; <a href="./references#CD012663-bbs2-0033" title="PanebiancoV , BarchettiF , SciarraA , CiardiA , IndinoEL , PapaliaR , et al. Multiparametric magnetic resonance imaging vs. standard care in men being evaluated for prostate cancer: a randomized study. Urologic Oncology2015;33(1):17.e1‐17.e7. ">Panebianco 2015</a>; <a href="./references#CD012663-bbs2-0041" title="TonttilaPP , LanttoJ , PääkköE , PiippoU , KauppilaS , LammentaustaE , et al. Prebiopsy multiparametric magnetic resonance imaging for prostate cancer diagnosis in biopsy‐naïve men with suspected prostate cancer based on elevated prostate‐specific antigen values: results from a randomized prospective blinded controlled trial. European Urology2016;69(3):419‐25. ">Tonttilla 2016</a>). </p> <p>Two multicentre randomised controlled trials (<a href="./references#CD012663-bbs2-0051" title="KasivisvanathanV , RannikkoAS , BorghiM , PanebiancoV , MynderseLA , VaaralaMH , et al. MRI‐targeted or standard biopsy for prostate‐cancer diagnosis. New England Journal of Medicine2018;378:1767‐77. ">Kasivisvanathan 2018</a>; <a href="./references#CD012663-bbs2-0057" title="PorpigliaF , ManfrediM , MeleF , CossuM , BollitoE , VeltriA , et al. Diagnostic pathway with multiparametric magnetic resonance imaging versus standard pathway: results from a randomized prospective study in biopsy‐naïve patients with suspected prostate cancer. European Urology2017;72(2):282‐8. ">Porpiglia 2017</a>) investigated the MRI pathway and systematic biopsy in biopsy‐naïve men. Furthermore, two high‐quality prospective multicentre cohort studies (<a href="./references#CD012663-bbs2-0038" title="RouvièreO , PuechP , Renard‐PennaR , ClaudonM , RoyC , Mège‐LechavallierF , et al. MRI‐FIRST Investigators. Use of prostate systematic and targeted biopsy on the basis of multiparametric MRI in biopsy‐naïve patients (MRI‐FIRST): a prospective, multicentre, paired diagnostic study. Lancet Oncology2019;20(1):100‐9. ">Rouvière 2019a</a>; <a href="./references#CD012663-bbs2-0043" title="Van derLeestMM , CornelEB , IsraëlB , HendriksRJ , PadhaniAR , HoogenboomM , et al. Head‐to‐head comparison of transrectal ultrasound‐guided prostate biopsy versus multiparametric prostate resonance imaging with subsequent magnetic resonance‐guided biopsy in biopsy‐naïve men with elevated prostate‐specific antigen: a large prospective multicenter clinical study. European Urology 23 November 2018 [Epub ahead of print];S0302‐2838(18):30880‐7. [DOI: 10.1016/j.eururo.2018.11.023] ">Van der Leest 2018</a>) investigated the agreement of prostate cancer detection between the MRI pathway and systematic biopsy. We did not include the randomised controlled trials in this review, as they did not meet the inclusion criteria of performing the index tests and/or reference standard in the same men. Both randomised controlled trials showed that the MRI pathway detected significantly more grade 2 or higher prostate cancer than systematic biopsy, in contrast to the results from the agreement analyses in this review, including the two cohort studies. The data can be compared as follows: </p> <p> <ul id="CD012663-list-0012"> <li> <p><a href="./references#CD012663-bbs2-0051" title="KasivisvanathanV , RannikkoAS , BorghiM , PanebiancoV , MynderseLA , VaaralaMH , et al. MRI‐targeted or standard biopsy for prostate‐cancer diagnosis. New England Journal of Medicine2018;378:1767‐77. ">Kasivisvanathan 2018</a>: The MRI pathway avoided 28% of biopsy procedures. The MRI pathway detected 37.7% (95% CI 31.7% to 43.7%; 95/252) men with grade 2 or higher prostate cancer versus 25.8% (95% CI 20.4% to 31.3%; 64/248) by systematic biopsy. The MRI pathway detected 9.1% (95% CI 5.6% to 12.7%; 23/252) men with grade 1 prostate cancer versus 22.2% (95% CI 17.0% to 27.3%; 55/248) by systematic biopsy. The MRI pathway detected significantly more men with grade 2 or higher prostate cancer (absolute difference 11.9%, 95% CI 3.8% to 20.0%) and beneficially reduced the detection of grade 1 prostate cancer (absolute difference 13.1%, 95% CI 6.8% to 19.3%). </p> </li> <li> <p><a href="./references#CD012663-bbs2-0057" title="PorpigliaF , ManfrediM , MeleF , CossuM , BollitoE , VeltriA , et al. Diagnostic pathway with multiparametric magnetic resonance imaging versus standard pathway: results from a randomized prospective study in biopsy‐naïve patients with suspected prostate cancer. European Urology2017;72(2):282‐8. ">Porpiglia 2017</a>: The MRI pathway avoided 24% of biopsy procedures. The MRI pathway detected 41.1% (95% CI 31.8% to 50.4%; 44/107) men with grade 2 or higher prostate cancer versus 13.3% (95% CI 6.8% to 19.8%; 14/105) by systematic biopsy. The MRI pathway detected 4.7% (95% CI 0.7% to 8.7%; 5/107) men with grade 1 prostate cancer versus 16.2% (95% CI 9.1% to 23.2%; 17/105) by systematic biopsy. The MRI pathway detected significantly more men with grade 2 or higher prostate cancer (absolute difference 27.8%, 95% CI 16.4% to 39.2%) and beneficially reduced the detection of grade 1 prostate cancer (absolute difference 11.5%, 95% CI 3.4% to 19.6%). </p> </li> <li> <p><a href="./references#CD012663-bbs2-0038" title="RouvièreO , PuechP , Renard‐PennaR , ClaudonM , RoyC , Mège‐LechavallierF , et al. MRI‐FIRST Investigators. Use of prostate systematic and targeted biopsy on the basis of multiparametric MRI in biopsy‐naïve patients (MRI‐FIRST): a prospective, multicentre, paired diagnostic study. Lancet Oncology2019;20(1):100‐9. ">Rouvière 2019a</a>: The total proportion of detected men with grade 2 or higher prostate cancer was 37.5% (95% CI 31.4% to 43.8%; 94/251). The MRI pathway could have avoided 17.9% (45/251) of biopsy procedures. The MRI pathway detected 32.3% (95% CI 26.5% to 38.1%; 81/251) men with grade 2 or higher prostate cancer versus 29.9% (95% CI 24.2% to 35.5%; 75/251) by systematic biopsy. The MRI pathway detected 9.2% (95% CI 5.6 to 12.7%; 23/251) men with grade 1 versus 22.3% (95% CI 17.2% to 27.5%; 56/251) by systematic biopsy. The MRI pathway detected an equivalent proportion of grade 2 or higher prostate cancer (absolute difference 2.4%, 95% CI −5.7% to 10.5%) and beneficially reduced the detection of grade 1 prostate cancer (absolute difference 13.1%, 95% CI 6.9% to 19.4%). </p> </li> <li> <p><a href="./references#CD012663-bbs2-0043" title="Van derLeestMM , CornelEB , IsraëlB , HendriksRJ , PadhaniAR , HoogenboomM , et al. Head‐to‐head comparison of transrectal ultrasound‐guided prostate biopsy versus multiparametric prostate resonance imaging with subsequent magnetic resonance‐guided biopsy in biopsy‐naïve men with elevated prostate‐specific antigen: a large prospective multicenter clinical study. European Urology 23 November 2018 [Epub ahead of print];S0302‐2838(18):30880‐7. [DOI: 10.1016/j.eururo.2018.11.023] ">Van der Leest 2018</a>: The total proportion of detected men with grade 2 or higher prostate cancer was 32.0% (95% CI 28% to 36%; 200/626). The MRI pathway could have avoided 49.4% of biopsy procedures. The MRI pathway detected 25.4% (95% CI 22% to 29%; 159/626) men with grade 2 or higher prostate cancer versus 23.3% (95% CI 20% to 27%; 146/626) by systematic biopsy. The MRI pathway detected 14.1% (95% CI 11% to 17%; 88/626) men with grade 1 versus 24.8% (95% CI 21% to 28%; 155/626) by systematic biopsy. The MRI pathway detected an equivalent proportion of men with grade 2 or higher prostate cancer (absolute difference 2.1%, 95% CI to 2.7% to 6.8%) and beneficially reduced the detection of grade 1 prostate cancer (absolute difference 10.7%, 95% CI 6.4% to 15.0%). </p> </li> <li> <p>This Cochrane review, Drost 2019: The total proportion of detected grade 2 or higher prostate cancer in biopsy‐naïve men was 27.7% (95% CI 23.7% to 32.6%; <a href="#CD012663-tbl-0015">Table 9</a>). The MRI pathway could have avoided 33% of biopsy procedures. The MRI pathway detected 23.4% (95% CI 19.3% to 28.1%) men with grade 2 or higher prostate cancer versus 21.4% (95% CI 17.2% to 26.5%) by systematic biopsy. The MRI pathway detected 13.5% (95% CI 10.7% to 17.2%) men with grade 1 versus 22.4% (95% CI 19.1% to 26.3%) by systematic biopsy. The MRI pathway detected an equivalent proportion of men with grade 2 or higher prostate cancer (absolute difference 2.0%, 95% CI 1.1% to 4.6%) and beneficially reduced the detection of grade 1 prostate cancer (absolute difference 8.2%, 95% CI 6.0% to 10.3%). </p> </li> </ul> </p> <p>The most remarkable differences are the following:</p> <p> <ul id="CD012663-list-0013"> <li> <p>In this Cochrane review, the proportion of negative MRIs was 33% (95% CI 26 to 41%), with similar rates in both the randomised controlled trials, while it was 49.4% in the cohort study <a href="./references#CD012663-bbs2-0043" title="Van derLeestMM , CornelEB , IsraëlB , HendriksRJ , PadhaniAR , HoogenboomM , et al. Head‐to‐head comparison of transrectal ultrasound‐guided prostate biopsy versus multiparametric prostate resonance imaging with subsequent magnetic resonance‐guided biopsy in biopsy‐naïve men with elevated prostate‐specific antigen: a large prospective multicenter clinical study. European Urology 23 November 2018 [Epub ahead of print];S0302‐2838(18):30880‐7. [DOI: 10.1016/j.eururo.2018.11.023] ">Van der Leest 2018</a>. This study classified only 6.4% of MRIs as PI‐RADS assessment score 3. Although in this Cochrane review most included studies used experienced radiologists, obviously a dedication to limit PI‐RADS assessment score 3, as strived for by <a href="./references#CD012663-bbs2-0043" title="Van derLeestMM , CornelEB , IsraëlB , HendriksRJ , PadhaniAR , HoogenboomM , et al. Head‐to‐head comparison of transrectal ultrasound‐guided prostate biopsy versus multiparametric prostate resonance imaging with subsequent magnetic resonance‐guided biopsy in biopsy‐naïve men with elevated prostate‐specific antigen: a large prospective multicenter clinical study. European Urology 23 November 2018 [Epub ahead of print];S0302‐2838(18):30880‐7. [DOI: 10.1016/j.eururo.2018.11.023] ">Van der Leest 2018</a>, may safely increase the proportion of negative MRIs and may avoid more biopsies. </p> </li> <li> <p>In this Cochrane review, an equivalent proportion of men with grade 2 or higher prostate cancer was detected by the MRI pathway and systematic biopsy, consistent with the two agreement studies of <a href="./references#CD012663-bbs2-0043" title="Van derLeestMM , CornelEB , IsraëlB , HendriksRJ , PadhaniAR , HoogenboomM , et al. Head‐to‐head comparison of transrectal ultrasound‐guided prostate biopsy versus multiparametric prostate resonance imaging with subsequent magnetic resonance‐guided biopsy in biopsy‐naïve men with elevated prostate‐specific antigen: a large prospective multicenter clinical study. European Urology 23 November 2018 [Epub ahead of print];S0302‐2838(18):30880‐7. [DOI: 10.1016/j.eururo.2018.11.023] ">Van der Leest 2018</a> and <a href="./references#CD012663-bbs2-0038" title="RouvièreO , PuechP , Renard‐PennaR , ClaudonM , RoyC , Mège‐LechavallierF , et al. MRI‐FIRST Investigators. Use of prostate systematic and targeted biopsy on the basis of multiparametric MRI in biopsy‐naïve patients (MRI‐FIRST): a prospective, multicentre, paired diagnostic study. Lancet Oncology2019;20(1):100‐9. ">Rouvière 2019a</a>. In contrast, the MRI pathway detected considerably more men with grade 2 or higher prostate cancer than systematic biopsy in the two randomised controlled trials: <a href="./references#CD012663-bbs2-0051" title="KasivisvanathanV , RannikkoAS , BorghiM , PanebiancoV , MynderseLA , VaaralaMH , et al. MRI‐targeted or standard biopsy for prostate‐cancer diagnosis. New England Journal of Medicine2018;378:1767‐77. ">Kasivisvanathan 2018</a> (absolute difference 11.9%, 95% CI 3.8% to 20.0%), and <a href="./references#CD012663-bbs2-0057" title="PorpigliaF , ManfrediM , MeleF , CossuM , BollitoE , VeltriA , et al. Diagnostic pathway with multiparametric magnetic resonance imaging versus standard pathway: results from a randomized prospective study in biopsy‐naïve patients with suspected prostate cancer. European Urology2017;72(2):282‐8. ">Porpiglia 2017</a> (absolute difference 27.8%, 95% CI 16.4% to 39.2%). Hence, while the randomised controlled trials showed a superiority of the MRI pathway over systematic biopsy, the agreement studies did not. Despite these inconsistencies, none of the studies showed an inferiority of the MRI pathway over systematic biopsy in detecting grade 2 or higher prostate cancer. </p> </li> <li> <p>In this Cochrane review, the proportion of men with grade 2 or higher prostate cancer detected by the MRI pathway was 23.4%, 95% CI 19.3 to 28.1%), significantly higher in the two randomised controlled trials (<a href="./references#CD012663-bbs2-0051" title="KasivisvanathanV , RannikkoAS , BorghiM , PanebiancoV , MynderseLA , VaaralaMH , et al. MRI‐targeted or standard biopsy for prostate‐cancer diagnosis. New England Journal of Medicine2018;378:1767‐77. ">Kasivisvanathan 2018</a>: 37.7%, 95% CI 31.7 to 43.7%; <a href="./references#CD012663-bbs2-0057" title="PorpigliaF , ManfrediM , MeleF , CossuM , BollitoE , VeltriA , et al. Diagnostic pathway with multiparametric magnetic resonance imaging versus standard pathway: results from a randomized prospective study in biopsy‐naïve patients with suspected prostate cancer. European Urology2017;72(2):282‐8. ">Porpiglia 2017</a>: 41.1%, 95% CI 31.8 to 50.4%). </p> </li> <li> <p>In this Cochrane review, the MRI pathway detected 13.5% (95% CI 10.7 to 17.2%) of men with grade 1 prostate cancer, while the MRI pathway detected 9.1% (95% CI 5.6 to 12.7%) in <a href="./references#CD012663-bbs2-0051" title="KasivisvanathanV , RannikkoAS , BorghiM , PanebiancoV , MynderseLA , VaaralaMH , et al. MRI‐targeted or standard biopsy for prostate‐cancer diagnosis. New England Journal of Medicine2018;378:1767‐77. ">Kasivisvanathan 2018</a> and 4.7% (95% CI 0.7 to 8.7%) in <a href="./references#CD012663-bbs2-0057" title="PorpigliaF , ManfrediM , MeleF , CossuM , BollitoE , VeltriA , et al. Diagnostic pathway with multiparametric magnetic resonance imaging versus standard pathway: results from a randomized prospective study in biopsy‐naïve patients with suspected prostate cancer. European Urology2017;72(2):282‐8. ">Porpiglia 2017</a>. </p> </li> </ul> </p> <p>Explanatory reasons for these inconsistencies might be multiple. With the published information and data in this review, we could not clarify these inconsistencies. However, we may discuss some general exploratory findings within the context of this review: </p> <p>The quality and methodology of the tests might influence results, as investigated by our heterogeneity analyses (<a href="#CD012663-tbl-0018">Table 12</a>). However, we could not objectify the influence of many quality and methodology covariates due to limited numbers in the subgroups and shortcomings in study focus. </p> <p>Although the systematic biopsy is suggested to be a standardised test and has a systematic approach, we still observed a remarkably large variance in detection rates in the included studies. We observed a similar large variance in detection rates for the MRI pathway. Next to differences in the proportion (and severity) of detected prostate cancer, this might also suggest differences in the quality of biopsy procedures. The introduction of software registration for MRI‐targeted biopsy and the visual feedback it provides during the performance of biopsy procedures might, in fact, train operators (i.e. urologists and radiologists) to distribute systematic biopsy cores more evenly throughout the prostate according to the standardised systematic biopsy protocol. This may lead to an improved prostate cancer detection rate by systematic biopsy. Furthermore, systematic biopsy protocols in a study may outperform daily clinical practice. Another explanation for equivalent outcome could be the lack of blinding for MRI results during the performance of systematic biopsy, which may influence systematic biopsy positively. In this review, however, a sensitivity analysis with only studies with a low risk of such bias resulted in an equal detection rate of both tests. Moreover, both the cohort studies, <a href="./references#CD012663-bbs2-0038" title="RouvièreO , PuechP , Renard‐PennaR , ClaudonM , RoyC , Mège‐LechavallierF , et al. MRI‐FIRST Investigators. Use of prostate systematic and targeted biopsy on the basis of multiparametric MRI in biopsy‐naïve patients (MRI‐FIRST): a prospective, multicentre, paired diagnostic study. Lancet Oncology2019;20(1):100‐9. ">Rouvière 2019a</a> and <a href="./references#CD012663-bbs2-0043" title="Van derLeestMM , CornelEB , IsraëlB , HendriksRJ , PadhaniAR , HoogenboomM , et al. Head‐to‐head comparison of transrectal ultrasound‐guided prostate biopsy versus multiparametric prostate resonance imaging with subsequent magnetic resonance‐guided biopsy in biopsy‐naïve men with elevated prostate‐specific antigen: a large prospective multicenter clinical study. European Urology 23 November 2018 [Epub ahead of print];S0302‐2838(18):30880‐7. [DOI: 10.1016/j.eururo.2018.11.023] ">Van der Leest 2018</a>, followed strict standardised biopsy protocols for systematic biopsy and results of both index tests were blinded but they observed no significant difference in detection rates between the MRI pathway and systematic biopsy. </p> <p>The number of MRI‐targeted biopsy cores may influence the outcome of the MRI pathway, owing to the fact that diagnostic accuracy depends on the intensity and trajectory of cores taken due to the potential presence of considerable tumour heterogeneity (<a href="./references#CD012663-bbs2-0109" title="HuoAS , HossackT , SymonsJL , PeBenitoR , DelpradoWJ , BrennerP , et al. Accuracy of primary systematic template guided transperineal biopsy of the prostate for locating prostate cancer: a comparison with radical prostatectomy specimens. Journal of Urology2012;187(6):2044‐9. ">Huo 2012</a>; <a href="./references#CD012663-bbs2-0128" title="PhamKN , PorterCR , Odem‐DavisK , WolffEM , JeldresC , WeiJT , et al. Transperineal template guided prostate biopsy selects candidates for active surveillance‐‐how many cores are enough?. Journal of Urology2015;194(3):674‐9. ">Pham 2015</a>; <a href="./references#CD012663-bbs2-0147" title="ValerioM , DonaldsonI , EmbertonM , EhdaieB , HadaschikBA , MarksLS , et al. Detection of clinically significant prostate cancer using magnetic resonance imaging‐ultrasound fusion targeted biopsy: a systematic review. European Urology2015;68(1):8‐19. ">Valerio 2015</a>). Therefore, a high number of MRI‐targeted biopsy cores per suspicious lesion may benefit the diagnostic yield. In this review, the included studies showed a large variation in the number of MRI‐targeted biopsy cores per lesions or per participant (<a href="./appendices#CD012663-sec-0144">Appendix 4</a>), and we could not perform a heterogeneity analysis. Although the biopsy protocols differed between the two randomised and two cohort studies, we could not draw any explanatory conclusions. <a href="./references#CD012663-bbs2-0051" title="KasivisvanathanV , RannikkoAS , BorghiM , PanebiancoV , MynderseLA , VaaralaMH , et al. MRI‐targeted or standard biopsy for prostate‐cancer diagnosis. New England Journal of Medicine2018;378:1767‐77. ">Kasivisvanathan 2018</a> used a maximal four cores per target; <a href="./references#CD012663-bbs2-0057" title="PorpigliaF , ManfrediM , MeleF , CossuM , BollitoE , VeltriA , et al. Diagnostic pathway with multiparametric magnetic resonance imaging versus standard pathway: results from a randomized prospective study in biopsy‐naïve patients with suspected prostate cancer. European Urology2017;72(2):282‐8. ">Porpiglia 2017</a> used three to six cores per target; <a href="./references#CD012663-bbs2-0043" title="Van derLeestMM , CornelEB , IsraëlB , HendriksRJ , PadhaniAR , HoogenboomM , et al. Head‐to‐head comparison of transrectal ultrasound‐guided prostate biopsy versus multiparametric prostate resonance imaging with subsequent magnetic resonance‐guided biopsy in biopsy‐naïve men with elevated prostate‐specific antigen: a large prospective multicenter clinical study. European Urology 23 November 2018 [Epub ahead of print];S0302‐2838(18):30880‐7. [DOI: 10.1016/j.eururo.2018.11.023] ">Van der Leest 2018</a> obtained two to four cores per target; and <a href="./references#CD012663-bbs2-0038" title="RouvièreO , PuechP , Renard‐PennaR , ClaudonM , RoyC , Mège‐LechavallierF , et al. MRI‐FIRST Investigators. Use of prostate systematic and targeted biopsy on the basis of multiparametric MRI in biopsy‐naïve patients (MRI‐FIRST): a prospective, multicentre, paired diagnostic study. Lancet Oncology2019;20(1):100‐9. ">Rouvière 2019a</a> obtained up to three cores. </p> <p>The proportion (and severity) of detected prostate cancer within a population may influence the final outcome of the test (<a href="./references#CD012663-bbs2-0038" title="RouvièreO , PuechP , Renard‐PennaR , ClaudonM , RoyC , Mège‐LechavallierF , et al. MRI‐FIRST Investigators. Use of prostate systematic and targeted biopsy on the basis of multiparametric MRI in biopsy‐naïve patients (MRI‐FIRST): a prospective, multicentre, paired diagnostic study. Lancet Oncology2019;20(1):100‐9. ">Rouvière 2019a</a>). In a high‐prevalence or high‐risk (large volume clinically significant prostate cancer) population, both tests are likely to detect more grade 2 or higher prostate cancer; a high pre‐test probability will result in a high post‐test probability. Hypothetically, in a high‐risk population, systematic biopsy might more easily detect an equivalent proportion of grade 2 or higher prostate cancer compared to the MRI pathway. This may influence the added value of the MRI pathway and systematic biopsy either way. Therefore, the population at risk (either biopsy‐naïve or prior‐negative biopsy men) may influence the diagnostic yield of either test. In the agreement analysis, the proportion of detected grade 2 or higher prostate cancer was 27.7% (95% CI 23.7% to 32.6%) in biopsy‐naïve men and 22.8% (20.0 to 26.2%) in prior‐negative biopsy men. We were unable to investigate within this review whether this difference explained the difference in detection ratios between the two population groups. </p> </section> </section> <section id="CD012663-sec-0121"> <h3 class="title" id="CD012663-sec-0121">Applicability of findings to the review question</h3> <section id="CD012663-sec-0122"> <h4 class="title">Participant selection</h4> <p>Inclusion criteria allowed a broad spectrum of men with a suspicion of prostate cancer and an indication for prostate biopsy to be investigated, in accordance with most clinical practices. We excluded from our analyses only men with a previous diagnosis of prostate cancer. </p> <p>We made a clear distinction between different types of population (biopsy naïve, prior‐negative biopsy or mixed). Importantly, in the test accuracy analysis, we could not perform a subgroup analysis between biopsy‐naïve and prior‐negative biopsy men for the MRI pathway and systematic biopsy because most studies presented data only as a mixed population, not per population type. This limits the extrapolation of the results to daily practice, in which distinguishing between both populations is critical. In the MRI pathway analysis, the number of men with prior‐negative biopsy (n = 1402) dominated the number of biopsy‐naïve men (n = 855). In contrast, in the systematic biopsy analysis, the number of biopsy‐naïve men (n = 3379) dominated the number of men with prior‐negative biopsy (n = 42). Therefore, caution is advised when extrapolating these results from a mixed population to populations of only biopsy‐naïve men or prior‐negative biopsy men. In the agreement analyses between MRI pathway and systematic biopsy, on the other hand, subgroup analysis showed a substantial difference in population type. In prior‐negative biopsy men, the pooled detection ratio for detecting grade 2 or higher prostate cancer was 1.44 (95% CI 1.19 to 1.75) in favour of the MRI pathway. However, in biopsy‐naïve men, the pooled detection ratio for detecting grade 2 or higher prostate cancer was only 1.05 (95% CI 0.95 to 1.16), not favouring one test over the other. </p> <p>We included very few studies with applicability concerns regarding the indication for biopsy (e.g. prostate cancer screening studies with a very low threshold for biopsy). However, studies may have used considerably different thresholds for the indication of a biopsy. </p> <p>Sensitivity and specificity are often regarded as independent of disease prevalence and results from one setting are transferred to another setting with a different prevalence of prostate cancer in the population. However, it should be acknowledged that sensitivity and specificity do depend on the spectrum of the disease (e.g. a more severe cancer is more easily recognised on MRI and diagnosed by biopsy). Furthermore, positive and negative predictive values are heavily dependent on disease prevalence and can, therefore, not be applied in settings with disease prevalence differing from that of the evaluated population (<a href="./references#CD012663-bbs2-0135" title="RouvièreO , SouchonR , MelodelimaC . Pitfalls in interpreting positive and negative predictive values: application to prostate multiparametric magnetic resonance imaging. Diagnostic and Interventional Imaging2018;99(9):515‐8. ">Rouvière 2018</a>). </p> <p>The prevalences and proportions of detected grade 2 or higher prostate cancer in the included studies in this review were rather high (<a href="#CD012663-tbl-0013">Table 7</a>; <a href="#CD012663-tbl-0016">Table 10</a>) compared to the setting of most clinical practices. These prevalences were based on template‐guided biopsy, and the proportions were based on the combined use of the MRI pathway and systematic biopsy. Moreover, it should be taken into account that the populations studied were mostly from referral (tertiary), high‐volume and expert centres, with the advantages of state‐of‐the‐art equipment, optimised protocols, and highly experienced subspecialised radiologists. Consequently, it is critical to consider the prevalence (and severity) of the disease and the setting of the population to be evaluated before applying the results of this review. </p> <p>The issues of prostate cancer diagnosis are global, but the current analysis is highly focused on Western populations. The literature shows an incomplete picture of other populations where the advantages of MRI may not be forthcoming because of the higher prevalence of advanced cancers. Prevalence differences have been investigated in subpopulations within the same country (<a href="./references#CD012663-bbs2-0133" title="RodgerJC , SupramaniamR , GibberdAJ , SmithDP , ArmstrongBK , DillonA , et al. Prostate cancer mortality outcomes and patterns of primary treatment for Aboriginal men in New South Wales, Australia. BJU International2015;115 Suppl 5:16‐23. ">Rodger 2015</a>) and between different populations and races (<a href="./references#CD012663-bbs2-0098" title="FelettoE , BangA , Cole‐ClarkD , ChalasaniV , RasiahK , SmithDP . An examination of prostate cancer trends in Australia, England, Canada and USA: is the Australian death rate too high?. World Journal of Urology2015;33(11):1677‐87. ">Feletto 2015</a>; <a href="./references#CD012663-bbs2-0112" title="KamangarF , DoresGM , AndersonWF . Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. Journal of Clinical Oncology2006;24(14):2137‐50. ">Kamangar 2006</a>; <a href="./references#CD012663-bbs2-0113" title="KellySP , RosenbergPS , AndersonWF , AndreottiG , YounesN , ClearySD , et al. Trends in the incidence of fatal prostate cancer in the United States by race. European Urolgy2017;71(2):195‐201. ">Kelly 2017</a>). These differences may influence the potential benefit of an MRI‐directed biopsy management in those populations. </p> </section> <section id="CD012663-sec-0123"> <h4 class="title">Index tests</h4> <p>All techniques for the performance of the MRI pathway (including MRI and MRI‐targeted biopsy) were eligible, with the only criteria being the use of T2‐weighted imaging and one functional imaging technique (DWI or DCE). The included studies used 1.5 or 3 Tesla MRI magnets and cognitive‐ or software‐guided MRI‐targeted biopsy via transrectal or transperineal routes, among other variations in methodology. These variations are likely to explain some amount of heterogeneity in the results, but we could not reliably investigate them as sources of heterogeneity in the diagnostic accuracy analyses and could only partially investigate them in the agreement analyses. </p> <p>Differences in MRI‐scoring system and thresholds for MRI positivity (and for MRI‐targeted biopsy) are likely to influence results. Applicability assessment showed multiple studies with alternative MRI scoring systems and lower or higher positivity thresholds than the default (defined as 3/5 or more) in both test accuracy and agreement analyses. The pooled estimates from both main analyses, however, did not change importantly after excluding studies with alternative MRI scoring systems and thresholds in the sensitivity analysis. This shows the robustness of the main pooled estimates. </p> <p>For systematic biopsy in the test accuracy and agreement analyses, there were almost no concerns of applicability, as systematic biopsy was mainly performed with 8 to 12 cores directed at the peripheral zone of the prostate in all studies. </p> </section> <section id="CD012663-sec-0124"> <h4 class="title">Reference standard</h4> <p>There were no applicability concerns regarding the reference standard (template‐guided biopsy), as the target conditions were based on histopathology findings according to the Gleason scoring system and the ISUP grade without any volume criteria. Although in clinical practice other definitions are being used, our target condition definitions enable and simplify comparison between tests and literature. </p> </section> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD012663-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/urn:x-wiley:14651858:media:CD012663:CD012663-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_t/tCD012663-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Clinical pathway flow diagram and study design" data-id="CD012663-fig-0001" src="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_n/nCD012663-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Clinical pathway flow diagram and study design</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/full#CD012663-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_n/nCD012663-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012663-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/urn:x-wiley:14651858:media:CD012663:CD012663-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_t/tCD012663-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Study flow chart  csPCa: clinically significant prostate cancer; MRI: magnetic resonance imaging; MRI pathway: magnetic resonance imaging with subsequent magnetic resonance imaging‐targeted biopsy; MRI‐TBx: magnetic resonance imaging‐targeted biopsy; SBx: systematic biopsy" data-id="CD012663-fig-0002" src="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_n/nCD012663-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Study flow chart<br/> <b>csPCa:</b> clinically significant prostate cancer; <b>MRI:</b> magnetic resonance imaging; MRI pathway<b>:</b> magnetic resonance imaging with subsequent magnetic resonance imaging‐targeted biopsy; <b>MRI‐TBx:</b> magnetic resonance imaging‐targeted biopsy; <b>SBx:</b> systematic biopsy </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/full#CD012663-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_n/nCD012663-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012663-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/urn:x-wiley:14651858:media:CD012663:CD012663-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_t/tCD012663-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Diagnostic test accuracy of magnetic resonance imaging (MRI) verified by template‐guided biopsy: risk of bias and applicability concerns summary: review authors' judgements about each domain for each included study" data-id="CD012663-fig-0003" src="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_n/nCD012663-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Diagnostic test accuracy of magnetic resonance imaging (MRI) verified by template‐guided biopsy: risk of bias and applicability concerns summary: review authors' judgements about each domain for each included study </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/full#CD012663-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_n/nCD012663-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012663-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/urn:x-wiley:14651858:media:CD012663:CD012663-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_t/tCD012663-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Diagnostic test accuracy of magnetic resonance imaging‐targeted biopsy (MRI‐TBx) in MRI‐positive men: risk of bias and applicability concerns summary: review authors' judgements about each domain for each included study" data-id="CD012663-fig-0004" src="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_n/nCD012663-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Diagnostic test accuracy of magnetic resonance imaging‐targeted biopsy (MRI‐TBx) in MRI‐positive men: risk of bias and applicability concerns summary: review authors' judgements about each domain for each included study </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/full#CD012663-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_n/nCD012663-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012663-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/urn:x-wiley:14651858:media:CD012663:CD012663-AFig-FIG05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_t/tCD012663-AFig-FIG05.png" target="_blank"><b></b></a></p> </div><img alt="Diagnostic test accuracy of the MRI pathway: risk of bias and applicability concerns summary: review authors' judgements about each domain for each included study" data-id="CD012663-fig-0005" src="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_n/nCD012663-AFig-FIG05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Diagnostic test accuracy of the MRI pathway: risk of bias and applicability concerns summary: review authors' judgements about each domain for each included study </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/full#CD012663-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_n/nCD012663-AFig-FIG05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012663-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/urn:x-wiley:14651858:media:CD012663:CD012663-AFig-FIG06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_t/tCD012663-AFig-FIG06.png" target="_blank"><b></b></a></p> </div><img alt="Diagnostic test accuracy of systematic biopsy (SBx): risk of bias and applicability concerns summary: review authors' judgements about each domain for each included study" data-id="CD012663-fig-0006" src="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_n/nCD012663-AFig-FIG06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p>Diagnostic test accuracy of systematic biopsy (SBx): risk of bias and applicability concerns summary: review authors' judgements about each domain for each included study </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/full#CD012663-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_n/nCD012663-AFig-FIG06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012663-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/urn:x-wiley:14651858:media:CD012663:CD012663-AFig-FIG07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_t/tCD012663-AFig-FIG07.png" target="_blank"><b></b></a></p> </div><img alt="Agreement analyses between the MRI pathway and systematic biopsy (SBx): risk of bias and applicability concerns summary: review authors' judgements about each domain for each included study" data-id="CD012663-fig-0007" src="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_n/nCD012663-AFig-FIG07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 7</div> <div class="figure-caption"> <p>Agreement analyses between the MRI pathway and systematic biopsy (SBx): risk of bias and applicability concerns summary: review authors' judgements about each domain for each included study </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/full#CD012663-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_n/nCD012663-AFig-FIG07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012663-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/urn:x-wiley:14651858:media:CD012663:CD012663-AFig-FIG08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_t/tCD012663-AFig-FIG08.png" target="_blank"><b></b></a></p> </div><img alt="Diagnostic test accuracy of MRI for indicating grade 2 and higher prostate cancer.Summary ROC plot of MRI verified by template‐guided biopsy. The 95% confidence region illustrates the uncertainty around the pooled summary point; the 95% prediction region illustrates the heterogeneity  MRI: magnetic resonance imaging" data-id="CD012663-fig-0008" src="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_n/nCD012663-AFig-FIG08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 8</div> <div class="figure-caption"> <p>Diagnostic test accuracy of MRI for indicating grade 2 and higher prostate cancer.</p> <p>Summary ROC plot of MRI verified by template‐guided biopsy. The 95% confidence region illustrates the uncertainty around the pooled summary point; the 95% prediction region illustrates the heterogeneity<br/> MRI: magnetic resonance imaging </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/full#CD012663-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_n/nCD012663-AFig-FIG08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012663-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/urn:x-wiley:14651858:media:CD012663:CD012663-AFig-FIG09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_t/tCD012663-AFig-FIG09.png" target="_blank"><b></b></a></p> </div><img alt="Diagnostic test accuracy of MRI‐targeted biopsy for detecting grade 2 and higher prostate cancerSummary ROC plot of MRI‐targeted biopsy (in an MRI‐positive population) verified by template‐guided biopsy. The 95% confidence region illustrates the uncertainty around the pooled summary point; the 95% prediction region illustrates the heterogeneity  MRI: magnetic resonance imaging" data-id="CD012663-fig-0009" src="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_n/nCD012663-AFig-FIG09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 9</div> <div class="figure-caption"> <p>Diagnostic test accuracy of MRI‐targeted biopsy for detecting grade 2 and higher prostate cancer </p> <p>Summary ROC plot of MRI‐targeted biopsy (in an MRI‐positive population) verified by template‐guided biopsy. The 95% confidence region illustrates the uncertainty around the pooled summary point; the 95% prediction region illustrates the heterogeneity<br/> MRI: magnetic resonance imaging </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/full#CD012663-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_n/nCD012663-AFig-FIG09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012663-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/urn:x-wiley:14651858:media:CD012663:CD012663-AFig-FIG10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_t/tCD012663-AFig-FIG10.png" target="_blank"><b></b></a></p> </div><img alt="Diagnostic test accuracy of the MRI pathway for detecting grade 2 and higher prostate cancerSummary ROC plot of the MRI pathway verified by template‐guided biopsy. The 95% confidence region illustrates the uncertainty around the pooled summary point; the 95% prediction region illustrates the heterogeneity  MRI: magnetic resonance imaging; MRI pathway: MRI with or without MRI‐targeted biopsy" data-id="CD012663-fig-0010" src="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_n/nCD012663-AFig-FIG10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 10</div> <div class="figure-caption"> <p>Diagnostic test accuracy of the MRI pathway for detecting grade 2 and higher prostate cancer </p> <p>Summary ROC plot of the MRI pathway verified by template‐guided biopsy. The 95% confidence region illustrates the uncertainty around the pooled summary point; the 95% prediction region illustrates the heterogeneity<br/> MRI: magnetic resonance imaging; MRI pathway: MRI with or without MRI‐targeted biopsy </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/full#CD012663-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_n/nCD012663-AFig-FIG10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012663-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/urn:x-wiley:14651858:media:CD012663:CD012663-AFig-FIG11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_t/tCD012663-AFig-FIG11.png" target="_blank"><b></b></a></p> </div><img alt="Test consequence graphic showing results that would be obtained if a hypothetical cohort of 1000 men were tested for prostate cancer using the MRI pathway." data-id="CD012663-fig-0011" src="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_n/nCD012663-AFig-FIG11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 11</div> <div class="figure-caption"> <p>Test consequence graphic showing results that would be obtained if a hypothetical cohort of 1000 men were tested for prostate cancer using the MRI pathway. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/full#CD012663-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_n/nCD012663-AFig-FIG11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012663-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/urn:x-wiley:14651858:media:CD012663:CD012663-AFig-FIG12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_t/tCD012663-AFig-FIG12.png" target="_blank"><b></b></a></p> </div><img alt="Diagnostic test accuracy of systematic biopsy for detecting grade 2 and higher prostate cancerSummary ROC plot of systematic biopsy verified by template‐guided biopsy" data-id="CD012663-fig-0012" src="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_n/nCD012663-AFig-FIG12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 12</div> <div class="figure-caption"> <p>Diagnostic test accuracy of systematic biopsy for detecting grade 2 and higher prostate cancer </p> <p>Summary ROC plot of systematic biopsy verified by template‐guided biopsy</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/full#CD012663-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_n/nCD012663-AFig-FIG12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012663-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/urn:x-wiley:14651858:media:CD012663:CD012663-AFig-FIG13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_t/tCD012663-AFig-FIG13.png" target="_blank"><b></b></a></p> </div><img alt="Test consequence graphic showing results that would be obtained if a hypothetical cohort of 1000 men were tested for prostate cancer using systematic biopsy." data-id="CD012663-fig-0013" src="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_n/nCD012663-AFig-FIG13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 13</div> <div class="figure-caption"> <p>Test consequence graphic showing results that would be obtained if a hypothetical cohort of 1000 men were tested for prostate cancer using systematic biopsy. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/full#CD012663-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_n/nCD012663-AFig-FIG13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012663-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/urn:x-wiley:14651858:media:CD012663:CD012663-AFig-FIG14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_t/tCD012663-AFig-FIG14.png" target="_blank"><b></b></a></p> </div><img alt="Comparison of diagnostic test accuracy between MRI and the MRI pathway for detecting grade 2 and higher prostate cancer.Summary ROC plot of MRI and the MRI pathway verified by template‐guided biopsy  G: International Society of Urological Pathology grade; MRI: magnetic resonance imaging; MRI pathway: MRI with or without MRI‐targeted biopsy" data-id="CD012663-fig-0014" src="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_n/nCD012663-AFig-FIG14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 14</div> <div class="figure-caption"> <p>Comparison of diagnostic test accuracy between MRI and the MRI pathway for detecting grade 2 and higher prostate cancer. </p> <p>Summary ROC plot of MRI and the MRI pathway verified by template‐guided biopsy<br/> G: International Society of Urological Pathology grade; MRI: magnetic resonance imaging; MRI pathway: MRI with or without MRI‐targeted biopsy </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/full#CD012663-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_n/nCD012663-AFig-FIG14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012663-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/urn:x-wiley:14651858:media:CD012663:CD012663-AFig-FIG15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_t/tCD012663-AFig-FIG15.png" target="_blank"><b></b></a></p> </div><img alt="Comparison of diagnostic test accuracy between the MRI pathway and systematic biopsy for detecting grade 2 and higher prostate cancer.Summary ROC plot of the MRI pathway versus systematic biopsy, verified by template‐guided biopsy  G: International Society of Urological Pathology grade; MRI: magnetic resonance imaging; MRI pathway: MRI with or without MRI‐targeted biopsy; SBx: systematic biopsy" data-id="CD012663-fig-0015" src="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_n/nCD012663-AFig-FIG15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 15</div> <div class="figure-caption"> <p>Comparison of diagnostic test accuracy between the MRI pathway and systematic biopsy for detecting grade 2 and higher prostate cancer. </p> <p>Summary ROC plot of the MRI pathway versus systematic biopsy, verified by template‐guided biopsy<br/> G: International Society of Urological Pathology grade; MRI: magnetic resonance imaging; MRI pathway: MRI with or without MRI‐targeted biopsy; SBx: systematic biopsy </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/full#CD012663-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_n/nCD012663-AFig-FIG15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012663-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/urn:x-wiley:14651858:media:CD012663:CD012663-AFig-FIG16" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_t/tCD012663-AFig-FIG16.png" target="_blank"><b></b></a></p> </div><img alt="MRI‐positivity threshold effect for indicating grade 2 and higher prostate cancer.Summary ROC plot of MRI verified by template‐guided biopsy, with different thresholds for positivity: intermediate (3/5) vs high (4/5)  G: International Society of Urological Pathology grade; MRI: magnetic resonance imaging" data-id="CD012663-fig-0016" src="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_n/nCD012663-AFig-FIG16.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 16</div> <div class="figure-caption"> <p>MRI‐positivity threshold effect for indicating grade 2 and higher prostate cancer.</p> <p>Summary ROC plot of MRI verified by template‐guided biopsy, with different thresholds for positivity: intermediate (3/5) vs high (4/5)<br/> G: International Society of Urological Pathology grade; MRI: magnetic resonance imaging </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/full#CD012663-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_n/nCD012663-AFig-FIG16.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012663-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/urn:x-wiley:14651858:media:CD012663:CD012663-AFig-FIG17" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_t/tCD012663-AFig-FIG17.png" target="_blank"><b></b></a></p> </div><img alt="MRI‐positivity threshold effect for indicating grade 3 and higher prostate cancer.Summary ROC plot of MRI verified by template‐guided biopsy, with different thresholds for positivity: intermediate (3/5) vs high (4/5)  G: International Society of Urological Pathology grade; MRI: magnetic resonance imaging" data-id="CD012663-fig-0017" src="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_n/nCD012663-AFig-FIG17.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 17</div> <div class="figure-caption"> <p>MRI‐positivity threshold effect for indicating grade 3 and higher prostate cancer.</p> <p>Summary ROC plot of MRI verified by template‐guided biopsy, with different thresholds for positivity: intermediate (3/5) vs high (4/5)<br/> G: International Society of Urological Pathology grade; MRI: magnetic resonance imaging </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/full#CD012663-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_n/nCD012663-AFig-FIG17.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012663-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/urn:x-wiley:14651858:media:CD012663:CD012663-AFig-FIG18" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_t/tCD012663-AFig-FIG18.png" target="_blank"><b></b></a></p> </div><img alt="Forest plots of the agreement analysis (MRI pathway vs systematic biopsy) for detecting grade 2 and higher prostate cancer" data-id="CD012663-fig-0018" src="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_n/nCD012663-AFig-FIG18.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 18</div> <div class="figure-caption"> <p>Forest plots of the agreement analysis (MRI pathway vs systematic biopsy) for detecting grade 2 and higher prostate cancer </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/full#CD012663-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_n/nCD012663-AFig-FIG18.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012663-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/urn:x-wiley:14651858:media:CD012663:CD012663-AFig-FIG19" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_t/tCD012663-AFig-FIG19.png" target="_blank"><b></b></a></p> </div><img alt="Added value of systematic biopsy plotted against the added value of the MRI pathway per population type in the agreement analysis, for detecting grade 2 and higher prostate cancer" data-id="CD012663-fig-0019" src="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_n/nCD012663-AFig-FIG19.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 19</div> <div class="figure-caption"> <p>Added value of systematic biopsy plotted against the added value of the MRI pathway per population type in the agreement analysis, for detecting grade 2 and higher prostate cancer </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/full#CD012663-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_n/nCD012663-AFig-FIG19.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012663-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/urn:x-wiley:14651858:media:CD012663:CD012663-TST-001" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_t/tCD012663-TST-001.xxx" target="_blank"><b></b></a></p> </div><img alt="Diagnostic accuracy of MRI ‐ G = 1." data-id="CD012663-fig-0020" src="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_n/nCD012663-TST-001.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 1</div> <div class="figure-caption"> <p>Diagnostic accuracy of MRI ‐ G = 1.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/references#CD012663-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_n/nCD012663-TST-001.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012663-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/urn:x-wiley:14651858:media:CD012663:CD012663-TST-002" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_t/tCD012663-TST-002.xxx" target="_blank"><b></b></a></p> </div><img alt="Diagnostic accuracy of MRI ‐ G ≥ 1." data-id="CD012663-fig-0021" src="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_n/nCD012663-TST-002.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 2</div> <div class="figure-caption"> <p>Diagnostic accuracy of MRI ‐ G ≥ 1.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/references#CD012663-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_n/nCD012663-TST-002.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012663-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/urn:x-wiley:14651858:media:CD012663:CD012663-TST-003" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_t/tCD012663-TST-003.xxx" target="_blank"><b></b></a></p> </div><img alt="Diagnostic accuracy of MRI ‐ G ≥ 2." data-id="CD012663-fig-0022" src="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_n/nCD012663-TST-003.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 3</div> <div class="figure-caption"> <p>Diagnostic accuracy of MRI ‐ G ≥ 2.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/references#CD012663-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_n/nCD012663-TST-003.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012663-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/urn:x-wiley:14651858:media:CD012663:CD012663-TST-004" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_t/tCD012663-TST-004.xxx" target="_blank"><b></b></a></p> </div><img alt="Diagnostic accuracy of MRI ‐ G ≥ 3." data-id="CD012663-fig-0023" src="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_n/nCD012663-TST-004.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 4</div> <div class="figure-caption"> <p>Diagnostic accuracy of MRI ‐ G ≥ 3.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/references#CD012663-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_n/nCD012663-TST-004.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012663-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/urn:x-wiley:14651858:media:CD012663:CD012663-TST-005" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_t/tCD012663-TST-005.xxx" target="_blank"><b></b></a></p> </div><img alt="Diagnostic accuracy of MRI ‐ MRI‐positvity threshold 4/5 ‐ G = 1." data-id="CD012663-fig-0024" src="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_n/nCD012663-TST-005.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 5</div> <div class="figure-caption"> <p>Diagnostic accuracy of MRI ‐ MRI‐positvity threshold 4/5 ‐ G = 1.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/references#CD012663-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_n/nCD012663-TST-005.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012663-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/urn:x-wiley:14651858:media:CD012663:CD012663-TST-006" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_t/tCD012663-TST-006.xxx" target="_blank"><b></b></a></p> </div><img alt="Diagnostic accuracy of MRI ‐ MRI‐positvity threshold 4/5 ‐ G ≥ 1." data-id="CD012663-fig-0025" src="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_n/nCD012663-TST-006.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 6</div> <div class="figure-caption"> <p>Diagnostic accuracy of MRI ‐ MRI‐positvity threshold 4/5 ‐ G ≥ 1.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/references#CD012663-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_n/nCD012663-TST-006.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012663-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/urn:x-wiley:14651858:media:CD012663:CD012663-TST-007" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_t/tCD012663-TST-007.xxx" target="_blank"><b></b></a></p> </div><img alt="Diagnostic accuracy of MRI ‐ MRI‐positvity threshold 4/5 ‐ G ≥ 2." data-id="CD012663-fig-0026" src="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_n/nCD012663-TST-007.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 7</div> <div class="figure-caption"> <p>Diagnostic accuracy of MRI ‐ MRI‐positvity threshold 4/5 ‐ G ≥ 2.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/references#CD012663-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_n/nCD012663-TST-007.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012663-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/urn:x-wiley:14651858:media:CD012663:CD012663-TST-008" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_t/tCD012663-TST-008.xxx" target="_blank"><b></b></a></p> </div><img alt="Diagnostic accuracy of MRI ‐ MRI‐positvity threshold 4/5 ‐ G ≥ 3." data-id="CD012663-fig-0027" src="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_n/nCD012663-TST-008.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 8</div> <div class="figure-caption"> <p>Diagnostic accuracy of MRI ‐ MRI‐positvity threshold 4/5 ‐ G ≥ 3.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/references#CD012663-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_n/nCD012663-TST-008.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012663-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/urn:x-wiley:14651858:media:CD012663:CD012663-TST-009" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_t/tCD012663-TST-009.xxx" target="_blank"><b></b></a></p> </div><img alt="Diagnostic accuracy of MRI ‐ Biopsy‐naïve ‐ G ≥ 1." data-id="CD012663-fig-0028" src="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_n/nCD012663-TST-009.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 9</div> <div class="figure-caption"> <p>Diagnostic accuracy of MRI ‐ Biopsy‐naïve ‐ G ≥ 1.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/references#CD012663-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_n/nCD012663-TST-009.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012663-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/urn:x-wiley:14651858:media:CD012663:CD012663-TST-010" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_t/tCD012663-TST-010.xxx" target="_blank"><b></b></a></p> </div><img alt="Diagnostic accuracy of MRI ‐ Biopsy‐naïve ‐ G ≥ 2." data-id="CD012663-fig-0029" src="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_n/nCD012663-TST-010.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 10</div> <div class="figure-caption"> <p>Diagnostic accuracy of MRI ‐ Biopsy‐naïve ‐ G ≥ 2.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/references#CD012663-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_n/nCD012663-TST-010.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012663-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/urn:x-wiley:14651858:media:CD012663:CD012663-TST-011" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_t/tCD012663-TST-011.xxx" target="_blank"><b></b></a></p> </div><img alt="Diagnostic accuracy of MRI ‐ Biopsy‐naïve ‐ G ≥ 3." data-id="CD012663-fig-0030" src="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_n/nCD012663-TST-011.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 11</div> <div class="figure-caption"> <p>Diagnostic accuracy of MRI ‐ Biopsy‐naïve ‐ G ≥ 3.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/references#CD012663-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_n/nCD012663-TST-011.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012663-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/urn:x-wiley:14651858:media:CD012663:CD012663-TST-012" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_t/tCD012663-TST-012.xxx" target="_blank"><b></b></a></p> </div><img alt="Diagnostic accuracy of MRI ‐ Prior‐negative biopsy ‐ G ≥ 1." data-id="CD012663-fig-0031" src="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_n/nCD012663-TST-012.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 12</div> <div class="figure-caption"> <p>Diagnostic accuracy of MRI ‐ Prior‐negative biopsy ‐ G ≥ 1.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/references#CD012663-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_n/nCD012663-TST-012.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012663-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/urn:x-wiley:14651858:media:CD012663:CD012663-TST-013" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_t/tCD012663-TST-013.xxx" target="_blank"><b></b></a></p> </div><img alt="Diagnostic accuracy of MRI ‐ Prior‐negative biopsy ‐ G ≥ 2." data-id="CD012663-fig-0032" src="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_n/nCD012663-TST-013.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 13</div> <div class="figure-caption"> <p>Diagnostic accuracy of MRI ‐ Prior‐negative biopsy ‐ G ≥ 2.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/references#CD012663-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_n/nCD012663-TST-013.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012663-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/urn:x-wiley:14651858:media:CD012663:CD012663-TST-014" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_t/tCD012663-TST-014.xxx" target="_blank"><b></b></a></p> </div><img alt="Diagnostic accuracy of MRI ‐ Prior‐negative biopsy ‐ G ≥ 3." data-id="CD012663-fig-0033" src="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_n/nCD012663-TST-014.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 14</div> <div class="figure-caption"> <p>Diagnostic accuracy of MRI ‐ Prior‐negative biopsy ‐ G ≥ 3.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/references#CD012663-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_n/nCD012663-TST-014.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012663-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/urn:x-wiley:14651858:media:CD012663:CD012663-TST-015" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_t/tCD012663-TST-015.xxx" target="_blank"><b></b></a></p> </div><img alt="Diagnostic accuracy of MRI ‐ Sensitivity analysis with composite reference standard (template‐guided biopsy + MRI‐TBx) ‐ G ≥ 2." data-id="CD012663-fig-0034" src="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_n/nCD012663-TST-015.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 15</div> <div class="figure-caption"> <p>Diagnostic accuracy of MRI ‐ Sensitivity analysis with composite reference standard (template‐guided biopsy + MRI‐TBx) ‐ G ≥ 2. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/references#CD012663-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_n/nCD012663-TST-015.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012663-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/urn:x-wiley:14651858:media:CD012663:CD012663-TST-016" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_t/tCD012663-TST-016.xxx" target="_blank"><b></b></a></p> </div><img alt="Diagnostic accuracy of TBx ‐ G = 1." data-id="CD012663-fig-0035" src="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_n/nCD012663-TST-016.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 16</div> <div class="figure-caption"> <p>Diagnostic accuracy of TBx ‐ G = 1.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/references#CD012663-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_n/nCD012663-TST-016.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012663-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/urn:x-wiley:14651858:media:CD012663:CD012663-TST-017" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_t/tCD012663-TST-017.xxx" target="_blank"><b></b></a></p> </div><img alt="Diagnostic accuracy of TBx ‐ G ≥ 1." data-id="CD012663-fig-0036" src="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_n/nCD012663-TST-017.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 17</div> <div class="figure-caption"> <p>Diagnostic accuracy of TBx ‐ G ≥ 1.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/references#CD012663-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_n/nCD012663-TST-017.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012663-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/urn:x-wiley:14651858:media:CD012663:CD012663-TST-018" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_t/tCD012663-TST-018.xxx" target="_blank"><b></b></a></p> </div><img alt="Diagnostic accuracy of TBx ‐ G ≥ 2." data-id="CD012663-fig-0037" src="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_n/nCD012663-TST-018.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 18</div> <div class="figure-caption"> <p>Diagnostic accuracy of TBx ‐ G ≥ 2.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/references#CD012663-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_n/nCD012663-TST-018.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012663-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/urn:x-wiley:14651858:media:CD012663:CD012663-TST-019" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_t/tCD012663-TST-019.xxx" target="_blank"><b></b></a></p> </div><img alt="Diagnostic accuracy of TBx ‐ G ≥ 3." data-id="CD012663-fig-0038" src="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_n/nCD012663-TST-019.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 19</div> <div class="figure-caption"> <p>Diagnostic accuracy of TBx ‐ G ≥ 3.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/references#CD012663-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_n/nCD012663-TST-019.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012663-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/urn:x-wiley:14651858:media:CD012663:CD012663-TST-020" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_t/tCD012663-TST-020.xxx" target="_blank"><b></b></a></p> </div><img alt="Diagnostic accuracy of the MRI‐pathway ‐ G = 1." data-id="CD012663-fig-0039" src="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_n/nCD012663-TST-020.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 20</div> <div class="figure-caption"> <p>Diagnostic accuracy of the MRI‐pathway ‐ G = 1.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/references#CD012663-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_n/nCD012663-TST-020.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012663-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/urn:x-wiley:14651858:media:CD012663:CD012663-TST-021" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_t/tCD012663-TST-021.xxx" target="_blank"><b></b></a></p> </div><img alt="Diagnostic accuracy of the MRI‐pathway ‐ G ≥ 1." data-id="CD012663-fig-0040" src="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_n/nCD012663-TST-021.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 21</div> <div class="figure-caption"> <p>Diagnostic accuracy of the MRI‐pathway ‐ G ≥ 1.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/references#CD012663-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_n/nCD012663-TST-021.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012663-fig-0041"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/urn:x-wiley:14651858:media:CD012663:CD012663-TST-022" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_t/tCD012663-TST-022.xxx" target="_blank"><b></b></a></p> </div><img alt="Diagnostic accuracy of the MRI‐pathway ‐ G ≥ 2." data-id="CD012663-fig-0041" src="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_n/nCD012663-TST-022.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 22</div> <div class="figure-caption"> <p>Diagnostic accuracy of the MRI‐pathway ‐ G ≥ 2.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/references#CD012663-fig-0041">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_n/nCD012663-TST-022.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012663-fig-0042"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/urn:x-wiley:14651858:media:CD012663:CD012663-TST-023" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_t/tCD012663-TST-023.xxx" target="_blank"><b></b></a></p> </div><img alt="Diagnostic accuracy of the MRI‐pathway ‐ G ≥ 3." data-id="CD012663-fig-0042" src="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_n/nCD012663-TST-023.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 23</div> <div class="figure-caption"> <p>Diagnostic accuracy of the MRI‐pathway ‐ G ≥ 3.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/references#CD012663-fig-0042">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_n/nCD012663-TST-023.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012663-fig-0043"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/urn:x-wiley:14651858:media:CD012663:CD012663-TST-024" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_t/tCD012663-TST-024.xxx" target="_blank"><b></b></a></p> </div><img alt="Diagnostic accuracy of SBx ‐ G = 1." data-id="CD012663-fig-0043" src="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_n/nCD012663-TST-024.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 24</div> <div class="figure-caption"> <p>Diagnostic accuracy of SBx ‐ G = 1.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/references#CD012663-fig-0043">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_n/nCD012663-TST-024.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012663-fig-0044"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/urn:x-wiley:14651858:media:CD012663:CD012663-TST-025" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_t/tCD012663-TST-025.xxx" target="_blank"><b></b></a></p> </div><img alt="Diagnostic accuracy of SBx ‐ G ≥ 1." data-id="CD012663-fig-0044" src="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_n/nCD012663-TST-025.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 25</div> <div class="figure-caption"> <p>Diagnostic accuracy of SBx ‐ G ≥ 1.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/references#CD012663-fig-0044">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_n/nCD012663-TST-025.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012663-fig-0045"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/urn:x-wiley:14651858:media:CD012663:CD012663-TST-026" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_t/tCD012663-TST-026.xxx" target="_blank"><b></b></a></p> </div><img alt="Diagnostic accuracy of SBx ‐ G ≥ 2." data-id="CD012663-fig-0045" src="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_n/nCD012663-TST-026.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 26</div> <div class="figure-caption"> <p>Diagnostic accuracy of SBx ‐ G ≥ 2.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/references#CD012663-fig-0045">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_n/nCD012663-TST-026.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012663-fig-0046"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/urn:x-wiley:14651858:media:CD012663:CD012663-TST-027" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_t/tCD012663-TST-027.xxx" target="_blank"><b></b></a></p> </div><img alt="Diagnostic accuracy of SBx ‐ G ≥ 3." data-id="CD012663-fig-0046" src="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_n/nCD012663-TST-027.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 27</div> <div class="figure-caption"> <p>Diagnostic accuracy of SBx ‐ G ≥ 3.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/references#CD012663-fig-0046">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_n/nCD012663-TST-027.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012663-fig-0047"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/urn:x-wiley:14651858:media:CD012663:CD012663-TST-028" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_t/tCD012663-TST-028.xxx" target="_blank"><b></b></a></p> </div><img alt="MRI‐pathway vs SBx ‐ G = 1." data-id="CD012663-fig-0047" src="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_n/nCD012663-TST-028.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 28</div> <div class="figure-caption"> <p>MRI‐pathway vs SBx ‐ G = 1.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/references#CD012663-fig-0047">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_n/nCD012663-TST-028.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012663-fig-0048"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/urn:x-wiley:14651858:media:CD012663:CD012663-TST-029" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_t/tCD012663-TST-029.xxx" target="_blank"><b></b></a></p> </div><img alt="MRI‐pathway vs SBx ‐ G ≥ 1." data-id="CD012663-fig-0048" src="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_n/nCD012663-TST-029.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 29</div> <div class="figure-caption"> <p>MRI‐pathway vs SBx ‐ G ≥ 1.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/references#CD012663-fig-0048">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_n/nCD012663-TST-029.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012663-fig-0049"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/urn:x-wiley:14651858:media:CD012663:CD012663-TST-030" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_t/tCD012663-TST-030.xxx" target="_blank"><b></b></a></p> </div><img alt="MRI‐pathway vs SBx ‐ G ≥ 2." data-id="CD012663-fig-0049" src="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_n/nCD012663-TST-030.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 30</div> <div class="figure-caption"> <p>MRI‐pathway vs SBx ‐ G ≥ 2.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/references#CD012663-fig-0049">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_n/nCD012663-TST-030.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012663-fig-0050"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/urn:x-wiley:14651858:media:CD012663:CD012663-TST-031" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_t/tCD012663-TST-031.xxx" target="_blank"><b></b></a></p> </div><img alt="MRI‐pathway vs SBx ‐ G ≥ 3." data-id="CD012663-fig-0050" src="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_n/nCD012663-TST-031.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 31</div> <div class="figure-caption"> <p>MRI‐pathway vs SBx ‐ G ≥ 3.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/references#CD012663-fig-0050">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_n/nCD012663-TST-031.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012663-fig-0051"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/urn:x-wiley:14651858:media:CD012663:CD012663-TST-032" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_t/tCD012663-TST-032.xxx" target="_blank"><b></b></a></p> </div><img alt="MRI‐pathway vs SBx ‐ Biopsy‐naïve ‐ G = 1." data-id="CD012663-fig-0051" src="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_n/nCD012663-TST-032.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 32</div> <div class="figure-caption"> <p>MRI‐pathway vs SBx ‐ Biopsy‐naïve ‐ G = 1.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/references#CD012663-fig-0051">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_n/nCD012663-TST-032.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012663-fig-0052"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/urn:x-wiley:14651858:media:CD012663:CD012663-TST-033" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_t/tCD012663-TST-033.xxx" target="_blank"><b></b></a></p> </div><img alt="MRI‐pathway vs SBx ‐ Biopsy‐naïve ‐ G ≥ 1." data-id="CD012663-fig-0052" src="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_n/nCD012663-TST-033.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 33</div> <div class="figure-caption"> <p>MRI‐pathway vs SBx ‐ Biopsy‐naïve ‐ G ≥ 1.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/references#CD012663-fig-0052">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_n/nCD012663-TST-033.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012663-fig-0053"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/urn:x-wiley:14651858:media:CD012663:CD012663-TST-034" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_t/tCD012663-TST-034.xxx" target="_blank"><b></b></a></p> </div><img alt="MRI‐pathway vs SBx ‐ Biopsy‐naïve ‐ G ≥ 2." data-id="CD012663-fig-0053" src="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_n/nCD012663-TST-034.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 34</div> <div class="figure-caption"> <p>MRI‐pathway vs SBx ‐ Biopsy‐naïve ‐ G ≥ 2.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/references#CD012663-fig-0053">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_n/nCD012663-TST-034.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012663-fig-0054"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/urn:x-wiley:14651858:media:CD012663:CD012663-TST-035" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_t/tCD012663-TST-035.xxx" target="_blank"><b></b></a></p> </div><img alt="MRI‐pathway vs SBx ‐ Biopsy‐naïve ‐ G ≥ 3." data-id="CD012663-fig-0054" src="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_n/nCD012663-TST-035.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 35</div> <div class="figure-caption"> <p>MRI‐pathway vs SBx ‐ Biopsy‐naïve ‐ G ≥ 3.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/references#CD012663-fig-0054">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_n/nCD012663-TST-035.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012663-fig-0055"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/urn:x-wiley:14651858:media:CD012663:CD012663-TST-036" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_t/tCD012663-TST-036.xxx" target="_blank"><b></b></a></p> </div><img alt="MRI‐pathway vs SBx ‐ Prior‐negative biopsy ‐ G = 1." data-id="CD012663-fig-0055" src="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_n/nCD012663-TST-036.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 36</div> <div class="figure-caption"> <p>MRI‐pathway vs SBx ‐ Prior‐negative biopsy ‐ G = 1.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/references#CD012663-fig-0055">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_n/nCD012663-TST-036.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012663-fig-0056"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/urn:x-wiley:14651858:media:CD012663:CD012663-TST-037" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_t/tCD012663-TST-037.xxx" target="_blank"><b></b></a></p> </div><img alt="MRI‐pathway vs SBx ‐ Prior‐negative biopsy ‐ G ≥ 1." data-id="CD012663-fig-0056" src="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_n/nCD012663-TST-037.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 37</div> <div class="figure-caption"> <p>MRI‐pathway vs SBx ‐ Prior‐negative biopsy ‐ G ≥ 1.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/references#CD012663-fig-0056">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_n/nCD012663-TST-037.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012663-fig-0057"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/urn:x-wiley:14651858:media:CD012663:CD012663-TST-038" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_t/tCD012663-TST-038.xxx" target="_blank"><b></b></a></p> </div><img alt="MRI‐pathway vs SBx ‐ Prior‐negative biopsy ‐ G ≥ 2." data-id="CD012663-fig-0057" src="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_n/nCD012663-TST-038.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 38</div> <div class="figure-caption"> <p>MRI‐pathway vs SBx ‐ Prior‐negative biopsy ‐ G ≥ 2.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/references#CD012663-fig-0057">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_n/nCD012663-TST-038.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012663-fig-0058"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/urn:x-wiley:14651858:media:CD012663:CD012663-TST-039" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_t/tCD012663-TST-039.xxx" target="_blank"><b></b></a></p> </div><img alt="MRI‐pathway vs SBx ‐ Prior‐negative biopsy ‐ G ≥ 3." data-id="CD012663-fig-0058" src="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_n/nCD012663-TST-039.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 39</div> <div class="figure-caption"> <p>MRI‐pathway vs SBx ‐ Prior‐negative biopsy ‐ G ≥ 3.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/references#CD012663-fig-0058">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_n/nCD012663-TST-039.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012663-fig-0059"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/urn:x-wiley:14651858:media:CD012663:CD012663-TST-040" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_t/tCD012663-TST-040.xxx" target="_blank"><b></b></a></p> </div><img alt="MRI‐pathway vs SBx ‐ Positive MRI ‐ G = 1." data-id="CD012663-fig-0059" src="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_n/nCD012663-TST-040.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 40</div> <div class="figure-caption"> <p>MRI‐pathway vs SBx ‐ Positive MRI ‐ G = 1.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/references#CD012663-fig-0059">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_n/nCD012663-TST-040.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012663-fig-0060"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/urn:x-wiley:14651858:media:CD012663:CD012663-TST-041" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_t/tCD012663-TST-041.xxx" target="_blank"><b></b></a></p> </div><img alt="MRI‐pathway vs SBx ‐ Positive MRI ‐ G ≥ 1." data-id="CD012663-fig-0060" src="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_n/nCD012663-TST-041.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 41</div> <div class="figure-caption"> <p>MRI‐pathway vs SBx ‐ Positive MRI ‐ G ≥ 1.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/references#CD012663-fig-0060">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_n/nCD012663-TST-041.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012663-fig-0061"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/urn:x-wiley:14651858:media:CD012663:CD012663-TST-042" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_t/tCD012663-TST-042.xxx" target="_blank"><b></b></a></p> </div><img alt="MRI‐pathway vs SBx ‐ Positive MRI ‐ G ≥ 2." data-id="CD012663-fig-0061" src="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_n/nCD012663-TST-042.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 42</div> <div class="figure-caption"> <p>MRI‐pathway vs SBx ‐ Positive MRI ‐ G ≥ 2.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/references#CD012663-fig-0061">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_n/nCD012663-TST-042.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012663-fig-0062"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/urn:x-wiley:14651858:media:CD012663:CD012663-TST-043" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_t/tCD012663-TST-043.xxx" target="_blank"><b></b></a></p> </div><img alt="MRI‐pathway vs SBx ‐ Positive MRI ‐ G ≥ 3." data-id="CD012663-fig-0062" src="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_n/nCD012663-TST-043.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 43</div> <div class="figure-caption"> <p>MRI‐pathway vs SBx ‐ Positive MRI ‐ G ≥ 3.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/references#CD012663-fig-0062">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_n/nCD012663-TST-043.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012663-fig-0063"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/urn:x-wiley:14651858:media:CD012663:CD012663-TST-044" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_t/tCD012663-TST-044.xxx" target="_blank"><b></b></a></p> </div><img alt="MRI‐pathway vs SBx ‐ Negative MRI ‐ G = 1." data-id="CD012663-fig-0063" src="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_n/nCD012663-TST-044.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 44</div> <div class="figure-caption"> <p>MRI‐pathway vs SBx ‐ Negative MRI ‐ G = 1.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/references#CD012663-fig-0063">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_n/nCD012663-TST-044.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012663-fig-0064"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/urn:x-wiley:14651858:media:CD012663:CD012663-TST-045" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_t/tCD012663-TST-045.xxx" target="_blank"><b></b></a></p> </div><img alt="MRI‐pathway vs SBx ‐ Negative MRI ‐ G ≥ 1." data-id="CD012663-fig-0064" src="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_n/nCD012663-TST-045.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 45</div> <div class="figure-caption"> <p>MRI‐pathway vs SBx ‐ Negative MRI ‐ G ≥ 1.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/references#CD012663-fig-0064">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_n/nCD012663-TST-045.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012663-fig-0065"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/urn:x-wiley:14651858:media:CD012663:CD012663-TST-046" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_t/tCD012663-TST-046.xxx" target="_blank"><b></b></a></p> </div><img alt="MRI‐pathway vs SBx ‐ Negative MRI ‐ G ≥ 2." data-id="CD012663-fig-0065" src="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_n/nCD012663-TST-046.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 46</div> <div class="figure-caption"> <p>MRI‐pathway vs SBx ‐ Negative MRI ‐ G ≥ 2.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/references#CD012663-fig-0065">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_n/nCD012663-TST-046.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012663-fig-0066"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/urn:x-wiley:14651858:media:CD012663:CD012663-TST-047" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_t/tCD012663-TST-047.xxx" target="_blank"><b></b></a></p> </div><img alt="MRI‐pathway vs SBx ‐ Negative MRI ‐ G ≥ 3." data-id="CD012663-fig-0066" src="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_n/nCD012663-TST-047.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 47</div> <div class="figure-caption"> <p>MRI‐pathway vs SBx ‐ Negative MRI ‐ G ≥ 3.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/references#CD012663-fig-0066">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_n/nCD012663-TST-047.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012663-fig-0067"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/urn:x-wiley:14651858:media:CD012663:CD012663-TST-048" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_t/tCD012663-TST-048.xxx" target="_blank"><b></b></a></p> </div><img alt="MRI‐pathway vs SBx ‐ Positive MRI ‐ Biopsy‐naïve ‐ G = 1." data-id="CD012663-fig-0067" src="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_n/nCD012663-TST-048.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 48</div> <div class="figure-caption"> <p>MRI‐pathway vs SBx ‐ Positive MRI ‐ Biopsy‐naïve ‐ G = 1.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/references#CD012663-fig-0067">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_n/nCD012663-TST-048.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012663-fig-0068"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/urn:x-wiley:14651858:media:CD012663:CD012663-TST-049" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_t/tCD012663-TST-049.xxx" target="_blank"><b></b></a></p> </div><img alt="MRI‐pathway vs SBx ‐ Positive MRI ‐ Biopsy‐naïve ‐ G ≥ 1." data-id="CD012663-fig-0068" src="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_n/nCD012663-TST-049.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 49</div> <div class="figure-caption"> <p>MRI‐pathway vs SBx ‐ Positive MRI ‐ Biopsy‐naïve ‐ G ≥ 1.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/references#CD012663-fig-0068">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_n/nCD012663-TST-049.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012663-fig-0069"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/urn:x-wiley:14651858:media:CD012663:CD012663-TST-050" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_t/tCD012663-TST-050.xxx" target="_blank"><b></b></a></p> </div><img alt="MRI‐pathway vs SBx ‐ Positive MRI ‐ Biopsy‐naïve ‐ G ≥ 2." data-id="CD012663-fig-0069" src="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_n/nCD012663-TST-050.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 50</div> <div class="figure-caption"> <p>MRI‐pathway vs SBx ‐ Positive MRI ‐ Biopsy‐naïve ‐ G ≥ 2.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/references#CD012663-fig-0069">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_n/nCD012663-TST-050.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012663-fig-0070"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/urn:x-wiley:14651858:media:CD012663:CD012663-TST-051" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_t/tCD012663-TST-051.xxx" target="_blank"><b></b></a></p> </div><img alt="MRI‐pathway vs. SBx ‐ Positive MRI ‐ Biopsy‐naïve ‐ G ≥ 3." data-id="CD012663-fig-0070" src="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_n/nCD012663-TST-051.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 51</div> <div class="figure-caption"> <p>MRI‐pathway vs. SBx ‐ Positive MRI ‐ Biopsy‐naïve ‐ G ≥ 3.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/references#CD012663-fig-0070">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_n/nCD012663-TST-051.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012663-fig-0071"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/urn:x-wiley:14651858:media:CD012663:CD012663-TST-052" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_t/tCD012663-TST-052.xxx" target="_blank"><b></b></a></p> </div><img alt="MRI‐pathway vs SBx ‐ Negative MRI ‐ Biopsy‐naïve ‐ G = 1." data-id="CD012663-fig-0071" src="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_n/nCD012663-TST-052.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 52</div> <div class="figure-caption"> <p>MRI‐pathway vs SBx ‐ Negative MRI ‐ Biopsy‐naïve ‐ G = 1.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/references#CD012663-fig-0071">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_n/nCD012663-TST-052.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012663-fig-0072"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/urn:x-wiley:14651858:media:CD012663:CD012663-TST-053" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_t/tCD012663-TST-053.xxx" target="_blank"><b></b></a></p> </div><img alt="MRI‐pathway vs SBx ‐ Negative MRI ‐ Biopsy‐naïve ‐ G ≥ 1." data-id="CD012663-fig-0072" src="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_n/nCD012663-TST-053.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 53</div> <div class="figure-caption"> <p>MRI‐pathway vs SBx ‐ Negative MRI ‐ Biopsy‐naïve ‐ G ≥ 1.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/references#CD012663-fig-0072">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_n/nCD012663-TST-053.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012663-fig-0073"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/urn:x-wiley:14651858:media:CD012663:CD012663-TST-054" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_t/tCD012663-TST-054.xxx" target="_blank"><b></b></a></p> </div><img alt="MRI‐pathway vs SBx ‐ Negative MRI ‐ Biopsy‐naïve ‐ G ≥ 2." data-id="CD012663-fig-0073" src="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_n/nCD012663-TST-054.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 54</div> <div class="figure-caption"> <p>MRI‐pathway vs SBx ‐ Negative MRI ‐ Biopsy‐naïve ‐ G ≥ 2.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/references#CD012663-fig-0073">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_n/nCD012663-TST-054.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012663-fig-0074"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/urn:x-wiley:14651858:media:CD012663:CD012663-TST-055" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_t/tCD012663-TST-055.xxx" target="_blank"><b></b></a></p> </div><img alt="MRI‐pathway vs SBx ‐ Negative MRI ‐ Biopsy‐naïve ‐ G ≥ 3." data-id="CD012663-fig-0074" src="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_n/nCD012663-TST-055.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 55</div> <div class="figure-caption"> <p>MRI‐pathway vs SBx ‐ Negative MRI ‐ Biopsy‐naïve ‐ G ≥ 3.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/references#CD012663-fig-0074">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_n/nCD012663-TST-055.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012663-fig-0075"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/urn:x-wiley:14651858:media:CD012663:CD012663-TST-056" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_t/tCD012663-TST-056.xxx" target="_blank"><b></b></a></p> </div><img alt="MRI‐pathway vs SBx ‐ Positive MRI ‐ Prior‐negative biopsy ‐ G = 1." data-id="CD012663-fig-0075" src="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_n/nCD012663-TST-056.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 56</div> <div class="figure-caption"> <p>MRI‐pathway vs SBx ‐ Positive MRI ‐ Prior‐negative biopsy ‐ G = 1.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/references#CD012663-fig-0075">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_n/nCD012663-TST-056.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012663-fig-0076"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/urn:x-wiley:14651858:media:CD012663:CD012663-TST-057" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_t/tCD012663-TST-057.xxx" target="_blank"><b></b></a></p> </div><img alt="MRI‐pathway vs SBx ‐ Positive MRI ‐ Prior‐negative biopsy ‐ G ≥ 1." data-id="CD012663-fig-0076" src="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_n/nCD012663-TST-057.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 57</div> <div class="figure-caption"> <p>MRI‐pathway vs SBx ‐ Positive MRI ‐ Prior‐negative biopsy ‐ G ≥ 1.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/references#CD012663-fig-0076">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_n/nCD012663-TST-057.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012663-fig-0077"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/urn:x-wiley:14651858:media:CD012663:CD012663-TST-058" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_t/tCD012663-TST-058.xxx" target="_blank"><b></b></a></p> </div><img alt="MRI‐pathway vs SBx ‐ Positive MRI ‐ Prior‐negative biopsy ‐ G ≥ 2." data-id="CD012663-fig-0077" src="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_n/nCD012663-TST-058.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 58</div> <div class="figure-caption"> <p>MRI‐pathway vs SBx ‐ Positive MRI ‐ Prior‐negative biopsy ‐ G ≥ 2.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/references#CD012663-fig-0077">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_n/nCD012663-TST-058.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012663-fig-0078"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/urn:x-wiley:14651858:media:CD012663:CD012663-TST-059" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_t/tCD012663-TST-059.xxx" target="_blank"><b></b></a></p> </div><img alt="MRI‐pathway vs SBx ‐ Positive MRI ‐ Prior‐negative biopsy ‐ G ≥ 3." data-id="CD012663-fig-0078" src="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_n/nCD012663-TST-059.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 59</div> <div class="figure-caption"> <p>MRI‐pathway vs SBx ‐ Positive MRI ‐ Prior‐negative biopsy ‐ G ≥ 3.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/references#CD012663-fig-0078">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_n/nCD012663-TST-059.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012663-fig-0079"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/urn:x-wiley:14651858:media:CD012663:CD012663-TST-060" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_t/tCD012663-TST-060.xxx" target="_blank"><b></b></a></p> </div><img alt="MRI‐pathway vs SBx ‐ Negative MRI ‐ Prior‐negative biopsy ‐ G = 1." data-id="CD012663-fig-0079" src="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_n/nCD012663-TST-060.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 60</div> <div class="figure-caption"> <p>MRI‐pathway vs SBx ‐ Negative MRI ‐ Prior‐negative biopsy ‐ G = 1.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/references#CD012663-fig-0079">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_n/nCD012663-TST-060.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012663-fig-0080"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/urn:x-wiley:14651858:media:CD012663:CD012663-TST-061" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_t/tCD012663-TST-061.xxx" target="_blank"><b></b></a></p> </div><img alt="MRI‐pathway vs SBx ‐ Negative MRI ‐ Prior‐negative biopsy ‐ G ≥ 1." data-id="CD012663-fig-0080" src="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_n/nCD012663-TST-061.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 61</div> <div class="figure-caption"> <p>MRI‐pathway vs SBx ‐ Negative MRI ‐ Prior‐negative biopsy ‐ G ≥ 1.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/references#CD012663-fig-0080">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_n/nCD012663-TST-061.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012663-fig-0081"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/urn:x-wiley:14651858:media:CD012663:CD012663-TST-062" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_t/tCD012663-TST-062.xxx" target="_blank"><b></b></a></p> </div><img alt="MRI‐pathway vs SBx ‐ Negative MRI ‐ Prior‐negative biopsy ‐ G ≥ 2." data-id="CD012663-fig-0081" src="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_n/nCD012663-TST-062.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 62</div> <div class="figure-caption"> <p>MRI‐pathway vs SBx ‐ Negative MRI ‐ Prior‐negative biopsy ‐ G ≥ 2.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/references#CD012663-fig-0081">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_n/nCD012663-TST-062.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012663-fig-0082"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/urn:x-wiley:14651858:media:CD012663:CD012663-TST-063" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_t/tCD012663-TST-063.xxx" target="_blank"><b></b></a></p> </div><img alt="MRI‐pathway vs SBx ‐ Negative MRI ‐ Prior‐negative biopsy ‐ G ≥ 3." data-id="CD012663-fig-0082" src="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_n/nCD012663-TST-063.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 63</div> <div class="figure-caption"> <p>MRI‐pathway vs SBx ‐ Negative MRI ‐ Prior‐negative biopsy ‐ G ≥ 3.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/references#CD012663-fig-0082">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/media/CDSR/CD012663/image_n/nCD012663-TST-063.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD012663-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Detecting ISUP grade 2 or higher prostate cancer by MRI, MRI‐targeted biopsy, MRI‐pathway and systematic biopsy</span></div> <tbody> <tr class="table-header separated"> <td align="left" class="table-header" colspan="11" rowspan="1" valign="top"> <p><b>Detecting ISUP grade 2 or higher prostate cancer by MRI, MRI‐targeted biopsy, MRI pathway and systematic biopsy</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="10" rowspan="1" valign="top"> <p>13,770 men with a suspicion of prostate cancer (PSA‐ or DRE‐based) undergoing their first biopsy (biopsy‐naïve men) or a repeat biopsy (prior‐negative biopsy men) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Setting</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="10" rowspan="1" valign="top"> <p>University hospitals and specialized care centers</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Index tests</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="10" rowspan="1" valign="top"> <p>MRI; MRI‐targeted biopsy (MRI‐TBx) in men with a positive MRI; the MRI pathway (MRI with or without MRI‐TBx); and systematic biopsy (SBx) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reference standard</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="10" rowspan="1" valign="top"> <p>Template‐guided biopsy, which comprehensively samples all zones of the prostate</p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Tests</b> </p> </td> <td align="center" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Population type (biopsy‐naïve, prior‐negative biopsy, or mixed)</b> </p> </td> <td align="center" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Summary<br/> sensitivity<br/> (95% CI)</b> </p> </td> <td align="center" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Summary<br/> specificity<br/> (95% CI)</b> </p> </td> <td align="center" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Detection<br/> ratio<br/> (95% CI)</b> </p> </td> <td align="center" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Missed grade 2 or higher prostate cancer per 1000 men (95% CI)<sup>a</sup> </b> </p> </td> <td align="center" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Number of<br/> participants<br/> (studies)</b> </p> </td> <td align="center" class="table-header" colspan="4" rowspan="1" valign="top"> <p><b>Number of studies with a<br/> high or unclear risk of bias</b> </p> </td> </tr> <tr class="table-header separated"> <td align="center" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Participant<br/> selection</b> </p> </td> <td align="center" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Index<br/> test(s)</b> </p> </td> <td align="center" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Reference<br/> standard</b> </p> </td> <td align="center" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Flow and timing</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MRI</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mixed</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0.91</b><br/> (0.83 to 0.95) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0.37</b><br/> (0.29 to 0.46) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>27</b><br/> (15 to 51) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3091 (12)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MRI‐TBx</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mixed</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0.80</b><br/> (0.69 to 0.87) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0.94</b><br/> (0.90 to 0.97) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>60</b><br/> (39 to 93) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1553 (8)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MRI pathway</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mixed</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0.72</b><br/> (0.60 to 0.82) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0.96</b><br/> (0.94 to 0.98) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>84</b><br/> (54 to 120) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2257 (8)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>SBx</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mixed</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0.63</b><br/> (0.19 to 0.93) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1.00</b><br/> (0.91 to 1.00) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>111</b><br/> (21 to 243) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3421 (4)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>MRI pathway<b>vs SBx</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mixed</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.12</b><br/> (1.02 to 1.23) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MRI pathway <b>missed 12% (2 to 23) less</b> than SBx </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6944 (25)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> </tr> <tr class="separated"> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Biopsy‐naïve</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1.05</b><br/> (0.95 to 1.16) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MRI pathway <b>missed 5% (−5 to 16) less</b> than SBx </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5219 (20)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> </tr> <tr class="separated"> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prior‐negative biopsy</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1.44</b><br/> (1.19 to 1.75) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MRI pathway <b>missed 44% (19 to 75) less</b> than SBx </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1564 (10)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="11" rowspan="1" valign=""> <p><b>DRE:</b> digital rectal exam; <b>ISUP:</b> International Society of Urological Pathology; <b>MRI:</b> magnetic resonance imaging; <b>MRI‐TBx:</b> MRI‐targeted biopsy; MRI pathway<b>:</b> magnetic resonance imaging with or without magnetic resonance imaging‐targeted biopsy; <b>N:</b> number; <b>NA:</b> not applicable; <b>PSA:</b> prostate‐specific antigen; <b>SBx:</b> systematic biopsy.<br/> <sup>a</sup>At the representative pre‐test probability of 30% of having grade 2 or higher prostate cancer, based on prevalence findings in the test accuracy analysis (proportion missed = [prevalence*1000]*[1‐sensitivity]). </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Detecting ISUP grade 2 or higher prostate cancer by MRI, MRI‐targeted biopsy, MRI‐pathway and systematic biopsy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/full#CD012663-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD012663-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Detecting ISUP grade 1 prostate cancer by MRI, MRI‐targeted biopsy, MRI‐pathway and systematic biopsy</span></div> <tbody> <tr class="table-header separated"> <td align="left" class="table-header" colspan="11" rowspan="1" valign="top"> <p><b>Detecting ISUP grade 1 prostate cancer by MRI, MRI‐targeted biopsy, MRI pathway and systematic biopsy</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="10" rowspan="1" valign="top"> <p>10,051 men with a suspicion of prostate cancer (PSA‐ or DRE‐based) undergoing their first biopsy (biopsy‐naïve men) or a repeat biopsy (prior‐negative biopsy men) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Setting</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="10" rowspan="1" valign="top"> <p>University hospitals and specialized care centers</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Index tests</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="10" rowspan="1" valign="top"> <p>MRI; MRI‐targeted biopsy (MRI‐TBx) in men with a positive MRI; the MRI pathway (MRI with or without MRI‐TBx); and systematic biopsy (SBx) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reference standard</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="10" rowspan="1" valign="top"> <p>Template‐guided biopsy, which comprehensively samples all zones of the prostate</p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Tests</b> </p> </td> <td align="center" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Population type (biopsy‐naïve, prior‐negative biopsy, or mixed)</b> </p> </td> <td align="center" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Summary<br/> sensitivity<br/> (95% CI)</b> </p> </td> <td align="center" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Summary<br/> specificity<br/> (95% CI)</b> </p> </td> <td align="center" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Detection<br/> ratio<br/> (95% CI)</b> </p> </td> <td align="center" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Avoided<br/> overdiagnosis<br/> per 1000<br/> men (95% CI)<sup>a</sup> </b> </p> </td> <td align="center" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Number of<br/> participants<br/> (studies)</b> </p> </td> <td align="center" class="table-header" colspan="4" rowspan="1" valign="top"> <p><b>Number of studies with a<br/> high or unclear risk of bias</b> </p> </td> </tr> <tr class="table-header separated"> <td align="center" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Participant<br/> selection</b> </p> </td> <td align="center" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Index<br/> test(s)</b> </p> </td> <td align="center" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Reference<br/> standard</b> </p> </td> <td align="center" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Flow and timing</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MRI</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mixed</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0.70</b><br/> (0.59‐0.80) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0.27</b><br/> (0.19‐0.37) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>63</b><br/> (42‐86) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1764 (10)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MRI‐TBx</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mixed</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0.51</b><br/> (0.21‐0.81) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1.00</b><br/> (0.77‐1.00) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>103</b><br/> (40‐166) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>497 (5)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MRI pathway</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mixed</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0.34</b><br/> (0.19‐0.53) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1.00</b><br/> (0.90‐1.00) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>139</b><br/> (99‐170) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>681 (5)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>SBx</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mixed</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0.55</b><br/> (0.25‐0.83) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0.99</b><br/> (0.81‐1.00) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>95</b><br/> (36‐158) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3421 (4)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>MRI pathway<b>vs SBx</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mixed</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.61</b><br/> (0.52‐0.71) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>MRI pathway<br/> <b>avoided more</b><br/> overdiagnosis<br/> (and biopsy<br/> procedures<sup>b</sup>)<br/> than SBx </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5442 (21)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> </tr> <tr class="separated"> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Biopsy‐naïve</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0.63</b><br/> (0.54‐0.74) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4079 (17)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> </tr> <tr class="separated"> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prior‐negative biopsy</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0.62</b><br/> (0.44‐0.88) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1202 (8)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="11" rowspan="1" valign=""> <p><b>DRE:</b> digital rectal exam; ISUP<b>:</b> International Society of Urological Pathology; <b>MRI:</b> magnetic resonance imaging; <b>MRI‐TBx:</b> MRI‐targeted biopsy; MRI pathway<b>:</b> magnetic resonance imaging with or without magnetic resonance imaging‐targeted biopsy; <b>N:</b> number; <b>NA:</b> not applicable; <b>PSA:</b> prostate‐specific antigen; <b>SBx:</b> systematic biopsy. </p> <p><sup>a</sup>At the representative pre‐test probability of 21% of having grade 1 prostate cancer, based on prevalence findings in the test accuracy analysis (proportion avoided = [prevalence*1000]*[1‐sensitivity]).<br/> <sup>b</sup>MRI‐TBx is not performed in 29% (24‐35) of men with a negative MRI, whereas SBx is performed in 100% of men. </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Detecting ISUP grade 1 prostate cancer by MRI, MRI‐targeted biopsy, MRI‐pathway and systematic biopsy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/full#CD012663-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD012663-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Should MRI be used to diagnose ISUP grade ≥ 2 prostate cancer in men suspected of having clinically significant prostate cancer?</span></div> <tbody> <tr class="table-header separated"> <td align="" class="table-header" colspan="6" rowspan="1" valign=""> <p><b>Question: Should MRI be used to diagnose ISUP grade 2 or higher prostate cancer in men suspected of having clinically significant prostate cancer?</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Population:</b> men suspected of having clinically significant prostate cancer undergoing their first biopsy (biopsy‐naïve men) or a repeat biopsy (prior‐negative biopsy men) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Setting:</b> university hospitals and specialized care centers </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>New test:</b> MRI only | <b>Cut‐off value:</b> MRI score ≥ 3 out of 5 </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Reference test:</b> template‐guided biopsy, which comprehensively samples all zones of the prostate | <b>Threshold:</b> ISUP grade 2 or higher prostate cancer </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Pooled sensitivity:</b> 0.91 (95% CI: 0.83 to 0.95) | <b>Pooled specificity:</b> 0.37 (95% CI: 0.29 to 0.46) </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="2" valign=""> <p><b>Test result</b> </p> </td> <td align="center" class="table-header" colspan="3" rowspan="1" valign="top"> <p><b>Number of results per 1,000 men tested (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="2" valign=""> <p><b>Number of participants (studies)</b> </p> </td> <td align="center" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence (GRADE)</b> </p> </td> </tr> <tr class="separated"> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Prevalence 10%</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Prevalence 30%</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Prevalence 40%</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="1" valign=""> <p><b>True positives</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9 (83 to 95)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>273 (249 to 285)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>364 (332 to 380)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>3091 (12)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕○○ LOW<sup>a, b</sup> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="1" valign=""> <p><b>False negatives</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9 (5 to 17)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27 (15 to 51)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36 (20 to 68)</p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="1" valign=""> <p><b>True negatives</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>333 (261 to 414)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>259 (203 to 322)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>222 (174 to 276)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>3091 (12)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕○○ LOW<sup>a, b</sup> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="1" valign=""> <p><b>False positives</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>567 (486 to 639)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>441 (378 to 497)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>378 (324 to 426)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>MRI:</b> magnetic resonance imaging; <b>ISUP:</b> International Society of Urological Pathology; <b>CI:</b> confidence interval </p> <p><sup>a</sup>A considerable number of studies had a high or unclear risk of bias, mainly in the participant selection and reference standard domains.<br/> <sup>b</sup>A considerable, clinically relevant heterogeneity was observed across pooled study results. </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Should MRI be used to diagnose ISUP grade ≥ 2 prostate cancer in men suspected of having clinically significant prostate cancer?</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/full#CD012663-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD012663-tbl-0004"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Should MRI‐targeted biopsy be used to diagnose ISUP grade ≥ 2 prostate cancer in men suspected of having clinically significant prostate cancer?</span></div> <tbody> <tr class="table-header separated"> <td align="" class="table-header" colspan="6" rowspan="1" valign=""> <p><b>Question: Should MRI‐targeted biopsy be used to diagnose ISUP grade 2 or higher prostate cancer in men suspected of having clinically significant prostate cancer?</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Population:</b> men with a positive MRI suspected of having clinically significant prostate cancer undergoing their first biopsy (biopsy‐naïve men) or a repeat biopsy (prior‐negative biopsy men) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Setting:</b> university hospitals and specialized care centers </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>New test:</b> MRI‐targeted biopsy | <b>Threshold:</b> ISUP grade 2 or higher prostate cancer </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Reference test:</b> template‐guided biopsy, which comprehensively samples all zones of the prostate | <b>Threshold:</b> ISUP grade 2 or higher prostate cancer </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Pooled sensitivity:</b> 0.80 (95% CI: 0.69 to 0.87) | <b>Pooled specificity:</b> 0.94 (95% CI: 0.90 to 0.97) </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="2" valign=""> <p><b>Test result</b> </p> </td> <td align="center" class="table-header" colspan="3" rowspan="1" valign="top"> <p><b>Number of results per 1,000 men tested (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="2" valign=""> <p><b>Number of participants (studies)</b> </p> </td> <td align="center" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence (GRADE)</b> </p> </td> </tr> <tr class="separated"> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Prevalence 10%</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Prevalence 30%</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Prevalence 40%</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="1" valign=""> <p><b>True positives</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80 (69 to 87)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>240 (207 to 261)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>320 (276 to 348)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>1553 (8)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕○○ LOW<sup>a, b</sup> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="1" valign=""> <p><b>False negatives</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20 (13 to 31)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60 (39 to 93)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80 (52 to 124)</p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="1" valign=""> <p><b>True negatives</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>846 (810 to 873)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>658 (630 to 679)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>564 (540 to 582)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>1553 (8)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕○○ LOW<sup>a, b</sup> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="1" valign=""> <p><b>False positives</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54 (27 to 90)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42 (21 to 70)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36 (18 to 60)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>MRI:</b> magnetic resonance imaging; <b>ISUP:</b> International Society of Urological Pathology; <b>CI:</b> confidence interval </p> <p><sup>a</sup>A considerable number of studies had a high or unclear risk of bias, mainly in the participant selection and reference standard domains.<br/> <sup>b</sup>A considerable, clinically relevant heterogeneity was observed across pooled study results. </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Should MRI‐targeted biopsy be used to diagnose ISUP grade ≥ 2 prostate cancer in men suspected of having clinically significant prostate cancer?</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/full#CD012663-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD012663-tbl-0005"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Should an MRI‐pathway be used to diagnose ISUP grade ≥ 2 prostate cancer in men suspected of having clinically significant prostate cancer?</span></div> <tbody> <tr class="table-header separated"> <td align="" class="table-header" colspan="6" rowspan="1" valign=""> <p><b>Question: Should an MRI pathway be used to diagnose ISUP grade 2 or higher prostate cancer in men suspected of having clinically significant prostate cancer?</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Population:</b> men suspected of having clinically significant prostate cancer undergoing their first biopsy (biopsy‐naïve men) or a repeat biopsy (prior‐negative biopsy men) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Setting:</b> university hospitals and specialized care centers </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>New test:</b> MRI pathway | <b>Threshold:</b> ISUP grade 2 or higher prostate cancer </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Reference test:</b> template‐guided biopsy, which comprehensively samples all zones of the prostate | <b>Threshold:</b> ISUP grade 2 or higher prostate cancer </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Pooled sensitivity:</b> 0.72 (95% CI: 0.60 to 0.82) | <b>Pooled specificity:</b> 0.96 (95% CI: 0.94 to 0.98) </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="2" valign=""> <p><b>Test result</b> </p> </td> <td align="center" class="table-header" colspan="3" rowspan="1" valign="top"> <p><b>Number of results per 1,000 men tested (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="2" valign=""> <p><b>Number of participants (studies)</b> </p> </td> <td align="center" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence (GRADE)</b> </p> </td> </tr> <tr class="separated"> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Prevalence 10%</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Prevalence 30%</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Prevalence 40%</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="1" valign=""> <p><b>True positives</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>72 (60 to 82)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>216 (180 to 246)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>288 (240 to 328)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>2257 (8)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕○○ LOW<sup>a, b</sup> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="1" valign=""> <p><b>False negatives</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28 (18 to 40)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>84 (54 to 120)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>112 (72 to 160)</p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="1" valign=""> <p><b>True negatives</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>864 (846 to 882)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>672 (658 to 686)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>576 (564 to 588)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>2257 (8)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕○○ LOW<sup>a, b</sup> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="1" valign=""> <p><b>False positives</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36 (18 to 54)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28 (14 to 42)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 (12 to 36)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>MRI pathway<b>:</b> magnetic resonance imaging with or without magnetic resonance imaging‐targeted biopsy; <b>ISUP:</b> International Society of Urological Pathology; <b>CI:</b> confidence interval </p> <p><sup>a</sup>A considerable number of studies had a high or unclear risk of bias, mainly in the participant selection and reference standard domains.<br/> <sup>b</sup>A considerable, clinically relevant heterogeneity was observed across pooled study results. </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Should an MRI‐pathway be used to diagnose ISUP grade ≥ 2 prostate cancer in men suspected of having clinically significant prostate cancer?</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/full#CD012663-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD012663-tbl-0006"> <div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Should systematic biopsy be used to diagnose ISUP grade ≥ 2 prostate cancer in men suspected of having clinically significant prostate cancer?</span></div> <tbody> <tr class="table-header separated"> <td align="" class="table-header" colspan="6" rowspan="1" valign=""> <p><b>Question: Should systematic biopsy be used to diagnose ISUP grade 2 or higher prostate cancer in men suspected of having clinically significant prostate cancer?</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Population:</b> men suspected of having clinically significant prostate cancer undergoing their first biopsy (biopsy‐naïve men) or a repeat biopsy (prior‐negative biopsy men) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Setting:</b> university hospitals and specialized care centers </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>New test:</b> systematic biopsy | <b>Threshold:</b> ISUP grade 2 or higher prostate cancer </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Reference test:</b> template‐guided biopsy, which comprehensively samples all zones of the prostate | <b>Threshold:</b> ISUP grade 2 or higher prostate cancer </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Pooled sensitivity:</b> 0.63 (95% CI: 0.19 to 0.93) | <b>Pooled specificity:</b> 1.00 (95% CI: 0.91 to 1.00) </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="2" valign=""> <p><b>Test result</b> </p> </td> <td align="center" class="table-header" colspan="3" rowspan="1" valign="top"> <p><b>Number of results per 1,000 men tested (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="2" valign=""> <p><b>Number of participants (studies)</b> </p> </td> <td align="center" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence (GRADE)</b> </p> </td> </tr> <tr class="separated"> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Prevalence 10%</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Prevalence 30%</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Prevalence 40%</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="1" valign=""> <p><b>True positives</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>63 (19 to 93)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>189 (57 to 279)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>252 (76 to 372)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>3421 (4)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕○ MODERATE<sup>a, b, c</sup> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="1" valign=""> <p><b>False negatives</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37 (7 to 81)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>111 (21 to 243)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>148 (28 to 324)</p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="1" valign=""> <p><b>True negatives</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>900 (819 to 900)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>700 (637 to 700)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>600 (546 to 600)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>3421 (4)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕○○ LOW<sup>a, b, c</sup> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="1" valign=""> <p><b>False positives</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 (0 to 81)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 (0 to 63)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 (0 to 54)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>ISUP:</b> International Society of Urological Pathology; <b>CI:</b> confidence interval </p> <p><sup>a</sup>A considerable number of studies had a high or unclear risk of bias, mainly in the participant selection and reference standard domains.<br/> <sup>b</sup>A considerable, clinically relevant heterogeneity was observed across pooled study results.<br/> <sup>c</sup>Important imprecision was noted, which contributed to decision to downgrade for inconsistency. </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Should systematic biopsy be used to diagnose ISUP grade ≥ 2 prostate cancer in men suspected of having clinically significant prostate cancer?</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/full#CD012663-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012663-tbl-0007"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">QUADAS‐2 tool for assessing methodological quality of included studies</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Domain 1: Participant selection</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>SQ 1</b>: Was a consecutive or random sample of participants enrolled? </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes: if stated that participants were consecutively or randomly selected</p> <p>No: if one of these criteria was not met</p> <p>Unclear: if insufficient information to make a judgement</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>SQ 2:</b> Did the study avoid inappropriate exclusions? </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes: if stated that the study did not exclude men 1) aged between 50 and 70 years, 2) with PSA values between 4 and 10 ng/mL, or 3) with an abnormal DRE </p> <p>No: if one of these criteria was not met</p> <p>Unclear: insufficient information to make a judgement</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Risk of bias</b> </p> <p>Could the selection of participants have introduced bias?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk: if ‘Yes’ for all SQ's</p> <p>High risk: if ‘No’ for at least 1 SQ</p> <p>Unclear risk: if 'Unclear' for at least 1 SQ</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Concerns for applicability</b> </p> <p>Are there concerns that the included participants and setting do not match the review question? </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low concern: the participants were referred because of a suspicion of prostate cancer.</p> <p>High concern: the participants were not referred because of a suspicion of prostate cancer, e.g. PSA‐screening trials are less applicable to the current clinical practice. </p> <p>Unclear concern: insufficient information to make a judgement</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Domain 2: Index texts</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>SQ 1</b>: If applicable, was the MRI assessed without knowledge of the results of the reference (or other index) biopsies? </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes: if stated that the radiologist was unaware of all biopsy results; or, if the order of testing was MRI before all biopsies for every participant </p> <p>No: if stated that the radiologist was aware of any biopsy results during MRI assessment</p> <p>Unclear: insufficient information to make a judgement</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>SQ 2</b>: If applicable, were the MRI‐targeted biopsies performed independently of the performance and the results of the reference (or other index) biopsies? </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes: if stated that the performance of MRI‐targeted biopsies was not influenced by the performance or trajectory of reference (or other index) biopsies </p> <p>No: if stated that MRI‐targeted biopsies were not, or differently, taken from locations already hit by the reference (or other index) biopsies; or, if the performance of MRI‐targeted biopsies was dependent on the judgement of the same operator that also performed the reference (or other index) biopsies without blinding </p> <p>Unclear: insufficient information to make a judgement</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>SQ 3</b>: If applicable, were the systematic biopsies taken independently of the performance and the results of the reference (of other index) biopsies? </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes: if stated that the systematic biopsies were taken blinded for</p> <p> <ol id="CD012663-list-0005"> <li> <p>the results of the MRI</p> </li> <li> <p>the reference or other index biopsy trajectories</p> </li> </ol> </p> <p>No: if stated that the systematic biopsy operator was not blinded for MRI results, or was the same operator that also performed the reference (or other index) biopsies without blinding </p> <p>Unclear: insufficient information to make a judgement</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Risk of bias</b> </p> <p>Could the conduct or interpretation of the index test have introduced bias?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk: ‘Yes’ for all applicable SQs</p> <p>High risk: ‘No’ for at least one applicable SQ</p> <p>Unclear risk: ‘Unclear’ for at least one applicable SQ</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Concerns for applicability</b> </p> <p>Are there concerns that the index tests, their conduct or their interpretation differ from the review question? </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low concern: if stated that, when applicable,</p> <p> <ol id="CD012663-list-0006"> <li> <p>a 1.5 or 3 Tesla magnet was used for MRI acquisition, with at least T2 and DWI or DCE sequencing; </p> </li> <li> <p>the MRI‐scoring system and positivity‐threshold for MRI‐targeted biopsy consisted of a 1‐5 score with threshold ≥ 3; </p> </li> <li> <p>software‐assisted, cognitive or in‐bore MRI‐targeted biopsies were taken,</p> </li> <li> <p>an extended sextant systematic biopsy was performed with 8‐19 cores distributed appropriately to sample the peripheral zone. </p> </li> </ol> </p> <p>High concern: the index test did not meet the criteria above</p> <p>Unclear concern: insufficient information to make a judgement</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Domain 3: Reference standard</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>SQ1</b>: Is the reference standard likely to correctly classify the target condition? (i.e. Is histological diagnosis made from appropriately sampled tissue?) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes: if stated that the whole prostate was comprehensively sampled by a full 5‐mm transperineal TTMB, or by a equivalently well described transperineal template‐guided biopsy method with a prostate volume based median of ≤ 20 biopsy cores. </p> <p>No: one of these criteria was not met (i.e. in‐house transperineal saturation biopsy or transrectal saturation biopsy are less likely to appropriately sample the whole prostate). </p> <p>Unclear: insufficient information to make a judgement</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>SQ2</b>: Was the reference standard performed independent of the index test? </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes: if stated that the reference biopsies were taken without knowledge of the MRI‐score and location of target lesions; and, if incorporation was avoided (i.e. the index test was not part of the reference standard). </p> <p>No: one of these criteria was not met</p> <p>Unclear: insufficient information to make a judgement</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Risk of bias</b> </p> <p>Could the reference standard, its conduct, or its interpretation have introduced bias?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk: 'Yes’ for all SQs</p> <p>High risk: ’No’ for at least 1 of the 3 SQs</p> <p>Unclear risk: ’Unclear’ for at least 1 SQ</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Concerns for applicability</b> </p> <p>Are there concerns that the target condition as defined by the reference standard does not match the question? </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low concern: data were presented for GS ≥ 3+4 without any volume criteria (ISUP grade ≥ 2), if necessary after requesting additional data from study authors </p> <p>High concern: data were presented for an alternative target condition definition and study authors did not provide additional data. </p> <p>Unclear: insufficient information to make a judgement</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Domain 4: Flow and timing</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>SQ1</b>: Did all participants receive the same biopsy methods (i.e. was differential verification avoided)? </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes: if stated that all participants received the same type of index test(s) and reference standard, prostate volume dependency was allowed. </p> <p>No: if one of these criteria was not met</p> <p>Unclear: if insufficient information to make a judgement</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>SQ2</b>: Were all enrolled participants included in the analysis, or were exclusions explained and not leading to a relevant bias? </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes: if stated that all eligible participants were enrolled and included in the final analyses; or, if reasons to excluded participants did not cause a relevant bias (e.g. participants with claustrophobia who refused MRI). </p> <p>No: one of these criteria was not met.</p> <p>Unclear: if insufficient information to make a judgement</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Risk of bias</b> </p> <p>Could the participant flow have introduced bias?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk: ’Yes’ for all SQs</p> <p>High risk: ’No’ for at least 1 SQ</p> <p>Unclear risk: ’Unclear’, for at least 1 SQ</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>DCE:</b> dynamic contrast‐enhanced; <b>DRE:</b> digital rectal examination; <b>DWI:</b> diffusion‐weighted imaging; <b>MRI:</b> magnetic resonance imaging; <b>PSA:</b> prostate‐specific antigen; <b>QUADAS:</b> Quality Assessment of Diagnostic Accuracy Studies; <b>SQ:</b> signalling question; <b>TTMB:</b> template‐guided mapping biopsy; <b>ISUP:</b> International Society of Urological Pathology </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">QUADAS‐2 tool for assessing methodological quality of included studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/full#CD012663-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012663-tbl-0008"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Study characteristics of the diagnostic test accuracy analyses studies</span></div> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="4" rowspan="1" valign="top"> <p><b>Study</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>MRI</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Index biopsy</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Reference standard</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Target<br/> conditions</b> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Consecutive<br/> enrolment<br/> (study design<sup>a</sup>)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>N of<br/> participants</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Index<br/> test(s)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MRI‐scale;<br/> threshold</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MRI‐TBx<br/> Technique/route</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Technique</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Median N<br/> cores (range)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Independence</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>ISUP<br/> grade<br/> (G)</b> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012663-bbs2-0001" title="Abd‐Alazeez , M , AryaHU , CharmanSC , AnastasiadisE , FreemanA , EmbertonM , et al. The accuracy of multiparametric MRI in men with negative biopsy and elevated PSA level‐Can it rule out clinically significant prostate cancer?. Urologic Oncology2014;32(1):45.e17‐45.e22. ">Abd‐Alazeez 2014</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No<br/> (retrospective) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MRI</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1‐5; ≥ 3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cognitive/transperineal</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TTMB</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45 (21‐137)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G = 1<br/> G ≥ 2<br/> G ≥ 3 </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012663-bbs2-0002" title="AhmedHU , El‐Shater BosailyA , BrownLC , GabeR , KaplanR , ParmarMK , et al. Diagnostic accuracy of multi‐parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. Lancet2017;389(10071):815‐22. ">Ahmed 2017</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes<br/> (prospective) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>576</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MRI, SBx</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1‐5; ≥ 3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA/transrectal</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TTMB</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&gt; 40<sup>b</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G = 1<br/> G ≥ 2<br/> G ≥ 3 </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012663-bbs2-0011" title="Dal MoroF , ZecchiniG , MorlaccoA , GardimanMP , LacognataCS , LauroA , et al. Does 1.5 T mpMRI play a definite role in detection of clinically significant prostate cancer? Findings from a prospective study comparing blind 24‐core saturation and targeted biopsies with a novel data remodeling model. Aging Clinical and Experimental Research2019;31(1):115‐23. ">Dal Moro 2019</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes<br/> (prospective) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>123</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MRI,<br/> MRI‐TBx,<br/> MRI‐pathway </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1‐5; ≥ 3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cognitive/transrectal</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TSB<sup>c</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24<sup>d</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G = 1<br/> G ≥ 2<br/> G ≥ 3 </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012663-bbs2-0013" title="DistlerFA , RadtkeJP , BonekampD , KeschC , SchlemmerHP , WieczorekK , et al. The value of PSA density in combination with PI‐RADS for the accuracy of prostate cancer prediction. The Journal of Urology2017;198(3):575‐82. ">Distler 2017</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes<br/> (prospective) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bx‐naïve: 597<br/> Prior‐negative Bx: 443 </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MRI,<br/> MRI‐TBx,<br/> MRI‐pathway </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1‐5; ≥ 3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Software/transperineal</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TSB<sup>e</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 (22‐25)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G ≥ 2</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012663-bbs2-0016" title="GreyAD , ChanaMS , PopertR , WolfeK , LiyanageSH , AcherPL . Diagnostic accuracy of magnetic resonance imaging (MRI) prostate imaging reporting and data system (PI‐RADS) scoring in a transperineal prostate biopsy setting. BJU International2015;115(5):728‐35. ">Grey 2015</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes<br/> (prospective) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bx‐naïve: 83<br/> Prior‐negative Bx: 103 </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MRI</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1‐5; ≥ 3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cognitive/transperineal</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TSB<sup>e</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(24‐40)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G = 1<br/> G ≥ 2<br/> G ≥ 3 </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012663-bbs2-0018" title="HansenN , PatrunoG , WadhwaK , GazievG , MianoR , BarrettT , et al. Magnetic resonance and ultrasound image fusion supported transperineal prostate biopsy using the Ginsburg protocol: technique, learning points, and biopsy results. Eurpean Urology2016;70(2):332‐40. ">Hansen 2016a</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes<br/> (prospective) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>295</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MRI,<br/> MRI‐TBx,<br/> MRI‐pathway </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1‐5; ≥ 3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Software/transperineal</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TSB<sup>e</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(18‐24)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G = 1<br/> G ≥ 2<br/> G ≥ 3 </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012663-bbs2-0020" title="HansenNL , BarrettT , KeschC , PepdjonovicL , BonekampD , O'SullivanR , et al. Multicentre evaluation of magnetic resonance imaging supported transperineal prostate biopsy in biopsy naïve men with suspicion of prostate cancer. BJU International2018;122(1):40‐9. ">Hansen 2018</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes<br/> (prospective) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Centre 1: 163<br/> Centre 3: 242 </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MRI</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1‐5; ≥ 3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Software,<br/> cognitive/transperineal </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TSB<sup>e</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 (22‐26<sup>f</sup>),<br/> 20 (20‐21<sup>f</sup>) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G = 1<br/> G ≥ 2<br/> G ≥ 3 </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012663-bbs2-0019" title="HansenNL , KeschC , BarrettT , KooB , RadtkeJP , BonekampD , et al. Multicentre evaluation of targeted and systematic biopsies using magnetic resonance and ultrasound image‐fusion guided transperineal prostate biopsy in patients with a previous negative biopsy. BJU International2017;120(5):631‐8. ">Hansen 2017</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear<br/> (prospective) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>287</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MRI,<br/> MRI‐TBx,<br/> MRI‐pathway </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1‐5; ≥ 3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Software/transperineal</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TSB<sup>e</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 (24‐25)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G ≥ 2</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012663-bbs2-0023" title="KeschC , RadtkeJP , PopeneciuIV , GaschC , DieffenbacherSC , KleinT , et al. TOP: prospective evaluation of a volume based, computer assisted method for transperineal optimized prostate biopsy. Urologia Internationalis2017;99(2):149‐55. ">Kesch 2017</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear<br/> (prospective) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bx‐naïve: 95<br/> Prior‐negative Bx: 51 </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MRI,<br/> MRI‐TBx,<br/> MRI‐pathway </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1‐5; ≥ 3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Software/transperineal</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TSB<sup>g</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 (23‐27<sup>f</sup>) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G = 1<br/> G ≥ 2<br/> G ≥ 3 </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012663-bbs2-0025" title="LawrenceEM , TangSY , BarrettT , KooB , GoldmanDA , WarrenAY , et al. Prostate cancer: performance characteristics of combined T2W and DW‐MRI scoring in the setting of template transperineal re‐biopsy using MR‐TRUS fusion. European Radiology2014;24(7):1497‐505. ">Lawrence 2014</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No<br/> (retrospective) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MRI,<br/> MRI‐TBx,<br/> MRI‐pathway </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1‐4; ≥2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Software/transperineal</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TSB<sup>e</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 (14‐34)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G = 1<br/> G ≥ 2 </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012663-bbs2-0028" title="MortezaviA , MärzendorferO , DonatiOF , RizziG , RuppNJ , WettsteinMS , et al. Diagnostic accuracy of multiparametric magnetic resonance imaging and fusion guided targeted biopsy evaluated by transperineal template saturation prostate biopsy for the detection and characterization of prostate cancer. Journal of Urology2018;200(2):309‐18. ">Mortezavi 2018</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes<br/> (retrospective) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>163<br/> 86 </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MRI,<br/> MRI‐TBx,<br/> MRI‐pathway </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1‐5; ≥ 3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Software/Transrectal</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TSB</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40 (30‐55)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G = 1<br/> G ≥ 2<br/> G ≥ 3 </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012663-bbs2-0029" title="MuthuveloeD , TelfordR , VineyR , PatelP . The detection and upgrade rates of prostate adenocarcinoma following transperineal template‐guided prostate biopsy – a tertiary referral centre experience. Central European Journal of Urology2016;69(1):42‐7. ">Muthuveloe 2016</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear<br/> (retrospective) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9<br/> 162 </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MRI</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1‐5; ≥ 3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TSB<sup>h</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 (24–28)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G = 1<br/> G ≥ 2<br/> G ≥ 3 </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012663-bbs2-0035" title="PepeP , GarufiA , PrioloG , CandianoG , PietropaoloF , PennisiM , et al. Prostate cancer detection at repeat biopsy: can pelvic phased array multiparametric MRI replace saturation biopsy?. Anticancer Research2013;33(3):1195‐200. ">Pepe 2013</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear<br/> (prospective) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>78</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MRI,<br/> MRI‐TBx,<br/> MRI‐pathway </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0‐1: ≥1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cognitive/transrectal</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TSB<sup>h</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28 (26‐32)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G = 1<br/> G ≥ 2 </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012663-bbs2-0040" title="ThompsonJE , VanLeeuwenPJ , MosesD , ShnierR , BrennerP , DelpradoW , et al. The diagnostic performance of multiparametric magnetic resonance imaging to detect significant prostate cancer. Journal of Urology2016;195(5):1428‐35. ">Thompson 2016</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes<br/> (prospective) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>344</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MRI</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1‐5; ≥ 3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Software,<br/> cognitive/transperineal </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TTMB</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G = 1<br/> G ≥ 2<br/> G ≥ 3 </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012663-bbs2-0042" title="TsivianM , GuptaRT , TsivianE , QiP , MendezMH , AbernMR , et al. Assessing clinically significant prostate cancer: diagnostic properties of multiparametric magnetic resonance imaging compared to three‐dimensional transperineal template mapping histopathology. International Journal of Urology2017;24(2):137‐43. ">Tsivian 2017</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear<br/> (retrospective) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MRI</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1‐5; ≥ 3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TTMB</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55 (42‐63<sup>f</sup>) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G = 1<br/> G ≥ 2<br/> G ≥ 3 </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012663-bbs2-0030" title="NafieS , MellonJK , DormerJP , KhanMA . The role of transperineal template prostate biopsies in prostate cancer diagnosis in biopsy naïve men with PSA less than 20 ng mL‐1. Prostate Cancer and Prostatic Diseases2014;17(2):170‐3. ">Nafie 2014</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear<br/> (prospective) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SBx</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA/transrectal</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TSB<sup>h</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G = 1<br/> G ≥ 2<br/> G ≥ 3 </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012663-bbs2-0031" title="NafieS , WanisM , KhanM . The efficacy of transrectal ultrasound guided biopsy versus transperineal template biopsy of the prostate in diagnosing prostate cancer in men with previous negative transrectal ultrasound guided biopsy. Urology Journal2017;14(2):3008‐12. ">Nafie 2017</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear<br/> (prospective) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SBx</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA/transrectal</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TSB<sup>h</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G = 1<br/> G ≥ 2 </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012663-bbs2-0036" title="PloussardG , NicolaiewN , MarchandC , TerryS , VacherotF , VordosD , et al. Prospective evaluation of an extended 21‐core biopsy scheme as initial prostate cancer diagnostic strategy. European Urology2014;65(1):154‐61. ">Ploussard 2014</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes<br/> (prospective) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2753</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SBx</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA/transrectal</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TSB<sup>c</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G = 1<br/> G ≥ 2 </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="10" rowspan="1" valign=""> <p><b>Bx:</b> biopsy; <b>ISUP G :</b> International Society of Urological Pathology grade; <b>MRI:</b> magnetic resonance imaging; <b>MRI‐pathway:</b> magnetic resonance imaging with or without magnetic resonance imaging‐targeted biopsy; <b>MRI‐TBx:</b> magnetic resonance imaging‐targeted biopsy; <b>N:</b> number; <b>NA:</b> not applicable; <b>PI‐RADS v1, v2:</b> Prostate Imaging Reporting Data System version 1 or 2; <b>SBx:</b> systematic biopsy; <b>TSB:</b> transperineal saturation biopsy; <b>TTMB:</b> transperineal template mapping biopsy </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="10"> <div class="table-footnote"> <p><sup>a</sup>Included participants were part of the same study cohort (no randomised populations were included).<br/> <sup>b</sup>Not reported but estimated.<br/> <sup>c</sup>Transrectal.<br/> <sup>d</sup>Mean value (as opposed to median).<br/> <sup>e</sup>Ginsburg biopsies.<br/> <sup>f</sup>Interquartile range (as opposed to range).<br/> <sup>g</sup>Transperineal optimised prostate biopsy (TOP).<br/> <sup>h</sup>In‐house transperineal saturation biopsy </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Study characteristics of the diagnostic test accuracy analyses studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/full#CD012663-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012663-tbl-0009"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Patient characteristics of the diagnostic test accuracy studies</span></div> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Patient characteristics of the included diagnostic test accuracy studies</b> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Population</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Median age<br/> (range/SD)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Median PSA<br/> in ng/mL (range)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Median prostate<br/> volume in cm<sup>3</sup><br/> (range)</b> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012663-bbs2-0001" title="Abd‐Alazeez , M , AryaHU , CharmanSC , AnastasiadisE , FreemanA , EmbertonM , et al. The accuracy of multiparametric MRI in men with negative biopsy and elevated PSA level‐Can it rule out clinically significant prostate cancer?. Urologic Oncology2014;32(1):45.e17‐45.e22. ">Abd‐Alazeez 2014</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prior‐negative Bx</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64 (39‐75)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 (2‐23)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>53 (19‐136)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012663-bbs2-0002" title="AhmedHU , El‐Shater BosailyA , BrownLC , GabeR , KaplanR , ParmarMK , et al. Diagnostic accuracy of multi‐parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. Lancet2017;389(10071):815‐22. ">Ahmed 2017</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bx‐naïve</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>63 (7.6)<sup>a</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.1 (2.9)<sup>a</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012663-bbs2-0011" title="Dal MoroF , ZecchiniG , MorlaccoA , GardimanMP , LacognataCS , LauroA , et al. Does 1.5 T mpMRI play a definite role in detection of clinically significant prostate cancer? Findings from a prospective study comparing blind 24‐core saturation and targeted biopsies with a novel data remodeling model. Aging Clinical and Experimental Research2019;31(1):115‐23. ">Dal Moro 2019</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prior‐negative Bx</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62 (57‐68<sup>b</sup>) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.3 (4,8‐8,9<sup>b</sup>) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55 (20‐149)<sup>a</sup> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012663-bbs2-0013" title="DistlerFA , RadtkeJP , BonekampD , KeschC , SchlemmerHP , WieczorekK , et al. The value of PSA density in combination with PI‐RADS for the accuracy of prostate cancer prediction. The Journal of Urology2017;198(3):575‐82. ">Distler 2017</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mixed<sup>c</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65 (60‐71<sup>b</sup>) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.2 (5.3‐10.4<sup>b</sup>) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45 (34‐64<sup>b</sup>) </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012663-bbs2-0016" title="GreyAD , ChanaMS , PopertR , WolfeK , LiyanageSH , AcherPL . Diagnostic accuracy of magnetic resonance imaging (MRI) prostate imaging reporting and data system (PI‐RADS) scoring in a transperineal prostate biopsy setting. BJU International2015;115(5):728‐35. ">Grey 2015</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mixed<sup>c</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64 (6.8)<sup>a</sup><br/> 65 (7.6)<sup>a</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13.3 (12,1)<sup>a</sup><br/> 12.6 (13.7)<sup>a</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>68 (35)<sup>a</sup><br/> 54 (31)<sup>a</sup> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012663-bbs2-0018" title="HansenN , PatrunoG , WadhwaK , GazievG , MianoR , BarrettT , et al. Magnetic resonance and ultrasound image fusion supported transperineal prostate biopsy using the Ginsburg protocol: technique, learning points, and biopsy results. Eurpean Urology2016;70(2):332‐40. ">Hansen 2016a</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prior‐negative Bx</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65 (59‐69<sup>b</sup>) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.8 (6.0‐12<sup>b</sup>) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65 (44‐83<sup>b</sup>) </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012663-bbs2-0020" title="HansenNL , BarrettT , KeschC , PepdjonovicL , BonekampD , O'SullivanR , et al. Multicentre evaluation of magnetic resonance imaging supported transperineal prostate biopsy in biopsy naïve men with suspicion of prostate cancer. BJU International2018;122(1):40‐9. ">Hansen 2018</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bx‐naïve</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64 (57‐69<sup>b</sup>)<br/> 65 (60‐70<sup>b</sup>) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.6 (4.6‐9.0<sup>b</sup>)<br/> 5.9 (4.6‐8.0<sup>b</sup>) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44 (33‐55<sup>b</sup>)<br/> 25 (24‐47<sup>b</sup>) </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012663-bbs2-0019" title="HansenNL , KeschC , BarrettT , KooB , RadtkeJP , BonekampD , et al. Multicentre evaluation of targeted and systematic biopsies using magnetic resonance and ultrasound image‐fusion guided transperineal prostate biopsy in patients with a previous negative biopsy. BJU International2017;120(5):631‐8. ">Hansen 2017</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prior‐negative Bx</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66 (61‐72<sup>b</sup>) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.7 (7.1‐13.9<sup>b</sup>) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52 (36‐75<sup>b</sup>) </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012663-bbs2-0023" title="KeschC , RadtkeJP , PopeneciuIV , GaschC , DieffenbacherSC , KleinT , et al. TOP: prospective evaluation of a volume based, computer assisted method for transperineal optimized prostate biopsy. Urologia Internationalis2017;99(2):149‐55. ">Kesch 2017</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mixed<sup>c</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65 (58‐71<sup>b</sup>) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.2 (5.4‐10.2<sup>b</sup>) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46 (36‐60<sup>b</sup>) </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012663-bbs2-0025" title="LawrenceEM , TangSY , BarrettT , KooB , GoldmanDA , WarrenAY , et al. Prostate cancer: performance characteristics of combined T2W and DW‐MRI scoring in the setting of template transperineal re‐biopsy using MR‐TRUS fusion. European Radiology2014;24(7):1497‐505. ">Lawrence 2014</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prior‐negative Bx</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64 (47‐77)<sup>a</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 (1.2‐36)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012663-bbs2-0028" title="MortezaviA , MärzendorferO , DonatiOF , RizziG , RuppNJ , WettsteinMS , et al. Diagnostic accuracy of multiparametric magnetic resonance imaging and fusion guided targeted biopsy evaluated by transperineal template saturation prostate biopsy for the detection and characterization of prostate cancer. Journal of Urology2018;200(2):309‐18. ">Mortezavi 2018</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bx‐naïve<br/> Prior‐negative Bx </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>63 (57‐68<sup>b</sup>)<br/> 64 (60‐69<sup>b</sup>) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.8 (4.4‐8.9<sup>b</sup>)<br/> 8.6 (5.7‐13<sup>b</sup>) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44 (34‐60<sup>b</sup>)<br/> 54 (41‐70<sup>b</sup>) </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012663-bbs2-0029" title="MuthuveloeD , TelfordR , VineyR , PatelP . The detection and upgrade rates of prostate adenocarcinoma following transperineal template‐guided prostate biopsy – a tertiary referral centre experience. Central European Journal of Urology2016;69(1):42‐7. ">Muthuveloe 2016</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bx‐naïve<br/> Prior‐negative Bx </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>68 (46‐81)<br/> 65 (47‐78)<sup>d</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11.5 (1.2‐92.5)</p> <p>10 (2.7‐61)<sup>d</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012663-bbs2-0035" title="PepeP , GarufiA , PrioloG , CandianoG , PietropaoloF , PennisiM , et al. Prostate cancer detection at repeat biopsy: can pelvic phased array multiparametric MRI replace saturation biopsy?. Anticancer Research2013;33(3):1195‐200. ">Pepe 2013</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prior‐negative Bx</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>63 (49‐72)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11 (3.7‐45)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012663-bbs2-0040" title="ThompsonJE , VanLeeuwenPJ , MosesD , ShnierR , BrennerP , DelpradoW , et al. The diagnostic performance of multiparametric magnetic resonance imaging to detect significant prostate cancer. Journal of Urology2016;195(5):1428‐35. ">Thompson 2016</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bx‐naïve</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>63 (56‐67<sup>b</sup>) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.2 (3.7‐7.1<sup>b</sup>) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40 (30‐54<sup>b</sup>) </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012663-bbs2-0042" title="TsivianM , GuptaRT , TsivianE , QiP , MendezMH , AbernMR , et al. Assessing clinically significant prostate cancer: diagnostic properties of multiparametric magnetic resonance imaging compared to three‐dimensional transperineal template mapping histopathology. International Journal of Urology2017;24(2):137‐43. ">Tsivian 2017</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prior‐negative Bx</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65 (61‐69<sup>b</sup>) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.1 (5.1‐13.6<sup>b</sup>) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44 (32‐65<sup>b</sup>) </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012663-bbs2-0030" title="NafieS , MellonJK , DormerJP , KhanMA . The role of transperineal template prostate biopsies in prostate cancer diagnosis in biopsy naïve men with PSA less than 20 ng mL‐1. Prostate Cancer and Prostatic Diseases2014;17(2):170‐3. ">Nafie 2014</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bx‐naïve</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>67 (54‐84)<sup>a</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 (4‐18)<sup>a</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>58 (19‐165)<sup>a</sup> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012663-bbs2-0031" title="NafieS , WanisM , KhanM . The efficacy of transrectal ultrasound guided biopsy versus transperineal template biopsy of the prostate in diagnosing prostate cancer in men with previous negative transrectal ultrasound guided biopsy. Urology Journal2017;14(2):3008‐12. ">Nafie 2017</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prior‐negative Bx</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65 (50‐75)<sup>a</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.3 (4.4‐19)<sup>a</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59 (21‐152)<sup>a</sup> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012663-bbs2-0036" title="PloussardG , NicolaiewN , MarchandC , TerryS , VacherotF , VordosD , et al. Prospective evaluation of an extended 21‐core biopsy scheme as initial prostate cancer diagnostic strategy. European Urology2014;65(1):154‐61. ">Ploussard 2014</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bx‐naïve</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64 (8)<sup>a</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12.5 (7.2)<sup>a</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46 (25)<sup>a</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Bx:</b> biopsy; <b>NR:</b> not reported; <b>PSA:</b> prostate specific antigen </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p><sup>a</sup>Mean (standard deviation or range) (as opposed to median (range)).<br/> <sup>b</sup>Interquartile range (as opposed to range).<br/> <sup>c</sup>Results not reported per population type.<br/> <sup>d</sup>Reported per transperineal saturation biopsy‐positive (n = 71) and transperineal saturation biopsy‐negative men (n = 103), respectively. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Patient characteristics of the diagnostic test accuracy studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/full#CD012663-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012663-tbl-0010"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Study characteristics of the agreement analyses studies</span></div> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="4" rowspan="1" valign="top"> <p><b>Study</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>MRI</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="4" rowspan="1" valign="top"> <p><b>Index biopsy</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Target<br/> conditions</b> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Study</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Consecutive<br/> enrolment<br/> (study design<sup>a</sup>)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>N of<br/> participants</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Index tests</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>MRI‐scale;<br/> threshold</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MRI‐TBx</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>SBx</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MRI‐TBx &amp;<br/> SBx</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>ISUP<br/> grade<br/> (G)</b> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Technique</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Median N<br/> cores (range)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Independence</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Route</b> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012663-bbs2-0003" title="AlbertsAR , SchootsIG , BokhorstLP , DrostFH , VanLeendersGJ , KrestinGP , et al. Characteristics of prostate cancer found at fifth screening in the European Randomized Study of Screening for Prostate Cancer Rotterdam: can we selectively detect high‐grade prostate cancer with upfront multivariable risk stratification and magnetic resonance imaging?. European Urology 19 June 2017 [Epub ahead of print];S0302‐2838(17):30514‐6. ">Alberts 2017</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes<br/> (prospective) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bx‐naïve: 74<br/> Prior‐negative Bx: 84 </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MRI‐pathway<br/> vs. SBx </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1‐5; ≥ 3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Software</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> <p>(12‐12<sup>b</sup>) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Transrectal</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G = 1<br/> G ≥ 2<br/> G ≥ 3 </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012663-bbs2-0004" title="BoesenL , NørgaardN , LøgagerV , BalslevI , ThomsenHS . A prospective comparison of selective multiparametric magnetic resonance imaging fusion‐targeted and systematic transrectal ultrasound‐guided biopsies for detecting prostate cancer in men undergoing repeated biopsies. Urologia Internationalis2017;99(4):384‐91. ">Boesen 2017a</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear<br/> (prospective) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>206</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MRI‐pathway<br/> vs. SBx </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1‐5; ≥ 3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Software</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> <p>(10‐10)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Transrectal</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G = 1<br/> G ≥ 2<br/> G ≥ 3 </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012663-bbs2-0005" title="BoesenL , NørgaardN , LøgagerV , BalslevI , BisbjergR , ThestrupK‐C , Winther , et al. Assessment of the diagnostic accuracy of biparametric magnetic resonance imaging for prostate cancer in biopsy‐naïve men the Biparametric MRI for Detection of Prostate Cancer (BIDOC) Study. JAMA Network Open2018;1(2):e180219. ">Boesen 2018</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes<br/> (prospective) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1020</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MRI‐pathway<br/> vs. SBx </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1‐5; ≥ 3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Software</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10<sup>c</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Transrectal</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G = 1<br/> G ≥ 2<br/> G ≥ 3 </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012663-bbs2-0006" title="CastellucciR , Linares QuevedoAI , Sánchez GómezFJ , Díez RodríguezJ , CogornoL , Cogollos AcuñaI , et al. Prospective nonrandomized study of diagnostic accuracy comparing prostate cancer detection by transrectal ultrasound‐guided biopsy to magnetic resonance imaging with subsequent MRI‐guided biopsy in biopsy‐naïve patients. Minerva Urologica e Nefrologica2017;69(6):589‐95. ">Castellucci 2017</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes<br/> (prospective) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>168</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MRI‐pathway<br/> vs. SBx </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1‐5; ≥ 3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cognitive</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(8‐19)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Transrectal</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G = 1<br/> G ≥ 2<br/> G ≥ 3 </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012663-bbs2-0007" title="ChangCH , ChiuHC , LinWC , HoTL , ChangH , ChangYH , et al. The influence of serum prostate‐specific antigen on the accuracy of magnetic resonance imaging targeted biopsy versus saturation biopsy in patients with previous negative biopsy. BioMed Research International2017;2017:7617148. ">Chang 2017</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes<br/> (retrospective) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MRI‐pathway<br/> vs. SBx </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1‐5; ≥ 3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cognitive</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18 (16.2‐19.8<sup>b</sup>) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Transrectal</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G = 1<br/> G ≥ 2<br/> G ≥ 3 </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012663-bbs2-0008" title="ChenJ , YiXL , JiangLX , WangR , ZhaoJG , LiYH , et al. 3‐tesla magnetic resonance imaging improves the prostate cancer detection rate in transrectral ultrasound‑guided biopsy. Experimental and Therapeutic Medicine2015;9(1):207‐12. ">Chen 2015</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes<br/> (prospective) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>420</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MRI‐pathway<br/> vs. SBx </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1‐5; ≥ 3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cognitive</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12<sup>d</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Transperineal</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G ≥ 2</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012663-bbs2-0009" title="CoolDW , RomagnoliC , IzawaJI , ChinJ , GardiL , TessierD , et al. Comparison of prostate MRI‐3D transrectal ultrasound fusion biopsy for first‐time and repeat biopsy patients with previous atypical small acinar proliferation. Canadian Urological Association Journal2016;10(9‐10):342‐8. ">Cool 2016</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear<br/> (prospective) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bx‐naïve: 50<br/> Prior‐negative Bx: 50 </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MRI‐pathway<br/> vs. SBx </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Other</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Software</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12‐14<sup>e</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Transrectal</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G = 1<br/> G ≥ 2 </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012663-bbs2-0010" title="CostaDN , BlochBN , YaoDF , SandaMG , NgoL , GenegaEM , et al. Diagnosis of relevant prostate cancer using supplementary cores from magnetic resonance imaging‐prompted areas following multiple failed biopsies. Magnetic Resonance Imaging2013;31(6):947‐52. ">Costa 2013</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No<br/> (retrospective) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MRI‐pathway<br/> vs. SBx </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1‐5; ≥4</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cognitive</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Transrectal</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G ≥ 2<br/> G ≥ 3 </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012663-bbs2-0012" title="DelongchampsNB , PeyromaureM , SchullA , BeuvonF , BouazzaN , FlamT , et al. Prebiopsy magnetic resonance imaging and prostate cancer detection: comparison of random and targeted biopsies. The Journal of Urology2013;189(2):493‐9. ">Delongchamps 2013</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes<br/> (prospective) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>391</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MRI‐pathway<br/> vs. SBx </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TZ: 0‐4; ≥2<br/> PZ: 0‐10; ≥6 </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Software</p> <p>Cognitive</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> <p>(10‐12)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Transrectal</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G ≥ 2</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012663-bbs2-0014" title="FilsonCP , NatarajanS , MargolisDJ , HuangJ , LieuP , DoreyFJ , et al. Prostate cancer detection with magnetic resonance‐ultrasound fusion biopsy: the role of systematic and targeted biopsies. Cancer2016;122(6):884‐92. ">Filson 2016</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes<br/> (prospective) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bx‐naïve: 329<br/> Prior‐negative Bx: 324 </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MRI‐pathway<br/> vs. SBx </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1‐5; ≥ 3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Software</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Transrectal</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G ≥ 2<br/> G ≥ 3 </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012663-bbs2-0015" title="Garcia BennettJ , VilanovaJC , Guma PadroJ , ParadaD , ConejeroA . Evaluation of MR imaging‐targeted biopsies of the prostate in biopsy naïve patients. A single centre study. Diagnostic and Interventional Imaging2017;98(10):677‐84. ">Garcia Bennett 2017</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear<br/> (prospective) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MRI‐pathway<br/> vs. SBx </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1‐5; ≥ 3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cognitive</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Transperineal</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G = 1<br/> G ≥ 2<br/> G ≥ 3 </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012663-bbs2-0017" title="GrönbergH , EklundM , PickerW , AlyM , JäderlingF , AdolfssonJ , et al. Prostate cancer diagnostics using a combination of the Stockholm3 blood test and multiparametric magnetic resonance imaging. European Urology2018;74(6):722‐8. ">Grönberg 2018</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes<br/> (prospective) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bx‐naïve: 387<br/> Prior‐negative Bx: 145 </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MRI‐pathway<br/> vs. SBx </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1‐5; ≥ 3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Software</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> <p>(10‐12)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Transrectal</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G = 1<br/> G ≥ 2<br/> G ≥ 3 </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012663-bbs2-0021" title="JamborI , KähkönenE , TaimenP , MerisaariH , SaunavaaraJ , AlanenK , et al. Prebiopsy multiparametric 3T prostate MRI in patients with elevated PSA, normal digital rectal examination, and no previous biopsy. Journal of Magnetic Resonance Imaging2015;41(5):1394‐404. ">Jambor 2015</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear<br/> (unclear) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>53</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MRI‐pathway<br/> vs. SBx </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1‐5; ≥4</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cognitive</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Transrectal</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G = 1<br/> G ≥ 2<br/> G ≥ 3 </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012663-bbs2-0022" title="JamborI , BoströmPJ , TaimenP , SyvänenK , KähkönenE , KallajokiM , et al. Novel biparametric MRI and targeted biopsy improves risk stratification in men with a clinical suspicion of prostate cancer (IMPROD Trial). Journal of Magnetic Resonance Imaging2017;46(4):1089‐95. ">Jambor 2017</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear<br/> (prospective) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bx‐naïve: 134<br/> Prior‐negative Bx: 27 </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MRI‐pathway<br/> vs. SBx </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1‐5; ≥ 3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cognitive</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12<sup>c</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Transrectal</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G = 1<br/> G ≥ 2<br/> G ≥ 3 </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012663-bbs2-0024" title="KimEH , WeaverJK , ShettyAS , VetterJM , AndrioleGL , StropeSA . Magnetic resonance imaging provides added value to the prostate cancer prevention trial risk calculator for patients with estimated risk of high‐grade prostate cancer less than or equal to 10%. Urology2017;102:183‐9. ">Kim 2017</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear<br/> (retrospective) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bx‐naïve: 183<br/> Prior‐negative Bx: 154 </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MRI‐pathway<br/> vs. SBx </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1‐5; ≥4</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Software Cognitive</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14<sup>c</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Transrectal</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G = 1<br/> G ≥ 2<br/> G ≥ 3 </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012663-bbs2-0026" title="LeeDH , NamJK , ParkSW , LeeSS , HanJY , LeeSD , et al. Visually estimated MRI targeted prostate biopsy could improve the detection of significant prostate cancer in patients with a PSA level. Yonsei Medical Journal2016;57(3):565‐71. ">Lee 2016</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear<br/> (retrospective) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>76</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MRI‐pathway<br/> vs. SBx </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1‐4; ≥2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cognitive</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> <p>(12‐12)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Transrectal</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G = 1<br/> G ≥ 2<br/> G ≥ 3 </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012663-bbs2-0027" title="LeeDH , NamJK , LeeSS , HanJY , LeeJW , ChungMK , et al. Comparison of multiparametric and biparametric MRI in first round cognitive targeted prostate biopsy in patients with PSA levels under 10 ng/mL. Yonsei Medical Journal2017;58(5):994‐9. ">Lee 2017</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear<br/> (retrospective) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>123</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MRI‐pathway<br/> vs. SBx </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1‐4; ≥2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cognitive</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Transrectal</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G = 1<br/> G ≥ 2<br/> G ≥ 3 </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012663-bbs2-0032" title="OkcelikS , SoydanH , AtesF , BerberU , SayginH , SonmezG , et al. Evaluation of PCA3 and multiparametric MRI's: collective benefits before deciding initial prostate biopsy for patients with PSA level between 3‐10ng/mL. International Brazillian Journal of Urology2016;42(3):449‐55. ">Okcelik 2016</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear<br/> (prospective) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MRI‐pathway<br/> vs. SBx </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0‐1: ≥1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cognitive</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Transrectal</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G = 1<br/> G ≥ 2 </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012663-bbs2-0033" title="PanebiancoV , BarchettiF , SciarraA , CiardiA , IndinoEL , PapaliaR , et al. Multiparametric magnetic resonance imaging vs. standard care in men being evaluated for prostate cancer: a randomized study. Urologic Oncology2015;33(1):17.e1‐17.e7. ">Panebianco 2015</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes<br/> (prospective) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bx‐naïve: 570<br/> Prior‐negative Bx: 355 </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MRI‐pathway<br/> vs. SBx </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1‐5; ≥ 3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cognitive</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10, 14 or 45<sup>f</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Transrectal</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G = 1<br/> G ≥ 2<br/> G ≥ 3 </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012663-bbs2-0034" title="PeltierA , AounF , LemortM , KwizeraF , PaesmansM , VanVelthovenR . MRI‐targeted biopsies versus systematic transrectal ultrasound guided biopsies for the diagnosis of localized prostate cancer in biopsy naïve men. Biomed Research International2015;2015:571708. ">Peltier 2015</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes<br/> (prospective) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>110</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MRI‐pathway<br/> vs. SBx </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1‐4; ≥2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Software</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15<br/> (12‐18) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Transrectal</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G = 1<br/> G ≥ 2<br/> G ≥ 3 </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012663-bbs2-0037" title="PokornyMR , DeRooijM , DuncanE , SchröderFH , ParkinsonR , BarentszJO , et al. Prospective study of diagnostic accuracy comparing prostate cancer detection by transrectal ultrasound‐guided biopsy versus magnetic resonance (MR) imaging with subsequent MR‐guided biopsy in men without previous prostate biopsies. European Urology2014;66(1):22‐9. ">Pokorny 2014</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes<br/> (prospective) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>223</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MRI‐pathway<br/> vs. SBx </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1‐5; ≥ 3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>In‐bore</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Transrectal</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G = 1<br/> G ≥ 2<br/> G ≥ 3 </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012663-bbs2-0038" title="RouvièreO , PuechP , Renard‐PennaR , ClaudonM , RoyC , Mège‐LechavallierF , et al. MRI‐FIRST Investigators. Use of prostate systematic and targeted biopsy on the basis of multiparametric MRI in biopsy‐naïve patients (MRI‐FIRST): a prospective, multicentre, paired diagnostic study. Lancet Oncology2019;20(1):100‐9. ">Rouvière 2019a</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes<br/> (prospective) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>251</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MRI‐pathway<br/> vs. SBx </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1‐5; ≥ 3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Software</p> <p>Cognitive</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12.2<sup>c</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Transrectal</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G = 1<br/> G ≥ 2<br/> G ≥ 3 </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012663-bbs2-0039" title="SayRK . MRI‐ultrasound fusion targeted biopsy in men with prior negative prostate biopsy for prostate cancer [PhD thesis]. Vol. 2078, New Haven, CT: Yale Medicine Thesis Digital Library, 2016. [elischolar.library.yale.edu/ymtdl/2078] ">Say 2016</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes<br/> (retrospective) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>143</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MRI‐pathway<br/> vs. SBx </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1‐4; ≥2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Software</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12<sup>c</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Transrectal</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G = 1<br/> G ≥ 2<br/> G ≥ 3 </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012663-bbs2-0041" title="TonttilaPP , LanttoJ , PääkköE , PiippoU , KauppilaS , LammentaustaE , et al. Prebiopsy multiparametric magnetic resonance imaging for prostate cancer diagnosis in biopsy‐naïve men with suspected prostate cancer based on elevated prostate‐specific antigen values: results from a randomized prospective blinded controlled trial. European Urology2016;69(3):419‐25. ">Tonttilla 2016</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes<br/> (prospective) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>53</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MRI‐pathway<br/> vs. SBx </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1‐4; ≥2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cognitive</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> <p>(12‐14)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Transrectal</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G = 1<br/> G ≥ 2<br/> G ≥ 3 </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012663-bbs2-0043" title="Van derLeestMM , CornelEB , IsraëlB , HendriksRJ , PadhaniAR , HoogenboomM , et al. Head‐to‐head comparison of transrectal ultrasound‐guided prostate biopsy versus multiparametric prostate resonance imaging with subsequent magnetic resonance‐guided biopsy in biopsy‐naïve men with elevated prostate‐specific antigen: a large prospective multicenter clinical study. European Urology 23 November 2018 [Epub ahead of print];S0302‐2838(18):30880‐7. [DOI: 10.1016/j.eururo.2018.11.023] ">Van der Leest 2018</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes<br/> (prospective) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>626</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MRI‐pathway<br/> vs. SBx </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1‐5; ≥ 3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>In‐bore</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12<sup>c</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Transrectal</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G = 1<br/> G ≥ 2<br/> G ≥ 3 </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="10" rowspan="1" valign=""> <p><b>Bx:</b> biopsy; <b>ISUP G :</b> International Society of Urological Pathology grade; <b>MRI:</b> magnetic resonance imaging; <b>MRI‐pathway:</b> magnetic resonance imaging with or without magnetic resonance imaging‐targeted biopsy; <b>MRI‐TBx:</b> magnetic resonance imaging‐targeted biopsy; <b>N:</b> number; <b>NA:</b> not applicable; <b>PI‐RADS v1, v2:</b> Prostate Imaging Reporting Data System version 1 or 2; <b>PZ:</b> peripheral zone; <b>SBx:</b> systematic biopsy; <b>TSB:</b> transperineal saturation biopsy; <b>TTMB:</b> transperineal template mapping biopsy; <b>TZ:</b> transition zone </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="10"> <div class="table-footnote"> <p><sup>a</sup>Included participants were part of the same study cohort (no randomised populations were included).<br/> <sup>b</sup>Interquartile range (as opposed to range).<br/> <sup>c</sup>Mean value (as opposed to median value).<br/> <sup>d</sup>10 cores in peripheral zone, two cores in transition zone.<br/> <sup>e</sup>2 additional cores in transitional zone in prior‐negative Bx men.<br/> <sup>f</sup>10 and 14 in Bx‐naïve men with positive and negative MRI, respectively; 10 and 45 in prior‐negative Bx men with a positive and negative MRI, respectively. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Study characteristics of the agreement analyses studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/full#CD012663-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012663-tbl-0011"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Patient characteristics of the agreement analyses studies</span></div> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Population</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Median age<br/> (range)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Median PSA<br/> in ng/mL (range)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Median prostate<br/> volume in cm<sup>3</sup><br/> (range)</b> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012663-bbs2-0003" title="AlbertsAR , SchootsIG , BokhorstLP , DrostFH , VanLeendersGJ , KrestinGP , et al. Characteristics of prostate cancer found at fifth screening in the European Randomized Study of Screening for Prostate Cancer Rotterdam: can we selectively detect high‐grade prostate cancer with upfront multivariable risk stratification and magnetic resonance imaging?. European Urology 19 June 2017 [Epub ahead of print];S0302‐2838(17):30514‐6. ">Alberts 2017</a><sup>a</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bx‐naïve<br/> Prior‐negative Bx </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>73 (72‐74<sup>b</sup>) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.2 (3.4–5.8<sup>b</sup>) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>53 (37‐71<sup>b</sup>) </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012663-bbs2-0004" title="BoesenL , NørgaardN , LøgagerV , BalslevI , ThomsenHS . A prospective comparison of selective multiparametric magnetic resonance imaging fusion‐targeted and systematic transrectal ultrasound‐guided biopsies for detecting prostate cancer in men undergoing repeated biopsies. Urologia Internationalis2017;99(4):384‐91. ">Boesen 2017a</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prior‐negative Bx</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65 (58‐68<sup>b</sup>) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12.8 (8.9‐19.6<sup>b</sup>) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012663-bbs2-0005" title="BoesenL , NørgaardN , LøgagerV , BalslevI , BisbjergR , ThestrupK‐C , Winther , et al. Assessment of the diagnostic accuracy of biparametric magnetic resonance imaging for prostate cancer in biopsy‐naïve men the Biparametric MRI for Detection of Prostate Cancer (BIDOC) Study. JAMA Network Open2018;1(2):e180219. ">Boesen 2018</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bx‐naïve</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>67 (61‐71<sup>b</sup>) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 (5.7‐13<sup>b</sup>) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>53 (40‐72<sup>b</sup>) </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012663-bbs2-0006" title="CastellucciR , Linares QuevedoAI , Sánchez GómezFJ , Díez RodríguezJ , CogornoL , Cogollos AcuñaI , et al. Prospective nonrandomized study of diagnostic accuracy comparing prostate cancer detection by transrectal ultrasound‐guided biopsy to magnetic resonance imaging with subsequent MRI‐guided biopsy in biopsy‐naïve patients. Minerva Urologica e Nefrologica2017;69(6):589‐95. ">Castellucci 2017</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bx‐naïve</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61 (8)<sup>c</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.3 (6.1)<sup>c</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49 (7)<sup>c</sup> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012663-bbs2-0007" title="ChangCH , ChiuHC , LinWC , HoTL , ChangH , ChangYH , et al. The influence of serum prostate‐specific antigen on the accuracy of magnetic resonance imaging targeted biopsy versus saturation biopsy in patients with previous negative biopsy. BioMed Research International2017;2017:7617148. ">Chang 2017</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prior‐negative Bx</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64 (60‐68<sup>b</sup>) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.9 (7.2‐14.7<sup>b</sup>) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48 (34‐63<sup>b</sup>) </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012663-bbs2-0008" title="ChenJ , YiXL , JiangLX , WangR , ZhaoJG , LiYH , et al. 3‐tesla magnetic resonance imaging improves the prostate cancer detection rate in transrectral ultrasound‑guided biopsy. Experimental and Therapeutic Medicine2015;9(1):207‐12. ">Chen 2015</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bx‐naïve</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>67 (45‐91)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.7 (2.4‐35.7)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45 (21‐83)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012663-bbs2-0009" title="CoolDW , RomagnoliC , IzawaJI , ChinJ , GardiL , TessierD , et al. Comparison of prostate MRI‐3D transrectal ultrasound fusion biopsy for first‐time and repeat biopsy patients with previous atypical small acinar proliferation. Canadian Urological Association Journal2016;10(9‐10):342‐8. ">Cool 2016</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bx‐naïve<br/> Prior‐negative Bx </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59 (8)<sup>c</sup><br/> 62 (7)<sup>c</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.0 (3.5)<sup>c</sup><br/> 7.9 (3.9)<sup>c</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38 (18)<sup>c</sup><br/> 56 (27)<sup>c</sup> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012663-bbs2-0010" title="CostaDN , BlochBN , YaoDF , SandaMG , NgoL , GenegaEM , et al. Diagnosis of relevant prostate cancer using supplementary cores from magnetic resonance imaging‐prompted areas following multiple failed biopsies. Magnetic Resonance Imaging2013;31(6):947‐52. ">Costa 2013</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prior‐negative Bx</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64 (48‐77)<sup>c</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14.4 (1.8‐33.1)<sup>c</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012663-bbs2-0012" title="DelongchampsNB , PeyromaureM , SchullA , BeuvonF , BouazzaN , FlamT , et al. Prebiopsy magnetic resonance imaging and prostate cancer detection: comparison of random and targeted biopsies. The Journal of Urology2013;189(2):493‐9. ">Delongchamps 2013</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bx‐naïve</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64 (7)<sup>c</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.5 (3.9)<sup>c</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56 (30)<sup>c</sup> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012663-bbs2-0014" title="FilsonCP , NatarajanS , MargolisDJ , HuangJ , LieuP , DoreyFJ , et al. Prostate cancer detection with magnetic resonance‐ultrasound fusion biopsy: the role of systematic and targeted biopsies. Cancer2016;122(6):884‐92. ">Filson 2016</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bx‐naïve<br/> Prior‐negative Bx </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64 (59‐69<sup>b</sup>)<br/> 66 (59‐70<sup>b</sup>) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.8 (4.4‐8.1<sup>b</sup>)<br/> 7.6 (5‐11.5<sup>b</sup>) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45(33‐62<sup>b</sup>)<br/> 58 (40‐84<sup>b</sup>) </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012663-bbs2-0015" title="Garcia BennettJ , VilanovaJC , Guma PadroJ , ParadaD , ConejeroA . Evaluation of MR imaging‐targeted biopsies of the prostate in biopsy naïve patients. A single centre study. Diagnostic and Interventional Imaging2017;98(10):677‐84. ">Garcia Bennett 2017</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bx‐naïve</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64 (6.7)<sup>c</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.2 (6‐9.4<sup>b</sup>) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48 (35‐63<sup>b</sup>) </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012663-bbs2-0017" title="GrönbergH , EklundM , PickerW , AlyM , JäderlingF , AdolfssonJ , et al. Prostate cancer diagnostics using a combination of the Stockholm3 blood test and multiparametric magnetic resonance imaging. European Urology2018;74(6):722‐8. ">Grönberg 2018</a><sup>a</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bx‐naïve<br/> Prior‐negative Bx </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64 (45–74)<sup>c</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.3 (4.4<sup>b</sup>) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(32‐70)<sup>d</sup> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012663-bbs2-0021" title="JamborI , KähkönenE , TaimenP , MerisaariH , SaunavaaraJ , AlanenK , et al. Prebiopsy multiparametric 3T prostate MRI in patients with elevated PSA, normal digital rectal examination, and no previous biopsy. Journal of Magnetic Resonance Imaging2015;41(5):1394‐404. ">Jambor 2015</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bx‐naïve</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66 (47‐76)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.4 (4‐14)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42 (17‐107)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012663-bbs2-0022" title="JamborI , BoströmPJ , TaimenP , SyvänenK , KähkönenE , KallajokiM , et al. Novel biparametric MRI and targeted biopsy improves risk stratification in men with a clinical suspicion of prostate cancer (IMPROD Trial). Journal of Magnetic Resonance Imaging2017;46(4):1089‐95. ">Jambor 2017</a><sup>a</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mixed</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65 (6)<sup>c</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.5 (5.7‐9.6<sup>b</sup>) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37 (28‐49<sup>b</sup>) </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012663-bbs2-0024" title="KimEH , WeaverJK , ShettyAS , VetterJM , AndrioleGL , StropeSA . Magnetic resonance imaging provides added value to the prostate cancer prevention trial risk calculator for patients with estimated risk of high‐grade prostate cancer less than or equal to 10%. Urology2017;102:183‐9. ">Kim 2017</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bx‐naïve<br/> Prior‐negative Bx </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64 (7)<sup>c</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.2 (15.1)<sup>c</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012663-bbs2-0026" title="LeeDH , NamJK , ParkSW , LeeSS , HanJY , LeeSD , et al. Visually estimated MRI targeted prostate biopsy could improve the detection of significant prostate cancer in patients with a PSA level. Yonsei Medical Journal2016;57(3):565‐71. ">Lee 2016</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bx‐naïve</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66 (43‐83)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.4 (3.3‐9.8)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39 (17‐127)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012663-bbs2-0027" title="LeeDH , NamJK , LeeSS , HanJY , LeeJW , ChungMK , et al. Comparison of multiparametric and biparametric MRI in first round cognitive targeted prostate biopsy in patients with PSA levels under 10 ng/mL. Yonsei Medical Journal2017;58(5):994‐9. ">Lee 2017</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bx‐naïve</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62 (10)<sup>c</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.4 (1.8)<sup>c</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40 (18)<sup>c</sup> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012663-bbs2-0032" title="OkcelikS , SoydanH , AtesF , BerberU , SayginH , SonmezG , et al. Evaluation of PCA3 and multiparametric MRI's: collective benefits before deciding initial prostate biopsy for patients with PSA level between 3‐10ng/mL. International Brazillian Journal of Urology2016;42(3):449‐55. ">Okcelik 2016</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bx‐naïve</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62 (43‐79)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 (3‐8.9)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45 (17‐93)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012663-bbs2-0033" title="PanebiancoV , BarchettiF , SciarraA , CiardiA , IndinoEL , PapaliaR , et al. Multiparametric magnetic resonance imaging vs. standard care in men being evaluated for prostate cancer: a randomized study. Urologic Oncology2015;33(1):17.e1‐17.e7. ">Panebianco 2015</a><sup>a</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bx‐naïve<br/> Prior‐negative Bx </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64 (51‐82)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012663-bbs2-0034" title="PeltierA , AounF , LemortM , KwizeraF , PaesmansM , VanVelthovenR . MRI‐targeted biopsies versus systematic transrectal ultrasound guided biopsies for the diagnosis of localized prostate cancer in biopsy naïve men. Biomed Research International2015;2015:571708. ">Peltier 2015</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bx‐naïve</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65 (7)<sup>c</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.4 (6.3)<sup>c</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49 (22)<sup>c</sup> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012663-bbs2-0037" title="PokornyMR , DeRooijM , DuncanE , SchröderFH , ParkinsonR , BarentszJO , et al. Prospective study of diagnostic accuracy comparing prostate cancer detection by transrectal ultrasound‐guided biopsy versus magnetic resonance (MR) imaging with subsequent MR‐guided biopsy in men without previous prostate biopsies. European Urology2014;66(1):22‐9. ">Pokorny 2014</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bx‐naïve</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>63 (57‐68<sup>b</sup>) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.3 (4.1‐6.6<sup>b</sup>) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41 (30‐59<sup>b</sup>) </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012663-bbs2-0038" title="RouvièreO , PuechP , Renard‐PennaR , ClaudonM , RoyC , Mège‐LechavallierF , et al. MRI‐FIRST Investigators. Use of prostate systematic and targeted biopsy on the basis of multiparametric MRI in biopsy‐naïve patients (MRI‐FIRST): a prospective, multicentre, paired diagnostic study. Lancet Oncology2019;20(1):100‐9. ">Rouvière 2019a</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bx‐naïve</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64 (59‐68<sup>b</sup>) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.5 (5.6‐9.6<sup>b</sup>) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50 (38‐63<sup>b</sup>) </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012663-bbs2-0039" title="SayRK . MRI‐ultrasound fusion targeted biopsy in men with prior negative prostate biopsy for prostate cancer [PhD thesis]. Vol. 2078, New Haven, CT: Yale Medicine Thesis Digital Library, 2016. [elischolar.library.yale.edu/ymtdl/2078] ">Say 2016</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prior‐negative Bx</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64 (47‐82)<sup>c</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11.59 (0.4‐96.9)<sup>c</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>69 (17‐309)<sup>c</sup> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012663-bbs2-0041" title="TonttilaPP , LanttoJ , PääkköE , PiippoU , KauppilaS , LammentaustaE , et al. Prebiopsy multiparametric magnetic resonance imaging for prostate cancer diagnosis in biopsy‐naïve men with suspected prostate cancer based on elevated prostate‐specific antigen values: results from a randomized prospective blinded controlled trial. European Urology2016;69(3):419‐25. ">Tonttilla 2016</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bx‐naïve</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>63 (60‐66<sup>b</sup>) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.1 (4.2‐9.9<sup>b</sup>) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28 (24‐37<sup>b</sup>) </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012663-bbs2-0043" title="Van derLeestMM , CornelEB , IsraëlB , HendriksRJ , PadhaniAR , HoogenboomM , et al. Head‐to‐head comparison of transrectal ultrasound‐guided prostate biopsy versus multiparametric prostate resonance imaging with subsequent magnetic resonance‐guided biopsy in biopsy‐naïve men with elevated prostate‐specific antigen: a large prospective multicenter clinical study. European Urology 23 November 2018 [Epub ahead of print];S0302‐2838(18):30880‐7. [DOI: 10.1016/j.eururo.2018.11.023] ">Van der Leest 2018</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bx‐naïve</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65 (59‐68<sup>b</sup>) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.4 (4.6‐8.2<sup>b</sup>) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55 (41‐77<sup>b</sup>) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Bx:</b> biopsy; <b>NR:</b> not reported; <b>PSA:</b> prostate specific antigen </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p><sup>a</sup>Results not reported per population type.<br/> <sup>b</sup>Interquartile range (as apposed to range).<br/> <sup>c</sup>Mean (SD or range) (as opposed to median (range)).<br/> <sup>d</sup>Range of interquartile ranges across three centres. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Patient characteristics of the agreement analyses studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/full#CD012663-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012663-tbl-0012"> <div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Diagnostic accuracy of the index tests</span></div> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>Diagnostic accuracy of the index tests verified by template‐guided biopsy as the reference standard</b> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Index test</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MRI<br/> population<sup>a</sup> </b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Target<br/> condition</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>N participants<br/> (studies)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Proportion<br/> negative MRI<br/> (95% CI)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sensitivity<br/> (95% CI)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Specificity<br/> (95% CI)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>P value</b> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>MRI</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Positive + negative</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G = 1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1764 (10)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.28 (0.20 to 0.38)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.70 (0.59 to 0.80)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.27 (0.19 to 0.37)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P &lt; 0.01<sup>b</sup> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>G ≥ 1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1764 (10)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.39 (0.30 to 0.50)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.84 (0.74 to 0.90)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.39 (0.30 to 0.50)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G ≥ 2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3091 (12)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.29 (0.22 to 0.37)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.91 (0.83 to 0.95)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.37 (0.29 to 0.46)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P &lt; 0.01<sup>b</sup> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G ≥ 3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1438 (7)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.31 (0.21 to 0.42)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.95 (0.87 to 0.99)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.35 (0.26 to 0.46)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ID</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>MRI‐TBx</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Positive</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G = 1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>497 (5)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.51 (0.21 to 0.81)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.00 (0.77 to 1.00)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>G ≥ 1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>611 (6)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.71 (0.61 to 0.80)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.93 (0.87 to 0.96)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G ≥ 2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1553 (8)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.80 (0.69 to 0.87)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.94 (0.90 to 0.97)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G ≥ 3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>428 (3)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ID</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ID</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ID</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>MRI‐pathway</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Positive + negative</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G = 1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>681 (5)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.24 (0.16 to 0.36)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.34 (0.19 to 0.53)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.00 (0.90 to 1.00)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P = 0.52<sup>c</sup> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>G ≥ 1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>844 (6)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.28 (0.21 to 0.35)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.58 (0.52 to 0.65)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.96 (0.92 to 0.98)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G ≥ 2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2257 (8)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.29 (0.24 to 0.35)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.72 (0.60 to 0.82)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.96 (0.94 to 0.98)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P = 0.06<sup>c</sup> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G ≥ 3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>604 (3)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.29 (0.26 to 0.33)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ID</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ID</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ID</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>SBx</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>NA</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G = 1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3421 (4)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.55 (0.25 to 0.83)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.99 (0.81 to 1.00)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>G ≥ 1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3421 (4)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.65 (0.31 to 0.88)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.00 (0.88 to 1.00)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G ≥ 2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3421 (4)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.63 (0.19 to 0.93)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.00 (0.91 to 1.00)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G ≥ 3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>626 (2)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ID</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ID</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ID</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>CI:</b> confidence interval; <b>G:</b> International Society of Urological Pathology grade; <b>ID:</b> inadequate data; <b>MRI:</b> magnetic resonance imaging; <b>MRI‐pathway:</b> magnetic resonance imaging with or without magnetic resonance imaging‐targeted biopsy; <b>MRI‐TBx:</b> magnetic resonance imaging‐targeted biopsy; <b>N:</b> number; <b>NA:</b> not applicable; <b>SBx:</b> systematic biopsy </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p><sup>a</sup>Data did not allow differentiation between the mix of included participants (biopsy‐naïve and prior‐negative biopsy men).<br/> <sup>b</sup>Comparing sensitivity between MRI and the MRI‐pathway.<br/> <sup>c</sup>Comparing sensitivity between the MRI‐pathway and SBx. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Diagnostic accuracy of the index tests</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/full#CD012663-tbl-0012">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012663-tbl-0013"> <div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">Predictive values of the index tests and prevalences</span></div> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Predictive values of the index tests and prostate cancer prevalences</b> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Test</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MRI<br/> population<sup>a</sup> </b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Target<br/> condition</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>N participants<br/> (studies)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Prevalence<sup>b</sup><br/> (95% CI)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>NPV<sup>c</sup><br/> (95% CI)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>PPV<sup>c</sup><br/> (95% CI)</b> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>MRI</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Positive + negative</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G = 1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1764 (10)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.20 (0.17 to 0.23)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.79 (0.74 to 0.82)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.20 (0.18 to 0.21)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G ≥ 2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3091 (12)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.29 (0.22 to 0.38)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.91 (0.86 to 0.94)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.37 (0.35 to 0.39)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G ≥ 3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1438 (7)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.14 (0.08 to 0.23)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.98 (0.95 to 0.99)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.19 (0.17 to 0.21)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>MRI‐TBx</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Positive</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G = 1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>497 (5)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.22 (0.19 to 0.26)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.88 (0.78 to 0.94)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.98 (0.23 to 1.00)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G ≥ 2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1553 (8)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.34 (0.24 to 0.46)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.90 (0.85 to 0.93)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.88 (0.80 to 0.92)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G ≥ 3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>428 (3)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.21 (0.12 to 0.35)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ID</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ID</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>MRI‐pathway</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Positive + negative</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G = 1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>681 (5)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.21 (0.18 to 0.24)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.85 (0.81 to 0.88)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.95 (0.38 to 1.00)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G ≥ 2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2257 (8)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.26 (0.18 to 0.36)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.91 (0.87 to 0.94)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.88 (0.80 to 0.92)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G ≥ 3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>604 (3)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.16 (0.09 to 0.27)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ID</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ID</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>SBx</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>NA</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G = 1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3421 (4)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.20 (0.16 to 0.25)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.90 (0.81 to 0.95)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.94 (0.37 to 1.00)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G ≥ 2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3421 (4)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.34 (0.21 to 0.51)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.84 (0.60 to 0.95)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.00 (0.76 to 1.00)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G ≥ 3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>626 (2)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.10 (0.08 to 0.12)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ID</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ID</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>CI:</b> confidence interval; <b>G:</b> International Society of Urological Pathology grade; <b>ID:</b> inadequate data; <b>MRI:</b> magnetic resonance imaging; <b>MRI‐pathway:</b> magnetic resonance imaging with or without magnetic resonance imaging‐targeted biopsy; <b>MRI‐TBx:</b> magnetic resonance imaging‐targeted biopsy; <b>NA:</b> not applicable; <b>NPV:</b> negative predictive value; <b>PPV:</b> positive predictive value; <b>SBx</b>: systematic biopsy </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Data did not allow differentiation between the mix of included participants (biopsy‐naïve and prior‐negative biopsy men).<br/> <sup>b</sup>Prevalence is pooled estimate of all detected cancer by template‐guided biopsy.<br/> <sup>c</sup>Based on the Bayes’ theorem using the point estimates and 95% confidence intervals of the pooled positive and negative likelihood ratio and the point estimate of the prevalence. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">Predictive values of the index tests and prevalences</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/full#CD012663-tbl-0013">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012663-tbl-0014"> <div class="table-heading"><span class="table-label">Table 8.</span> <span class="table-title">MRI‐positivity threshold effect</span></div> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>MRI‐positivity threshold effect, verified by template‐guided biopsy as the reference standard, with threshold ≥ 3and ≥ 4 out of 5 for identifying prostate cancer</b> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MRI threshold</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Target<br/> condition</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>N participants<br/> (studies)<sup>a</sup> </b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Proportion<br/> negative MRI<br/> (95% CI)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sensitivity<br/> (95% CI)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Specificity<br/> (95% CI)</b> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>≥ 3/5</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G = 1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1647 (8)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.29 (0.21 to 0.40)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.68 (0.57 to 0.77)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.28 (0.19 to 0.39)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G ≥ 2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2974 (10)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.30 (0.23 to 0.38)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.89 (0.82 to 0.94)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.39 (0.32 to 0.47)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G ≥ 3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1438 (7)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.31 (0.21 to 0.42)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.96 (0.87 to 0.99)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.35 (0.26 to 0.46)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>≥ 4/5</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G = 1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>834 (4)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.60 (0.38 to 0.78)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.26 (0.16 to 0.40)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.57 (0.36 to 0.76)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G ≥ 2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1083 (5)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.59 (0.43 to 0.74)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.72 (0.52 to 0.86)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.78 (0.68 to 0.86)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G ≥ 3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>834 (4)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.60 (0.38 to 0.78)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.86 (0.51 to 0.97)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.68 (0.51 to 0.81)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>CI:</b> confidence interval; <b>G:</b> International Society of Urological Pathology grade; <b>MRI:</b> magnetic resonance imaging; <b>N:</b> number </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Data did not allow differentiation between the mix of included participants (biopsy‐naïve and prior‐negative biopsy men). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 8.</span> <span class="table-title">MRI‐positivity threshold effect</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/full#CD012663-tbl-0014">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012663-tbl-0015"> <div class="table-heading"><span class="table-label">Table 9.</span> <span class="table-title">Agreement analysis: detection ratio MRI‐pathway versus systematic biopsy</span></div> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Population</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Target</b> </p> <p><b>condition</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>N participants</b> </p> <p><b>(studies)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Proportion prostate cancer detected in % (95% CI)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Detection ratio<sup>b</sup><br/> (95% CI)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Difference<br/> between<br/> populations,<br/> P value<sup>c</sup> </b> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Biopsy status</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>MRI, proportion in % (95% CI)<sup>a</sup> </b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MRI‐pathway and SBx combined (total cancer detected)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MRI‐pathway</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>SBx</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>MRI‐pathway versus SBx</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>P value</b> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="8" valign=""> <p><b>Mixed<sup>d</sup> </b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>Positive + negative<br/> 100 (100 to 100) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>G = 1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5442 (21)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25.6 (22.8 to 28.8)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12.3 (10.1 to 15.1)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20.8 (18.0 to 24.1)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.61 (0.52 to 0.71)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P &lt; 0.01</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>G ≥ 1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6524 (24)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50.2 (46.4 to 54.3)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>37.9 (33.4 to 42.6)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>43.3 (39.1 to 47.8)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.88 (0.81 to 0.95)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P &lt; 0.01</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>G ≥ 2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6944 (25)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26.7 (23.3 to 30.7)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22.9 (19.5 to 26.8)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19.4 (15.9 to 23.5)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.12 (1.02 to 1.23)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.01</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>G ≥ 3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5981 (21)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15.0 (12.7 to 18.0)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12.7 (10.5 to 15.6)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.7 (7.5 to 12.7)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.20 (1.06 to 1.36)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P &lt; 0.01</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>Positive<br/> 67.6 (60.2 to 74.3) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>G = 1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3460 (19)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29.5 (26.0 to 33.8)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18.8 (15.2 to 23.4)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22.4 (18.9 to 26.9)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.85 (0.75 to 0.97)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.01</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>G ≥ 1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3998 (20)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>68.0 (62.3 to 73.5)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>61.1 (54.1 to 67.7)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>58.9 (51.5 to 65.9)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.03 (0.95 to 1.10)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.52</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>G ≥ 2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3998 (20)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42.6 (37.6 to 48.1)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37.9 (32.7 to 43.7)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31.6 (26.2 to 37.9)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.17 (1.07 to 1.28)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P &lt; 0.01</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>G ≥ 3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3902 (18)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24.2 (20.9 to 28.1)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21.0 (17.8 to 24.8)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16.3 (13.1 to 20.3)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.24 (1.11 to 1.38)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P &lt; 0.01</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="8" valign=""> <p><b>Biopsy‐naïve</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>Positive + negative<br/> 100 (100 to 100) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>G = 1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4079 (17)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27.2 (23.9 to 31.1)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13.5 (10.7 to 17.2)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22.4 (19.1 to 26.3)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.63 (0.54 to 0.74)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P &lt; 0.01</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.91</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>G ≥ 1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4799 (19)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>53.2 (48.7 to 57.9)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>41.0 (35.8 to 46.4)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>47.8 (42.8 to 52.9)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.85 (0.77 to 0.93)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P &lt; 0.01</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.12</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>G ≥ 2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5219 (20)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27.7 (23.7 to 32.6)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23.4 (19.3 to 28.1)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21.4 (17.2 to 26.5)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.05 (0.95 to 1.16)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.35</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P &lt; 0.01</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>G ≥ 3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4306 (16)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15.5 (12.6 to 19.5)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12.7 (9.9 to 16.5)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.8 (8.0 to 14.8)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.09 (0.94 to 1.26)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.27</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P &lt; 0.01</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>Positive<br/> 67.0 (58.7 to 74.4) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>G = 1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2682 (16)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31.8 (27.7 to 36.9)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21.3 (17.0 to 26.9)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23.7 (19.6 to 29.1)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.85 (0.74 to 0.98)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.03</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.35</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>G ≥ 1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2955 (17)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>70.9 (65.0 to 76.6)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63.7 (56.3 to 70.6)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63.8 (56.2 to 70.7)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.99 (0.92 to 1.08)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.88</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.05</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>G ≥ 2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2955 (17)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44.2 (38.6 to 50.4)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39.2 (33.3 to 45.7)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34.4 (28.3 to 41.3)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.12 (1.01 to 1.23)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.03</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P &lt; 0.01</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>G ≥ 3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2899 (15)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24.8 (21.0 to 29.6)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21.2 (17.4 to 25.7)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17.5 (13.8 to 22.3)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.16 (1.02 to 1.31)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.02</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P &lt; 0.01</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="8" valign=""> <p><b>Prior‐negative</b> </p> <p><b>biopsy</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>Positive + negative<br/> 100 (100 to 100) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>G = 1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1202 (8)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23.0 (18.0 to 30.2)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.9 (7.9 to 15.3)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17.8 (12.7 to 25.2)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.62 (0.44 to 0.88)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P &lt; 0.01</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.91</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>G ≥ 1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1564 (10)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40.7 (35.1 to 47.2)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30.0 (24.1 to 37.0)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30.3 (24.3 to 37.5)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.97 (0.85 to 1.11)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.70</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.12</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>G ≥ 2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1564 (10)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22.8 (20.0 to 26.2)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20.5 (17.7 to 23.5)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13.2 (10.8 to 16.4)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.44 (1.19 to 1.75)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P &lt; 0.01</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P &lt; 0.01</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>G ≥ 3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1514 (9)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12.6 (10.5 to 15.6)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11.5 (9.4 to 14.2)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.3 (4.4 to 9.1)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.64 (1.27 to 2.11)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P &lt; 0.01</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P &lt; 0.01</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>Positive<br/> 69.6 (54.7 to 81.3) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>G = 1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>655 (7)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27.9 (22.1 to 36.2)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18.2 (12.8 to 26.7)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18.9 (13.3 to 27.5)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.03 (0.89 to 1.18)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.71</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.35</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>G ≥ 1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>920 (8)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>54.8 (44.6 to 66.4)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48.5 (37.0 to 61.5)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>39.4 (27.1 to 53.9)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.16 (1.02 to 1.32)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.02</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.05</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>G ≥ 2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>920 (8)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31.3 (27.4 to 36.1)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28.6 (24.7 to 33.1)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18.3 (15.1 to 22.5)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.49 (1.22 to 1.82)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P &lt; 0.01</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P &lt; 0.01</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>G ≥ 3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>880 (7)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17.9 (14.3 to 22.9)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16.7 (13.1 to 21.5)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.4 (6.4 to 14.2)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.65 (1.30 to 2.09)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P &lt; 0.01</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P &lt; 0.01</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="10" rowspan="1" valign=""> <p><b>CI:</b> confidence interval; <b>G:</b> International Society of Urological Pathology grade; <b>MRI:</b> magnetic resonance imaging; <b>MRI‐pathway:</b> magnetic resonance imaging with or without magnetic resonance imaging‐targeted biopsy; <b>MRI‐TBx:</b> magnetic resonance imaging‐targeted biopsy; <b>N:</b> number; <b>SBx:</b> systematic biopsy </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="10"> <div class="table-footnote"> <p><sup>a</sup>Proportion of participants with a positive or negative magnetic resonance imaging result, based on the studies reporting grade 2 or higher.<br/> <sup>b</sup>Detection ratio is detection rate of magnetic resonance imaging‐pathway divided by detection rate of systematic biopsy; the detection rate is the pooled number of positive results of the test divided by the pooled total number of positive results from both tests.<br/> <sup>c</sup>Evaluating the difference in detection ratio's between the populations (biopsy‐naïve men versus prior‐negative biopsy) for each target condition.<br/> <sup>d</sup>Mixed: biopsy‐naïve and prior‐negative biopsy men. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 9.</span> <span class="table-title">Agreement analysis: detection ratio MRI‐pathway versus systematic biopsy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/full#CD012663-tbl-0015">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012663-tbl-0016"> <div class="table-heading"><span class="table-label">Table 10.</span> <span class="table-title">Agreement analysis: added values of MRI‐pathway and systematic biopsy</span></div> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Population</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Target<br/> condition</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>N participants<br/> (studies)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Proportion prostate cancer detected in % (95% CI)</b> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Biopsy status</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MRI,<br/> proportion in % (95% CI)<sup>a</sup> </b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MRI‐pathway and SBx combined (total cancer detected)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MRI‐pathway</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>SBx</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Both MRI‐pathway and SBx</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Only MRI‐pathway (added value<sup>b</sup>)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Only SBx (added value<sup>b</sup>)</b> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="12" valign=""> <p><b>Mixed<sup>c</sup> </b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>Positive + negative<br/> 100 (100 to 100) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>G = 1<sup>d</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5442 (21)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19.5 (16.9 to 22.7)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10.3 (8.1 to 13.1)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16.8 (14.2 to 19.9)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.6 (5.5 to 10.2)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.7 (1.8 to 4.0)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9.2 (7.4 to 11.4)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>G ≥ 1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6524 (24)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50.2 (46.4 to 54.3)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>37.9 (33.4 to 42.6)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>43.3 (39.1 to 47.8)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30.9 (26.3 to 36.0)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6.9 (5.2 to 9.2)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12.4 (10.2 to 14.9)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>G ≥ 2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6944 (25)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26.7 (23.3 to 30.7)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22.9 (19.5 to 26.9)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19.4 (15.9 to 23.6)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15.6 (12.2 to 19.6)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.3 (5.9 to 9.0)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.8 (2.5 to 5.7)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>G ≥ 3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5981 (21)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15.0 (12.7 to 18.0)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12.7 (10.5 to 15.6)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9.7 (7.5 to 12.7)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.4 (5.3 to 10.2)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.3 (4.3 to 6.5)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.3 (1.4 to 3.7)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>Positive<br/> 67.6 (60.2 to 74.3) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>G = 1<sup>d</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3460 (19)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19.7 (15.9 to 24.7)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15.8 (12.2 to 20.7)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15.8 (12 to 20.8)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12.0 (8.4 to 16.8)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.9 (2.6 to 5.7)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.8 (2.3 to 6.2)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>G ≥ 1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3998 (20)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>68.0 (62.3 to 73.5)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>61.1 (54.1 to 67.7)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>58.9 (51.5 to 65.9)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52.0 (43.6 to 59.9)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9.1 (5.9 to 13.5)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6.9 (4.6 to 10.1)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>G ≥ 2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3998 (20)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42.6 (37.6 to 48.1)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>37.9 (32.7 to 43.7)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31.6 (26.2 to 37.9)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27.0 (21.4 to 33.4)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10.9 (8.5 to 13.9)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.6 (2.9 to 7.2)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>G ≥ 3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3902 (18)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24.2 (20.9 to 28.1)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21 (17.8 to 24.8)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16.3 (13.1 to 20.3)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13.2 (10.1 to 16.9)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.9 (6.3 to 9.7)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.1 (1.9 to 5.2)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>Negative<br/> 32.4 (25.7 to 39.8) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>G = 1<sup>d</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1666 (19)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16.8 (12.9 to 21.6)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16.8 (12.9 to 21.6)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16.8 (12.9 to 21.6)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>G ≥ 1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1781 (20)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23.1 (19.7 to 26.9)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23.1 (19.7 to 26.9)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23.1 (19.7 to 26.9)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>G ≥ 2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1781 (20)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.2 (5.3 to 9.8)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.2 (5.3 to 9.8)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.2 (5.3 to 9.8)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>G ≥ 3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1725 (18)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.7 (1.6 to 4.6)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.7 (1.6 to 4.6)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.7 (1.6 to 4.6)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="12" valign="top"> <p><b>Biopsy‐naïve</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Positive + negative<br/> 100 (100 to 100) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G = 1<sup>d</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4079 (17)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20.9 (18.0 to 24.7)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11.2 (8.4 to 14.9)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18.5 (15.6 to 22.2)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.8 (6.2 to 12.3)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.4 (1.4 to 4.0)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.8 (8.0 to 11.8)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>G ≥ 1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4799 (19)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>53.2 (48.7 to 57.9)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>41.0 (35.8 to 46.4)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>47.8 (42.8 to 52.9)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35.6 (30.2 to 41.2)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.4 (3.6 to 8.0)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12.2 (8.7 to 16.7)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G ≥ 2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5219 (20)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27.7 (23.7 to 32.6)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23.4 (19.4 to 28.2)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21.4 (17.2 to 26.5)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17.1 (13.0 to 22)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.3 (4.8 to 8.2)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.3 (2.6 to 6.9)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G ≥ 3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4306 (16)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15.5 (12.6 to 19.5)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12.7 (9.9 to 16.5)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.8 (8.0 to 14.8)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.0 (5.4 to 11.6)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.7 (3.5 to 6.3)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.8 (1.7 to 4.8)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Positive<br/> 67.0 (58.7 to 74.4) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G = 1<sup>d</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2682 (16)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21.1 (16.7 to 27.1)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17.0 (12.6 to 22.9)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17.7 (13.3 to 23.8)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13.6 (9.3 to 19.5)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.4 (2.1 to 5.3)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.1 (2.5 to 6.7)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>G ≥ 1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2955 (17)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>70.9 (65.0 to 76.6)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63.7 (56.3 to 70.6)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63.8 (56.2 to 70.7)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>56.6 (47.7 to 64.6)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.1 (4.2 to 11.9)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.2 (4.7 to 10.8)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G ≥ 2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2955 (17)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44.2 (38.6 to 50.4)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39.2 (33.3 to 45.7)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34.4 (28.3 to 41.3)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>29.5 (23.2 to 36.5)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.8 (7.1 to 13.2)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.9 (2.8 to 8.3)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G ≥ 3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2899 (15)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24.8 (21.0 to 29.6)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21.2 (17.4 to 25.7)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17.5 (13.8 to 22.3)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13.9 (10.3 to 18.3)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.3 (5.4 to 9.7)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.7 (2.2 to 6.1)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Negative<br/> 33.0 (25.6 to 41.3) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G = 1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1287 (16)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18.4 (14.2 to 23.7)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18.4 (14.2 to 23.7)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18.4 (14.2 to 23.7)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>G ≥ 1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1343 (17)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25.5 (20.7 to 30.9)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25.5 (20.7 to 30.9)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25.5 (20.7 to 30.9)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G ≥ 2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1343 (17)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.1 (5.6 to 11.6)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.1 (5.6 to 11.6)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.1 (5.6 to 11.6)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G ≥ 3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1297 (15)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.0 (1.6 to 5.5)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.0 (1.6 to 5.5)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.0 (1.6 to 5.5)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="12" valign="top"> <p><b>Prior‐negative</b> </p> <p><b>biopsy</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Positive + negative<br/> 100 (100 to 100) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G = 1<sup>d</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1202 (8)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17.6 (13.0 to 25.0)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.8 (6.9 to 14.3)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13.5 (8.9 to 21.0)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.8 (3.2 to 10.0)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.1 (2.6 to 6.2)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.7 (3.9 to 14.8)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>G ≥ 1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1564 (10)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40.7 (35.1 to 47.2)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30.0 (24.1 to 37.0)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30.3 (24.3 to 37.5)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19.6 (13.7 to 27.1)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10.3 (7.5 to 13.9)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10.7 (7.4 to 15)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G ≥ 2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1564 (10)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22.8 (20.0 to 26.2)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20.5 (17.7 to 23.5)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13.2 (10.8 to 16.4)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10.9 (8.7 to 13.5)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.6 (7.7 to 11.8)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.3 (1.2 to 4.5)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G ≥ 3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1514 (9)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12.6 (10.5 to 15.6)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11.5 (9.4 to 14.2)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.3 (4.4 to 9.1)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.1 (3.4 to 7.7)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.3 (5.2 to 7.7)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.1 (0.5 to 2.6)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Positive<br/> 69.6 (54.7 to 81.3) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G = 1<sup>d</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>655 (7)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19.5 (13.9 to 28.8)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16.5 (11.0 to 25.2)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12.4 (7.2 to 21.6)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9.4 (4.6 to 17.9)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.1 (4.1 to 11.8)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.0 (1.0 to 8.0)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>G ≥ 1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>920 (8)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>54.8 (44.6 to 66.4)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48.5 (37.0 to 61.5)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>39.4 (27.1 to 53.9)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>33.1 (20.1 to 48.7)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15.4 (8.2 to 26.4)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6.3 (3.8 to 9.8)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G ≥ 2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>920 (8)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31.3 (27.4 to 36.1)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28.6 (24.7 to 33.1)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18.3 (15.1 to 22.5)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15.7 (12.7 to 19.1)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13.0 (9.7 to 17.0)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.7 (1.2 to 5.7)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G ≥ 3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>880 (7)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17.9 (14.3 to 22.9)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16.7 (13.1 to 21.5)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.4 (6.4 to 14.2)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.2 (5.2 to 12.6)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.5 (6.1 to 11.5)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.2 (0.4 to 3.2)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Negative<br/> 30.4 (18.7 to 45.3) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G = 1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>341 (7)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14.2 (5.9 to 30.2)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14.2 (5.9 to 30.2)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14.2 (5.9 to 30.2)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>G ≥ 1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>400 (8)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19.5 (12.9 to 28.3)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19.5 (12.9 to 28.3)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19.5 (12.9 to 28.3)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G ≥ 2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>400 (8)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.3 (3.1 to 8.9)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.3 (3.1 to 8.9)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.3 (3.1 to 8.9)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G ≥ 3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>390 (7)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.3 (1.7 to 6.3)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.3 (1.7 to 6.3)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.3 (1.7 to 6.3)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="10" rowspan="1" valign=""> <p><b>CI:</b> confidence interval; <b>G:</b> International Society of Urological Pathology grade; <b>MRI:</b> magnetic resonance imaging; <b>MRI‐pathway:</b> magnetic resonance imaging with or without magnetic resonance imaging‐targeted biopsy; <b>MRI‐TBx:</b> magnetic resonance imaging‐targeted biopsy: <b>N:</b> number; <b>NA:</b> not applicable; <b>SBx:</b> systematic biopsy </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="10"> <div class="table-footnote"> <p><sup>a</sup>Proportion of participants with a positive or negative MRI result, based on the studies reporting grade 2 or higher.<br/> <sup>b</sup>Added value MRI‐pathway is the proportion of prostate cancer not detected by systematic biopsy but only by the MRI‐pathway; added value of systematic biopsy is the proportion of prostate cancer not detected by the MRI‐pathway but only by systematic biopsy.<br/> <sup>c</sup>Mixed: biopsy‐naïve and prior‐negative biopsy men.<br/> <sup>d</sup>The tests are considered as 'add‐on tests', taking into account grade reclassification by each test (<a href="./appendices#CD012663-sec-0143">Appendix 3</a>). Therefore, G = 1 results differ from results in <a href="#CD012663-tbl-0015">Table 9</a>, where the tests are considered as 'replacement tests', not taking into account grade reclassification. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 10.</span> <span class="table-title">Agreement analysis: added values of MRI‐pathway and systematic biopsy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/full#CD012663-tbl-0016">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012663-tbl-0017"> <div class="table-heading"><span class="table-label">Table 11.</span> <span class="table-title">Agreement analysis: number needed to biopsy</span></div> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p><b>Agreement analysis: number needed to biopsy by systematic biopsy to detect one extra prostate cancer not detected by the MRI‐pathway</b> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Population</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Target<br/> condition</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>NNB<sup>a</sup><br/> (95% CI)</b> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Biopsy status</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MRI</b> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>Biopsy‐naïve</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Positive</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G = 1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 (15 to 40)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G ≥ 2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20 (12 to 36)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G ≥ 3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27 (16 to 45)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Negative</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G = 1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 (4 to 7)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G ≥ 2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13 (9 to 18)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G ≥ 3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33 (18 to 63)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>Prior‐negative biopsy</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Positive</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G = 1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33 (13 to 100)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G ≥ 2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37 (18 to 83)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G ≥ 3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>83 (31 to 250)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Negative</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G = 1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7 (3 to 17)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G ≥ 2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19 (11 to 32)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G ≥ 3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31 (16 to 63)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p><b>CI:</b> confidence interval; <b>G:</b> International Society of Urological Pathology grade; <b>MRI:</b> magnetic resonance imaging; <b>MRI‐pathway:</b> magnetic resonance imaging with or without magnetic resonance imaging‐targeted biopsy; <b>N:</b> number; <b>NA:</b> not applicable; NNB: number needed to biopsy; <b>SBx:</b> systematic biopsy </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="4"> <div class="table-footnote"> <p><sup>a</sup>Number needed to biopsy by systematic biopsy is 100 divided by the added value of systematic biopsy. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 11.</span> <span class="table-title">Agreement analysis: number needed to biopsy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/full#CD012663-tbl-0017">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012663-tbl-0018"> <div class="table-heading"><span class="table-label">Table 12.</span> <span class="table-title">Heterogeneity exploration in the agreement analysis</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Heterogeneity exploration in the agreement analysis: detection ratio MRI‐pathway vs systematic biopsy for G ≥ 2 prostate cancer</b> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Covariate</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Category</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>N participants<br/> (studies)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Detection ratio<br/> for G ≥ 2 PCa<br/> (95% CI)<sup>a</sup> </b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>P value</b> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Population</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Biopsy‐naïve</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5219 (20)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.05 (0.95 to 1.16)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>0.002</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Prior to negative biopsy</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1564 (10)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.44 (1.19 to 1.75)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Field strength</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3T</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5407 (19)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ID</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ID</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.5T</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1143 (4)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ID</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ID</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Endorectal coil</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1815 (6)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.42 (1.07 to 1.88)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>0.008</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4082 (14)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.03 (0.94 to 1.12)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p><b>MRI pulse sequence</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>mpMRI</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4941 (16)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.18 (1.05 to 1.33)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>0.233</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>bpMRI</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1775 (6)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.03 (0.91 to 1.17)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>mpMRI + spectroscopy</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>105 (2)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ID</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ID</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p><b>MRI risk threshold</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>605 (6)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.18 (1.03 to 1.35)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>0.556</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intermediate</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5859 (15)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.14 (1.03 to 1.26)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>High</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>428 (3)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ID</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ID</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p><b>MRI‐TBx technique</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Software</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3313 (9)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.15 (0.99 to 1.33)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>0.483</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cognitive</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2194 (12)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.17 (1.00 to 1.36)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>In‐bore</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>849 (2)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ID</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ID</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Route index test</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Transrectal</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6464 (23)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ID</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ID</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Transperineal</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>480 (2)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ID</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ID</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>bpMRI:</b> biparametric magnetic resonance imaging; <b>CI:</b> confidence interval; <b>G:</b> International Society of Urological Pathology grade; <b>ID:</b> inadequate data; <b>mpMRI:</b> multiparametric magnetic resonance imaging; <b>MRI:</b> magnetic resonance imaging; <b>MRI‐pathway:</b> magnetic resonance imaging with or without magnetic resonance imaging‐targeted biopsy; <b>MRI‐TBx:</b> magnetic resonance imaging‐targeted biopsy; <b>N:</b> number; <b>SBx:</b> systematic biopsy </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p><sup>a</sup>Detection ratio is the detection rate of MRI‐pathway divided by detection rate of systematic biopsy; the detection rate = the pooled number of positive results of the test divided by the pooled total number of positive results from both tests. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 12.</span> <span class="table-title">Heterogeneity exploration in the agreement analysis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/full#CD012663-tbl-0018">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012663-tbl-0019"> <div class="table-heading"><span class="table-label">Table 13.</span> <span class="table-title">Sensitivity analysis of the diagnostic test accuracy analyses</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="9" rowspan="1" valign=""> <p><b>Sensitivity analyses of the diagnostic test accuracy of MRI and the MRI‐pathway for detecting G ≥ 2 prostate cancer, verified by template‐guided biopsy as the reference standard</b> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="2" valign=""> <p><b>Covariate</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Category</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>MRI</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>MRI‐pathway<sup>a</sup> </b> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>N<br/> studies</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Sensitivity<br/> (95% CI)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Specificity<br/> (95% CI)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>N<br/> studies</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Sensitivity<br/> (95% CI)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Specificity<br/> (95% CI)</b> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Main analyses (as reference</b>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No selection</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.91 (0.83 to 0.95)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.37 (0.29 to 0.46)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.72 (0.60 to 0.82)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.96 (0.94 to 0.98)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="7" valign=""> <p><b>QUADAS domains</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Participant selection</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Only low risk of bias</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.86 (0.83 to 0.88)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.39 (0.31 to 0.47)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.61 (0.54 to 0.69)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.97 (0.92 to 0.99)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Only low applicability concern</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.91 (0.83 to 0.96)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.36 (0.28 to 0.46)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.69 (0.60 to 0.77)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.97 (0.94 to 0.98)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Index test</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Only low risk of bias</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.91 (0.83 to 0.95)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.37 (0.29 to 0.46)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.72 (0.60 to 0.82)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.96 (0.94 to 0.98)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Only low applicability concern</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.90 (0.85 to 0.94)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.37 (0.31 to 0.43)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.68 (0.59 to 0.77)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.97 (0.94 to 0.99)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Reference standard</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Only low risk of bias</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.93 (0.82 to 0.98)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.34 (0.24 to 0.45)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ID</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ID</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Only low applicability concern</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.91 (0.83 to 0.95)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.37 (0.29 to 0.46)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.72 (0.60 to 0.82)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.96 (0.94 to 0.98)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Flow and timing</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Only low risk of bias</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.91 (0.83 to 0.96)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.36 (0.28 to 0.46)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.72 (0.60 to 0.82)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.96 (0.94 to 0.98)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="7" valign=""> <p><b>Additional analyses</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>MRI positivity threshold</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Only threshold 3/5</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.89 (0.82 to 0.94)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.39 (0.32 to 0.47)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.68 (0.59 to 0.77)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.97 (0.94 to 0.98)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>MRI positivity threshold effect</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MRI positivity threshold 3/5 (only studies with also 4/5)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.87 (0.73 to 0.94)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.45 (0.33 to 0.57)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ID</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ID</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MRI positivity threshold 4/5 (only studies with also 3/5)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.72 (0.52 to 0.86)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.78 (0.68 to 0.86)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ID</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ID</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>MRI vs MRI‐pathway</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Only MRI and MRI‐pathway in the same men (paired data)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.92 (0.83 to 0.96)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.35 (0.27 to 0.44)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.72 (0.60 to 0.82)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.96 (0.94 to 0.98)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Reference standard</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Only TTMB, TSB or TOP</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.90 (0.84 to 0.93)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.36 (0.29 to 0.44)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.69 (0.58 to 0.78)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.96 (0.93 to 0.97)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Template‐guided biopsy + MRI‐TBx (composite reference standard)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.94 (0.91 to 0.96)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.00 (1.00 to 1.00)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.72 (0.63 to 0.80)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.00 (1.00 to 1.00)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Experience of radiologist</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Only high experience</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.91 (0.85 to 0.95)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.34 (0.27 to 0.42)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.69 (0.60 to 0.77)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.97 (0.94 to 0.98)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="9" rowspan="1" valign=""> <p><b>CI:</b> confidence interval; <b>G:</b> International Society of Urological Pathology grade; <b>ID:</b> inadequate data; <b>MRI:</b> magnetic resonance imaging; <b>MRI‐pathway:</b> magnetic resonance imaging with or without magnetic resonance imaging‐targeted biopsy; <b>MRI‐TBx:</b> magnetic resonance imaging‐targeted biopsy; <b>N:</b> number; <b>NA:</b> not applicable; <b>QUADAS:</b> Quality Assessment of Diagnostic Accuracy Studies; <b>SBx:</b> systematic biopsy; <b>TOP:</b> transperineal optimised prostate biopsy;<b>TSB:</b> Ginsburg transperineal saturation biopsy; <b>TTMB:</b> transperineal template mapping biopsy </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="9"> <div class="table-footnote"> <p><sup>a</sup>The diagnostic test accuracy analyses of magnetic resonance imaging‐targeted biopsy are based on the same studies as the MRI‐pathway. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 13.</span> <span class="table-title">Sensitivity analysis of the diagnostic test accuracy analyses</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/full#CD012663-tbl-0019">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012663-tbl-0020"> <div class="table-heading"><span class="table-label">Table 14.</span> <span class="table-title">Sensitivity analysis of the agreement analyses</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Sensitivity analyses of the agreement between the MRI‐pathway vs systematic biopsy for detecting G ≥ 2 prostate cancer</b> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Covariate</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Category</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>N<br/> studies</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Detection ratio<br/> (95% CI)<sup>a</sup> </b> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Main analyses (as reference)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mixed population</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.12 (1.02 to 1.23)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="7" valign=""> <p><b>QUADAS domains</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Patient selection</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Only low risk of bias</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.08 (1.00 to 1.17)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Only low applicability concern</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.09 (1.01 to 1.17)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Index test (MRI‐pathway)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Only low risk of bias</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.11 (1.02 to 1.22)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Only low applicability concern</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.13 (1.01 to 1.26)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Index test (SBx)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Only low risk of bias</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.04 (0.94 to 1.15)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Only low applicability concern</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.07 (0.99 to 1.15)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Flow and timing</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Only low risk of bias</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.10 (1.00 to 1.22)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p><b>Additional analyses</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>MRI positivity threshold</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Only threshold 3/5</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.14 (1.03 to 1.26)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Biopsy‐naïve (only studies with also prior‐negative biopsy men)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.98 (0.76 to 1.28)<sup>b</sup> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Prior‐negative biopsy (only studies with also biopsy‐naïve men)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.42 (1.03 to 1.95)<sup>b</sup> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Experience of radiologist</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Only high experience</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.13 (1.03 to 1.24)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>CI:</b> confidence interval; <b>G:</b> International Society of Urological Pathology grade; <b>MRI‐pathway:</b> magnetic resonance imaging (MRI) with or without MRI‐targeted biopsy; <b>N:</b> number; <b>QUADAS:</b> Quality Assessment of Diagnostic Accuracy Studies; <b>SBx:</b> systematic biopsy </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p><sup>a</sup>Detection ratio is the detection rate of the MRI‐pathway divided by detection rate of systematic biopsy; the detection rate is the pooled number of positive results of the test divided by the pooled total number of positive results from both tests.<br/> <sup>b</sup>The reference detection ratio for these categories are 1.05 (95% CI 0.95 to 1.16) for the biopsy‐naïve men and 1.44 (95% CI 1.19 to 1.75) for the prior‐negative biopsy men (<a href="#CD012663-tbl-0015">Table 9</a>). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 14.</span> <span class="table-title">Sensitivity analysis of the agreement analyses</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/full#CD012663-tbl-0020">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012663-tbl-0021"> <div class="table-heading"><span class="table-label">Table Tests.</span> <span class="table-title">Data tables by test</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p>Test</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">1 Diagnostic accuracy of MRI ‐ G = 1 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1764</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">2 Diagnostic accuracy of MRI ‐ G ≥ 1 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1764</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">3 Diagnostic accuracy of MRI ‐ G ≥ 2 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3091</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">4 Diagnostic accuracy of MRI ‐ G ≥ 3 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1438</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">5 Diagnostic accuracy of MRI ‐ MRI‐positvity threshold 4/5 ‐ G = 1 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>834</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">6 Diagnostic accuracy of MRI ‐ MRI‐positvity threshold 4/5 ‐ G ≥ 1 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>834</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">7 Diagnostic accuracy of MRI ‐ MRI‐positvity threshold 4/5 ‐ G ≥ 2 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1083</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">8 Diagnostic accuracy of MRI ‐ MRI‐positvity threshold 4/5 ‐ G ≥ 3 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>834</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">9 Diagnostic accuracy of MRI ‐ Biopsy‐naïve ‐ G ≥ 1 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>748</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">10 Diagnostic accuracy of MRI ‐ Biopsy‐naïve ‐ G ≥ 2 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>748</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">11 Diagnostic accuracy of MRI ‐ Biopsy‐naïve ‐ G ≥ 3 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>748</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">12 Diagnostic accuracy of MRI ‐ Prior‐negative biopsy ‐ G ≥ 1 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>870</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">13 Diagnostic accuracy of MRI ‐ Prior‐negative biopsy ‐ G ≥ 2 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1157</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">14 Diagnostic accuracy of MRI ‐ Prior‐negative biopsy ‐ G ≥ 3 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>544</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">15 Diagnostic accuracy of MRI ‐ Sensitivity analysis with composite reference standard (template‐guided biopsy + MRI‐TBx) ‐ G ≥ 2 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3192</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">16 Diagnostic accuracy of TBx ‐ G = 1 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>497</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">17 Diagnostic accuracy of TBx ‐ G ≥ 1 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>611</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">18 Diagnostic accuracy of TBx ‐ G ≥ 2 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1553</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">19 Diagnostic accuracy of TBx ‐ G ≥ 3 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>428</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">20 Diagnostic accuracy of the MRI‐pathway ‐ G = 1 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>681</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">21 Diagnostic accuracy of the MRI‐pathway ‐ G ≥ 1 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>844</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">22 Diagnostic accuracy of the MRI‐pathway ‐ G ≥ 2 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2257</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">23 Diagnostic accuracy of the MRI‐pathway ‐ G ≥ 3 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>604</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">24 Diagnostic accuracy of SBx ‐ G = 1 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3421</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">25 Diagnostic accuracy of SBx ‐ G ≥ 1 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3421</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">26 Diagnostic accuracy of SBx ‐ G ≥ 2 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3421</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">27 Diagnostic accuracy of SBx ‐ G ≥ 3 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>626</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">28 MRI‐pathway vs SBx ‐ G = 1 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5442</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">29 MRI‐pathway vs SBx ‐ G ≥ 1 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6524</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">30 MRI‐pathway vs SBx ‐ G ≥ 2 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6944</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">31 MRI‐pathway vs SBx ‐ G ≥ 3 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5981</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">32 MRI‐pathway vs SBx ‐ Biopsy‐naïve ‐ G = 1 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4079</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">33 MRI‐pathway vs SBx ‐ Biopsy‐naïve ‐ G ≥ 1 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4799</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">34 MRI‐pathway vs SBx ‐ Biopsy‐naïve ‐ G ≥ 2 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5219</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">35 MRI‐pathway vs SBx ‐ Biopsy‐naïve ‐ G ≥ 3 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4306</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">36 MRI‐pathway vs SBx ‐ Prior‐negative biopsy ‐ G = 1 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1202</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">37 MRI‐pathway vs SBx ‐ Prior‐negative biopsy ‐ G ≥ 1 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1564</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">38 MRI‐pathway vs SBx ‐ Prior‐negative biopsy ‐ G ≥ 2 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1564</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">39 MRI‐pathway vs SBx ‐ Prior‐negative biopsy ‐ G ≥ 3 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1514</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">40 MRI‐pathway vs SBx ‐ Positive MRI ‐ G = 1 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3460</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">41 MRI‐pathway vs SBx ‐ Positive MRI ‐ G ≥ 1 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3998</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">42 MRI‐pathway vs SBx ‐ Positive MRI ‐ G ≥ 2 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3998</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">43 MRI‐pathway vs SBx ‐ Positive MRI ‐ G ≥ 3 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3902</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">44 MRI‐pathway vs SBx ‐ Negative MRI ‐ G = 1 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1666</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">45 MRI‐pathway vs SBx ‐ Negative MRI ‐ G ≥ 1 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1781</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">46 MRI‐pathway vs SBx ‐ Negative MRI ‐ G ≥ 2 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1781</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">47 MRI‐pathway vs SBx ‐ Negative MRI ‐ G ≥ 3 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1725</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">48 MRI‐pathway vs SBx ‐ Positive MRI ‐ Biopsy‐naïve ‐ G = 1 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2682</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">49 MRI‐pathway vs SBx ‐ Positive MRI ‐ Biopsy‐naïve ‐ G ≥ 1 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2955</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">50 MRI‐pathway vs SBx ‐ Positive MRI ‐ Biopsy‐naïve ‐ G ≥ 2 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2955</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">51 MRI‐pathway vs. SBx ‐ Positive MRI ‐ Biopsy‐naïve ‐ G ≥ 3 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2899</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">52 MRI‐pathway vs SBx ‐ Negative MRI ‐ Biopsy‐naïve ‐ G = 1 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1287</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">53 MRI‐pathway vs SBx ‐ Negative MRI ‐ Biopsy‐naïve ‐ G ≥ 1 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1343</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">54 MRI‐pathway vs SBx ‐ Negative MRI ‐ Biopsy‐naïve ‐ G ≥ 2 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1343</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">55 MRI‐pathway vs SBx ‐ Negative MRI ‐ Biopsy‐naïve ‐ G ≥ 3 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1297</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">56 MRI‐pathway vs SBx ‐ Positive MRI ‐ Prior‐negative biopsy ‐ G = 1 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>655</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">57 MRI‐pathway vs SBx ‐ Positive MRI ‐ Prior‐negative biopsy ‐ G ≥ 1 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>920</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">58 MRI‐pathway vs SBx ‐ Positive MRI ‐ Prior‐negative biopsy ‐ G ≥ 2 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>920</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">59 MRI‐pathway vs SBx ‐ Positive MRI ‐ Prior‐negative biopsy ‐ G ≥ 3 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>880</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">60 MRI‐pathway vs SBx ‐ Negative MRI ‐ Prior‐negative biopsy ‐ G = 1 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>341</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">61 MRI‐pathway vs SBx ‐ Negative MRI ‐ Prior‐negative biopsy ‐ G ≥ 1 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>400</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">62 MRI‐pathway vs SBx ‐ Negative MRI ‐ Prior‐negative biopsy ‐ G ≥ 2 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>400</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">63 MRI‐pathway vs SBx ‐ Negative MRI ‐ Prior‐negative biopsy ‐ G ≥ 3 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>390</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table Tests.</span> <span class="table-title">Data tables by test</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012663.pub2/references#CD012663-tbl-0021">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD012663.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD012663-note-0001">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD012663-note-0005">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD012663-note-0023">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD012663-note-0003">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD012663-note-0007">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ms#CD012663-note-0002">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pl#CD012663-note-0004">Polski</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD012663-note-0006">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012663\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012663\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012663\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012663\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012663\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012663\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012663\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012663\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012663\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012663\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012663\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012663\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012663\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012663\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012663\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012663\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012663\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012663\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=ZCrlluee&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012663.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD012663.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD012663.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD012663.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012663.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740727898836"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD012663.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740727898840"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD012663.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918eb747dbab937f',t:'MTc0MDcyNzg5OS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 